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Abstract 
The role of infectious bronchitis virus accessory proteins 3a, 3b and 4b 
Mr Ross Howden Hall 
Infectious bronchitis (IB) is a respiratory disease in domestic fowl caused by the 
gammacoronavirus infectious bronchitis virus (IBV). Current approaches to 
combat this disease are hindered due to vaccines unable to cross-protect against 
the many different strains of IBV. To develop novel therapies or more cross-
protective vaccines, a better understanding of IBV molecular biology is required. 
IBV is known to express four accessory proteins, 3a, 3b, 5a, and 5b, as well as a 
sub-genomic RNA that has the potential to code for an additional 11 kDa protein, 
referred to as 4b. The role of this sub-genomic RNA is not known, as is whether 
this transcript is translated during infection. IBV accessory proteins are 
dispensable for replication and are thought to play a role in virulence or 
pathogenicity. The functions of 3a and 3b are unknown, although they have been 
shown to play a part in the interferon response in a yet unknown manner. Using 
in vitro assays and mass spectrometry, the mechanism of action of 3a on the 
interferon response was determined. IBV 3a inhibits and stimulates interferon 
expression in a dose-dependent manner by regulating the turnover of interferon 
signalling proteins, MAVS and IRF7. Flow cytometry has identified a role for IBV 
3b in inducing apoptosis during infection, possibly by interacting with apoptotic 
proteins VDAC2 or BAG6. Lastly, using an antibody raised against the predicted 
4b peptide sequence, 4b was detected during infection, confirming it as the fifth 
IBV accessory protein. Furthermore, mass spectrometry was utilised to identify a 
role for 4b in regulating cellular translation and the stress granule response. 
Accessory proteins are highly conserved in the many different strains of IBV and 
are usually pathogenicity factors making them potential targets for novel therapies. 
Researching the role of these accessory proteins is essential to understand how 
IBV causes IB and for the development of more targeted therapies 
 or more cross-protective vaccines.  
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RTC – Replication-Transcription Complex 
rVV – Recombinant Vaccinia Virus 
S – Viral Spike Protein 
SARS-CoV – Severe Acute Respiratory Syndrome Coronavirus 
SDS-PAGE – Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SG – Stress Granule 
sgRNA – Sub-genomic RNA 
STAT1/3/7 – Signal Transducer and Activator of Transcription 1/3/7 
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TCoV – Turkey Coronavirus 
TBK1 – TANK-Binding Kinase 1 
TDS – Transient Dominant Selection 
TGEV – Transmissible Gastroenteritis Virus  
TIA-1 – T-Cell-Restricted Intracellular Antigen-1 
TIAR – TIA-1-Related Protein 
TLR3/7 – TOLL-Like Receptor 3/7 
TNF – Tumour necrosis factor 
TRAF3 – TNF Receptor-Associated Factor 3 
TRIM25 – Tripartite Motif-Containing Protein 25 
TRS – Transcription Regulatory Sequence 
TRS-B – TRS-Body 
TRS-L – TRS-Leader 
UPR – Unfolded Protein Response 
UTR – Untranslated Region 
VDAC – Voltage-dependent Anion Channel 
VLP – Virus-Like Particle 
WT – Wild-type 
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1. Introduction 
1.1 Infectious Bronchitis Disease 
Infectious bronchitis (IB) is a highly contagious globally endemic disease that 
infects domestic fowl (Gallus gallus). Symptoms of this respiratory disease 
include snicking, coughing, red eyes, and rales. Infected fowl can also suffer from 
poor weight gain and lower/poorer egg production (Chen et al. 1996, Cavanagh 
2003). Due to these symptoms, the disease causes a significant economic loss 
to the British poultry industry of around £24 million per year (Defra 2002). The 
etiological agent, infectious bronchitis virus (IBV), mainly infects the epithelial 
cells of the respiratory tract but can also infect the epithelial cells of the kidneys; 
where it can cause nephrotoxicity, as well as the ovaries and oviduct. Current 
vaccine strategies against IBV rely on the use of live attenuated and inactivated 
vaccines. These vaccines offer poor cross-protection against the many different 
strains of IBV and are resource intensive to manufacture. There is thus a growing 
need to better understand IBV molecular biology to develop more novel therapies 
(Tomley et al. 1987, Koch et al. 1990).   
 
1.2 Infectious Bronchitis Virus 
IBV belongs to the gammacoronavirinae genus, of the coronavirinae subfamily, in 
the Nidovirales order. The coronavirinae subgroup is split into four genera, alpha-, 
beta-, gamma- and deltacoronaviruses, summarised in Table 1.1. Coronaviruses 
contain a single-stranded positive-sense RNA genome (+ssRNA), which are 
among the largest RNA genomes found in viruses. Coronavirus genomes are 
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around 26 – 32Kb in length and have both a 5′-end methylated cap and 3′-end 
polyadenylated tail (Masters 2006). The genome of IBV is around 26.7Kb and is 
currently organised into six regions, expressed as six messenger RNAs (mRNA). 
Messenger RNA 1 contains two open-reading frames (ORFs); 1a and 1b, which 
comprises two-thirds of the genome at the 5′-end. ORF 1b overlaps with 1a and 
is only translated after a -1 ribosomal frameshift (Brierley et al. 1987) (Figure 
1.1A). Polyproteins 1a (pp1a) and 1ab (pp1ab) are cleaved by two virus-encoded 
proteases (Lim et al. 1998, Lim et al. 1998) into 15 non-structural proteins (nsps) 
(Ziebuhr et al. 2000). The 3′-end of the genome encodes the structural and 
accessory proteins. Four structural mRNAs are expressed from the genome in 
the order spike (S) – envelope (E) – membrane (M) – nucleocapsid (N) along with 
two mRNAs that express four known accessory proteins, 3a, 3b, 5a, and 5b. 
Structural protein E is expressed from the same mRNA as 3a and 3b and is 
regulated by an internal ribosome entry site (IRES) (Liu et al. 1992). A recently 
identified transcript, known as mRNA 4b, is expressed from the intergenic region 
(IR) between M and 5a (Bentley et al. 2013). It is not known whether mRNA 4b is 
translated during infection. Untranslated regions (UTRs) are present at both the 
5′- and 3′-end of the genome and have been shown to be involved in RNA 
replication and viral translation (Dalton et al. 2001). The viral genome is 
encapsulated by protein N to form a ribonucleoprotein (RNP). This RNP is in turn 
encased by a lipid envelope containing the three other structural proteins, S, E 
and M. A single virion is pleomorphic and approximately 120 nm in diameter 
(Figure 1.1B,C) (Masters 2006). There are many different strains of IBV, amongst 
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the most studied strains are Beaudette-CK (Beau-CK) and Massachusetts 41-CK 
(M41-CK). Beau-CK is an apathogenic lab strain that was obtained by serial 
passage in eggs, while M41-CK is a pathogenic lab strain (Beaudette 1937, Van 
Roekel 1950, Casais et al. 2003). 
 
Table 1.1 Viruses within the coronavirinae subfamily 
Prototype viruses in the respective genera are labelled in bold 
 
 
 
Coronavirinae 
Alphacoronavirus Betacoronavirus Gammacoronavirus 
Transmissible 
gastroenteritis 
coronavirus (TGEV) 
Murine Hepatitis Virus 
(MHV) Infectious bronchitis virus (IBV) 
Canine coronavirus 
(CCoV) Bovine coronavirus (BCoV) 
Beluga whale coronavirus SW1 
(BeCoV) 
Feline coronavirus 
(FCov) 
Human coronavirus HKU1 
(HCoV-HKU1) Turkey coronavirus (TCoV) 
Human coronavirus 229E 
(HCoV-229E) 
Human coronavirus OC43 
(HCoV-OC43) Deltacoronavirus 
Human coronavirus NL63 
(HCoV-NL63) 
Middle-East Respiratory 
coronavirus (MERS-CoV) 
Porcine deltacoronavirus 
(PDCoV) 
Porcine epidemic 
diarrhoea virus (PEDV) 
Severe acute respiratory 
syndrome coronavirus 
(SARS-CoV) 
Bulbul coronavirus HKU11 (BuCoV) 
  Munia coronavirus HKU13 (MunCoV) 
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Figure 1.1 Schematic diagram of the IBV genome/ virion, and an electron micrograph 
of IBV.  
(A) IBV genome expresses six mRNAs and one putative mRNA known as 4b and is flanked 
by untranslated regions at the 5′- and 3'-end. A pseudoknot and slippery sequence are 
responsible for mediating the -1 frameshift during pp1ab translation, while an IRES mediates 
translation of E. (B) The IBV lipid envelope contains three structural proteins, spike (S), 
envelope (E) and membrane (M) and encapsulates the positive-sense single-stranded RNA 
(+ssRNA) genome bound to nucleocapsid (N) protein. (C) Transmission electron micrograph 
of IBV virions (Dr Fred Murphy; Sylvia Whitfield, Centers for Disease Control). 
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1.3 Coronavirus Replication 
1.3.1 Attachment and Entry 
Coronavirus cell entry is mediated by the S protein, a large type I transmembrane 
protein. The IBV S protein is around 1,160 amino acids and is cleaved by furin, a 
cellular protease, into two functional domains, S1 and S2 (Yamada et al. 2009). 
The gammacoronavirus spike protein is cleaved between domains S1 and S2 
during assembly but is rarely cleaved in alpha- and beta- coronaviruses 
(Belouzard et al. 2012). The S1 domain contains the receptor binding domain 
(RBD) and mediates cell attachment (Promkuntod et al. 2014). IBV attachment 
and entry into cells is dependent on α-2,3-linked sialic acid, a cell surface 
molecule (Winter et al. 2006). Due to the ubiquitous nature of sialic acid, it is 
believed that another unknown cell receptor is required for cell entry, as IBV has 
restricted cellular tropism (Schultze et al. 1992, Winter et al. 2006). IBV may enter 
the cell by clathrin-mediated endocytosis, although alternative mechanisms have 
not been disproved (Yamada et al. 2009) (Figure 1.2A). The mechanism of 
coronavirus cell entry and fusion differs between coronaviruses and strains 
(Belouzard et al. 2012). In the case of IBV, fusion is pH dependent. After 
endocytosis, IBV-cellular fusion is initiated by an acidic environment, which 
causes a conformational change in the S protein, exposing the class I viral fusion 
peptide residing in the S2 domain. The coronavirus fusion peptide is inserted into 
vesicle membranes and mediates fusion with the viral lipid envelope (Bosch et al. 
2003). Fusion releases the ribonucleoprotein (RNP) and thus the viral genome 
into the cytoplasm (Figure 1.2B). 
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1.3.2 Replication, Transcription and Translation 
After entry of the RNP into the cell cytoplasm, ORF1a and ORF1ab are translated 
by host-cellular machinery into pp1a and pp1ab. Translation of pp1ab occurs after 
a -1 frameshift (Brierley et al. 1989). The -1 ribosomal frameshift occurs when the 
ribosome encounters a slippery site sequence in the coronavirus RNA. This site 
induces ribosomal and mRNA unpairing and then repairing but in the -1 reading 
frame. A downstream pseudoknot called the stimulatory element is responsible 
for the pause in translation allowing the frameshift to occur. After the frameshift, 
the pseudoknot is unwound by the ribosome allowing translation to continue, 
resulting in a protein with an extended C-terminus, known as pp1ab (Brierley et 
al. 1987, Inglis et al. 1990). These polyproteins are cleaved by the virally encoded 
proteases; nsp3 and nsp5, into individual nsps, of which some assemble into the 
replication-transcription complex (RTC) (Figure 1.2C) (Ziebuhr et al. 2001). The 
RTC produces negative-sense sub-genomic (sg)RNAs by discontinuous 
transcription, and negative-sense full-length genome templates by continuous 
transcription (Sawicki et al. 2007) (Sawicki et al. 1995) (Figure 1.3). The 
mechanism of transcription is not fully understood but is dependent on a 
conserved transcription regulatory sequence (TRS) (Hiscox et al. 1995). There is 
a TRS-leader (TRS-L) present at the 5′-end of the genome, and a TRS-body 
(TRS-B) found upstream of each gene block to regulate the transcription of 
negative-sense sgRNA. The sequence of the TRSs are conserved in both IBV 
and the closely related Turkey Coronavirus (TCoV) (CUUAACAA), except IBV 
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mRNA 3 and S, which are regulated by a slightly altered TRS (CUGAACAA). The 
recently discovered 4b transcript is regulated by a non-canonical TRS (CAA) 
(Bentley et al. 2013). Transcription is initiated by the RTC at the 3′-end of the full-
length genome and continues upstream until a TRS-B is encountered, at which 
point transcription pauses (Pasternak et al. 2001). Transcription can either 
continue until the next TRS-B or can jump to the 5′-end due to complementary 
base pairing between TRS-B and TRS-L. Transcription continues resulting in an 
anti-leader sequence at the 3′-end of the negative-sense sgRNA (van Marle et al. 
1999) (Zuniga et al. 2004). This discontinuous transcription creates a collection 
of negative-sense sgRNAs of varying length. The abundance of these sgRNAs is 
in part dependent on proximity to the 3′-end of the genome, with shorter sgRNA 
more abundant than longer sgRNA (van der Most et al. 1995). The negative-sense 
sgRNA and full-length transcripts are used as templates for synthesis of positive-
sense viral sgRNA and full-length genomes. Each viral sgRNA is capped at the 
5′-end and polyadenylated at the 3′-end (Figure 1.2D) (Masters 2006). Viral 
sgRNA are translated into the structural proteins, S, E, M, and N, and the 
accessory proteins 3a, 3b, 5a, and 5b. ORFs at the 5′-end are translated by host-
cell machinery. Translation is believed to occur in a cap-dependent manner due 
to the presence of a 5′-end M7G cap (Nakagawa et al. 2016). The translation of 
downstream ORFs; 3b in mRNA 3 and 5b in mRNA 5, are translated by leaky 
ribosomal scanning (Liu et al. 1992). Expression of E; the third ORF in mRNA 3, 
is regulated by an IRES present upstream in the 3a/3b RNA secondary structure 
(Figure 1.2E) (Liu et al. 1992, Le et al. 1994). A feature of coronavirus replication 
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is the production of double-stranded RNA (dsRNA), which occurs at around 3-5 
hours post infection (h.p.i) (Hagemeijer et al. 2012, Maier et al. 2016). While 
historically dsRNA was believed to be an intermediate of ssRNA synthesis, this 
has recently been questioned as dsRNA does not colocalise with the RNA-
dependent RNA polymerase or nascent RNA (Maier et al. 2013) (Hagemeijer et 
al. 2012) (Knoops et al. 2008). The role of this dsRNA is unknown.  
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Figure 1.2 Schematic diagram of the lifecycle of IBV. 
 (A) IBV S protein attaches to an unknown cell surface receptor and enters the cell by 
endocytosis. (B) Virions fuse with the cell membrane and release the RNP into the cytoplasm. 
(C) Replicase proteins pp1a and pp1ab are translated by host-cell machinery and once cleaved 
assemble to form the viral RTC. (D) The RTC transcribes sgRNA and full-length genomes. (E) 
SgRNAs are translated into structural proteins and accessory proteins. (F) Structural proteins 
are translated at the ER and translocate to the Golgi or ER-GIC. Protein N binds to newly 
synthesised full-length genomic RNA. (G) New virions bud into the ER-GIC lumen. (H) The cell 
secretory pathway releases viral progeny by exocytosis at around 6-8 h.p.i. 
A 
B 
C 
D 
E
F
G 
H 
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1.3.3 Coronavirus-induced membrane rearrangement 
Positive-sense RNA viruses induce membrane rearrangement during infection; 
this provides a platform for viral replication and/or assembly, while also allowing 
compartmentation of viral PAMPs (Denison 2008, van Hemert et al. 2008). 
Coronaviruses have been extensively studied for their ability to induce membrane 
rearrangement. Betacoronaviruses; SARS-CoV and MHV, generate double-
membrane vesicles (DMVs) as well as complex membranous structures known 
as convoluted membranes (CM) during infection (Gosert et al. 2002, Goldsmith 
et al. 2004, Knoops et al. 2008). IBV has also been shown to induce DMVs 
(Figure 1.4A), as well as a novel structure known as zippered ER which has 
attached vesicles (Figure 1.4D). These vesicles are termed spherules and are 
dispersed along the zippered ER structure with a small channel connecting the 
interior of the spherule to the cytoplasm (Figure 1.4C) (Maier et al. 2013). The 
exact site of IBV or coronavirus RNA synthesis is unknown, although a possible 
site are these spherules. The observed pores would allow the transfer of viral 
Figure 1.3 Schematic diagram of IBV transcription.  
RNA transcripts are transcribed by continuous and discontinuous transcription of the 
genomic RNA. Continuous and discontinuous transcription is initiated at the 3′-end of the 
genome by the viral RTC and moves upstream until a TRS-body (TRS-B) is encountered, 
at which point transcription can either continue or jump to the TRS-leader (TRS-L). 
Discontinuous transcription creates a nested set of 3′-co-terminal negative-sense sgRNA 
of varying length each with a common sequence at the 5′- and 3′-end. These sgRNA act 
as templates for the synthesis of positive-sense sgRNA, which are later translated into 
viral proteins. Continuous transcription occurs when transcription is not halted at a TRS-
B, creating a negative-sense full-length genome, which is used as a template for 
synthesis of new +ssRNA genomes. 
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RNA and proteins to and from the cytoplasm, while also providing protection from 
cellular detection. Historically, dsRNA produced during +ssRNA infection was 
thought to be an intermediate component of ssRNA synthesis. However, the role 
of dsRNA during IBV and indeed coronavirus infection is unclear and does not 
necessarily suggest the site of RNA synthesis. Early during MHV infection, dsRNA 
has been shown to colocalise with newly synthesised RNA but at later time points 
this colocalisation declines (Hagemeijer et al. 2012). In addition, during SARS-
CoV infection, dsRNA has been shown to localise to the interior of DMVs. Unlike 
IBV induced spherules, DMVs lack pores or any connection to the cytoplasm, 
further questioning if these are the site of RNA synthesis (Knoops et al. 2008). In 
the case of IBV, only 1.5% of dsRNA colocalises with Nsp12; the RNA-dependent-
RNA polymerase, suggesting that the location of dsRNA is not the primary site of 
RNA synthesis (Maier et al. 2013). IBV-induced membrane rearrangement 
appears not to be a determinant of pathogenicity, as M41, a pathogenic lab strain 
produces fewer spherules than the apathogenic strain, Beau-R (Maier et al. 2016), 
although it is possible that other virus-induced double membrane structures 
compensate, and it is structure, rather than shape that is an important determinant 
of viral pathogenicity. IBV and other coronaviruses further manipulate 
membranous structures to compartmentalise and release progeny virions by 
exocytosis, utilising the host-cell secretory pathway (Ruch et al. 2011) (Figure 
1.4B). 
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1.3.4 Assembly and Budding 
Structural proteins S, E, and M are translated and inserted into the ER (Figure 
1.2F) (Krijnselocker et al. 1994) and are shuttled to the ER-GIC via the cell 
secretory pathway. Full-length genomic RNA, produced during replication, 
associates with newly synthesised N protein into a helical RNP structure (Zhou et 
al. 2000). RNPs bud into the ER-GIC lumen to form new virions by binding to M 
(Figure 1.2G) (Tooze et al. 1987) (Klumperman et al. 1994) (Narayanan et al. 
Figure 1.4 Schematic diagram of IBV-induced membrane rearrangement.  
During infection, IBV induces four types of membrane rearrangement, (A) double-
membrane vesicles (DMVs), (B) vesicles for the export of progeny viruses and (C) 
zippered-ER structures with (D) spherules.  
B 
A 
D 
C 
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2000). The S protein is first glycosylated at the ER and is then incorporated into 
virions at the ER-GIC by interacting with M (Hurst et al. 2005, Youn et al. 2005). 
Nascent virions are transported in vesicles to the cell surface and released by 
exocytosis (Emmott et al. 2013). IBV begins to release progeny virions by 6-8 
hours post infection in a non-lytic manner (Maier et al. 2013) (Figure 1.2H). IBV 
E has been shown to be essential for virion egress by altering the host-cell 
secretory pathway, as well as inducing viral membrane curvature and viral particle 
scission (Ruch et al. 2011). IBV E protein is post-translationally modified with the 
addition of palmitic acid onto cysteine residues. In MHV this modification has been 
shown to increase VLP yield and production of infectious virions (Boscarino et al. 
2008) (Corse et al. 2002). Expression of M and E is sufficient for coronavirus VLP 
assembly, but when co-expressed with N, VLP yield is significantly higher (Corse 
et al. 2000) (Vennema et al. 1996).  
 
1.4 Structural Proteins 
Coronaviruses express four structural proteins, S, E, M, and N. These proteins 
form part of the virus particle and are essential for the synthesis of infectious 
virions (Sturman et al. 1980, Delmas et al. 1990, Vennema et al. 1996). Most of 
the research on structural proteins are collated from other coronaviruses, and 
although some differences do occur, the primary role of these proteins is 
conserved within the coronavirinae family.  
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1.4.1 Membrane (M) 
The M protein is 25 kDa and the most abundant viral protein (Stern et al. 1982). 
M protein is a type III transmembrane protein that transverses the lipid envelope 
three times and interacts with N through its C-terminal cytoplasmic domain 
(Rottier et al. 1984). The IBV M protein accumulates at the cis-Golgi membrane 
when expressed alone, but accumulates at the ER-GIC during infection due to its 
interaction with N (Klumperman et al. 1994, Narayanan et al. 2000). The M protein 
has also been shown to interact with the S protein during SARS-CoV infection, 
which results in spike retention at the ER-GIC (McBride et al. 2007). Expression 
of IBV M and E alone is enough for the synthesis of VLPs (Corse et al. 2000, 
Corse et al. 2003) 
 
1.4.2 Envelope (E) 
The smallest coronavirus structural protein, E, is 12 kDa and the least abundant 
component of the viral envelope. Most of the protein remains within the cell (Liu 
et al. 1992). The protein transverses the IBV lipid envelope once and has a single 
hydrophobic membrane domain flanked by two hydrophilic domains (Corse et al. 
2000, Ruch et al. 2011). Protein E is a viroporin and forms a cation-selective ion 
channel in lipid bilayers, thought to aid membrane permeability and curvature 
(Wilson et al. 2004, Wilson et al. 2006). During IBV infection, E localises to the 
Golgi membrane due to a signalling motif in the cytoplasmic tail (Corse et al. 2000). 
The coronavirus E protein is thought to play a role in membrane curvature or virion 
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scission as well as virus assembly and egress (Fischer et al. 1997, Fischer et al. 
1998, Raamsman et al. 2000). 
 
1.4.3 Nucleocapsid (N) 
The IBV N protein has a molecular weight of 45 kDa. The N protein contains a 
high ratio of serine residues, which are phosphorylated during infection, and a 
high basic residue content (Lomniczi et al. 1981). The N-terminal domain of N 
binds to and packages nascent full-length genomes into new virions as a helical 
RNP structure and interacts with M through its C-terminal domain (Calvo et al. 
2005, Yu et al. 2006, McBride et al. 2014) (Fan et al. 2005). The N protein also 
interacts with genomic RNA through the leader sequence at the 5′-end and the 
UTR at the 3′-end. As these regions have a role in transcription, N is believed to 
play a role in sgRNA production (Zhou et al. 1996). During infection, IBV N protein 
localises to both the cytoplasm and nucleolus. Due to this distribution, it has been 
suggested that N may play a role in regulating host-cellular translation by 
interfering with ribosome assembly and rRNA synthesis (Tahara et al. 1994, Wurm 
et al. 2001). Furthermore, mass spectrometry analysis of IBV N pull-downs have 
identified a high number of cellular proteins involved in translation and RNA 
modification/processing (Emmott et al. 2013). Lastly, N protein has been shown 
to have a role in viral budding, and immune suppression (Denison et al. 1999, Siu 
et al. 2008, Zhou et al. 2008) (Lu et al. 2011).  
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1.4.4 Spike (S)   
The IBV spike protein is a 180 kDa glycoprotein and protrudes from the virus 
envelope as a homotrimer (Delmas et al. 1990). The coronavirus S protein is a 
type I glycoprotein and the largest viral protein composed of two main domains, 
S1 and S2. The S1 subunit binds to host-cell receptors, including α-2,3-linked 
sialic acid, through its RBD. The spike protein from Beaudette also contains a 
putative heparan sulfate binding domain, and it has been suggested that heparan 
sulfate may be an attachment factor (Madu et al. 2007). The S2 subunit is 
responsible for viral–cell fusion resulting in entry of the RNP (Degroot et al. 1987). 
During infection, the S protein is translated as a single polypeptide and due to a 
signal motif localises to the ER, where it oligomerises (Delmas et al. 1990). The 
IBV S protein is cleaved into two subunits by furin proteases which target a rich 
basic sequence present in between the two domains (Abraham et al. 1990) 
(Luytjes et al. 1987). The protein is further processed at the Golgi where 
oligosaccharides are added (Cavanagh 1983). The coronavirus S protein is the 
primary target for neutralising antibodies and plays a role in cell tropism (Kubo et 
al. 1994, Casais et al. 2003). The Beaudette strain of IBV has broad cell tropism 
and can infect primary and secondary cell lines, while M41-CK can only infect 
primary chicken cells. Replacement of the Beaudette S gene with the S gene from 
M41 restricts cell tropism to primary chicken cells, suggesting the S protein is a 
major determinant of cell tropism (Casais et al. 2003). The extended cell tropism 
of IBV Beaudette has been linked to the presence of the heparan sulfate binding 
site. Vaccination against IBV relies on the induction of neutralising antibodies 
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against the S1 domain, but due to frequent mutations and recombination events 
in this domain, which generates a large number of serotypes, vaccines are rarely 
cross-protective (Britton 2007).   
 
1.5 Non-structural Proteins 
The 5′-end of the IBV genome encodes two large polyproteins pp1a and pp1ab. 
Expression of pp1ab occurs after a -1 frameshift, which occurs in roughly 30% of 
translation events (Brierley et al. 1989). These polyproteins are proteolytically 
cleaved by the virally encoded proteases, nsp3 and nsp5, into 15 nsps. Alpha-, 
beta- and delta- coronaviruses encode 16 nsps, while gammacoronaviruses only 
encode 15 nsps (Ziebuhr et al. 2000, Ma et al. 2015). Gammacoronaviruses do 
not encode nsp1, instead expressing a larger nsp2 due to the lack of a cleavage 
site (Lim et al. 1998). IBV ORF1a encodes nsp 2-11 while ORF1b encodes nsp 
12-16. The function of some IBV nsps have not been confirmed but can be 
inferred by their similarity to other coronaviruses. Their function is summarised in 
Table 2. 
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Table 1.2 Summary of non-structural protein (nsp) functions 
 
 
  
Nsp Activity 
1 Host mRNA degradation, translation inhibition, cell cycle arrest, inhibition of IFN signalling (Kamitani et al. 2006) 
2 Unknown, dispensable for replication in MHV and SARS-CoV (Graham et al. 2005) 
3 Papain-like proteases, polyprotein processing, IFN antagonist, DMV formation (Putics et al. 2005) (Lim et al. 1998, Oostra et al. 2008) 
4 DMV formation (Oostra et al. 2007) 
5 Cysteine-like protease, polyprotein processing (Lu et al. 1996) 
6 DMV formation, induce autophagy (Oostra et al. 2008) (Maier et al. 2013) 
7 Single stranded RNA binding, forms a complex with nsp8 (Velthuis et al. 2012) 
8 Primase (RNA polymerase) (Imbert et al. 2006) (Velthuis et al. 2012) 
9 Replicase complex protein (Egloff et al. 2004, Sutton et al. 2004) 
10 Replicase complex protein (Decroly et al. 2008) (Chen et al. 2011) 
11 Unknown 
12 RNA-dependent RNA polymerase (RdRp) (Imbert et al. 2006)  
13 Helicase, nucleoside triphosphate activity (Ivanov et al. 2004, Ivanov et al. 2004) 
14 3′ – 5′ exonuclease, RNA cap formation, methyltransferase (Chen et al. 2009) 
15 Endonuclease (Bhardwaj et al. 2012) 
16 RNA cap formation (2 'O-methyltransferase) (Decroly et al. 2008) 
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1.6 Accessory proteins from other Coronaviruses 
All coronaviruses encode accessory proteins. These accessory proteins are 
considered non-essential for replication in vitro but may play a role in virulence or 
pathogenicity (Hodgson et al. 2006, Narayanan et al. 2008). Even though 
accessory proteins are present in all coronaviruses, they share little or no 
sequence homology, and no functional information can be derived from their 
genome location or name (Hodgson et al. 2006, Cavanagh et al. 2007, McBride 
et al. 2012, Liu et al. 2014, Fang et al. 2016). Nonetheless, IBV as with other 
coronaviruses will be subject to similar host-cell pressures. For example, several 
coronavirus accessory proteins function as interferon (IFN) antagonists (Liu et al. 
2014). The role of coronavirus accessory proteins is summarised in Table 1.3, 
highlighting the range of roles these proteins have. 
 
1.6.1 Alphacoronaviruses 
The alphacoronavirus genus in the coronavirinae subfamily includes 
transmissible gastroenteritis virus (TGEV), feline and porcine viruses and human 
coronaviruses, NL63 (HCoV-NL63) and 229E (HCoV-229E). Viruses within this 
genus encode two or three accessory proteins between the structural genes, S 
and M. Some viruses within this genus also encode an extra ORF downstream of 
N, known as ORF7. TGEV expresses three known accessory proteins, 3a and 3b, 
encoded between gene S and E, and protein 7 encoded downstream of gene N. 
Deletion of 3a and 3b had a limited effect on replication and cell tropism in vitro 
(Hodgson et al. 2006), while deletion of protein 7 from TGEV resulted in increased 
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cytopathic effect (CPE) and cell death compared to wild-type. Furthermore, 
recombinant viruses lacking ORF7 were more pathogenic and caused earlier 
death in piglets (Cruz et al. 2011). This result suggested that protein 7 is involved 
in host-cell antiviral responses essential to prevent extensive tissue damage. 
Feline infectious peritonitis virus (FIPV) expresses five accessory proteins, 3a, 3b, 
3c, 7a, and 7b. Deletion of ORF3, which encodes 3abc, did not affect viral titres 
in vitro, although it severely restricted pathogenicity and cell tropism in vivo 
(Dedeurwaerder et al. 2013), while ORF7 has been shown to be essential for 
efficient replication in vitro and important for virulence in vivo (Dedeurwaerder et 
al. 2013). Studies have shown that recombinant FIPV lacking ORF7a rendered 
the virus more susceptible to IFN-a treatment. Complementing the virus with 
ORF7a only restored resistance to IFN-a, in the presence of ORF3, suggesting 
ORF7a is dependent on ORF3 for functionality (Annelike Dedeurwaerder 2014). 
Porcine Respiratory coronavirus (PRCoV) ORF3 and ORF7 both play a role in 
virulence (Tung et al. 1992, Paul et al. 1997). HCoV-229E clinical isolates contain 
a single ORF in gene 4, resulting in a single polypeptide. Conversely, lab-adapted 
strains of HCoV-229E contain either a truncation, resulting in a smaller ORF4, or 
two ORFs corresponding to ORF4a and ORF4b. Transcription of ORF4b in these 
lab-adapted strains has not been shown, and no mechanism of ribosome entry 
for ORF4b has been postulated. Protein 4 from clinical isolates is highly 
conserved and has been identified as a viroporin, with deletions of this protein 
causing a reduction in viral titres (Zhang et al. 2014). 
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1.6.2 Betacoronaviruses 
Betacoronaviruses are an important coronavirus genus regarding human health 
and include human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory 
syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome 
coronavirus (MERS-CoV) along with the mouse hepatitis coronavirus (MHV) 
(Table 1.1) (To et al. 2013). These viruses can encode numerous accessory 
proteins with a variety of functions. SARS-CoV encodes eight known accessory 
proteins, 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9 (Narayanan et al. 2008), while MERS-
CoV expresses four accessory proteins, 3, 4a, 4b, and 5, encoded between gene 
S and gene E. SARS-CoV accessory proteins have been studied extensively and 
have been implicated in a wide variety of functions. SARS-CoV 3a is a minor 
structural protein and has been detected in VLPs by electron microscopy (Ito et 
al. 2005). Deletion of ORF3a caused a log reduction in viral titres compared to 
wild-type suggesting that although 3a is non-essential for replication, it may be 
beneficial (Yount et al. 2005). SARS-CoV 3b is also expressed from mRNA3 and 
localises to both the nucleus and mitochondria where it inhibits MAVS signalling 
and IRF3 activation, respectively (Spiegel et al. 2005, Freundt et al. 2009). Protein 
3b has an apoptotic phenotype when expressed alone and further modulates the 
immune response by binding to the transcription factor, Runt Related 
Transcription Factor 1b (RUNX1b) (Khan et al. 2006, Kopecky-Bromberg et al. 
2007). SARS-CoV protein 6 is not required for replication but does play a role in 
virulence (Zhao et al. 2009). GFP-tagged protein 6 was shown to localise to the 
ER and Golgi apparatus (Geng et al. 2005, Pewe et al. 2005). Overexpression of 
Chapter 1: Introduction  The role of IBV accessory proteins 3a, 3b and 4b 
 
 
48 
protein 6 inhibits interferon-beta (IFNβ) expression and prevents signal 
transducer and activator of transcription 1 (STAT1) nuclear translocation in IFN 
treated cells by sequestering the STAT1 nuclear import factor karyopherin alpha 
1 (KPNA1) (Zhao et al. 2009). Deletion of SARS-CoV 7a did not effect in vitro and 
in vivo replication (Pekosz et al. 2006). Overexpression of protein 7a was also 
shown to induce cell-cycle arrest and induce caspase-dependent apoptosis as 
well as inhibit cellular translation (Tan et al. 2004, Kopecky-Bromberg et al. 2006, 
Tan et al. 2007). Protein 7b is also dispensable for viral replication in vitro (Yount 
et al. 2005, Schaecher et al. 2007). Conversely, recombinant virus lacking ORF7b 
resulted in higher titres in vivo suggesting this protein may play a role in 
attenuation (Pfefferle et al. 2009). MERS-CoV encodes four accessory proteins, 
3, 4a, 4b, and 5 encoded between gene S and gene E. Proteins 3 and 5 localise 
to the ER-GIC while proteins 4a and 4b have a diffuse cytoplasmic distribution as 
well as a nuclear localisation. Proteins 4a, 4b, and 5 are all IFN antagonists (Liu 
et al. 2014). Protein 4a binds to dsRNA to prevent detection by MDA-5 and RIG-
I (Niemeyer et al. 2013) and has been shown to inhibit the stress granule pathway, 
increasing cellular translation (Rabouw et al. 2016). MERS-CoV also contains an 
ORF known as 8b in gene N that has not been characterised (van Boheemen et 
al. 2012, Raj et al. 2014). 
 
1.6.3 Gammacoronaviruses 
IBV is the prototype coronavirus within this genus, with TCoV considered a close 
relative (Guy 2000). IBV is known to express four accessory proteins during 
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infection, 3a, 3b, 5a, and 5b (Liu et al. 1991, Casais et al. 2005, Hodgson et al. 
2006). TCoV also expresses these four accessory proteins which all have a high 
sequence identity with IBV (Britton 2007).  
 
1.6.4 Deltacoronaviruses 
Deltacoronaviruses are the most recently described genus within the 
coronavirinae subfamily and as such little is known about this genus of 
coronaviruses, including the function of the accessory proteins. These viruses 
mainly infect wild birds and pigs (Woo et al. 2012). The prototype virus, porcine 
deltacoronavirus (PDCoV), is predicted to express four accessory proteins, ORF6 
located between gene M and gene N, and ORF7, encoding 7a, 7b, and 7c, located 
downstream of N (Woo et al. 2012, Fang et al. 2016). Currently, only accessory 
proteins 6 and 7a have been shown to be translated during infection. Production 
of sgRNA7a is regulated by a non-canonical TRS (Fang et al. 2017).  
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Table 1.3 The role of coronavirinae accessory proteins 
Coronavirus Name Role 
FIPV 
3a, b, c Restricts cell tropism to the intestine (Adam Balint 2014) 
7a, 7b IFN antagonist (dependent on ORF3) (Annelike Dedeurwaerder 2014) 
TGEV 
3a Limited role in virulence and cell tropism (Kim et al. 2000) 
3b Limited role in virulence and cell tropism (Galan et al. 2009) 
7 
Deletion decreases cell death and cytopathic effect.  
Interacts with phosphatase protein 1c (Ortego et al. 2003, Cruz 
et al. 2011) 
HCoV 229E 4a Viroporin (Zhang et al. 2014) 
PRCoV 3a, 3b Unknown 
MERS-CoV 
3 Unknown 
4a IFN antagonist(Siu et al. 2014) Stress granule inhibitor (Rabouw et al. 2016) 
4b IFN antagonist (Yang et al. 2015) 
5 IFN antagonist (Yang et al. 2013) 
8b Unknown 
MHV 
HE Sialate-O-acetylesterase (Siddell et al. 1983) Non-essential structural protein (Lissenberg et al. 2005) 
2a Cleaves 2'-5′-oligoadenylate synthase (OAS) (Zhao et al. 2012) 
4a 
Role in pathogenicity  (de Haan et al. 2002) 
IFN antagonist  
Stress granule inhibitor (Raaben et al. 2007) 
5a IFN antagonist (Koetzner et al. 2010) 
SARS-CoV 
3a Induces cellular membrane rearrangement (Ito et al. 2005) Activates the PERK pathway (Minakshi et al. 2009) 
3b 
IFN antagonist by inhibiting IRF3 activity 
Interacts with activator protein 1 (AP-1)  
Interacts with runt-related transcription factor 1b (RUX1b) 
(McBride et al. 2012) 
6 
IFN antagonist  
Interacts with N-Myc and karyopherin α2  
Essential for replication and present in virions 
Induces cellular DNA synthesis(McBride et al. 2012) 
7a 
Induces apoptosis in a caspase-3 and p38 MAPK dependent 
manner  Interacts with virions (McBride et al. 2012) (Tan et al. 
2007)  
7b Non-essential for replication Role in apoptosis (Schaecher et al. 2007)  
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1.7 IBV Accessory Proteins 
The 3′-end of the coronavirus genome encodes accessory proteins as well as the 
structural proteins. IBV expresses four known accessory proteins during infection, 
3a, 3b, 5a, and 5b. These accessory proteins are dispensable for replication in 
vitro (Britton et al. 2006). Along with these four proteins, IBV also expresses an 
additional transcript referred to as 4b, although the translation of this transcript 
has not yet been demonstrated (Bentley et al. 2013). Coronavirus accessory 
proteins are non-essential for in vitro replication but are usually highly conserved 
and often play a role in regulating IFN expression, cellular translation and 
apoptosis (Table 1.3) (Liu et al. 2014). While coronavirus accessory proteins may 
share similar functions, they have limited sequence homology to one another.  
8a Forms an ion-channel in lipid bilayers (Chen et al. 2011) 
8b Inhibits expression of the E viral protein (McBride et al. 2012) 
9b 
Apoptosis inducer 
Interacts with chromosomal maintenance (CRM1) 
Associated with virions (McBride et al. 2012)  
IBV 
3a,3b 
No role in replication in vitro (Kint et al. 2015) 
Regulates expression of IFNβ (Casais et al. 2005, Hodgson et 
al. 2006) 
5a No role in replication in vitro (Casais et al. 2005, Hodgson et al. 2006) 
5b Host-cell translational shut-off (Kint et al. 2016) 
PDCoV 
6 Detected during infection (Fang et al. 2016) 
ORF7 Potentially encodes three accessory proteins, only 7a has been detected (Woo et al. 2012, Fang et al. 2017) 
Alphacoronavirinae (red), Betacoronavirinae (blue), Gammacoronavirinae (green), Deltacoronavirinae (yellow), 
FIPV (feline infectious peritonitis virus), FCoV (feline coronavirus), TGEV (transmissible gastroenteritis 
coronaviruses), MERS-CoV (Middle East respiratory syndrome coronavirus), MHV (mouse hepatitis virus), 
SARS-CoV (serve acute respiratory syndrome coronavirus), IBV (infectious bronchitis virus), PRCoV (porcine 
respiratory coronavirus), PDCoV (Porcine deltacoronavirus) 
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1.7.1 Gene 3 accessory proteins 
Messenger RNA 3 is polycistronic and encodes three proteins, accessory proteins 
3a and 3b and structural protein E. IBV 3a and 3b have been detected during IBV 
infection in chicken kidney (CK) cells utilising antibodies raised against the 
predicted peptide sequence (Liu et al. 1991). Recombinant IBVs that do not 
express 3a and 3b due to a scrambled start codon grew to similar titres in vitro, 
in ovo, and in ex vivo organ culture, suggesting these proteins are not required 
for in vitro replication (Hodgson et al. 2006).  
 
IBV 3a is a 6 kDa protein and the first protein expressed from mRNA 3. IBV 3a is 
highly conserved among the many different IBV strains, with an 81 – 86.2% 
similarity in polypeptide sequences (Jia et al. 1997). The relatively high degree of 
sequence preservation suggests an important role for this protein. IBV 3a 
contains a signal peptide which directs 3a to the ER membrane, but due to the 
small size of 3a, this signal peptide sequence is not effectively recognised by 
signal recognition particles (Pendleton et al. 2005). This explains the dual 
localisation pattern seen for 3a during infection and transfection in Vero cells, 
which is either membrane-bound at the smooth ER or diffuse in the cytoplasm 
(Pendleton et al. 2005).  This theory is further supported as the extension of 3a 
with a GFP-tag resulted in more membrane-bound 3a, compared to 3a expression 
alone. During infection in Vero cells, membrane-bound 3a has been shown to 
span the membrane once, with the C-terminus exposed to the cytoplasm and the 
N-terminus to the lumen of the smooth ER (Pendleton et al. 2005). IBV 3a has 
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also been shown to closely localise with MxA, which is a small GTPase that has 
antiviral activity (Pendleton et al. 2005, Haller et al. 2011). Protein 3a has also 
been shown to inhibit IFNb mRNA transcription at 24 h.p.i, while also inducing 
IFNb protein expression at 36 h.p.i (Kint et al. 2015). The mode of action of IBV 
3a on IFN expression is unknown.  
 
IBV 3b is a 7.4 kDa protein and the second protein translated from sgRNA 3 via 
leaky ribosomal scanning (Liu et al. 1992). IBV 3b predominantly localises to the 
nucleus in mammalian cells while in avian cells appears predominantly in the 
cytoplasm (Pendleton et al. 2006). Furthermore, IBV 3b turnover is proteasome-
dependent in mammalian cells and proteasome-independent in avian cells. The 
differences seen in avian and mammalian cells highlight the importance of using 
an appropriate cell line for experiments. In addition, the half-life of 3b is short, 
making it very difficult to detect this protein during infection and transient 
expression (Pendleton et al. 2006). A truncated form of 3b has been detected in 
a strain of Beau-CK serially passaged in Vero cells. This truncation was an 
advantageous mutation that conferred higher growth kinetics in vitro and higher 
virulence in ovo (Shen et al. 2003). Interestingly, this truncation changed the 
localisation of 3b from the nucleus to a diffuse cytoplasmic pattern in Vero cells, 
suggesting the C-terminal proportion is responsible for nuclear localisation in 
mammalian cells (Pendleton et al. 2006). There is little understanding of the 
function and mechanism of this small protein, although previous work has shown 
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that 3b plays a role in conferring IBV resistance to IFN expression (Kint et al. 
2015). 
 
1.7.2 Transcript 4b 
Positioned between the gene M and gene 5 is the intergenic region (IR), which 
contains a putative ORF known as 4b. Due to the lack of an upstream TRS, this 
ORF was previously thought to be a pseudogene (Stern et al. 1980). However, 
Bentley et al. (2013) showed by northern blot that a sgRNA is expressed from the 
intergenic region during Beau-R infection, referred to as sgRNA 4b (Bentley et al. 
2013). The presence of sgRNA 4b was also identified in RNA extracted from M41 
infected avian trachea. While other proteins have an upstream canonical TRS 
(CUUAACAA), gene 4b is regulated by a non-canonical TRS (CAA). This non-
canonical TRS resulted in transcription of mRNA 4b at a lower level than expected 
for its genome location. Furthermore, the related coronavirus, TCoV, also 
expresses this previously unidentified 4b transcript. The 4b transcript is not 
required for in vitro replication, suggesting if a protein is translated, it is most likely 
an accessory protein (Bentley et al. 2013). Replacement of ORF4b with GFP did 
result in GFP expression, suggesting that the transcript can act as a mRNA. The 
gene is also present in the Beau-R strain of IBV, although the potential protein is 
truncated to 5 kDa due to a stop codon present in the middle of the ORF (Bentley 
et al. 2013). Whether this transcript is translated during IBV infection is not known, 
nor is the function of this putative protein.  
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1.7.3 Gene 5 accessory proteins 
Messenger RNA 5 is dicistronic and encodes two accessory proteins, 5a and 5b, 
8 kDa and 9 kDa respectively (Liu et al. 1992). These proteins have been detected 
during IBV infection in CK cells using antibodies raised against the predicted 
amino acid sequences (Liu et al. 1992). Recombinant IBV lacking 5a or 5b grew 
to similar titres to wild-type virus in vitro, in ovo and ex vivo organ culture 
suggesting they are non-essential for replication (Casais et al. 2005). Protein 5a 
displays a diffuse pattern throughout the whole cell while 5b displays a more 
perinuclear granular pattern (Davies 2009). Kint et al. (2014) showed that protein 
5b is involved in host translational shut-off. Wild-type Beau-R inhibited cellular 
translation while recombinant IBV lacking 5b expression did not. Translation of 
IBV proteins was not affected, suggesting 5b may target host-cell translation 
specifically. This reduction in host-cell translation can explain, in part, why there 
are high levels of IFNβ mRNA but low levels of IFNβ protein during IBV infection 
(Kint et al. 2016).  
 
1.8 Coronavirus–Host Interaction 
1.8.1 Interferon response to viral infection 
The IFN signalling cascade is a cellular response to infection and is one of the 
first lines of defence against invading pathogens. The innate immune response 
detects ‘non-self’ signals known as pathogen-associated molecular patterns 
(PAMPs). These PAMPs include dsRNA, 5′-C-phosphate-G-3′ (CpG), 
lipopolysaccharides and dsDNA, among others, and are recognised by specific 
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pathogen recognition receptors (PRRs) (Thompson et al. 2011). Detection of 
PAMPs by the cell activates the IFN signalling cascade to induce the expression 
of IFNs, cytokines, and chemokines (Wu et al. 2014). IFN induces the expression 
of IFN stimulated genes (ISGs), which induces an antiviral state in the cell and 
neighbouring cells to prevent further viral replication (Stark et al. 2012).  PRRs 
responsible for the detection of viral PAMPs such as dsRNA include RIG-I-like 
receptors (RLRs), and TOLL-like receptors (TLRs). So far 10 TLRs and 2 RLRs 
have been identified in domestic fowl compared to 11 and 3 in humans, 
respectively (Kannaki et al. 2010). While chickens express the membrane-bound 
PPRs, TLR3 and TLR7, used to detect dsRNA and ssRNA, respectively, chickens 
do not express the cytosolic dsRNA sensing PRR, RIG-I (Zou et al. 2009). 
However, the other dsRNA sensing RLRs in humans, MDA-5 and Laboratory of 
Genetics and Physiology 2 (LGP2) are expressed (Barber et al. 2013). MDA-5 
detects and binds to dsRNA, and subsequently interacts with and activates the 
mitochondrial antiviral signalling protein (MAVS) (Figure 1.5A). MAVS is a 
membrane-bound protein that localises to the mitochondria, mitochondrial-
associated membrane (MAM) structures and peroxisomes (Seth et al. 2005). 
MDA-5 activation induces MAVS aggregation, which then recruits downstream 
signalling proteins including TANK-binding kinase 1 (TBK1), NF-kappa-B 
essential modulator (NEMO) and TNF receptor-associated factor 3 (TRAF3) 
(Figure 1.5B) (Kawai et al. 2005). Mitochondria remodelling results in mitofusion 
and aggregation of signalling proteins, enhancing antiviral signalling (Figure 
1.5C) (Castanier et al. 2010). Phosphorylation of TBK1 leads to the 
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phosphorylation of interferon regulatory factor 3 (IRF3) and 7 (IRF7) (Figure 1.5D, 
E). Phosphorylated IRF3/7 dimerises and translocates to the nucleus where it 
transcribes IFNβ mRNA (Figure 1.5F, G). Chickens express an IRF that closely 
resembles IRF7 but appear to have selectively lost IRF3 (Grant et al. 1995, 
Cormican et al. 2009). After translation, IFNβ is secreted from the cell and binds 
to IFN receptors (IFNAR) on the same cell and neighbouring cells, activating the 
JAK-STAT pathway (Stark et al. 2012). This pathway leads to the dimerisation of 
STAT3 and STAT7 which mediates expression of ISGs. ISGs include a wide 
variety of proteins involved in creating an antiviral state within the cell leading to 
viral suppression along with immunomodulation. Overexpression of IFN can 
induce a hyperimmune state which can be deleterious to the body. For this reason, 
the IFN signalling cascade is highly regulated after activation by controlling levels 
of IFN signalling proteins including MAVS and RIG-I (Lin et al. 2006, Castanier et 
al. 2012, Fuchs 2012, Hu et al. 2016). MAVS, as the gateway protein of the IFN 
signalling cascade, is targeted for degradation in a negative-feedback loop by the 
E3-ligases, Tripartite motif-containing protein 25 (TRIM25), glycoprotein 78 
(gp78), and RING finger protein 5 (RNF5) to prevent further downstream 
signalling. This helps to turn off the IFN signalling cascade after infection (Zhong 
et al. 2010, Castanier et al. 2012, Jacobs et al. 2013). 
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1.8.2 Viruses and the interferon response 
The innate immune response represents a significant barrier to viral replication. 
The selective pressure of the IFN response has created an evolutionary arms 
race, with viruses that inhibit this pathway having an advantage. Many viruses 
Figure 1.5 Schematic diagram of the interferon signalling cascade in chickens.  
(A) Viral dsRNA is detected by MDA-5. (B) MDA-5 is then recruited to MAVS at the 
mitochondria, peroxisome or mitochondrial-associated membrane (MAM) structures. (C) 
Mitochondrial remodelling concentrates IFN signalling proteins. (D) MAVS activation 
leads to aggregation and recruitment of downstream signalling proteins including TBK1, 
NEMO and TRAF3. (E) Phosphorylated TBK1 leads to the dimerisation and 
phosphorylation of IRF7. (F) Activated IRF7 translocates to the nucleus where it 
mediates transcription of IFNβ. (G) Once translated, IFNβ is released from the cell and 
induces antiviral states in the same and neighbouring cells.  
A B 
C 
D E F 
G 
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express proteins that antagonise IFN expression, with the aim to prevent the cell 
inducing an antiviral state. These proteins can target the signalling cascade at 
any point, from the detection of PAMPs to nuclear translocation of IRFs, to the 
expression of IFN. A classic example of this is the multi-functional NS1 protein of 
Influenza A virus (IAV), which shields dsRNA from RLR detection, preventing 
MAVS activation and thus IFN expression (Hatada et al. 1992). Coronavirus 
accessory proteins, nsps and structural proteins have been shown to inhibit IFN 
expression. For example, SARS-CoV N is a potent IFN antagonist and inhibits 
IFN expression by interfering with TRIM25-mediated RIG-I ubiquitination (Hu et 
al. 2017). MERS-CoV proteins M and 4b inhibit IFN expression by inhibiting TBK1 
phosphorylation and MDA-5 dsRNA sensing, respectively (Niemeyer et al. 2013, 
Lui et al. 2016). Nsp3 from SARS-CoV and HCoV-NL63 have been shown to 
antagonise IFN expression independent of its normal protease activity (Clementz 
et al. 2010, Sun et al. 2012). Alpha- and betacoronaviruses nsp1 have been 
shown to induce host translation shut-off, limiting translation of IFN (Kamitani et 
al. 2006) (Tohya et al. 2009) (Huang et al. 2011) (Wang et al. 2010). IBV lacks 
nsp1, but most likely expresses multiple proteins that target the IFN signalling 
cascade. The innate immune response to IBV is important for the pathogenicity 
and outcome of the disease in domestic fowl, with resistant and susceptible 
chicken lines showing a different initial innate immune response (Smith et al. 
2015). Type I interferon response are upregulated in the trachea during IBV 
infection at around 3 days post infection. Increased levels of pro-inflammatory 
cytokines are associated with viral lesions and high viral load (Kameka et al. 2014, 
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Okino et al. 2014). IL-6 is considered a marker for poor outcome, with susceptible 
lines expressing 20 times more IL-6 compared to resistant line (Asif et al. 2007, 
Chhabra et al. 2015). Immunopathology is an important factor in disease progress 
and outcome, with strong innate responses associated with serve symptoms 
(Smith et al. 2015, Okino et al. 2017). The arming of the adaptive immune 
response is crucial for clearance of the virus, with local cell-mediated immune 
(CMI) response mediated by an influx of CD3+, CD8+ and CD4+ cells to the 
trachea at 3 to 7 days post infection (Okino et al. 2014). The IFN response to IBV 
infection has been investigated extensively (Kint 2015). MDA-5 is an essential 
PPR for the recognition of IBV-induced dsRNA and is required for the initiation of 
the IFN signalling cascade (Kint et al. 2015). IFNβ expression is the main IFN 
subtype produced during IBV infection, with interferon-α (IFNα) undetectable (Kint 
2015). IBV fails to induce IFNβ expression until 24 h.p.i, suggesting IBV actively 
inhibits the IFN cascade during early infection. Interestingly, treatment of IBV 
infected cells with poly(I:C) during early infection resulted in a higher IFN 
response, compared to poly(I:C) treatment alone, suggesting that IBV can 
agonise IFN expression once stimulated upstream. IBV accessory proteins 3b 
have been shown to inhibit IFNβ mRNA expression during infection at 24 and 36 
h.p.i. IBV 3a has also been shown to inhibit IFN mRNA transcription but only 
significantly at 24 h.p.i compared to the wild-type. Recombinant IBV lacking 3a 
was also shown to induce higher levels of IFN expression at 36 h.p.i, suggesting 
that 3a can also induce IFN expression and appears to have a dual effect on the 
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IFN cascade. The mechanism of action for 3a and 3b is not known (Kint et al. 
2015).  
 
1.8.3 Stress Granule pathway 
The stress granule (SG) pathway is a cellular response to external and internal 
stimuli that induce cellular stress. The SG pathway is induced to preserve 
resources and energy until a return to cellular homeostasis is achieved (Buchan 
et al. 2009). A range of stimuli can activate the SG pathway including ER stress, 
through the protein kinase R (PKR)-like ER kinase (PERK) pathway, nutrient 
starvation through the General control non-derepressible 2 (GNC2) pathway, and 
heme deficiency and oxidative stress through the Heme-regulated eIF2α kinase 
(HRI) pathway (Beckham et al. 2008, Lian et al. 2009, Narayanaswamy et al. 
2009, Moutaoufik et al. 2014). The SG pathway can also be activated during 
infection to inhibit viral protein translation. During infection, viral dsRNA can be 
detected by protein kinase R (PKR) (Figure 1.6A), which in turn phosphorylates 
the serine residue in eukaryotic inhibition factor 2a (eIF2a) at position 51 (Figure 
1.6B) (Nanduri et al. 2000, Dauber et al. 2009). Compared to the 
unphosphorylated form, the phosphorylated form of eIF2a has a higher affinity for 
the eukaryotic initiation factor 2B (eIF2B). This higher affinity binding to eIF2B 
prevents eIF2a from exchanging GDP for GTP, which is essential for recruitment 
of the initiator methionine transfer RNA (tRNA) (Figure 1.6C). Protein 
phosphatase 1 (PP1) is the primary regulatory protein of eIF2α-induced 
translational arrest and can directly bind to and dephosphorylate eIF2α to return 
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the protein to its active state (Figure 1.6G). Stalled initiation complexes aggregate 
forming large granular structures within the cytoplasm referred to as SGs 
(Kedersha et al. 1999). SGs contain stalled mRNAs, translation initiation factors 
and small ribosomal subunits along with SG regulatory proteins, such as T cell 
intracellular antigen-1 (TIA-1) and TIA-1 related protein (TIAR) (Figure 1.6D). SG 
regulatory proteins play an integral role in SG formation and the shuttling of mRNA 
in and out of SGs (Kedersha et al. 2000). The Ras-GTPase activating protein-
binding protein-1 (G3BP1) is essential for SG formation and is activated during 
cellular stress (Tourriere et al. 2003). SGs are highly dynamic structures that can 
respond quickly to changes in the cellular environment. The precise composition 
of SGs varies depending on the stress stimulus (Kedersha et al. 2005). Viruses 
lack their own translational system and are thus dependent on the host-cell 
machinery for production of viral proteins (Beckham et al. 2008). Stress-induced 
translational shut-off by the host, in theory, prevents translation of both cellular 
and viral proteins, preventing further viral replication. If the infection is not 
resolved mRNA within SGs can be shuttled to processing-bodies (p-bodies) 
where they can be targeted for degradation (Figure 1.6E) (Balagopal et al. 2009).  
If the infection is cleared, SGs can disassemble and translation can be reinitiated 
(Figure 1.6F) (Mollet et al. 2008).  
 
1.8.4 Viruses and the stress granule pathway 
Host triggered translational-shutoff and SGs are a significant barrier to viral 
infection, preventing synthesis of viral proteins required for replication and 
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assembly. For this reason, several viruses express proteins that modulate SG 
formation and eIF2a phosphorylation. Sendai virus inhibits SG formation by 
interacting with TIA-1/TIAR through an AU-rich domain in viral RNA transcripts 
(Iseni et al. 2002). While poliovirus (PV) 3c protease cleaves G3BP1 disrupting 
SG formation (White et al. 2007). Semliki Forest virus (SFV) and Mammalian 
orthoreovirus (MRV) inhibit SG formation in a time-dependent manner, with SGs 
only detectable early in infection (Qin et al. 2009, Qin et al. 2011). Other viruses 
have been shown to target PKR and eIF2α. Indeed, the African swine fever virus 
(ASFV) DP71L protein can bind to and recruit PP1c to eIF2α to induce 
dephosphorylation, while IAV NS1 can bind to dsRNA preventing detection by 
PKR (Bergmann et al. 2000, Zhang et al. 2010). Alternatively, viruses can also 
induce SGs to inhibit cellular protein translation and to facilitate viral replication. 
Respiratory syncytial virus (RSV) replication benefits from the presence of SGs, 
while Newcastle disease virus (NDV) induces SGs to reduce global host-
translation while maintaining viral protein translation by a yet unknown 
mechanism (Sun et al. 2017). 
 
Within the coronavirinae subfamily MERS-CoV, TGEV and MHV have been 
investigated for their ability to manipulate the SG pathway. MERS-CoV accessory 
protein 4a inhibits dsRNA-mediated PKR-dependent SG formation by binding to 
dsRNA directly. Conversely, MHV has been shown to induce eIF2α 
phosphorylation and SG formation (Raaben et al. 2007, Rabouw et al. 2016). SGs 
also appear during TGEV infection with the occurrence of SGs linked to 
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decreased viral replication (Sola et al. 2011). IBV accessory protein 5b has been 
shown to inhibit host-cell translation (Kint et al. 2016). Furthermore, previous work 
has shown that Beau-R infection can induce assembly of SGs, although this was 
independent of 5b (Kint 2015). Simultaneously, Beau-R infected cells could 
strongly inhibit sodium arsenite-induced SG formation, suggesting that while IBV 
infection can induce SGs, the virus also expresses an as yet unknown protein or 
proteins that can also inhibit their formation (Kint 2015). Collectively, this 
highlights the dynamic and responsive nature of mRNA movement between active 
ribosomes, SGs and P-bodies during the IBV life-cycle (Decker et al. 2012).  
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Figure 1.6 Schematic diagram of the stress granule pathway.  
(A) Viral dsRNA is detected by the cytosolic sensor, protein kinase R (PKR). (B) PKR 
mediates phosphorylation of eIF2α (p-eIF2α). (C) When p-eIF2α is recruited to the translation 
initiation complex, translation is inhibited. (D) Multiple stalled initiation complexes aggregate 
with stress granule (SG) regulatory proteins such as G3BP1/TIA-1/TIAR to form an SG. (E) 
If viral infection is cleared, translation can be reinitiated. (F) Alternatively, mRNA can be 
shuttled to processing bodies (p-bodies) where they can be further stored or degraded. (G) 
Phosphatase protein 1c (PP1c) dephosphorylates eIF2α, inhibiting translational arrest.  
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1.8.5 Apoptosis 
Apoptosis or programmed cell death (PCD) is a cellular response to extreme 
stress, wherein cellular homeostasis is no longer viable, and cell death is 
preferable. During viral infection, the cell can induce apoptosis to reduce viral 
progeny release, reducing disease outcome in the host. Apoptosis is regarded as 
the last resort for infected cells, although can be favourable to prevent viral spread 
and to activate other parts of the immune system (Campisi et al. 2014). Apoptosis 
is a highly-regulated system that can be triggered by two main pathways; the 
extrinsic and intrinsic pathways, which are triggered by the activation of the death 
receptor and through mitochondrial damage, respectively (Thorburn 2004). Each 
cascade leads to the cleavage of caspase-3, which results in DNA and protein 
degradation and irreversible apoptosis (Figure 1.7) (Cohen 1997). Although both 
pathways have a role in the immune response to infection, the intrinsic pathway 
is the primary cellular response to viral infection, for which mitochondria play an 
important role (Benedict et al. 2002). Mitochondria are the powerhouse of the cell 
and contain a matrix surrounded by an inner membrane (IM), and an 
intermembrane space surrounded by an outer membrane (OM). Under normal 
conditions, these membranes help to protect the cell from catabolic enzymes 
while also creating an electrical imbalance for adenosine triphosphate (ATP) 
production (Bertram et al. 2006, Kroemer et al. 2007). The integrity of the 
mitochondrial membrane is maintained by a balance of anti-apoptotic and pro-
apoptotic regulatory factors, including members of the B-cell lymphoma 2 (Bcl-2) 
protein family. Viral infection can cause a shift in balance from anti- to pro-
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apoptotic factors through a range of cellular pathways, including Ca2+ release 
from ER stress and dsRNA detection, while production of reactive oxygen species 
(ROS) can directly affect mitochondrial membrane integrity (Figure 1.7A). ROS 
and pro-apoptotic factors lead to mitochondrial membrane permeabilisation 
(MMP) (Figure 1.7B), which causes the release of intermembrane proteins 
including cytochrome C. These factors are released through mitochondrial pores 
composed of Bcl-2-associated X (Bax) and Bcl-2 homologous antagonist killer 
(Bak) proteins, as well as mitochondrial channels such as the Voltage-dependent 
anion channel (VDAC) (Figure 1.7C). Once released into the cytoplasm, 
cytochrome C can recruit apoptosis protease-activating factor 1 (apaf-1) and pro-
caspase 9 to form the apoptosome (Figure 1.7D). This multiprotein complex 
leads to stimulation of the apoptosis cascade resulting in activation of cysteine 
proteases such as caspase 3 and 7.  These proteases induce a range of cellular 
modifications, including membrane blebbing, DNA fragmentation, cellular 
shrinkage and finally cell death. Mitochondria can also release endonuclease G 
(EndoG) and apoptosis-inducing factor (AIF) to induce caspase-independent 
apoptosis (Li et al. 2001, Cande et al. 2004). 
 
1.8.6 Viruses and Apoptosis 
Viruses can express both anti-apoptotic proteins and/or pro-apoptotic proteins. 
Anti-apoptotic proteins increase the length of time that the cell is viable for viral 
replication, while pro-apoptotic proteins can aid viral release and pathogenicity 
(Barber 2001, McLean et al. 2008). Indeed, many oncogenic viruses encode anti-
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apoptotic proteins to establish persistent infections aiding disease progression 
and the formation of tumours (Fuentes-Gonzalez et al. 2013).  Epstein-Barr virus 
(EBV) expresses a viral Bcl-2 homologue, BHRF1, which localises to 
mitochondrial membranes and stabilises membrane integrity by binding to and 
thus inhibiting pro-apoptotic factors (Kvansakul et al. 2010). While apoptosis is a 
cellular response to infection and stress, viruses do not necessarily solely inhibit 
this pathway. Influenza A virus (IAV), protein PB1-F2 and infectious bursal disease 
virus (IBDV) protein VP5 bind to the outer mitochondrial membrane-bound 
proteins VDAC1 and VDAC2, respectively. This induces MMP resulting in 
cytochrome C release and caspase-3 activation (Zamarin et al. 2005, Li et al. 
2012). SARS-CoV accessory protein 7a induces caspase-dependent apoptosis 
by binding to the anti-apoptotic protein B-cell lymphoma extra-large (BcL-XL). 
However, the role of SARS-CoV protein 7a during infection is unknown as deletion 
of 7a does not affect replication or pathogenicity (Tan et al. 2004) (Tan et al. 2007). 
No anti-apoptotic proteins have been identified for coronaviruses to date, 
although SARS-CoV has been shown to activate the anti-apoptotic AKT pathway 
(Mizutani et al. 2004). Caspase-dependent apoptosis has been observed during 
IBV infection in Vero cells. However, inhibition of apoptosis had no significant 
effect on IBV titres suggesting that apoptosis is not required for replication in vitro 
(Liu et al. 2001). Furthermore, IBV-induced apoptosis is, in part, inhibited and 
modulated by the pro-survival IRE1α-XBP1 ER stress pathway, suggesting IBV 
actively induces apoptosis during infection (Fung et al. 2014).  
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Figure 1.7 Schematic diagram of the intrinsic apoptosis pathway.  
(A) Internal stimuli including ER stress, DNA damage or viral pro-apoptotic proteins can 
increase levels of cytosolic Ca2+ and ROS levels or inactivate anti-apoptotic proteins. (B) 
ROS and Ca2+ can permeabilise the mitochondrial membrane directly, while pro-apoptotic 
proteins can form pores. (C) Permeabilisation releases apoptosis effector proteins 
including cytochrome C, AIF and EndoG. (D) Cytochrome C assembles with pro-caspase 
9 and APAF-1 leading to the formation of the apoptosome. (E)  The apoptosome leads to 
activation of pro-caspase 3/7. (F) Caspase 3/7 along with caspase-independent effectors 
(AIF, EndoG) mediate a range of cellular changes including DNA fragmentation and 
membrane blebbing resulting in cellular apoptosis.  
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1.9 Aims 
The aim of this project is to identify any host-cell interaction partners for IBV 
accessory proteins 3a and 3b that may allude to their function and to determine 
the role of ORF4b. A series of objectives were established to accomplish this aim. 
 
Objective 1 
The first objective is to utilise mass spectrometry to determine any cellular 
proteins that interact with IBV 3a and 3b that may allude to function. 
 
Objective 2 
The second objective is to characterise the role of 3a on the IFN response 
utilising IFN assays and mass spectrometry data. 
 
Objective 3 
To determine if ORF4b is translated into a protein during infection by 
optimising an antibody raised against the predicted peptide sequence or 
by using mass spectrometry. 
 
Objective 4 
To determine the role of ORF4b or the putative 4b protein using reverse 
genetics and/or mass spectrometry. 
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2. Materials and Methods 
2.1 Cells and Media 
All cell stocks were maintained by the Central Services Unit (Pirbright) or 
Microbiology Services department (Compton) at The Pirbright Institute and grown 
at 37 °C and 5% CO2.  
 
2.1.1 Baby Hamster Kidney 21 (BHK-21) cells 
Continuous fibroblast cell line derived from the kidneys of five 1-day-old hamsters 
(Meager et al. 1977). BHKs were maintained in Glasgow Minimum Essential 
Media (GMEM) (Table 2.1). 
 
2.1.2 Chicken Kidney (CK) cells 
Primary CK cells were prepared using a combination of manual and trypsin 
disaggregation of kidneys collected from 2-3-week-old specific pathogen free 
(SPF) Rhode Island Red chicks (Oct 14 - Feb 16) or clean VALO chickens (March 
16 – March 17) (Maier et al. 2015). CK cells were grown in CK growth media, and 
experiments performed using 1x N,N-bis[2-hydroxethyl]-2-Aminoethanesulfonic 
acid (BES) (Table 2.2). 
  
2.1.3 DF-1 Cells  
DF-1 cells are a continuous cell line of chicken embryo fibroblasts derived from 
10-day old East Lansing strain eggs (Himly et al. 1998). DF-1 cells were 
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maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% foetal calf 
serum (FCS).  
2.1.4 Human embryonic kidney 293T (HEK-293T) Cells  
A continuous cell line of human embryonic kidney cells stably expressing the 
SV40 large T-antigen (Shaw et al. 2002). HEK-293Ts were grown and maintained 
in DMEM with 10% FCS.  
 
2.1.5 Vero cells  
A continuous kidney epithelial cell line derived from the African Green monkey 
(Chlorocebus spp.) (Yasumura 1963). Vero cells were maintained in Eagle's 
Minimum Essential Medium (EMEM) with 10% FCS.  
 
2.1.6 Cell Media 
Table 2.1 GMEM for BHK-21 cell culture 
Reagent Final Concentration 
GMEM 1x 
FCS (Sigma) 1% v/v 
Tryptose Phosphate Broth (TPB) 0.29% v/v 
Nystatin (Sigma) 250,000 U/L 
Penicillin/Streptomycin (Sigma) 100,000 U/L 
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Table 2.2 1x CK cell maintenance media (1x BES) 
Reagent Final Concentration 
10X EMEM (Sigma) 1x 
TPB 10% v/v 
Bovine serum albumen (BSA) (Sigma) 1% v/v 
N,N-bis[2-hydroxethyl]-2-
Aminoethanesulfonic acid (BES) 
(Sigma) 
20 mM 
Sodium bicarbonate  0.2% w/v 
L-glutamine (Gibco) 2 mM 
Nystatin (Sigma) 250,000 U/L 
Penicillin and streptomycin (Sigma) 100,000 U/L 
 
Table 2.3 CK cell maintenance media (2x BES) for IBV plaque assays 
Reagent Final Concentration 
10x EMEM 2x 
TPB 20% v/v 
BSA (Sigma) 2% v/v 
BES 40 mM 
Sodium bicarbonate 0.4% w/v 
L-glutamine (Gibco) 4 mM 
Penicillin/Streptomycin (Sigma) 200,000 U/L  
Nystatin (Sigma) 500,000 U/L 
 
Chapter 2: Materials and Methods   The role of IBV accessory protein 3a, 3b and 4b 
74 
 
2.2 Virological methods 
2.2.1 Viruses 
IBV Beau-R: A molecular clone of the IBV strain, Beaudette-CK (Beau-CK). 
Beau-CK has been serially passaged in embryonated eggs to adapt the virus to 
grow in CK, BHK-21, DF-1 and Vero cells. Beau-R is apathogenic in domestic 
fowl (Casais et al. 2001).  
 
M41-CK: A pathogenic strain of IBV that has been adapted to grow in CK cells. 
M41-CK is unable to grow in BHK-21, DF-1 or Vero cells.  
 
M41-K/M41-R: Molecular clones of M41-CK. M41-K is pathogenic, while M41-R 
is non-pathogenic.  
 
BeauR-Sc3aAUG: Beau-R with the 3a AUG start codon scrambled (ATG>AAC) 
(Hodgson et al. 2006).This virus is unable to express IBV 3a.  
 
BeauR-Sc3bAUG: Beau-R with the 3b AUG start codon scrambled (ATG>AAC). 
This virus is unable to express IBV 3b.  
 
M41K-del4b: M41-K with ORF4b deleted. The non-canonical TRS is still present, 
so a shorter sgRNA is expressed that does not contain ORF4b. This virus was 
designed and generated by Sarah Keep.  
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M41K-BeauR(S): M41-K virus containing the S gene from Beau-R instead of 
M41-K. This virus can grow in Vero cells, unlike M41-K due to extended host 
range of Beau-R spike.  
 
BeauR (M41R-IR): Recombinant IBV based on Beau-R with the intergenic region 
(IR) from the M41-K strain of IBV. The IR is the region in-between gene M and 
gene 5 and contains ORF4b. 
 
2.2.2 IBV titration 
Plaque assays were performed in CK cells in a 12-well plate (70-80% confluence). 
Virus samples were serially diluted in 1x BES by a factor of 10, up to 10-7. Three 
wells were inoculated for each dilution. Cells were washed twice with Phosphate 
Buffered Saline a (PBSa) and 250 µl of inoculum added to the cells. Cells were 
incubated at 37 °C and 5% CO₂ for 1 hour. Viral inoculum was then removed and 
2 ml of 1% agar,1x BES was added to each well. Cells were incubated for three 
days at 37 °C and 5% CO₂. To fix the cells, 10% paraformaldehyde (PFA) in PBSa 
was overlaid onto to the agar and incubated for 15 minutes. Agar was removed 
from each well and cells stained with 0.1% crystal violet (w/v) for 10 minutes. 
Single defined plaques were counted for the lowest serial dilution and averaged 
from three wells. The number of plaques is expressed as viral plaque forming 
units (PFU) per ml of viral inoculum. 
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2.2.3 Growth curves 
The M41K-del4b growth curve virus was completed by Sarah Keep, as part of the 
quality control for synthesis of recombinant IBV. CK cells were seeded in a 12-
well plate (70-80% confluency) and infected at an MOI of 0.1, diluted in 1x BES. 
After 1 hour at 37 °C, the inoculum was removed and fresh 1x BES added. The 
cell media was harvested at 1, 24, 48, 72 and 96 h.p.i. Viral titre was calculated 
by CK plaque assay (2.2.2). Growth titres were averaged from three biological 
replicates.  
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2.3 Reagents 
2.3.1 Expression vectors 
Expression vectors were either cloned or a gift and were used in western blotting 
and/or immunofluorescence experiments (Table 2.4). Construction of vectors is 
described in 2.4 below and confirmed by Sanger sequencing (Source Bioscience) 
(Table 2.17). 
 
Table 2.4 List of plasmids used for immunofluorescence, western blot and mass 
spectrometry. 
Plasmid Expression Tag/ reporter Source 
pEGFPC2-3aB Beau 3a  GFP N-terminal Cloned 
pEGFPN1-3aB Beau 3a GFP C-terminal Cloned 
pEGFPC2-3aM M41 3a  GFP N-terminal Cloned 
pEGFPN1-3aM M41 3a GFP C-terminal Cloned 
pEGFPC2-3bB Beau 3b GFP N-terminal Cloned 
pEGFPN1-3bB Beau 3b GFP C-terminal Cloned 
pEGFPC2-3bM M41 3b GFP N-terminal Cloned 
pEGFPN1-3bM M41 3b GFP C-terminal Cloned 
pEGFPC2-4bB Beau 4b GFP N-terminal Cloned 
pEGFPC2-4bM M41 4b GFP N-terminal Cloned 
pEGFPN1-4bM M41 4b GFP C-terminal Cloned 
pFLAG-CMV2-
3aB Beau 3a FLAG N-terminal  
Mark Davis 
(Davies 2009) 
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Plasmid Expression Tag/ reporter Source 
pCAGGS-NS1 IAV NS1 N/A Gift from Joe James 
peIF-V5-chIRF7 chIRF7-V5 V5 N-terminal Gift from Steve Goodbourne 
pRL-CMV vector Renilla N/A 
Promega, gift 
from Jess 
Purcell 
pEF1a-FLAG-
chMAVS chMAVS-FLAG FLAG  
Gift from Steve 
Goodbourne 
pLUC-chIFNβ-
promoter 
chIFNβ promoter - 
luciferase 
Luciferase C-
terminal 
Gift from Steve 
Goodbourne 
 
2.3.2 Antibodies 
Antibodies were used for labelling of cellular or viral targets for western blotting 
and/or immunofluorescence (Table 2.5). Antibodies were diluted in blocking 
buffer at the specified concentration. 
 
Table 2.5 Primary antibodies used for immunofluorescence and western blot.  
Antibody Target Application Dilution Source 
Anti-dsRNA (J2) dsRNA IF 1:1000 Scicons 
Anti-3a (JH3480) IBV 3a IF/WB 1:1000/1:5,000 
Gift from 
Carolyn 
Machamer 
(Pendleton et 
al. 2005) 
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Antibody Target Application Dilution Source 
Anti-N (48.8) IBV N IF/WB 1:500/1:1000 Acris Antibodies 
Anti-4b 4b (M41) IF/WB 1:50/1:100 
Cambridge 
Research 
Biochemicals 
Anti-GFP GFP   Santa Cruz 
Anti-V5 V5 Tag IF/WB 1:200/1:500 Santa Cruz 
Anti-FLAG (M2) FLAG tag IF/WB 1:500/1:1000 Sigma 
Anti-MDA5 huMDA5 WB 1:200 Sigma 
Anti-MAVS (E-3) huMAVS IF/WB 1:200 Santa Cruz 
Anti-IRF3 (C-20) huIRF3 IF/WB 1:500 Santa Cruz 
Anti-IRF7 (C-20) huIRF7 IF/WB 1:500 Santa Cruz  
Anti-CANDI (48) CANDI IF/WB 1:1000 Santa Cruz 
Anti-RNF5 (G-15) RNF5 IF 1:100 Santa Cruz 
Anti-RPS25 (C-
16) RPS25 IF/WB 1:250 Santa Cruz 
Anti-G3BP1 
(611126) G3BP1 IF 1:500 Invitrogen 
Anti-G3BP1 G3BP1 IF 1:200 Abcam 
Anti-eIF2a P-eIF2a WB 1:500 GeneTex 
Anti-LAP2 (Y-20)  LAP2 IF 1:200 Santa Cruz  
Anti-β-Actin β-Actin IF/WB 1:10,000 Cell Signalling technology 
Anti-FNDC3a FNDC3a IF 1:200 Santa Cruz 
Anti-SUCGL2 SUCGL2 IF 1:200 Santa Cruz 
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IBV specific antibodies (blue), epitope tag antibodies (red), interferon-related antibodies (green), 
translation-related antibodies (purple), miscellaneous (grey). Clone number for monoclonal 
antibodies are noted in parentheses. 
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2.4 Cloning  
2.4.1 Primers and DNA fragments 
Primers (Sigma) were designed to amplify specific IBV cDNA sequences (Table 
2.6). DNA fragments were designed and ordered from GeneArt (Invitrogen).  
 
Table 2.6 Primers and DNA fragments for accessory protein expression plasmids.  
Primers/DNA 
fragments Direction Sequence (5′ – 3′) 
Restriction 
Site (Bold) 
GFP-3aB 
FWD CATGAAGCTTGATGATCCAAAGTCCCACGTCC HindIII 
REV GTACCCGCGGTTAGTCTAGACTGTGCCAAAGGG  SacII 
GFP-3aM 
FWD CATGAAGCTTGATGATTCAAAGTCCCACGTCC HindIII 
REV GTACCCGCGGTTAGTCTAGACTGTGACAAAGGGTCAG SacII 
GFP-3bB 
FWD CATGAAGCTTGATGTTAAACTTAGAAGTAATTATTGAAACTGG HindIII 
REV GTACCCGCGGTTATTCAATAAATTCATCATCACCTG  SacII 
GFP-3bM 
FWD CATGAAGCTTGATGTTAAACTTAGAAGCAATTATTGAAACTGG HindIII 
REV GTACCCGCGGTTATTCAATAAATTCATCATCACCTG SacII 
GFP-4bM 
FWD CATGAAGCTTGATGTGTGTGTGTAGAGAGTATTTAAAATTATTC HindIII 
REV GTACCCGCGGTTAATCTTTTTTATAACTCAACCACAACC SacII 
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Primers/DNA 
fragments Direction Sequence (5′ – 3′) 
Restriction 
Site (Bold) 
4bB-C2 Fragment 
CATGAAGCTTATGTGTGTGTGTAGAGA
GTATTTAAAATTATTCTTTAATAGCGC
CTCTGTTTTAAGAGCGCATAAGAGTAT
TTATTTTGAGGATACTAATATAAATCC
TCTTTGTTTTATACTCTCCTTTCAAGA
GCTATTAACGGTGTTACCTTTCAAGTA
AGGATCCCATG 
HindIII / 
BamHI 
3aB-GFP 
FWD CATGAAGCTTACCATGATCCAAAGTCCCACGTCC HindIII 
REV GTACCCGCGGGTCTAGACTGTGCCAAAGGG  SacII 
3aM-GFP 
FWD CATGAAGCTTACCATGATTCAAAGTCCCACGTCC HindIII 
REV GTACCCGCGGGTCTAGACTGTGACAAAGGGTCAG SacII 
3bB-GFP 
FWD CATGAAGCTTACCATGTTAAACTTAGAAGTAATTATTGAAACTGG HindIII 
REV GTACCCGCGGTTCAATAAATTCATCATCACCTG SacII 
3bM-GFP 
FWD CATGAAGCTTACCATGTTAAACTTAGAAGCAATTATTGAAACTGG HindIII 
REV GTACCCGCGGTTCAATAAATTCATCATCACCTG SacII 
4bM-GFP 
FWD CATGAAGCTTACCATGTGTGTGTGTAGAGAGTATTTAAAATTATTC HindIII 
REV GTACCCGCGGATCTTTTTTATAACTCAACCACAACC SacII 
Start codon (green), Stop codon (red), Kozak sequence (purple). 
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2.4.2 Reverse transcription 
Cellular and viral RNA was isolated from the supernatant of infected cells using 
RNA clean-up protocol from the RNeasy Mini Kit (Qiagen). RNA was first 
incubated with random primer for 5 minutes at 65 °C (Table 2.7). Superscript III 
reverse transcriptase (Life Technologies) was then added to the reaction mix 
(Table 2.8) to reverse transcribe total RNA into cDNA as per the manufacturer’s 
instructions (Table 2.9). 
 
Table 2.7 Reagent mix for first strand cDNA synthesis (I) 
Reagent Volume (μl) 
Random Primer (10 μm) 1 
dNTPs (10 μm) 1 
RNA 5 
Water 6 
 
Table 2.8 Reagent mix for first strand cDNA synthesis (II) 
Reagent Volume (μl) 
First Strand Buffer (Invitrogen) 4 
Dithiothreitol (DTT) (0.1 M) 1 
RNase Out (Life Technologies) 1 
Superscript III reverse transcriptase 
(Life Technologies) 1 
Water 10 
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Table 2.9 Reverse transcription thermal cycle 
Temperature Time 
25 °C 10 minutes 
50 °C  1 hour 
70 °C  
 15 minutes 
2.4.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify specific DNA sequences 
in IBV or vaccinia virus (VV) cDNA. PCR was performed using Q5 (NEB) high-
fidelity DNA polymerase (Table 2.10), using a thermal cycler (Applied Biosciences 
2720) and cycle program per the manufacturer’s instructions (Table 2.11). 
 
Table 2.10 Reagent concentrations for PCR 
Reagent Final concentration (50 μl Reaction volume) 
Q5 Buffer (5x) (NEB) 1x 
dNTPs (10 mM) 200 μM 
Primers (Forward and back) 25 μM 
Q5 Taq (NEB) 0.02 U/μl 
cDNA 5 μl 
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Table 2.11 PCR thermal cycle 
Cycles Temperature Time 
1 95 °C 2 minutes 
25 
95 °C 30 seconds 
Highest primer Tm -5 °C 30 seconds 
72 °C 1 minute/kb of template length 
1 72 °C 10 minutes 
 
2.4.4 Site-directed mutagenesis 
Site-directed mutagenesis (SDM) was performed using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent) as per the manufacturer’s instructions. Primers 
for SDM were 25-40 nucleotides in length and designed to have a high GC content 
(>40%) and melting temperature (Tm) (>78 °C).  
 
Table 2.12 Reagent concentrations for SDM 
Reagent Final Concentration (Reaction volume 50 μl) 
SDM reaction buffer (Aligent) 1x 
dNTPs (Aligent) 10 mM 
Primers (Forward and Reverse) 25 μM 
Pfu Turbo (Agilent) 2.5 units 
Vector  10 ng 
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Table 2.13 SDM thermal cycle 
Cycles Temperature Time 
1 95 °C 1 minute 
16 
95 °C 50 seconds 
60 °C 50 seconds 
68 °C 1 minute/kb of template length 
1 68 °C 7 minutes 
 
The sizes of the PCR products were confirmed by gel electrophoresis (0.6% 
agarose gel). Once confirmed the PCR products were digested with 2 μl of DpnI 
(10 U) to digest methyl groups that will only be present on parent plasmid. 
 
2.4.5 Agarose gel electrophoresis 
DNA was separated and visualised using gel electrophoresis. Each gel contained 
0.8-1% agarose dissolved in 1x Tris-borate EDTA (TBE) buffer (Invitrogen) or 1x 
Tris-acetic acid EDTA (TAE) buffer (Invitrogen) with 1x SYBR Safe 
(ThermoFisher). DNA loading buffer (Table 2.14) was added to each sample and 
loaded into a well. A 1 kb+ DNA ladder (Invitrogen) was added to a separate well 
to determine DNA size. The gel was submerged in TBE or TAE buffer, respectively, 
and a 150V current applied for 1 hour or until effective separation was seen. DNA 
was visualised by exposing the gel to 260 nm UV light.   
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Table 2.14 Recipe for DNA loading buffer 
Reagent Final concentration 
Glycerol 60% v/v 
Ficoll 400 25 µM 
Bromophenol blue 15 mM 
 
2.4.6 Restriction digest 
Restriction digests were performed at 37 °C for 1 hour in the appropriate digestion 
buffer as per NEB instructions (NEB Double Digest Finder). For incompatible 
restriction enzymes, reactions were purified using the Nucleotide Removal Kit 
(Qiagen) and protocol in-between digests. Enzymes were deactivated by heating 
to 50 °C for 10 minutes before ligation and transformation. 
 
2.4.7 Gel extraction/ PCR purification 
PCR products and digested DNA fragments were purified and cleaned using the 
QIAquick PCR Purification Kit (Qiagen). PCR products were diluted in 30 μl of 
water and quantity calculated using the Nanodrop 1000. For purification of DNA 
fragments from digested plasmids, DNA was first separated by gel 
electrophoresis in a 0.8% TAE gel with 4 μl of SYBR Safe (ThermoFisher). DNA 
was extracted from exercised gel segments using the QIAquick Gel Extraction Kit 
(Qiagen) and protocol. DNA was reconstituted in 20 μl of RNase-free water and 
quantified using the Nanodrop 1000.  
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2.4.8 PCR purification 
Plasmid DNA was purified using the PCR purification kit and protocol (QIAGEN) 
as per the manufacturer’s instructions and eluted in 30 µl of RNase-free water.  
 
2.4.9 DNA dephosphorylation 
Digested plasmid was dephosphorylated before ligation to prevent self-ligation 
using shrimp alkaline phosphatase (Promega), per the manufacturer’s 
instructions.  
 
2.4.10 Ligation 
T4 ligase (NEB) was used for ligation per the manufacturer’s instructions (Table 
2.15). An insert: vector molar ratio of 3:1 was used, and the reaction was 
performed at either room temperature for 3 hours or overnight at 4 °C.  
 
Table 2.15 Reagent mix for ligation 
Reagent Volume 
T4 DNA ligase (NEB) 1 µl 
10x DNA ligase buffer (NEB) 2 µl 
Vector DNA 50 ng 
Insert DNA 3:1 Vector: insert ratio 
Nuclease-free water  To final 20 µl volume 
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2.4.11 Transformation 
Plasmids were transformed into DH5α-T1R library competent E. coli (NEB). After 
ligation, 5 μl of the sample was added to 50 μl of competent cells and incubated 
on ice for 30 minutes. The cells were then heat-shocked at 42 °C for 30 seconds 
before incubating on ice for 2 minutes. SOC media (Invitrogen) (350 μl) was 
added to the competent cells and incubated at 37 °C for 1 hour in a shaking 
incubator. After 1 hour, 350 μl of the transformation mix was plated onto Lysogeny 
broth-agar (LB-agar) plates containing ampicillin (100 µg/ml) or kanamycin (50 
µg/ml). The plates were incubated for 16 hours at 37 °C. 
 
Table 2.16 Reagent concentrations for Lysogeny broth 
Component Final concentration 
Bacto tryptone 1% w/v 
Yeast extract 0.5% w/v 
NaCl 170 mM 
 
2.4.12 DNA miniprep 
Colonies were picked from LB-agar plates and placed in 5 ml of LB containing 
either ampicillin (100 µg/ml) or kanamycin (50 µg/ml). Cultures were incubated at 
37 °C on a shaker overnight. Bacterial cultures were placed in a 15 ml falcon and 
centrifuged at 1,000 × g for 5 minutes to pellet the bacteria. Plasmids were then 
purified using the Plasmid Miniprep Kit (Qiagen) and protocol. Plasmids were 
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eluted in 50 μl of sterile RNase-free water. Plasmids were then sequenced by 
Sanger sequencing.  
 
2.4.13 DNA maxiprep 
Colonies were picked and grown in 2 ml of LB containing ampicillin (100 µg/ml) 
or kanamycin (50 µg/ml) for 8 hours. After which, 1 ml was then transferred to 100 
ml of LB containing either ampicillin (100 µg/ml) or kanamycin (50 µg/ml) and 
incubated overnight on a shaker at 37 °C. Plasmids were then extracted and 
purified using the Plasmid DNA Maxiprep Kit (Qiagen) and protocol. Plasmids 
were reconstituted in 50 μl of RNase-free water. DNA concentration was 
determined using the NanoDrop 1000. 
 
2.4.14 Sequencing 
Plasmids were sent to Source Bioscience for sequencing by Sanger sequencing. 
Primers for sequencing of plasmids were provided by Source Bioscience. For 
sequencing of IBV specific sequences, primers were designed and ordered from 
Sigma. The sequences of primers are below (Table 2.17).  
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Table 2.17 Primers used for sequencing of expression vectors and IBV cDNA 
Primer Sequence (5ʹ- 3ʹ) Sequencing Region  Direction 
EGFP_C_FWD CATGGTCCTGCTGGAGTTCGTG pEGFPC2 MCS  FWD 
EGFP_C_REV GTTCAGGGGGAGGTGTG pEGFPC2 MCS  REV 
EGFP_N_REV CGTCGCCGTCCAGCTCGACCAG pEGFPN1 MCS  REV 
pEF1a_FWD ATTTGCCCTTTTTGAGTTTGG pEF1a MCS FWD 
CMVF_pCDNA3 CAACGGGACTTTCCAAAATG pcDNA6.1 MCS  FWD 
M42 CACCAACAACAACACCTAG M41 ORF3ab  FWD 
M43 CTTCCATTTTCCTCTAGCG M41 ORF3ab REV 
M46 GCATCCAAGTTATGAGGATTG M41 ORF4b FWD 
M47 GTTAGCGGGCTGGTCCTGTTCC M41 ORF4b REV 
BG-69 CGAAAACGGTGATAATAGAAG Beau-R ORF3ab FWD 
BG-142 AGGGATCAAATACTTCTGTG Beau-R ORF3ab REV 
BG-56 GTTGTCGGCGGGTTTCTTC IBV 3′-end FWD FWD 
93/100 GCTCTAACTCTATACTAGCCT IBV 3′-end FWD REV 
FWD – Forward primer, REV – Reverse primer, MCS – multiple cloning site, Source Bioscience 
primers (blue), in-house designed primers (red) 
Chapter 2: Materials and Methods   The role of IBV accessory protein 3a, 3b and 4b 
92 
 
2.5 Transfection 
DF-1 or Vero cells were seeded on coverslips in a 24-well plate, 12-well plate or 
6- well plate (70-80% confluence). Cells were washed once with PBSa and fresh 
growth media added to each well. Cells were transfected with expression vectors 
(Table 2.4), using Lipofectamine 2000 (Invitrogen) at a ratio of 1:3 DNA (μg) to 
lipofectamine (μl) and per the manufacturer’s instructions. After 16-24 hours at 
37 °C, the cells were washed twice with cold PBSa before processing.  
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2.6 Western blotting 
2.6.1 Proteasome inhibitor 
To inhibit the cellular proteasome during infection, 5 – 20 μm of MG132 (Sigma) 
dissolved in DMSO was added to cell media, 6 – 12 hours before harvesting. 
DMSO alone was added in equal volumes as a control. To inhibit the proteasome 
during transfection, media was removed and fresh media containing 5 – 20 μm 
MG132 was added to each well 4 – 8 hours before lysing cells. Mock transfected 
cells were replenished with fresh media containing DMSO. 
 
2.6.2 Cell lysis 
Cells were washed once with cold PBSa before being lysed with cold RIPA lysis 
buffer (Table 2.18) with 1x protease inhibitor cocktail (PIC) (ThermoFisher) added 
immediately before use. Lysis buffer containing phosphatase inhibitor cocktail 
(Sigma) was added for analysis of anti-eIF2a(P) levels. Cells were either 
harvested by adding 100 μl lysis buffer directly to the well or cell were scraped 
into cold PBSa and pelleted at 10,000 x g for 2 minutes before lysis. Cells were 
incubated in lysis buffer on ice for 20 minutes with regular agitation, centrifuged 
at 14,000 x g to pellet debris and lysates stored at -20 °C. 
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Table 2.18 Reagent composition of RIPA lysis buffer 
Reagent Final concentration  
Sodium chloride (NaCl) 5 M 
Trisaminomethane hydrochloric acid 
(Tris-HCl) buffer (pH 7.4) 1 M 
Igepal 5% v/v 
Sodium deoxycholate (C24H39NaO4) 5% w/v 
Sodium orthovanadate (Na3VO4) 1 M 
Sodium fluoride (NaF) 1 M 
PIC (added immediately before use) 1x 
 
2.6.3 SDS-PAGE 
Cell lysates were denatured using 1x Laemmli Sample Buffer (BIO-RAD) 
containing 5% Beta-mercaptoethanol and heating at 80 °C for 10 minutes. 
Samples were then loaded onto a Mini-PROTEAN TGX 4% - 20% gradient 
Precast gel (BIO-RAD) with Tris/Glycine SDS running buffer (Table 2.19). The gel 
was electrophoresed at 150V for 50 minutes. 
 
Table 2.19 SDS Running Buffer 
Reagent Final Concentration 
Glycine 1.92 M 
Tris-HCl buffer (pH 7.4) 247 mM  
SDS 34 mM 
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2.6.4 Western Blotting 
Protein samples were transferred onto a 0.2 µm nitrocellulose membrane (BIO-
RAD) using the Trans-Blot Turbo System (BIO-RAD) and 1x Trans-Blot turbo 
transfer buffer (BIO-RAD). Membranes were blocked for 1 hour at room 
temperature or overnight at 4 °C in either 5% milk powder (w/v) (Marvel) or 2% 
fish gelatine (w/v) (Sigma), both diluted in 0.1% Tween in PBSa (PBS-T). 
Membranes were labelled with primary antibodies (Table 2.5) diluted in either 5% 
milk powder or 2% fish gelatine blocking solution for 1 hour and then washed 
three times for 15 minutes in PBS-T. Secondary fluorescent IRDye antibodies (LI-
COR) were added at a concentration of 1:10,000, diluted in PBS-T for 1 hour in 
the dark. Membranes were washed three times with PBS-T for 15 minutes and 
then washed once with sterile water. Membranes were visualised and quantified 
using the Odyssey Clx Imaging System and Image Studio software (LI-COR). The 
fluorescence of the protein of interest was normalised against actin or a viral 
protein, giving semi-quantification of protein levels. 
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2.7 Indirect Immunofluorescence 
2.7.1 Fixation 
DF-1 or Vero cells were seeded on glass coverslips in a 24-well plate (70-80% 
confluency). Cells were inoculated with 125 µl of IBV or transfected with 0.5 - 2 
µg of an expression vector. Cells were washed once with PBSa and then fixed for 
20 minutes with 0.5 ml of 4% paraformaldehyde (PFA) in PBSa. For staining 
mitochondria, cells were incubated with MitoTracker Red CMXRos 
(ThermoFisher) at a final concentration of 400 nM in media for 30 minutes before 
fixing.  
 
2.7.2 Labelling 
For intracellular labelling, cells were permeabilised with 0.1% Triton X-100 
(Sigma) in PBSa for 10 minutes. After permeabilisation, cells were washed twice 
with PBSa and blocked for 1 hour using 0.5% BSA in PBSa on a shaker at 4 °C. 
Subsequently, cells were incubated with primary antibody (Table 2.5) for 1 hour, 
diluted to a working concentration in 0.5% BSA in PBSa. For labelling of IBV 4b, 
cells were incubated with anti-4b overnight at 4 °C. Cells were then washed three 
times for 5 minutes with PBSa. Alexa Fluor secondary antibodies (Invitrogen) 
were diluted in 0.5% BSA in PBSa to 1:500 and cells incubated in the dark for 1 
hour on a shaker. Cells were washed three times for 5 minutes with PBSa. The 
nuclei of the cells were labelled with DAPI (4',6-diamidino-2-phenylindole) 
(1:20,000) or TO-PRO-3 iodide (1:10,000) (ThermoFisher) diluted in sterile water 
or PBSa respectively. Cells were washed once with sterile water for 5 minutes 
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then mounted upside down onto glass microscope slides with Vectashield 
Antifade Mounting Media (Vector Laboratories) and sealed with nail varnish. Cells 
were visualised and imaged using a Leica SP5 confocal microscope. 
 
2.7.3 Image Analysis 
Fluorescence signal was measured using the ImageJ software and Coloc2 plug-
in. A region of interest was selected and levels of each fluorescence signal 
quantified. Colocalisation of the signal was also calculated using the Coloc2 plug-
in. A region of interest was selected and percentage of the fluorescent signal that 
colocalises with a secondary signal calculated. In total, colocalisation was 
measured in 20 randomly selected cells, and average percentage determined.  
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2.8 Immunoprecipitation 
2.8.1 Cell lysis 
Cells were infected or transfected as described in 2.5 above. Cells were washed 
once with cold PBSa and then harvested in 1 ml of cold PBSa and centrifuged at 
2,500 x g for 2 minutes. Pierce lysis buffer (25 μl/cm2) (Table 2.20) with 1x 
Protease Inhibitor Cocktail (PIC) was added directly to the cells and placed on ice 
on a shaker for 20 minutes with extensive pipetting every 5 minutes. For lysis of 
cells for dsRNA immunoprecipitation, RIP RNA lysis buffer (25 μl /cm3) (Table 
2.21) was used with fresh 1x PIC and RNase (Invitrogen) added. 
 
Table 2.20 Reagent composition of Pierce lysis buffer 
Reagent Final concentration 
Tris-HCL buffer (pH 7.4) 25 mM 
NaCl 150 mM 
EDTA 1 mM 
Igepal 1% v/v 
Glycerol 5% v/v 
PIC (added immediately prior to use) 1x 
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Table 2.21 Reagent composition of RNA RIPA buffer 
Reagent Final concentration  
NaCl 100 mM 
Tris-HCl (pH 7.4) 10 mM 
EDTA 1 mM 
Igepal 0.5% v/v 
PIC (added immediately prior to use) 1x 
RNaseI (added immediately prior to 
use) 100 units/ml 
 
2.8.2 Immunoprecipitation (IBV 4b) 
Cell lysates were incubated with 10 µl of anti-4b overnight at 4 °C with regular 
agitation. Samples were incubated for 4 hours with 50 µl of Protein G Dynabeads 
(ThermoFisher). Dynabeads were separated using a magnetic separator and 
supernatant discarded. Beads were washed three times with IP wash buffer 
(Table 2.22). Protein-antibody complexes were eluted using 50 µl of 200 mM 
glycine (pH 2.5).   
 
Table 2.22 Reagent composition of IP wash buffer 
Reagent Final Concentration 
Tris-HCl (pH 7.4) 10 mM 
NaCl 150 mM 
EDTA 0.5 mM 
 
Chapter 2: Materials and Methods   The role of IBV accessory protein 3a, 3b and 4b 
100 
 
2.9 Reverse genetics system 
2.9.1 pGPT vectors 
Plasmids (pGPT) containing the desired IBV mutation with a xanthine-guanine 
phosphoribosyltransferase (gpt) gene from E. coli were constructed. The pGPT 
vector is used to insert the mutation into a recombinant vaccinia virus (rVV) 
containing the full-length IBV cDNA genome. The pGPT-FullTRS4b was 
constructed by ligating a DNA fragment containing a full TRS (CTGAACAA) 
sequence (GeneArt, Invitrogen) into a SalI digested pGPT vector. For the 
synthesis of pGPT-Sc3aM, primers were designed to amplify a 678bp fragment 
from M41 cDNA. The 3a start codon was situated in the middle of the DNA 
fragment. This fragment was then cloned into a pGPT vector using SalI restriction 
sites. Site-directed mutagenesis was then used to mutate the 3a start codon from 
ATG to AAC in the pGPT vector (Table 2.23). 
 
Table 2.23 DNA fragments and primers for the synthesis of pGPT expression 
vectors.  
Primer/ DNA 
fragments Sequence (5′ – 3′) Mutation 
M41 3a 
Primers 
GTACGTCGACCCCAAAAATTACCTCCTCTG 
CATGGTCGACGCTACCAGACTTTGACAAATTC  
Sc3aAUG 
SDM Primers 
CAGACCTAAAAAGTCTGTTTAAACATTCAAAGTCC
CACGTCC 
GTCTGGATTTTTCAGACAAATTTGTAAGTTTCAGG
GTGCAGG 
 
ATG > AAC 
SalI restriction sites (purple), mutated sequences (red), non-canonical TRS (green).  
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2.9.2 Transfection and infection 
Recombinant vaccinia virus (VV) containing the M41 cDNA was sonicated for 2 
minutes and diluted in 500 μl of EMEM to an MOI of 0.2. Vero cells seeded in a 
6-well plate (70% confluence) were infected with rVV-M41-K in duplicate and left 
for 2 hours at 37 °C and 5% CO2. Vero cells were washed twice with OPTI-MEM 
(Invitrogen) and transfected with 10 μg of pGPT vector using Lipofectin (Life 
Technologies) at a ratio of 1:2.4 DNA (μg): lipofectamine (μl) per the 
manufacturer’s instructions (Figure 2.1A). Vaccinia replicates in the cytoplasm of 
the cell. The cells were incubated at 37 °C for 90 minutes then washed with and 
5 ml of fresh 1x EMEM added. After overnight incubation at 37 °C, MXH selection 
reagents (75 μM mycophenolic acid (MPA), 165 μM Xanthine, 184 μM 
Hypoxanthine) were added to each well and incubated for a further two days at 
37 °C to allow the first homologous recombination event to occur (Figure 2.1B). 
After incubation, the cells were carefully scraped off the wells and pipetted into a 
screw cap vial. Samples were stored at -20 °C.  
 
2.9.3 Transient dominant selection 
Vero cells were inoculated with serial dilutions of the recombinant VV generated 
above (10-1, 10-2, 10-3) in 500 μl of 1x EMEM. The inoculum was removed after 2 
hours at 37 °C. Cells were then overlaid with 1% agar, 1x EMEM and MXH 
selection media (Table 2.24) and incubated for three days. Cells were stained 
with 0.01% neutral red in 1x EMEM and 1% agar and placed back in the incubator 
for 24 hours. Single isolated plaques were picked using a cut 1 ml pipette tip and 
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stored in 400 μl of 1x EMEM at -20 °C. Further two rounds of plaque purification 
in the presence of MXH was performed using isolated plaques from the previous 
round (Figure 2.1C). The plaques were then grown in the absence of selection 
reagents, to induce the second homologous recombination event, this is 
performed three times using plaques from the previous round (Figure 2.1D). 
 
Table 2.24 MXH selection media for TDS 
Reagent Final Concentration 
2x E-MEM 1x 
2% Agar 1% w/v 
MPA (Mycophenolic Acid) 75 μM 
Xanthine 165 μM 
Hypoxanthine 184 μM 
 
 
2.9.4 BHK stocks 
Two recombinant VV isolates with the desired mutation in the IBV cDNA were 
selected for further processing. BHKs were seeded into 11x T150s flasks (70-80% 
confluency). Each flask was inoculated with 2 ml of rVV at an MOI of 0.1 diluted 
in 1x GMEM. The cells were incubated at 37 °C with the inoculum for 2 hours with 
regular rocking. After incubation, 25 ml of GMEM was added, and flasks were 
incubated until extensive CPE was visible. BHK cells were agitated to release any 
attached cells. The supernatant was pooled and transferred to 50 ml falcons. Cells 
were pelleted by centrifugation at 500 x g for 20 minutes at 4 °C. The supernatant 
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was removed and the cell pellet resuspended in 11 ml of TE buffer (pH 9.0) (Table 
2.25). A stock of 1ml of rVV was stored at -80 °C. 
 
2.9.5 Ministocks 
After plaque purification, ministocks of the recombinant VV were grown for GPT 
screening and mutation sequencing. Recombinant VV with the most diverse 
lineage possible were screened to increase the chance of a identifying a 
successful recombination event. Vero cells were infected with 150 μl of rVV in 500 
μl 1x BES for 2 hours at 37 °C. Afterwards, 1x BES was added and cells incubated 
for four days or until cytopathic effect (CPE) was visible. The cells were then 
carefully scraped off the well into the media and placed in a screw-capped vial. 
Viral stocks were deactivated and DNA extracted using the QIAmp DNA mini kit 
(Qiagen) and protocol. Extracted DNA was then screened by PCR for the absence 
or presence of the GPT gene and the presence of the IBV region containing the 
desired mutation (Figure 2.1E). Any samples lacking GPT and containing the 
region of interest were sequenced to confirm the mutation in the recombinant VV.  
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2.9.6 Purification and DNA extraction 
Cells were freeze-thawed three times and sonicated for 2 minutes to extensively 
lyse the cells. Lysates were centrifuged at 1,200 × g at 4 °C for 10 minutes to 
remove the cell nuclei. The supernatant was removed, and 13 ml of TE (pH 9.0) 
buffer added. The rVV was then partially purified through a sucrose gradient. The 
supernatant was layered onto 16 ml of 30% sucrose diluted in TE (pH 9.0) buffer 
(Table 2.25) and ultracentrifuged at 36,000 x g for 1 hour at 4 °C. The pellet was 
resuspended in 10 ml TE (pH 9.0) buffer. Proteinase K buffer (Table 2.26) 
containing 0.2 mg/ml of Proteinase K was added in equal volume to the partially 
purified rVV in TE buffer and was incubated at 50 °C for 2.5 hours. After digestion, 
rVV DNA was extracted from the samples using phenol/chloroform 
(ThermoFisher).  The samples were divided into two 10 ml aliquots, and 10 ml of 
phenol-chloroform containing 8-hydroxyquinoline was added. The samples were 
Figure 2.1 Schematic diagram of the M41-K reverse genetics system. 
(A) A vector containing the GPT gene along with the desired mutation was transfected 
into Vero cells along with recombinant VV containing the IBV M41-K cDNA genome. (B) 
The first homologous recombination event occurs between the pGPT vector and IBV 
cDNA due to identical flanking regions. (C) Successful recombination is selected for by 
treating cells with MXH selection media. (D) After three rounds of plaque purification, the 
cells are treated in media in the absence of MXH, and the highly unstable intermediate 
undergoes a second recombination event. (E) Recombinant VV are sequenced for the 
presence of the desired mutation and screened for the absence of the GPT gene. (F) CK 
cells are transfected and infected with extracted DNA from successful rVV, Fowl-pox 
virus and pCI-Neo to induce expression of IBV cDNA under the control of a T7 promoter. 
Rescued recombinant IBV are passaged and then sequenced. 
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extensively mixed and then centrifuged at 1,200 × g for 15 minutes at 4 °C. The 
upper aqueous phase was removed, being careful not to remove the interphase, 
into a new 50 ml falcon. The phenol-chloroform extraction was repeated to purify 
the DNA. After the second extraction, a chloroform extraction was used to purify 
the DNA further and remove salts and sugars. The DNA was then precipitated by 
adding 0.1 volume of 3 M sodium acetate and 2.5 volumes of 100% ethanol (-
20 °C). Samples were centrifuged for 30 minutes at 2,300 × g at 4 °C. The 
supernatant was discarded, and the pellet washed for 5 minutes with 10 ml of 
70% ethanol (v/v) at 4 °C. Samples were centrifuged for 30 minutes at 2,300 × g. 
The ethanol supernatant was discarded, and any remaining ethanol carefully 
removed using blue roll. The pellet was air dried for 30 minutes before re-
suspending in 100 µl sterile water. The pellet was left overnight at 4 °C to dissolve 
the DNA completely. DNA was quantified using the NanoDrop 1000.  
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Table 2.25 Recipe for TE buffer 
Reagent Final Concentration  
Tris-HCl (pH 9.0) 10 mM 
EDTA 1 mM 
  
Table 2.26 Recipe for proteinase K buffer (2x) 
Reagent Final Concentration  
NaCl 400 mM 
Tris-HCl (pH 7.4) 200 mM 
EDTA 10 mM 
SDS 0.4 mM 
 
 
2.9.7 Recombinant IBV rescue 
CK cells were plated in a 6-well plate (50-60% confluence). Cells were infected 
with 1 ml of recombinant Fowlpox virus that expresses the bacteriophage T7 RNA 
polymerase (rFPV-T7) (Britton et al. 1996) at an MOI of 10. Cells were incubated 
for one hour at 37 °C and then washed once with OPTIMEM (Invitrogen). Cells 
were transfected with 10 μg of rVV DNA and 5 μg of a plasmid expressing the IBV 
N protein (pCi-Nuc). Protein N is expressed in complement as it required for the 
synthesis and egress of new virions (Siu et al. 2008). Plasmids were diluted in 1.5 
ml of OPTI-MEM (Invitrogen) and then added dropwise to 50 μl of Lipofectin in 
1.5 ml of OPTI-MEM. The transfection solution was added to the cells and then 
incubated overnight at 37 °C (Figure 2.1F). Transfection media was removed, 
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and 3 ml of 1x BES added. The cells were then incubated at 37 °C until extensive 
rFPV CPE was visible. The supernatant was harvested and rFPV removed by 
filtering through a 0.22 μm filter. The resulting solution was stored at -80 °C. To 
determine whether rIBV was successfully rescued, samples were serially 
passaged three times to increase viral titre. CK cells (6-well plate, 70-80 
confluence) were inoculated with 1 ml of supernatant and incubated for 1 hour at 
37 °C followed by addition of 2 ml of 1x BES. Cells were incubated for 2-3 days 
at 37 °C until CPE was visible. The supernatant was removed and passaged a 
further two times. After the third passage, RNA was extracted from the viral 
samples and screened to confirm rescue of rIBV and to identify the presence of 
the desired mutation.   
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2.10 Liquid Chromatography-Mass Spectrometry/Mass 
Spectrometry 
2.10.1 Transfection 
HEK293T cells were grown to 40 - 50% confluency in 10 cm2 culture plates. Cells 
were transfected with plasmids expressing either GFP or GFP-tagged accessory 
proteins. Plasmids were chemically transfected using calcium phosphate. 
Plasmids were diluted in 2 M CaCl2 (w/v) and then added dropwise to 2x Hank's 
Balanced Salt Solution (HBBS) recipe. The transfection solution was incubated at 
room temperature for 25 minutes and then added dropwise to the cells. Cells were 
incubated for 16 hours and were then washed once with cold PBSa and lysed 
with co-IP lysis buffer (Table 2.27). 
 
Table 2.27 Co-IP lysis buffer 
Reagent Final Concentration 
Tris-HCl buffer (pH 7.4) 10 mM 
NaCl 150 mM 
EDTA 0.5 mM 
Igepal 0.5% v/v 
 
 
2.10.2 GFP capture 
GFP was immunoprecipitated using the GFP-Trap (ChromoTek) Kit and protocol. 
Each sample was incubated overnight at 4 °C with GFP beads. Beads were 
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centrifuged at 500 x g for 5 minutes and then washed three times with 1x Dilution 
Buffer (Table 2.28). Proteins were eluted from the beads in 50 μl glycine (50 mM, 
pH 2.7) for 5 minutes with 1 minute of vortexing. To concentrate the samples, the 
elution step was repeated in an additional 50 μl of glycine. Samples were stored 
at -20 °C until processing at the University of Liverpool.  
 
Table 2.28 1x Dilution buffer  
Reagent Final Concentration 
Tris-HCl (pH 7.5) 10 mM 
NaCl 150 mM 
EDTA 0.5 Mm 
Sodium Azide 0.018% w/v 
 
 
2.10.3 LC-MS/MS 
Eluted samples were processed for liquid chromatography-mass 
spectrometry/mass spectrometry by Dr Stuart Armstrong or Dr Weining Wu. 
Samples were diluted 1:1 volume with 25 mM ammonium bicarbonate (NH4HCO3). 
Rapigest SF surfactant (Waters) was added to increase protein digestion at a final 
concentration of 0.05% (w/v) and boiled for 10 minutes at 80 °C. Proteins were 
reduced with 3 mM dithiothreitol (Sigma) and heated at 60 °C for 10 minutes. The 
samples were returned to room temperature, and 9mM iodoacetamide (Sigma) 
added for 30 minutes in the dark to alkylate the proteins. Proteins were trypsinised 
with 0.2 μg of proteomic grade trypsin (Sigma) and left to incubate at 37 °C 
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overnight. The resulting peptide samples were then treated with 1% (v/v) 
Trifluoroacetic acid (TFA) and heated to 37 °C for 2 hours to precipitate the 
Rapigest. Samples were centrifuged at 12,000 x g for 60 minutes at 4 °C to 
remove the Rapigest precipitate. Peptides were concentrated and desalted using 
C18 Stage tips (ThermoFisher Scientific) and then samples dried using a 
centrifugal vacuum concentrator (Jouan). Resulting precipitates were 
resuspended in solution containing 0.1% (v/v) trifluoroacetic acid and 3% (v/v) 
acetonitrile. For high-performance liquid chromatography (HPLC), the on-line 
nanoACQUITY-nLC system (Waters) was used. The Nano ACQUITY UPLCTM 
BEH130 (C18, 15 cm x 75 μm, 1.7 μm) (Waters) analytical column was used at a 
flow rate of 300 nl/minute to separate 2 μl of the peptide sample against a 3−40% 
acetonitrile in 0.1% formic acid gradient for 50 minutes ramping up to a gradient 
of 40−85% acetonitrile in 0.1% formic acid for 3 minutes. The mass spectrometer, 
LTQ-Orbitrap Velos (ThermoFisher Scientific) was used to acquire the full-scan 
MS spectra (MS1) at a resolution of 30,000. The 20 most intense ions were 
selected for a tandem in space mass analysis and were fragmented by collision-
induced dissociation (CID) before spectra detection by the LTQ ion trap.  
 
2.10.4 Analysis 
MS spectra data was analysed by label-free quantification using the MaxQuant 
software (MQ) and searched against a human protein database (Uniprot release-
2013_03) using the Andromeda search engine. The false discovery rate (FDR) 
was set to 0.01, and a decoy database was included in the search to remove 
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false-positives. LFQ results were further processed by the Perseus software (MQ) 
to determine significance between GFP alone compared to GFP tagged 
accessory proteins. Statistical T-test analysis was used to analyse intensity 
values. Proteins with a p-value <0.05 and a fold change >2 (Log2) were 
considered statistically significant. Identification and statistical analysis of the 
mass spectrometry data were performed by either Stuart Armstrong or Weining 
Wu. 
 
Downstream analysis of mass spectrometry data was performed by me. Proteins 
were analysed using both String DB (v10.0) to identify interacting proteins and 
Panther DB to group similar proteins based on GO (v1.2) and PANTHER (v11.1) 
annotations.     
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2.11 Interferon methods 
2.11.1 Interferon luciferase reporter assay 
DF-1 cells seeded in a 24-well format (80-90% confluence) were washed once 
with PBSa, and 500 μl of 1x DMEM (10% FCS) added to each well. OPTI-MEM I 
reduced serum media (Invitrogen) was added to 500 ng of pFLAG-CMV2-3aB, 
pEGFPC2-3aB, pEGFPC2-3aM, pCAGGS-NS1-IAVPR8 or pEGFPC2, 80 ng of 
chIFNβ-luciferase reporter and 40 ng of Renilla luciferase plasmid pRL-CMV. The 
reporter construct consists of a chicken IFN-β promoter sequence upstream of a 
chemiluminescent Firefly luciferase gene. In a separate tube, 50 μl of OPTI-MEM 
was added to 7.5 μl of lipofectamine 2000 (Invitrogen). The samples were 
incubated at room temperature for 5 minutes, after which the DNA mixture was 
added to the lipofectamine in a drop-wise manner and incubated for a further 25 
minutes. During incubation, the cell media was replaced with 400 μl of fresh 1x 
DMEM (10% FCS). The transfection mixture was added to the well, drop-wise 
and incubated for 16 hours at 37 °C. Poly(I:C) (dsRNA analogue) at a final 
concentration of 5 μg/ ml was transfected into each well 8 hours before lysis. In 
one tube 100 μl of OPTI-MEM was added to the poly(I:C) (Invivogen), and in a 
separate tube, 100 μl of OPTI-MEM added to 7.5 μl of lipofectamine 2000. The 
DNA and lipofectamine mixtures were incubated at room temperature for 5 
minutes, the lipofectamine mixture was added dropwise to the poly(I:C) and 
incubated for a further 25 minutes. The transfection mixture was added directly to 
the well in a drop-wise manner and incubated at 37 °C for 2 hours to induce the 
interferon response. Afterwards, the media was removed and replaced with fresh 
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1x DMEM (10% FCS) and incubated at 37 °C for a further 16 hours. After 16 hours, 
the media was removed, and the cells washed once with PBSa. The Dual-Glo 
Luciferase Reporter Assay System (Promega) was used for lysis and to measure 
luminescence activity. Passive lysis buffer (100 μl) was added to each well. The 
plates were subsequently frozen for 30 minutes at -80 °C. The plates were thawed 
at room temperature on a shaker. Afterwards, 10 μl of lysate was added to a well 
of an opaque white 96-well plate. Firefly and Renilla luciferase were activated with 
the Dual-luciferase kit by adding 50 μl of LAR II and then Stop-and-Glo buffer 
sequentially. Luminescence was measured using the Glo-Max plate reader. 
Luminescence data was normalised using Renilla luminescence levels. Lysates 
(26 μl) were separated by SDS-PAGE and immunoblotted with anti-3a, as 
described in 2.6, to confirm successful expression of pEGFPC2-3aB and pFLAG-
CMV2-3a.  
 
2.11.2 Chicken interferon MxA reporter assay 
Chicken type I interferon (chIFNβ) levels were quantified using a quail reporter 
cell line, CEC-32, expressing luciferase under the control of the MxA promoter 
(Peter Staeheli) (Schwarz et al. 2004). CK cells were seeded in a 24-well plate 
(70-80% confluent). Cells were washed twice with PBSa and infected with IBV at 
an MOI of 0.1 for 1 hour. The inoculum was removed and replaced with 1x BES 
media. Cells were incubated and supernatant harvested at the specified time. 
Samples were heat treated for 30 minutes hour at 56 °C to inactivate IBV before 
sampling. Samples were serially diluted and incubated with CEC-32 cells (96-well 
plate, 70-80% confluence) for 6 hours. Luciferase activity was then measured 
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using the Stop-and-Glo Luciferase Kit and protocol (Promega). Interferon levels 
were measured against a standard curve using two-fold dilutions of recombinant 
chIFNb starting at 25 U/ml (Abbexa).  
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2.12 Apoptosis methods 
2.12.1 Caspase 3/7 activity assay 
DF-1 cells seeded in a 24-well plate (70-80% confluence) were transfected or 
infected. Cells were either mock infected or infected with IBV at an MOI of 4 for 1 
hour. The inoculum was replaced with 1x DMEM (10% FCS). Transfected cells 
were either transfected with an empty plasmid or a plasmid expressing a tagged 
accessory protein as described in 2.5. As a positive control, staurosporine was 
added at a concentration of 10 µM in DMEM for 6 hours. Caspase 3/7 activity was 
measured using the Caspase-Glo 3/7 assay (Promega) and protocol. At the 
allocated time post infection/transfection, 900 µl of media was removed, and an 
equal volume of caspase substrate added directly to the cells. Cells were shaken 
for 1 minute and then incubated for 30 minutes in the dark. Cleavage of caspase-
Glo substrate by caspase 3/7 results in aminoluciferin release and subsequent 
luciferase activity. Samples were added to an opaque 96-well plate, and caspase 
luminescence measured using the GloMAX luminometer (Promega).   
 
2.12.2 Annexin-V-FITC FACS assay 
DF-1 cells seeded in a 12-well plate (70-80% confluence) were transfected or 
infected. Cells were either mock infected or infected with IBV. As a positive control, 
staurosporine was added at a concentration of 10 µM in DMEM for 6 hours. After 
infection, cell media was harvested and cells detached using Accutase Cell 
Detachment solution (BD Bioscience) in PBS. The cell media and detached cells 
were pooled and centrifuged at 1,200 × g and then washed once with cold PBSa 
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and re-centrifuged at the same speed for 5 minutes to pellet the cells. Apoptosis 
was measured using the Annexin V Apoptosis Detection kit II (BD Bioscience) 
and protocol. The cell pellet was resuspended in 1ml 1x binding buffer and 100 µl 
of the sample transferred to a FACS tube. Five µl of Annexin V antibody was 
added to the sample and vortexed. Samples were incubated for 25 minutes at 
4 °C on a rotator in the dark. Afterwards, 5 µl of Propidium iodide was added and 
samples incubated for 5 minutes. An additional 400 µl of 1x Binding Buffer was 
added to each sample. Cells were sorted, and fluorescence was measured and 
analysed using the MACS QUANT flow cytometry. Data analysis was completed 
using FCS Express (v5.0).  
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2.13 Stress granule methods 
2.13.1 SG induction 
Vero cells were seeded in a 24-well plate (70-80% confluence) and then 
transfected or infected. During infection experiments, cells were either mock 
infected or infected with IBV. Transfected cells were transfected with either an 
empty control plasmid or a plasmid expressing a tagged accessory protein. As an 
SG positive control, sodium arsenite was added 45 minutes before fixation at a 
final concentration of 0.5 mM. Stress granules were labelled with anti-G3BP1, a 
stress granule marker, and visualised by confocal microscopy. For each sample, 
20 GFP positive cells were randomly selected and the number of stress granule 
positive cells counted. Any cells containing a single SG were considered SG 
positive. 
 
2.13.2 Gene expression and translation efficiency 
DF-1 or Vero cells seeded in a 24-well plate (70-80% confluence) were 
transfected with pRL-CMV, a Renilla luciferase expressing plasmid under control 
of a CMV promoter, along with either pEGFP-C2 or pEGFPC2-4b. After 16 hours, 
cells were washed once with PBSa, cells lysed and Renilla activated using the 
Stop and Glo (Promega) kit and protocol. Luminescence was measured using the 
GloMax 96-microplate luminometer (Promega). Background luminesce was 
determined by adding Renilla to media alone and subtracted from all samples.  
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2.14 Bioinformatics analysis 
2.14.1 Sequence Alignment 
Complete IBV sequences were downloaded from the VIPR Coronavirus database 
(http://www.viprbrc.org) (Jan 2017) and aligned using the BioEdit (Staden) 
program. Sequences were analysed using the unsorted six-frame translation tool 
to locate ORF4b. ORF4b sequences were then compiled into a new database for 
each IBV strain. ORF4b sequence identity and similarity were calculated by 
comparing all sequences against each other using the SIAS tool 
(imed.med.ucm.es/). 
 
2.14.2 Eukaryotic Linear Motif Search 
The complete M41 4b peptide sequence was entered into an ELM search, and 
results organised by the probability of the motif sequence occurring randomly 
(elm.eu.org/search/).  
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3. The role of accessory protein 3a 
3.1. Introduction 
IBV 3a is a 6 kDa accessory protein expressed from the first ORF in mRNA 3 (Liu 
et al. 1991). Previous work has shown that 3a is not required for replication in 
vitro, in ovo and ex vivo organ culture (Hodgson et al. 2006). Due to the high 
peptide sequence conservation between IBV strains, 3a is believed to be 
important and may be involved in pathogenicity (Jia et al. 1997). In vitro studies 
in Vero cells have shown that during infection, 3a localises to two main cellular 
compartments, the cytoplasm where it is diffuse and the smooth ER where it is 
membrane-bound, due to a transmembrane domain at the N-terminus (Pendleton 
et al. 2005). IBV 3a has also been shown to closely localise with the small GTPase, 
MxA (Pendleton et al. 2005). Kint et al. showed that 3a plays a role in both 
inhibiting and stimulating interferon-beta (IFNb) expression in a time-dependent 
manner, with recombinant IBV lacking ORF3a expressing higher levels of IFNβ 
transcript 24 h.p.i, while at 36 h.p.i IFNβ translation was inhibited (Kint et al. 2015). 
The mechanism of action of how IBV 3a modulates IFNb expression is not known. 
In this chapter, the mechanism of action of 3a on IFNβ expression is investigated. 
Utilising a chicken(ch)IFNβ luciferase assay, IBV 3a is shown to have a dose-
dependent effect on IFNβ expression, and can both stimulate and inhibit 
expression by targeting two IFN signalling proteins, MAVS and IRF7. IBV 3a can 
both increase levels of MAVS while simultaneously decreasing levels of IRF7 in 
a dose-dependent proteasome-dependent manner. Furthermore, mass 
spectrometry has identified two interacting cellular partners for 3a which play a 
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role in regulating MAVS and IRF7 turnover, RNF5, and CAND1, respectively. 
RNF5 targets MAVS for proteasomal degradation while CAND1 is an E3-SCF 
ligase regulatory protein, a ligase complex that targets IRF3/7 for degradation 
(Zheng et al. 2002, Prakash et al. 2006, Zhong et al. 2010).  
 
Results 
3.2. Generation of GFP-tagged 3a expression vectors 
Vectors for expression of GFP-tagged 3a from Beau-R (3aB) and M41-CK (3aM) 
were generated for in vitro IFN assays, immunofluorescence visualisation and for 
mass spectrometry protein purification. The expression vector, pFLAG-3aB was 
previously generated by Mark Davies (Davies 2009). Expression vectors with 
GFP-tagged at either the N- or C- terminus of 3a for both Beau-R and M41-CK 
were generated. For the generation of these vectors, RNA from Beau-R and M41-
CK was isolated and reverse transcribed into cDNA using random primers. 
Complementary primers with flanking restriction sites were designed to amplify 
ORF3a by PCR. Resulting PCR products were purified and digested with the 
relevant restriction enzymes. Expression plasmids, pEGFPC2 (Clontech) and 
pEGFPN1 (Clontech), were digested with the same enzymes and purified by gel 
extraction. Digested expression plasmids and PCR products were ligated and 
transformed into competent cells. Vectors were purified and sequenced using 
Sanger sequencing. Four expression vectors, pEGFPC2-3aB, pEGFPC2-3aM, 
pEGFPN1-3aB, and pEGFPN1-3aM were generated (Figure 3.1). To confirm the 
generation of GFP-tagged 3a expression vectors, the molecular weight of GFP-
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3aM, 3aM-GFP, GFP-3aB, and 3aB-were compared to GFP. Vero cells were 
transfected with each vector, and after 16 hours, cells were lysed, separated by 
SDS-PAGE, transferred to a membrane and labelled with anti-GFP. The molecular 
weight of GFP-tagged 3aB and 3aM were identified as expected (34 kDa) (Figure 
3.1E).  
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Figure 3.1 Plasmid map and confirmation of expression of the GFP-tagged 3a 
expression vectors. 
(A) pEGFPC2-3aB (B) pEGFPN1-3aB (C) pEGFPC2-3aM (D) pEGFPN1-3aM (E) Vero 
cells were transfected with pEGFPC2, pEGFPC2-3aB/3aM, pEGFPN1-3aB/3aM 
expression vectors. After 16 hours, cells were lysed, proteins separated by SDS-PAGE 
and transferred to a membrane. Membranes were incubated with anti-GFP. 
A B 
C D 
E 
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3.3. Testing anti-3a (JH3480) 
Anti-3a (JH3480) was a gift from Carolyn Machamer. The antibody was tested 
against 3a expression to confirm this antibody can label both M41 and Beaudette 
isoforms of 3a. DF-1 cells were transfected with 3aB-FLAG or GFP-3aM 
expression vectors. After 16 hours, cells were lysed, proteins separated by SDS-
PAGE, transferred to a membrane and labelled with anti-3a, anti-FLAG or anti-
GFP. Blots were labelled with anti-GFP or anti-FLAG to confirm expression of 
GFP-3aM or 3aB-FLAG, with a band appearing at approximately ~35 kDa and 8 
kDa, respectively. Anti-3a was also able to label both GFP-3aM and 3aB-FLAG, 
confirming that anti-3a can label both 3aB and 3aM by western blot (Figure 
3.2A,B). Anti-3a failed to label a band in the pFLAG control, suggesting anti-3a 
was labelling 3a expression only (Figure 3.2C). Anti-3a was then tested against 
3aB-FLAG expression. DF-1 cells were transfected with the 3aB-FLAG 
expression vector, and after 16 hours, cells were fixed, permeabilised and labelled 
with anti-3a. The antibody could label 3a in DF-1 cells (Figure 3.2D), confirming 
that anti-3a can label both 3a by indirect immunofluorescence. 
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Figure 3.2 Anti-3a can label both 3aB and 3aM.  
DF-1 cells were transfected with either (A) GFP-3aM, (B) 3aB-FLAG, (C) pFLAG or 3aB-
FLAG expression vectors. After 16 hours, cells were lysed, proteins separated by SDS-
PAGE, transferred to a membrane and labelled with anti-3a, anti-GFP or anti-FLAG. (C) 
DF-1 cells were transfected with 3aB-FLAG expression vectors. After 16 hours, cells were 
fixed, permeabilised and labelled with anti-3a. The nucleus was stained with DAPI. 
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3.4. Characterisation of IBV 3a effect on IFNβ expression 
3.4.1. IBV 3a both inhibits and stimulates IFNβ expression 
Previous work has shown that 3a can modulate IFNβ expression, with rIBV 
lacking 3a expression inducing less IFNβ expression 36 h.p.i compared to wild-
type IBV (Kint et al. 2015). To further characterise this effect, a chicken(Ch)-IFNβ 
luciferase reporter assay was used, utilising a reporter plasmid expressing a 
luciferase gene under the control of a chicken IFNβ promoter (Liniger, 2012). This 
assay allows Firefly luciferase activity to be measured as a proxy for IFNβ 
promoter activity. The IFN signalling cascade can be simplistically split into five 
sections, detection of dsRNA by MDA-5, activation and aggregation of MAVS, 
phosphorylation of TBK1, phosphorylation of IRF7 and finally IFNβ transcription 
(Wu et al. 2014). To determine at which point in the IFN cascade IBV 3a affects 
IFNβ expression, cells were stimulated with either dsRNA, MDA-5, MAVS or IRF7. 
DF-1 cells were transfected with increasing levels of the pFLAG-3aB expression 
vector, made up to 1 µg with pFLAG. Increasing levels of pFLAG-3aB were 
transfected to determine if any effect observed was dose-dependent. The amount 
of transfected vector remained the same for each transfection. Cells were 
simultaneously transfected with a ch-IFNβ reporter plasmid and a Renilla 
luciferase plasmid as a transfection control. An influenza NS1 (IAV-PR8) 
expression vector was used as a positive control, as IAV NS1 is a potent IFNβ 
antagonist (Hatada et al. 1992, Gack et al. 2009, Rajsbaum et al. 2012). The IFN 
cascade was then stimulated by transfecting cells with either poly(I:C) or with 
plasmids expressing chicken MDA-5, MAVS or IRF7. After 16 hours, cells were 
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lysed, and luciferase activity measured. Firefly luciferase activity was normalised 
against Renilla luciferase expression. Firefly luciferase activity was shown as fold-
change compared to the empty vector control. An aliquot of each sample was 
separated by SDS-PAGE, transferred to a membrane and labelled with anti-FLAG 
to confirm successful transfection for one replicate, and is shown as a 
representative of the three biological replicates performed subsequently. When 
cells were transfected with poly(I:C) and low levels of 3aB-FLAG (250 ng), Firefly 
luciferase activity was higher compared to the empty vector control meaning the 
IFNβ promoter is activated. Increasing levels of 3aB-FLAG did not increase this 
effect, with 1 µg of 3aB-FLAG inducing less luciferase activity compared to the 
empty vector control (Figure 3.3A). The positive control, IAV NS1, significantly 
inhibited poly(I:C) induced IFNβ expression. The same effect for poly(I:C) was 
observed when cells were transfected with the chMDA-5 vector. At low levels of 
3aB-FLAG expression, Firefly luciferase activity was higher compared to the 
empty vector control (Figure 3.3B). Increasing levels of 3aB-FLAG had an overall 
inhibitory effect on luciferase activity. Conversely, when cells were transfected 
with chMAVS; 3aB-FLAG only had an inhibitory effect on luciferase activity 
(Figure 3.3C). The effect was not dose-dependent, with higher doses of 3aB-
FLAG vector not significantly inhibiting Firefly luciferase activity compared to 
lower doses. When cells were overexpressing chIRF7, increasing levels of 3aB-
FLAG also had an inhibitory effect on luciferase activity, but in comparison to 
MAVS overexpression, the effect was dose-dependent (Figure 3.3D). Expression 
of 3aB-FLAG alone without poly(I:C) treatment did not induce luciferase activity, 
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suggesting 3a alone does not induce IFN expression. As IRF7 is the last protein 
involved in IFN cascade, 3a most likely affects IRF7 activity in some manner. A 
different effect was observed upstream suggesting 3a also affects the cascade at 
either poly(I:C) detection, MDA-5 activity or possibly even MAVS activity. IBV 3a 
alone was unable to induce IFN expression when induced with poly(I:C), MDA-5, 
MAVS or IRF7. Overall this suggests that 3a has a dual mechanism of action on 
chIFNβ expression.  
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3.4.2. IBV 3a from Beau-R and M41 have the same effect on IFNβ expression 
IBV 3a is a highly conserved accessory protein and is expressed by both the 
apathogenic lab strain, Beau-R, and the pathogenic lab strain, M41-CK. Beau-R 
and M41-CK 3a have a high sequence identity of 96.48% with only two amino 
acids different at the C-terminal end (Figure 3.4A). To determine if this difference 
in peptide sequence affects the observed function of 3a on IFN expression, 3a 
from M41 and BeauR were compared. DF-1 cells were transfected with a chIFNβ 
luciferase reporter plasmid along with either GFP-3aB, GFP-3aM or GFP 
expression vectors. A Renilla luciferase plasmid was co-transfected as a 
transfection control. Cells were then transfected with either poly(I:C) or with 
vectors expressing chMDA-5, chMAVS or chIRF7. After 16 hours, cells were lysed, 
and luciferase activity measured. Results were normalised to Renilla luciferase 
expression and are represented as fold-change compared to the empty vector 
control. As seen previously, GFP-3aB had a stimulatory effect on IFNβ promoter 
Figure 3.3 IBV 3a protein induces and inhibits IFNβ expression in a dose-
dependent manner.  
DF-1 cells were transfected with vectors expressing 3aB-FLAG/FLAG at varying ratios 
and with a chIFNβ Firefly luciferase reporter plasmid. Cells were also transfected with 
(A) poly(I:C) for 12 hours or with plasmids expressing (B) chMDA5-V5, (C) chMAVS-V5, 
(D) IRF7-FLAG. After 16 hours, cells were lysed, and luciferase activity measured. 
Results were normalised using a Renilla luciferase transfection control. Firefly luciferase 
activity is measured as fold-change in luminescence over the empty vector control. 
Successful transfection and expression of 3aB-FLAG vectors was confirmed by western 
blot and includes data from three biological replicates. Unpaired t-test * significant at p < 
0.05, **significant at p < 0.01, *** significant p < 0.005, **** significant p < 0.0005, non-
significant (ns) p > 0.05. Error bars represent one standard derivation from the mean.  
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activity when induced with poly(I:C) or MDA-5, the same effect is seen with GFP-
3aM (Figure 3.4B). Furthermore, GFP-3aM expression also inhibited IFNβ 
promoter activity when induced with MAVS or IRF7 to similar levels as GFP-3aB. 
Expression of 3aB or 3aM alone did not increase IFNβ Firefly luciferase activity 
compared to the GFP control, suggesting that 3a only has a stimulatory effect on 
IFN expression when induced with either poly(I:C) or MDA-5. Overall, this 
suggests that 3a from M41 and BeauR have a similar effect on IFNβ expression.  
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A 
B 
Figure 3.4 IBV 3a from M41-CK and Beau-R have the same effect on IFNβ signalling. 
(A) Protein sequence alignment of Beau-R 3a (blue) and M41-CK 3a (red). (B) DF-1 cells 
were transfected with GFP, GFP-3aB or GFP-3aM expression vectors and a chIFNβ-
luciferase reporter plasmid. Cells were then either transfected with poly(I:C) for 12 hours or 
transfected with plasmids expressing chMDA-5, chMAVS, chIRF7 or mock transfected. A 
renilla luciferase plasmid was used as a transfection control. Firefly luciferase activity is 
shown as fold-change compared to the GFP control. Results are representative of three 
biological replicates. * significant p < 0.05, # non-significant p > 0.05.  
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3.5. Mass spectrometry analysis of GFP-3aM IPs 
Mass spectrometry was utilised to identify any interacting partners for 3aM, that 
may help to determine IBV 3a mechanism of action on IFNβ expression and any 
additional functions. HEK-293T cells were transfected with pEGFPC2-3aM or 
pEGFPC2 expression vectors. After 16 hours, cells were lysed and GFP-3aM or 
GFP immunoprecipitated using GFP ‘capture’ beads (Chromotek). This assay 
was completed in triplicate for each plasmid, performed on different days. Input 
and eluate samples were analysed by western blot to confirm successful 
transfection of pEGFPC2-3aM and immunoprecipitation of GFP-3aM (Figure 3.5). 
GFP immunoprecipitation could be confirmed by directly visualising the GFP 
Figure 3.5 Confirmation of GFP-3aM transfection and IP.  
HEK-293T cells were transfected with pEGFPC2-3aM or pEGFPC2. After 16 
hours, cells were lysed, and GFP-3aM immunoprecipitated using GFP ‘capture’ 
beads. Input and eluate samples were separated by SDS-PAGE, transferred to 
a membrane and labelled with anti-GFP. 
 
3aM-GFP 
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fluorescence when attached to the GFP capture beads. After confirmation, 
samples were analysed by LC-MS/MS (for method see 2.10.3) by Weining Wu.  
 
In total 554 proteins were identified in higher levels in the GFP-3aM eluate 
compared to the GFP control (Appendix, Table 7.1). Proteins were identified by 
comparing unique peptides to a database of human proteins. Proteins where only 
a single unique peptide was identified, were removed to reduce the chance of 
identifying the wrong protein. For each protein identified, the fold-change (Log2) 
in relative abundance was calculated by comparing GFP-3aM to the GFP control. 
From the three replicates the p-value, as determined by two-way ANOVA, was 
calculated. A p-value above one (-Log10) along with a fold-change (Log2) above 
two were considered significant interactions and had the highest chance of 
interacting with 3aM. For each protein, the confidence score (-Log2) was 
calculated, which is the cumulative value of p; the probability of the identified 
peptide sequence occurring randomly, for each unique peptide identified. In total 
135 proteins were identified as significant (Table 3.1, Figure 3.6).  
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Table 3.1 Cellular proteins identified my LC-MS/MS that significantly interact with GFP-3aM. 
Name Unique Peptides Confidence 
Relative Protein Abundance 
p Value  
(-Log10) 
Fold-change 
GFP-3aM/GFP 
(Log2) 
pEGFPC2-3aM pEGFPC2 
1 2 3 1 2 3 
SUCB2 2 51.8 34391.31213 56821.77764 41196.20091 0 0 0 6.777403376 15.42968233 
FND3A 2 34.79 74980.93704 24630.06568 33157.9421 0 0 0 5.344140575 15.43359571 
GCP2 2 197.65 235809.9946 105676.1593 110856.7974 0 345.0779654 89.30009403 1.897724605 10.02425004 
PLCD 2 67.93 84058.48747 29179.2505 55446.0788 337.888514 0 0 1.888070933 8.963558546 
RNF5 3 65.41 40010.10628 41698.36451 40304.88571 23.67064605 0.851848723 533.6542995 1.847905735 7.772101223 
SYIM 2 166.85 5264.343093 38673.28811 35924.49767 272.9815635 348.4995779 0 1.313803241 7.005657106 
DAAF5 6 260.95 185725.9629 107943.9298 164079.893 1605.611852 2255.546652 1306.758243 4.399280401 6.468832572 
CAND1 3 99.7 26745.14688 119865.8145 61450.09147 1327.312472 803.21403 283.1585313 2.681942232 6.429625692 
DRS7B 2 69.99 73008.75546 24830.37773 40296.64166 0 2227.736805 0 1.410611949 5.954364395 
ODR4 2 83.56 94227.5916 30091.39846 43740.62521 0 3355.46799 20.37944099 1.332618828 5.637579572 
SAAL1 2 59.11 224746.8404 137702.9975 147900.2826 3261.366937 7876.208585 2769.976351 3.298068207 5.197546941 
STX18 2 108.09 107680.8457 55375.96374 76556.75843 763.3016918 4024.461995 2021.70543 2.704016395 5.137023465 
REEP5 5 390.12 749915.828 305879.2859 410196.8144 18877.25139 19977.9151 8195.371688 3.037728514 4.961522125 
AL9A1 2 67.04 4154.176253 40434.74772 21783.00598 708.3351856 1021.334608 754.4832324 1.885859908 4.739747273 
F134C 4 272.76 1141784.237 364034.8883 527764.8573 11166.44445 44095.2193 28322.67335 2.442071003 4.604648142 
CLCC1 5 219 168918.3877 94932.29125 125618.1712 4675.755832 7539.017183 4068.684829 3.658382062 4.580028948 
WLS 3 121.35 299226.2514 122157.0627 191376.7091 3018.354566 14975.83988 9071.20919 2.417495595 4.500800369 
TRABD 3 258.46 356891.6626 151716.4333 245364.0152 13656.55863 13034.83679 9349.082979 3.395254749 4.386821094 
MA1A2 2 66.59 215645.5795 96319.35766 62781.13751 1646.540633 14837.10708 1696.101165 1.879797504 4.36550919 
COQ9 2 60.35 110354.4636 76056.90201 122233.2208 7079.981262 2429.067748 5573.197655 3.020661266 4.355023232 
ERGI1 3 88.57 184876.8847 77101.71274 100338.6505 8938.181852 4635.605864 4641.070818 3.029781331 4.314065791 
IPO8 2 119.01 127020.6783 69452.4371 88508.53162 3149.79612 8148.584352 3345.938955 2.995663854 4.282455959 
CHCH9 2 160.86 67572.62096 360826.731 302878.3555 15159.59511 20122.69634 5962.35567 1.893115032 4.148140585 
ABHGA 4 127.54 189095.1787 78592.56183 128659.5804 9674.639923 9766.763034 4021.874744 2.729636927 4.078288755 
ALG1 4 151.32 170129.9637 82346.94547 107946.4187 8060.06312 15773.06095 58.78622242 1.07826702 3.915098275 
EMD 6 265.85 354469.7995 237282.4663 259536.9101 42448.24268 5526.157523 9727.697304 2.103879379 3.882953619 
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PSMD9 2 85.09 97466.21523 109471.8329 93926.33154 8888.832258 4863.059305 6760.611141 3.944032605 3.874537882 
TOIP2 3 84.63 77623.31948 39297.2789 53983.44755 4152.550815 3693.52834 3819.042182 3.727616163 3.872913332 
NU205 3 209.73 165607.2579 73567.56396 88393.00183 12717.15794 3246.093207 7151.734314 2.375776447 3.824893291 
UBQL2 2 205.45 156916.6578 90090.28071 134626.7302 2436.664802 12446.06126 12506.86639 2.122942277 3.800488751 
HSBP1 3 258.09 1069888.163 432952.447 680367.7133 55457.68021 64433.27794 39498.43168 2.999605956 3.775822299 
ETFB 4 185.54 41798.71172 207835.8111 108182.2776 7522.672393 17400.36104 2073.603152 1.607173674 3.728369544 
COG6 2 71.11 180632.3455 78810.92161 115020.1304 16867.94446 9927.445399 2235.819871 1.89616613 3.689148112 
RAB18 2 117.45 243256.9894 169447.9014 189251.4121 21479.72484 6982.005359 18221.40531 2.713937351 3.688685394 
ADCK4 2 85.8 94351.38794 124276.4933 169895.0733 9743.372986 5945.63161 14697.11473 2.93702803 3.676515496 
NU188 2 84.14 95331.89597 53360.69943 64829.48226 13794.7404 3787.279944 72.7493266 1.123306796 3.596255344 
ERGI3 2 53.68 219301.3449 102332.5309 127577.4655 6756.005925 21309.44446 9099.654538 2.468726847 3.595373766 
BAG6 15 916.5 1063956.239 530962.658 711738.9269 42002.06133 91895.37871 63409.09066 2.908753429 3.547293393 
TMX3 3 184.24 177673.0447 90569.12216 113261.9522 17618.31514 12170.97451 3153.771662 2.034140564 3.533652102 
UB2V1 2 100.47 27592.55046 130924.2247 72665.3887 12104.53234 6519.486272 1478.853929 1.538065097 3.523556524 
MPU1 2 108.56 206718.9505 115636.736 154836.9192 11968.55877 16688.87392 13403.17914 3.617445411 3.504029947 
UCHL5 2 38.07 92429.56 63525.80973 72599.37128 7537.009138 7284.613162 5715.556648 4.170116506 3.476229818 
TNPO3 2 71.37 144621.9199 89592.6772 120392.315 338.2526679 21920.99861 10189.34018 1.206894959 3.449992898 
HSDL1 3 128.07 238412.8931 138049.5039 165886.3749 9517.300629 9194.526284 34139.25141 2.255200215 3.359216101 
DHC24 7 401.81 1051291.496 339981.1588 610383.6646 68147.61699 62371.05979 66381.60123 2.60705999 3.345657234 
ASNS 4 218.18 27236.7698 171430.9769 107043.9983 14413.26977 13620.8357 3076.178357 1.39532784 3.296708518 
CY1 2 175.68 390624.129 223018.99 286975.9681 28300.7047 61543.82476 3119.625862 1.4398207 3.276170592 
FACD2 10 514.36 595535.0484 319918.416 363208.044 28414.5887 51827.93688 54517.52588 2.873840686 3.24616961 
OLA1 3 84.02 6739.60173 96279.51464 45580.26839 1905.775694 11890.49948 2289.52478 1.010022552 3.207568554 
AFG32 2 87.66 266218.8291 69763.81298 129982.134 29522.17136 10236.30475 12436.5197 1.884998623 3.1582375 
NCLN 3 110.84 151810.5306 118798.335 51161.51211 4026.983579 5593.222541 27600.09858 1.635810305 3.111869746 
TM109 3 193.95 2128557.196 741617.905 1571766.115 116270.3236 309108.138 91861.27652 1.979519337 3.102285278 
ABCE1 2 100.28 180280.4528 228714.1151 176016.8733 5853.351265 15469.80009 47476.7658 1.812994348 3.087986108 
APT 2 69.2 81678.52251 294963.2647 132224.1422 10003.55635 31941.67625 18455.73939 1.85368189 3.074641929 
TMX2 2 106.81 371290.2604 164004.6936 155805.9568 30719.98496 41544.65033 9831.420076 1.87689274 3.073511572 
PIGS 2 107.23 138516.2391 42629.73737 87801.7788 4391.904365 26815.13072 1538.305236 1.372564613 3.037964418 
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OPA1 4 134.56 130650.4255 74911.63272 80284.10455 3403.949867 28348.88231 3080.573341 1.614628993 3.036695492 
VAPB 4 268.94 416506.9089 248489.2161 232945.3183 7744.79615 68440.53099 34218.44871 1.637538183 3.023831853 
RN126 3 251.08 525994.1889 280502.4686 334225.2035 67045.77592 49805.14736 23678.40168 2.392041083 3.021003945 
RAC2 2 102.54 80460.41231 167604.9329 103378.7411 12685.50953 15828.63451 14877.31877 3.091374769 3.017812051 
THEM6 3 179.98 302460.6286 180902.6637 221584.6424 21322.33488 46595.37978 20573.93694 2.650100687 2.993903447 
DCAKD 3 114 153464.2264 83490.88646 117275.0733 15636.9141 17987.39211 11058.22892 3.081243797 2.986904211 
SRPRB 13 1168.22 2356606.499 1252445.881 1772697.713 158027.6169 300604.9945 235622.8531 2.842057521 2.954536867 
MPRD 2 63.4 403758.5618 189455.7616 276185.7067 69385.26371 22423.46862 22296.68755 2.094753638 2.929652826 
VDAC2 2 165.53 185298.4981 63587.4718 71200.78036 12150.61983 26309.77203 3554.436452 1.509309944 2.929492465 
XPOT 5 315.05 192152.0222 87834.0223 111134.1342 18165.44461 22238.0125 11344.55236 2.552757573 2.918036695 
CB047 2 115.34 284719.5493 130033.8812 190940.3121 8955.553702 55631.74442 15759.10915 1.746291063 2.914283087 
LAT1 3 283.6 534554.2065 250774.0012 333575.6027 27904.31074 80223.30157 42965.13305 2.250548912 2.88857972 
EI24 3 79.84 198309.5484 94782.3236 94516.17662 7846.197007 26812.32063 19324.82657 1.992223219 2.84401227 
UCK2 4 351.21 631346.4811 332289.1155 395077.2849 65389.18535 73917.666 50587.2553 3.02699373 2.838973586 
VATH 2 90.98 456719.8086 188749.7682 292946.563 46618.49369 49388.45914 38127.75768 2.675757196 2.80654521 
AAAS 5 212.77 362041.0814 157400.2565 256438.8803 25003.63463 43440.29387 42638.97024 2.502024053 2.804197213 
FUND2 3 170.07 155872.4144 66284.67575 81778.76974 789.0479602 2925.884841 40106.34656 1.207379135 2.794063392 
SC61B 3 258.61 869805.8076 438596.665 524439.0833 17462.80943 148948.4918 98268.19402 1.495266895 2.791763736 
PSD13 5 257.79 277050.6305 256645.2022 295326.395 32953.82472 64093.08353 22728.28042 2.569841114 2.791081698 
RDH11 7 463.66 850810.1228 437694.0325 614862.5361 85815.05262 120185.5841 69154.65644 2.811724745 2.790235542 
PSD11 5 162 444330.9905 280377.2573 290097.3742 31561.4464 94631.09858 21669.9923 1.972596832 2.778874937 
AMFR 7 463.85 533332.3635 261206.8513 292356.2496 23102.56658 85447.40766 50282.16974 1.985911313 2.774638376 
DDRGK 3 267.52 191321.119 126482.1814 121025.2369 24844.11805 34792.27865 5121.311773 1.626837608 2.760533508 
NTPCR 4 209.44 224270.7179 168624.377 238995.4131 14326.87493 46072.97841 33918.06515 2.264501734 2.74407081 
DJB12 2 137.64 357081.3372 141342.3714 266288.1612 77299.67567 20968.1364 18545.99923 1.726837144 2.710705409 
CERS2 4 176.44 588705.7071 301052.9363 440293.7639 51635.83294 96843.20871 54830.06952 2.600350873 2.709736317 
HM13 2 130.39 383225.6361 102529.1486 156671.5571 23272.99079 59221.12809 19069.04482 1.59629211 2.661153809 
SAE1 2 72.69 3890.241389 36693.09155 21523.55023 2610.669668 4297.940906 3084.428027 1.013332855 2.635757835 
CND1 6 200.77 257381.7777 128069.9417 154547.4966 20634.99669 47027.58195 19621.23527 2.214347347 2.629171265 
PTN1 4 183.41 264518.1559 108556.2263 131336.4813 11256.64812 52480.40639 18327.22862 1.677121747 2.619772988 
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PLCA 2 193.64 441886.5586 180590.0349 272120.6475 54541.70239 41216.35918 50904.62574 2.521353275 2.60873643 
DHRS7 4 237.89 401883.9402 226211.3298 335157.6891 49773.69627 69167.30762 39677.61297 2.815173693 2.602352605 
AT2B4 3 154.72 257229.1241 140766.591 216913.1939 27902.04311 46870.77667 26887.84526 2.683630362 2.596611135 
DPM3 2 151.82 578373.8828 313474.5882 356597.4686 35643.24243 63884.25145 107629.4208 2.133913771 2.591337469 
FANCI 7 434.1 395294.5467 231748.3048 266809.9435 23677.31952 100412.6155 24300.87146 1.794114836 2.590635546 
RTN4 6 613.34 2121249.96 1560747.279 2014244.737 159811.5296 493862.9157 303631.4221 2.277626803 2.572958576 
RBM4B 2 98.18 61416.63114 33119.93986 38152.43033 4916.94302 8950.836281 8663.772401 2.556655045 2.558030212 
PSMD3 2 245.18 114804.9216 146011.2766 98208.84142 10785.86589 37228.27732 13231.40081 2.055153907 2.551407678 
PEX19 3 111.31 256611.5387 124402.0876 204015.0439 36221.04114 34849.66186 29990.88899 2.826869318 2.533272516 
PIGT 2 48.14 39631.64016 16687.27352 21902.80234 3557.777583 6985.109388 2970.958715 2.071575356 2.5331309 
MTX1 2 107.82 199779.0345 56382.52488 205912.0841 29400.98041 29975.51966 21267.56121 1.658718923 2.5184826 
ARF4 2 414.66 83496.06429 106467.4647 86529.65113 5987.003745 24529.6364 17948.45289 1.917368162 2.51222597 
ETFD 2 146.39 254740.0909 81643.01257 124750.6509 20051.33662 39664.18429 22563.43741 1.869501809 2.486589839 
STX12 4 147.51 307407.5334 145356.9347 210470.3903 61214.81117 28791.95736 31703.75157 2.223126199 2.446065961 
RAB21 4 383.93 430263.783 217757.6447 316930.8193 83941.37533 71040.20029 23516.33662 1.795960819 2.434550349 
STX7 3 183.19 149866.5358 72172.90691 81657.27117 11483.51137 31535.27042 13658.48211 1.961911663 2.421789279 
LCLT1 3 168.03 200207.5912 111411.7384 119419.2734 5447.028811 55163.06776 21584.71025 1.34525365 2.39069793 
UBAC2 5 251.41 668492.4328 174492.2968 234308.6343 93470.15552 68910.54127 44404.09217 1.521798462 2.381209202 
PCH2 7 370.58 274138.1814 148990.0612 178754.7844 87842.22272 8037.414571 27574.76832 1.297333141 2.285504812 
SURF4 3 450.51 2326733.372 836510.7474 1029086.667 144164.5799 454369.4798 265216.8944 1.593777903 2.279065249 
COPB 4 332.27 296998.3826 236737.9807 266841.8865 35332.90626 98141.41381 31800.93454 2.02700218 2.276171684 
FACR1 9 593.27 1131804.623 441702.1667 696066.4254 213096.4901 103756.5821 154503.4005 1.966736971 2.267530585 
STX5 2 93.65 326547.1604 161188.8443 221641.6748 44161.93164 35794.55173 67578.96681 2.316270349 2.265492286 
RAB14 3 338.45 524554.0248 288185.7662 361188.4104 50150.38516 130743.0036 65390.84296 2.071224371 2.252948007 
MET7A 2 139.31 229386.7968 112371.5828 151099.6361 13528.88939 27408.65651 62597.17065 1.601637099 2.251057486 
SMN 4 207.52 262084.9768 233184.8888 193074.1244 48302.97518 76662.02219 24690.24407 2.048564816 2.201486903 
RFT1 2 140.05 324282.9051 121907.1591 149878.7574 45844.43004 46461.21891 37649.44843 2.029915184 2.197465689 
CHIP 2 65.87 28242.34548 61483.79093 58918.28396 6133.876898 12710.07019 13884.49323 1.860971788 2.183248553 
F10A1 10 779.1 3605670.176 2452277.739 3487307.46 679652.1486 888615.1282 546578.9523 2.896366525 2.174231028 
ABCD3 2 88.1 222127.9399 164279.1518 123607.2643 5461.72324 48391.36376 59235.48518 1.135779148 2.173084707 
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RDH10 3 163.73 658740.3396 289840.3984 429233.7152 90977.6557 181422.7298 33755.62092 1.426778706 2.170042724 
DIC 3 191.4 355047.2263 153114.2225 218580.3995 62962.51284 45317.41289 55214.31943 2.274592668 2.152203129 
PO210 7 264.46 224424.012 183069.182 169095.6943 34828.00755 54028.21941 44162.32255 3.19640142 2.11591559 
P5CR2 2 362.2 165490.5299 197684.6675 178764.2287 25452.9813 54442.29878 46460.18873 2.497937846 2.1006435 
PRRC1 2 121.83 191405.489 114688.5823 129522.4701 15714.16825 35294.36761 51502.05182 1.794921878 2.087285813 
S23IP 4 265.91 333884.4498 232062.4698 223640.2458 29033.73614 102326.7892 54677.72385 1.806077084 2.085499271 
T161A 2 63.17 108825.4657 61651.22554 68263.3478 15846.4006 18637.01003 22077.70179 2.683946144 2.077558141 
TMED9 5 363.38 1253653.149 578157.0519 672913.3144 183378.6419 264903.5635 149474.1244 2.074456562 2.067021953 
AR6P1 3 131.23 489285.9693 288949.3972 338721.8629 92220.09666 40426.1019 138925.167 1.726018494 2.040170668 
RAB5B 2 287.25 209507.8602 128353.7983 178747.3835 41129.10539 41887.6554 43006.70038 3.181315249 2.035380556 
ATD3A 6 832.07 2174020.325 732954.0369 1057578.753 370243.8775 219969.4182 378111.5939 1.663259947 2.033595172 
SUCB1 2 224.49 125568.8631 179226.2471 151200.0127 25714.07654 69586.44793 16196.27991 1.639898078 2.032016032 
TMM33 7 354.95 1913965.496 630100.331 842094.0235 229505.3295 316503.1442 283805.0703 1.702447933 2.02879097 
RCN1 4 328.55 114844.7278 393001.1036 246926.7618 47442.28536 74828.6619 63206.94519 1.565444115 2.024794799 
MPCP 11 551.93 1519012.27 599678.7053 776219.856 211155.7967 436821.1525 65996.64336 1.208816589 2.019576291 
SCO1 3 135.25 267182.7672 158740.3064 192179.9676 39971.35238 73570.49852 38950.57203 2.279390498 2.019109804 
HAT1 2 70.98 176300.8231 231910.0048 138430.4227 15584.79959 56372.4518 63386.10531 1.504908034 2.013970258 
MARC1 3 233.52 285533.5531 147277.7749 223659.877 82800.02608 21974.86641 58031.0013 1.561397873 2.011578803 
SRP68 3 193.7 247354.2736 223401.8082 249725.8688 58556.49659 51674.64419 69666.83771 3.925192934 2.001783313 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-3aM. Protein identifier (ID) and the number of 
unique peptides used to identify proteins are indicated. Relative abundance score for each protein is shown. Confidence score (-Log2) is the score of the 
probability of the peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in 
protein identification. The p-value (-Log10) is a comparison of the cellular protein abundance between GFP-3aM and GFP. The higher the p-value, the higher 
the probability the protein interacts with 3aM. The fold-change (Log2) is the change in the relative abundance of the cellular protein detected between GFP-
3aM and GFP. 
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Figure 3.6 Scatter plot representing results from the GFP-3aM co-IP.  
Proteins were identified in the GFP-3aM eluate by LC-MS/MS. Proteins were plotted by 
fold-change in abundance (Log2) compared to the GFP control and p-value (-Log10) of 
the t-test. Proteins with a p-value (-Log10) above one and a fold change (Log2) above 
two have the highest chance of interacting with 3aM and are considered significant 
(green). Proteins with a fold-change (Log2) in relative abundance above 5 over the GFP 
control are labelled. Results are from three biological replicates.  
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A panther over-representation test (pantherdb.org) was performed to categorise 
the cellular localisation of the significant proteins identified in the GFP-3aM eluate 
by LC-MS/MS. This test grouped cellular proteins by their Gene Ontology (GO) 
cellular compartment annotation and helped to determine if these cellular 
compartments are over-represented in the dataset. The test compared the 
number of proteins you would expect to find in the data set for each GO cellular 
compartment, to the actual number of proteins identified. A higher actual number 
of proteins would suggest that the interacting partners identified for 3aM localise 
to a specific cellular component (Appendix, Table 7.2). Cellular compartments 
with a p-value below 0.05 were considered significant. The number of proteins 
that localise to these significant GO cellular components were represented as a 
Venn diagram (Figure 3.7). Of the 135 proteins identified, 78 of the proteins can 
localise to membrane structures of the cell with a significant proportion of proteins 
localising to the nuclear envelope, ER, ER-GIC, mitochondria and Golgi 
membrane. Other cellular components that these interacting partners localise to 
also include the proteasome and peroxisome. The remaining 58 proteins, did not 
localise to a GO cellular component that was over-represented in the data set.  
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Figure 3.7 GO cellular component annotations of cellular proteins that interact with 
GFP-3aM.  
Significant proteins identified by LC-MS/MS were analysed by a panther over-
representation test (pantherDB.org). Proteins which localise to cellular components that 
are over-represented (p < 0.05) were collated and represented as a Venn diagram. 
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3.6. IBV 3a interaction with RNF5 and CAND1 
Due to the role of 3a in IFNβ expression, proteins identified by LC-MS/MS that 
play a role in the IFN cascade were investigated. Three proteins were identified 
that play a regulatory role in IFN expression, RING Finger 5 (RNF5), Cullin-
Associated NEDD8-Dissociated protein 1 (CAND1) and Autocrine Motility 
Factor Receptor (AMFR). RNF5 and AMFR both target MAVS for degradation 
by the addition of ubiquitin, while CAND1 is a regulatory protein of the E3-
Skp1-Cul1-Fbox (SCF) ligase complex, which plays a role in IRF3/IRF7 
degradation (Zheng et al. 2002, Zhong et al. 2010, Jacobs et al. 2014). RNF5 
and CAND1 were the fifth and eighth highest confidence interacting partners 
for 3aM (Table 3.1). The interaction was first verified by looking at GFP-3aM 
and RNF5/CAND1 colocalisation. Vero cells were transfected with GFP-3aM 
or GFP expression vectors. After 16 hours, cells were fixed, permeabilised and 
labelled with anti-GFP and anti-CAND1 or anti-RNF5. To determine what 
percentage of 3a signal colocalised with RNF5 and CAND1, twenty cells 
expressing 3aB-FLAG were analysed using ImageJ. For each region of 
interest, the amount of anti-GFP signal that colocalised with anti-RNF5 or anti-
CAND1 signal was calculated and averaged. This demonstrated that 9.63% 
and 27.4% of 3a-GFP signal colocalised with RNF5 and CAND1, respectively. 
Overexpressed GFP-3aM therefore partially colocalises with both CAND1 and 
RNF5 (Figure 3.8A,B), while 3a also partially colocalised with RNF5 during 
infection (Figure 3.8C). The result suggests that 3a does interact with RNF5 
and CAND1 as the mass spectrometry data suggested.  
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Figure 3.8 IBV 3a partially colocalises with RNF5 and CAND1.  
Vero cells were transfected with GFP-3aM expression vectors. After 16 hours, cells were 
fixed, permeabilised, and labelled with (A) anti-RNF5 or (B) anti-CAND1. (C) Vero cells were 
mock infected or infected with M41-CK at an MOI above 4 for 24 hours. Cells were fixed and 
labelled with anti-RNF5. The nucleus was stained with DAPI.  
A 
B 
C 
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3.7. Characterisation of IBV 3a interaction with MAVS  
Mass spectrometry data identified two E3 ligases which regulate IFN 
expression through interaction with MAVS, RNF5 and AMFR (Zheng et al. 
2002, Prakash et al. 2006, Zhong et al. 2010, Jacobs et al. 2014). RNF5 and 
AMFR poly-ubiquitinate MAVS, targeting MAVS for proteasomal degradation. 
The levels of MAVS was measured in the presence of 3aM, to determine the 
effect of these interactions. 
 
3.7.1. IBV 3a increases levels of MAVS 
The effect of 3a on MAVS was first investigated by quantifying levels of MAVS 
by western blot. Vero cells were transfected with pFLAG-3aB or pFLAG 
expression vector. Cells were then transfected with poly(I:C) to stimulate the 
IFN signalling cascade. After 12 hours, cells were lysed, samples separated 
by SDS-PAGE, transferred to a membrane and labelled with anti-MAVS 
(human), anti-3a and anti-actin. MAVS can be expressed as multiple isoforms, 
full-length MAVS (flMAVS) at around ~75 kDa and short MAVS (sMAVS) which 
is between 30 – 50 kDa. These MAVS isoforms play different roles in IFN 
signalling, with the flMAVS the primary signalling protein for the IFN cascade 
(Seth et al. 2005, Jacobs et al. 2013). Anti-MAVS can label both isoforms. 
Signal fluorescence was measured for flMAVS and sMAVS and then 
normalised against actin signal. Levels of flMAVS was visibly higher when 
expressed with 3aB-FLAG compared to the empty vector control (Figure 3.9A), 
while levels of sMAVS was unaffected (Figure 3.9B). This result suggests that 
3a can stabilise or increase MAVS expression.  
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3.7.2. IBV 3a localises with MAVS 
To further characterise the effect of 3a on MAVS, immunofluorescence was 
used to establish if MAVS and 3a colocalise. DF-1 cells were transfected with 
plasmids expressing 3aB-FLAG and chMAVS-V5. After 16 hours, cells were 
fixed, permeabilised and labelled with anti-V5, anti-FLAG and the nucleus 
stained with DAPI. Colocalisation of chMAVS and 3aB-FLAG was observed, 
as indicated by the yellow signal, although there was not perfect colocalisation 
B A 
Figure 3.9 IBV 3a increases levels of MAVS. 
(A) Vero cells were transfected with vectors expressing FLAG or 3aB-FLAG. After 16 
hours cells were lysed, proteins separated by SDS-PAGE, transferred to a membrane 
and incubated with anti-3a, anti-MAVS and anti-actin. (B) Levels of full-length MAVS 
(75 kDa) and small MAVS (30-50 kDa) were semi-quantified by normalising 
fluorescence signal against actin using the Image Studio software (Li-Cor).  
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(Figure 3.10A). To determine what percentage of 3a signal colocalises with 
MAVS, twenty cells expressing 3aB-FLAG were analysed using ImageJ. For 
each region of interest, the amount of anti-FLAG signal that colocalises with 
anti-MAVS signal was calculated and averaged. Only 4.6% of 3aB-FLAG 
signal colocalised with MAVS. Nonetheless, 3aB-FLAG signal does visually 
localise closely with MAVS suggesting they localise to a similar domain 
(Figure 3.10A). 
 
Vero cells were then infected with Beau-R, to determine if 3a also localises 
with MAVS during infection. At 24 or 48 h.p.i cells were fixed, permeabilised 
and labelled with anti-3a or anti-MAVS. During infection, 3a localised with 
MAVS signal at 24 hours. At 48 h.p.i 3a and MAVS signal did localise again, 
and colocalisation was visible. Anti-MAVS signal was visibly lower compared 
to non-infected cells at 48 h.p.i (Figure 3.10B). This result further suggests 
that 3a localises with MAVS although they may not interact directly. 
Furthermore, it appears MAVS levels decline at least 48 h.p.i.  
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Figure 3.10 IBV 3a localises with MAVS. 
(A) DF-1 cells were transfected with pFLAG-3aB and chMAVS-V5. After 16 hours, cells were 
fixed, permeabilised and labelled with anti-FLAG and anti-V5. The yellow box indicates the 
enlarged area. The model was generated using the Imaris software (Bitplane) 3D tool. (B) Vero 
cells were infected with Beau-R at a MOI above 4. After 24 or 48 h.p.i cells were fixed, 
permeabilised and labelled with anti-MAVS or anti-3a. The yellow outline indicates infected cells. 
A 
B 
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3.7.3. IBV 3a agonises IFNβ expression by interfering with MAVS 
IBV 3a had a stimulatory effect on IFN expression when induced with poly(I:C) 
or chMDA-5 (Figure 3.3A,B). Conversely, it was shown that 3a had an 
inhibitory effect on IFN expression when induced with MAVS overexpression. 
The effect was not dose-dependent suggesting that the inhibitory effect is most 
likely because of the effect of 3a on IRF7 downstream (Figure 3.3C,D). For 
this reason, the chIFNβ-luciferase assay was repeated, and the effect of 
poly(I:C) stimulation along with MAVS overexpression on IFNβ expression was 
evaluated. DF-1 cells were transfected with increasing levels of 3aB-FLAG 
vector, made up to 1 µg with pFLAG. Cells were simultaneously transfected 
with the chMAVS-V5 vector. A Renilla luciferase expression vector was used 
as a transfection control. After 8 hours, cells were either mock transfected or 
transfected with poly(I:C). After 12 hours, cells were lysed, and luciferase 
activity measured. As seen before, 3aB-FLAG had an inhibitory effect on 
Firefly luciferase activity when induced with MAVS overexpression. When the 
cells were treated with poly(I:C) as well as 3aB-FLAG, there was a dose-
dependent increase in Firefly luciferase activity (Figure 3.11A). This result 
could suggest that while 3aB-FLAG increases MAVS levels, this does not 
induce IFNβ expression unless stimulated upstream with poly(I:C) or even 
MDA-5. To further confirm this effect, the chIFNβ luciferase assay was 
repeated using four conditions. DF-1 cells were transfected with a combination 
of poly(I:C), MAVS and/or 3aB-FLAG expression vector as indicated and 
luciferase activity measured after 16 hours. As expected, transfection of MAVS 
and poly(I:C) induced significantly higher levels of Firefly luciferase activity 
compared to the poly(I:C) control. Low levels of 3a (250 ng), with poly(I:C) 
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treatment, induced higher levels of luciferase activity compared to poly(I:C) 
alone, as seen previously. Expression of MAVS, 3a, and treatment with 
poly(I:C) induced the highest level of Firefly luciferase activity (Figure 3.11B), 
suggesting that IBV 3a agonises IFNβ expression at the point of MAVS only 
after stimulation with poly(I:C). When the IFN cascade is not stimulated, 3a still 
increases MAVS levels, but no increase in IFNβ expression is observed. This 
effect could be due to the inhibitory effect of 3a on IRF7 activity downstream. 
When stimulated with poly(I:C) or MDA-5 upstream, signalling is exacerbated 
by increased MAVS levels; this is enough to overcome the inhibitory effect of 
3a on IRF7 activity and thus an increase in IFN expression is observed.  
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Figure 3.11 IBV 3a agonises IFNβ expression by interfering with MAVS, only after 
stimulation with poly(I:C).  
(A) DF-1 cells were transfected with FLAG/ 3aB-FLAG and chMAVS-V5 expression vector 
along with a chIFNb-luciferase reporter plasmid. After 8 hours, cells were either mock 
transfected or transfected with poly(I:C). After 12 hours cells were lysed and luciferase 
activity measured. A renilla luciferase plasmid was used as a transfection control. (B) DF-1 
cells were transfected with plasmids expressing chMAVS-V5, 3aB-FLAG or/and transfected 
with poly(I:C) as indicated along with a chIFNb-luciferase reporter plasmid. Empty V5/FLAG 
expression vectors were transfected to maintain levels of total plasmid transfected. Cells 
were lysed after 16 hours and luciferase activity measured. A renilla luciferase plasmid was 
used as a transfection control. Results are representative of three biological replicates. * 
significance p < 0.05, ** significance p < 0.01, *** significance p < 0.001. 
*** 
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3.8. Characterisation of IBV 3a interaction with IRF3/IRF7 
3.8.1. IBV 3a degrades IRF3/7  
Mass spectrometry data and immunofluorescence suggested that IBV 3a 
interacts with the IRF3/7 regulatory protein CAND1. CAND1 binds to Cullin-1 
(CUL1) to inhibit the formation of the E3-SCF ligase complex, a complex that 
mediates the degradation of IRF3/7 (Zheng et al. 2002). To determine whether 
this interaction leads to a decrease in IRF3/7 levels, levels of IRF3 were measured 
in the presence of 3aB-FLAG. Endogenous levels of human IRF3 (huIRF3) were 
first measured in Vero cells as there is no antibody against chicken IRF7. Vero 
cells were transfected with pFLAG-3aB or pFLAG expression vectors. After 16 
hours, cells were lysed, separated by SDS-PAGE and transferred to a membrane. 
The membrane was labelled with anti-huIRF3 and anti-3a. Compared to cells 
transfected with pFLAG, cells expressing 3a expressed lower levels of IRF3 
(Figure 3.12A). 
 
There is no antibody against chicken IRF7, so to determine if 3a has the same 
effect on the chicken isoform a V5-tagged chicken IRF7 expression vector was 
used. DF-1 cells were transfected with increasing levels of pFLAG-3aB and made 
up to 1 µg with pFLAG, along with 500 ng of pEF1a-chIRF7-V5. After 16 hours, 
cells were lysed, separated by SDS-PAGE and transferred to a membrane. 
Membranes were incubated with anti-V5, anti-FLAG, and anti-actin. Levels of 
chIRF7 decreased as levels of 3aB-FLAG increased (Figure 3.12B). This result 
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suggests that 3aB-FLAG can decrease levels of chIRF7 in a dose-dependent 
manner. 
 
To determine if this effect is due to proteasomal degradation, a proteasomal 
inhibitor, MG132, was used. DF-1 cells were transfected with GFP-3aM 
expression vector along with chIRF7-V5 for 12 hours. Cells were then treated with 
either MG132 or DMSO for 8 hours. Cells were lysed, proteins separated by SDS-
PAGE, transferred to a membrane and incubated with anti-V5 and anti-GFP. 
Compared to DMSO treatment, cells transfected with GFP-3aM treated with 
MG132 expressed higher levels of IRF7-FLAG (Figure 3.12C). This result 
suggests that 3a initiates IRF7 degradation in a dose-dependent manner, 
proteasome-dependent manner.  
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Figure 3.12 IBV 3a induces degradation of IRF7 in a dose-dependent, proteasome-
dependent manner.  
(A) Vero cells were transfected with either 3aB-FLAG or FLAG expression vectors. After 
16 hours, cells were lysed, separated by SDS-PAGE and transferred to a membrane. The 
membrane was labelled with anti-huIRF3 and anti-3a. (B) DF-1 cells were transfected with 
increasing levels of 3aB-FLAG expression vector made up to 1µg with pFLAG along with 
an IRF7-V5 expression vector. After 16 hours, cells were lysed, proteins separated by 
SDS-PAGE and transferred to a membrane. Membranes were labelled with anti-V5 and 
anti-FLAG. (C) DF-1 cells were transfected with either GFP or GFP-3aM expression 
vectors along with the chIRF7-V5 vector. After 12 hours, cells were treated with either 
DMSO or MG132 for 8 hours. Cells were then lysed, separated by SDS-PAGE, transferred 
to a membrane and labelled with anti-GFP and anti-FLAG.  
A B 
C 
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3.8.2. IBV 3a colocalises with IRF7 
IBV 3a affects the activity of IRF7, to further characterise this effect, colocalisation 
of 3aM and IRF7 was investigated. DF-1 cells were transfected with plasmids 
expressing chIRF7-V5 and GFP-3aM or GFP. Cells were fixed, permeabilised and 
labelled with anti-V5. Cells were visualised, and images taken using a Leica SP5 
confocal microscope. GFP-3aM signal colocalised with the IRF7-V5 signal 
(yellow), while GFP signal alone did not (Figure 3.13). This result shows that 
GFP-3aM colocalises with IRF7 and they may interact. 
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Figure 3.13 IBV 3a colocalises with IRF7.  
DF-1 cells were co-transfected with vectors expressing chIRF7-V5 or GFP-
3aM /GFP. After 16 hours, cells were fixed, permeabilised and labelled with 
anti-V5.  
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3.9. Effect of 3a levels on IFNβ during infection 
The effect of IBV 3a on poly(I:C)-induced IFNβ expression was dose-dependent 
with low levels of 3a having a stimulatory effect on IFNβ expression and higher 
levels of 3a having an overall inhibitory effect on IFNβ expression (Figure 3.3). 
Levels of 3a were semi-quantified with IFNβ expression to determine the effect of 
changes in expression on the action of 3a. CK cells were infected with Beau-R or 
BeauR-Sc3aAUG at an MOI of 0.1. The supernatant was harvested at 24, 36, 48 
and 60 h.p.i. The supernatant was heat inactivated for 1 hour at 65 °C to inactivate 
IBV. Levels of IFNb was then quantified using a quail reporter cell line (CEC-32) 
with a MxA promoter upstream of a Firefly luciferase reporter gene (Schwarz et 
al. 2004). A standard curve was generated to calculate IFNβ levels relative to 
Firefly luciferase activity using serial dilutions of recombinant chIFNβ. As seen in 
previous studies, there was no difference in IFNb levels 24 h.p.i between Beau-R 
and BeauR-Sc3aAUG (Figure 3.14A). While at and after 36 h.p.i, BeauR-
Sc3AUG induced less IFNβ expression compared to wild-type Beau-R, 
suggesting 3a induces IFNβ expression late in infection.  
 
Levels of 3a can affect the role of this protein in inducing or inhibiting IFN 
expression. To determine if induction of IFNβ by 3a during infection is coupled 
with lower levels of 3a, a time course was performed. CK cells were infected with 
Beau-R at an MOI of 0.1 for 4, 8, 12, 16, 24, 36 and 48 hours. Cells were then 
lysed, proteins separated by SDS-PAGE, transferred to a membrane and labelled 
with anti-3a and anti-actin. Peak levels of 3a occurred at 24 h.p.i and declined at 
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36 h.p.i (Figure 3.14C). The decline in 3a levels coincided with increased IFNβ 
levels, possibly suggesting low levels of 3a are, in part, responsible for the 
induction of IFNβ expression seen during infection, although the role of other IBV 
viral proteins has not been discounted.    
 
An MG132 proteasome inhibitor was then used to determine if this decrease in 
3a levels is due to proteasomal degradation. DF-1 cells were infected with Beau-
R and after 28 hours, cells were either treated with DMSO or 5/10 µM of MG132. 
After 8 hours, cells were lysed, proteins separated by SDS-PAGE, transferred to 
a membrane. Membranes were labelled with anti-3a. Higher levels of 3a were 
detected for infected cells treated with 10 µM of MG132 (Figure 3.14C). This 
result suggests that proteasome degradation of 3a is, in part, responsible for the 
decrease in 3a levels 36 h.p.i. 
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Figure 3.14 IBV 3a induces IFNβ expression during infection, coinciding with a 
decrease in 3a levels.  
(A) CK cells were infected with Beau-R or BeauR-Sc3aAUG at an MOI of 0.1. At each 
indicated time-point the supernatant was removed and IFNβ levels quantified using a MxA-
luciferase reporter cell line. Recombinant chIFNb was used to generate a standard curve. 
Results are from three biological replicates. (B) CK cells were infected with Beau-R at an MOI 
of 0.1. At 4, 8, 12, 24, 36 and 48 h.p.i, cells were lysed, proteins separated by SDS-PAGE 
and transferred to a membrane. Membranes were incubated with anti-3a and anti-actin. (C) 
CK cells were infected with Beau-R at an MOI of 0.1. Cells were treated with DMSO or 5/10 
µM of MG132. After 8 hours, cells were lysed, proteins separated by SDS-PAGE, transferred 
to a blot and labelled with anti-3a. Results are representative of three biological replicates. * 
significance p < 0.05. 
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3.10. Discussion 
Previous work has shown that IBV 3a localises to two compartments during 
infection and transfection in Vero cells, the cytoplasm; where it is diffuse, and the 
smooth ER, where it is membrane-bound (Pendleton et al. 2005). Analysis of the 
GFP-3aM mass spectrometry data predominantly identified membrane-bound ER 
proteins but did also identify proteins that localise to the Golgi, mitochondria, and 
ER-GIC membrane as well as the nuclear envelope and proteasome regulatory 
units (Figure 3.7). Previous work has shown that adding a GFP-tag to 3a 
increased ER membrane localisation while decreasing cytoplasmic localisation 
(Pendleton et al. 2005). It was suggested that extension of the 3a peptide 
sequence increased the efficiency of the signal peptide sequence in 3a, 
increasing ER translocation by signal recognition particles. (Pendleton et al. 2005). 
This observation could explain why a significant proportion of proteins detected 
in the GFP-3aM co-IP eluate were ER membrane proteins (Figure 3.7). A GFP-
tag was used in the co-IP as GFP ‘capture’ beads are highly efficient in pulling 
down GFP and are thus suited for LC-MS/MS. Nonetheless, as the GFP-tag may 
have skewed the localisation of 3a to the ER, a different, smaller tag should be 
used in any future repeats. A smaller epitope tag would better replicate the pattern 
of 3a localisation seen during infection and would give more representative mass 
spectrometry results, potentially allowing other 3a functions to be identified. The 
GFP co-IP was used with 3a from M41-CK as opposed to Beau-R. Beau-R and 
M41-CK 3a have a high sequence similarity (Figure 3.4A) and are unlikely to 
have different roles or functions when overexpressed alone. Furthermore, 3aB 
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and 3aM have a similar effect on IFNβ promoter activity suggesting they are 
functionally comparable (Figure 3.4B). The mass spectrometry data identified a 
range of proteins that interact with GFP-3aM, and while many were membrane-
bound, there was no consensus regarding their cellular role (data not shown). The 
identification of membrane proteins in a range of cellular components suggests 
that 3a can localise to a range of cellular structures when expressed alone 
(Figure 3.7). These cellular membrane proteins can often localise to multiple 
cellular organelles and highlight the dynamic nature that exists between the ER, 
ER-GIC and Golgi, and the ER, mitochondria, and peroxisomes, through 
membrane-associated membrane (MAM) structures (Prinz 2014). The mass 
spectrometry was not repeated with a vector expressing 3aM-GFP, which may 
have identified proteins that interact with the N-terminus or additional proteins. 
Instead, the decision was made to save time and cost by focusing on proteins 
identified in the LC-MS/MS that play a role in the IFN cascade (Figure 3.3). Future 
work should focus on the other proteins identified by mass spectrometry as they 
may allude to additional functions for 3a. Furthermore, expression vectors with 3a 
tagged at the N- and C- terminus should also be used to identify the full repertoire 
of 3a interacting partners. 
 
Previous work has shown that 3a plays a role in regulating the IFNβ response 
during IBV infection (Kint et al. 2015). Recombinant viruses lacking 3a showed 
increased IFNβ transcription but only at 24 h.p.i. No effect on IFNβ protein 
expression was observed at this time. Conversely, deletion of 3a caused a 
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decrease in IFNβ protein expression at 48 h.p.i. The reason for this discrepancy 
is unknown but does show a possible complicated relationship between 3a and 
the IFN cascade  (Kint et al. 2015). This result was confirmed here in CK cells 
(Figure 3.14). The reason for this seemingly contradictory effect is not fully 
understood, as is the mechanism of action of 3a on the IFN cascade (Kint 2015). 
To determine the mechanism of action, a chIFNβ-luciferase assay was used to 
measure IFNβ promoter activity in DF-1 cells. By stimulating the IFN cascade at 
different points, the effect of 3a activity on each section of the cascade could be 
investigated. When the cascade was induced with poly(I:C), low levels of 3a 
exacerbated IFNβ expression, while at higher levels IFNβ expression dropped 
until it was not significantly different to the poly(I:C) control (Figure 3.3A). This 
observation was also seen with MDA-5 overexpression (Figure 3.3B). This result 
correlates with previous work which has shown that IBV infected cells, once 
stimulated with poly(I:C), leads to higher levels of IFN expression compared to 
either poly(I:C) transfection or IBV infection alone and suggests 3a is responsible 
for this previously observed feature (Kint et al. 2015). Conversely, 3a only had an 
inhibitory effect on MAVS and IRF7 induced IFNβ expression, with the effect on 
IRF7 being dose-dependent (Figure 3.3C,D). Therefore, IBV 3a interacts with the 
IFN cascade in two ways, by i) exacerbating MDA-5 and poly(I:C) signalling and 
ii) inhibiting IRF7 activity. These two interactions affect the overall action of 3a on 
IFNβ expression. Higher levels of 3a favour the inhibitory role of 3a, while lower 
levels favour the stimulatory role on IFNβ expression. This result suggests that 
3a is more efficient at stimulating IFNβ expression but is less responsive to 
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increases in 3a, most likely suggesting there is a cap on how much 3a can 
stimulate IFNβ expression. Conversely, the 3a inhibitory effect is not efficient 
enough at low levels to overcome the stimulatory effect upstream but is more 
responsive to increases in dose. This implies there is a tipping point between 
when the stimulatory effect and the inhibitory effect is observed, dependent on 
levels of 3a. A similar effect was seen during infection, where the decline in 3a 
levels coincided with increased levels of IFNβ expression (Figure 3.14A). During 
infection, 3a was detectable at 4 h.p.i and reached peak levels at 24 h.p.i (Figure 
3.14B), after which levels started to decline due to both a reduction in viral 
expression and proteasome-dependent degradation (Figure 3.14C). These 
changes in 3a levels could have a significant effect on the role of this protein 
during infection. The decline in 3a levels at 36 h.p.i could mark the tipping point 
between the inhibitory effect and stimulatory effect of 3a. At 24 h.p.i the inhibitory 
effect of 3a counteracts the stimulatory effect, but after 36 h.p.i, the decline in 3a 
levels causes a shift, and the stimulatory effect is observed, resulting in an 
increase in IFNβ expression. As seen in previous studies there was no difference 
in IFNβ expression pre-24 h.p.i between the BeauR-Sc3aAUG and wild-type 
Beau-R (Kint et al. 2015). While this could imply that 3a does not have an 
inhibitory effect on IFNβ expression early on in infection, this most likely reflects 
the role of other viral proteins in inhibiting IFNβ expression. Indeed, IBV accessory 
protein 5b has been shown to inhibit cellular translation to prevent IFN expression 
(Kint et al. 2016). Future work should aim to qualify the role of 3a in the context 
of infection and relate it to the other IBV IFN antagonists.  
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The mechanism of action of 3a on IFN signalling can be explained by the 
interacting partners identified by mass spectrometry. Three proteins were 
identified that play a role in regulating the IFN cascade, RNF5, AMFR and CAND1 
(Table 3.1, Figure 3.6). RNF5 and AMFR regulate the turnover of MAVS, while 
CAND1 is a protein that regulates the formation of the SCF-E3 ligase, a multi-
protein complex that degrades IRF3/7 (Zheng et al. 2002, Prakash et al. 2006, 
Zhong et al. 2010). RNF5 and CAND1 were identified as significant 3aM 
interacting partners and colocalise with 3a during transfection and infection for 
RNF5 (Figure 3.8). RNF5 is an E3 ubiquitin ligase that controls IFN expression 
in a negative feedback loop (Zhong et al. 2010). During infection, IFN increases 
RNF5 expression and causes it to translocate from the ER to MAM structures 
where it interacts with MAVS (Zhong et al. 2010). These MAM structures are an 
important structure for IFN signalling cascade as a site for MAVS aggregation and 
activation (Jacobs et al. 2014). RNF5 polyubiquitinates MAVS to target it for 
proteasomal-degradation and thus inhibits IFN signalling. The IFN cascade is a 
highly controlled cellular pathway as over-expression of IFN can have a 
deleterious effect on the cell and the organism as a whole (Hu et al. 2016). Post-
translational conjugation of ubiquitin and degradation of IFN signalling proteins is 
a major mechanism used to regulate the IFN signalling cascade, both positively 
and negatively (Lin et al. 2006, Castanier et al. 2012, Fuchs 2012, Hu et al. 2016). 
The interaction between RNF5 and 3a could explain the increase in MAVS levels 
observed during 3a expression (Figure 3.9). Expression of 3a increased or 
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stabilised levels of MAVS (Figure 3.9), this increase was responsible for the 
agnostic effect of 3a on IFN signalling (Figure 3.11), that is, 3a increased MAVS 
levels which exacerbated RLR signalling. This effect could be due to 3a inhibiting 
RNF5 activity and thus preventing turnover of MAVS (Figure 3.15A). Future work 
should aim to determine if these proteins interact during infection and determine 
if overexpression of RNF5 can abrogate the agonistic effect of 3a on IFNβ 
expression. While a small proportion of 3a did colocalise with MAVS during 
transfection in DF-1 cells, most of the signal was juxtaposed (Figure 3.10A). 
Immunoprecipitation of 3a failed to identify MAVS as a 3aM binding partner by co-
transfection (data not shown) and was not identified in the GFP-3aM mass 
spectrometry data. This result implies that MAVS and 3a do not interact directly 
but may localise to similar cellular compartments, possibly even MAM structures.    
 
The other IFN regulatory protein identified by mass spectrometry was CAND1. 
This protein inhibits the recruitment of CUL1 to the SCF-E3 ligase complex, a 
complex which is involved in the degradation of IRF3/IRF7 (Zheng et al. 2002, 
Prakash et al. 2006). Expression of 3a decreased levels of IRF7 in a dose-
dependent, proteasome-dependent manner (Figure 3.12). This effect coincides 
with the dose-dependent effect of 3a on IRF7 induced IFNβ expression (Figure 
3.3D). A proposed mechanism of action was that 3a interacts with CAND1, 
increasing CUL1 recruitment to the SCF-E3 ligase, thus increasing degradation 
of IRF7 (Figure 3.15B). Future work should aim to confirm this mechanism of 
action and determine if CAND1 overexpression can abrogate the decrease in 
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IRF7 levels by 3a. While CAND1 and 3aM do colocalise; as determined by 
immunofluorescence (Figure 3.8), future work should also aim to confirm this 
interaction during infection by IP.  
 
Manipulating the cellular ubiquitin degradation pathway is an attractive option for 
viruses, as it allows viruses to modulate the host-cell environment by targeting 
cellular proteins for degradation. IAV NS1 targets RNF135, a protein essential for 
the ubiquitination and activation of RIG-I, while SARS-CoV N has been shown to 
interact with the RLR and MAVS regulatory protein TRIM25 (Rajsbaum et al. 2012, 
Hu et al. 2017). Hepatitis B virus (HBV) protein HBx directly interacts with MAVS 
and targets it for degradation through the addition of ubiquitin residues, while 
KSHV RTA protein has been shown to amplify the activity of RAUL, an E2 ligase 
involved in the ubiquitination of IRF3 and IRF7 (Wei et al. 2010, Yu et al. 2010). 
The main aim of these viral proteins is to inhibit IFN signalling by modulating levels 
of IFN signalling proteins. This appears to be how IBV 3a effects IFNβ expression, 
by interacting with RNF5 and CAND1, 3a can modulate levels of both MAVS and 
IRF7. This interaction appears to be dynamic, allowing 3a to both inhibit and 
stimulate IFN expression depending on dose and thus time. While it is more 
common for viral proteins to inhibit IFN expression, it is not unheard of for viral 
proteins to stimulate IFN expression too. Mopeia Virus L protein has been shown 
to induce IFN expression by activating the RLR/MAVS pathway (Zhang et al. 
2016), while HCV RdRp has been shown to actively produce dsRNA based on 
cellular RNA that can induce IFN expression (Yu et al. 2012). This function may 
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seem counterproductive for the virus, but it can help to prevent excessive host 
damage or disease that can be detrimental for viral replication. For example, 
piglets infected with a recombinant TGEV that does not express accessory protein 
7, showed increased pathogenicity, suggesting protein 7 plays a role in inhibiting 
excessive host damage (Cruz et al. 2011).  
 
The interesting dynamic between 3a and the host could have serious implications 
for pathogenicity. While it may seem counterproductive to induce IFN expression, 
it may be beneficial in a disease which is associated with immunopathology 
(Zhong et al. 2012, Kameka et al. 2014). IBV pathogenesis has been linked to an 
exacerbated immune response with serve symptoms like nephrotoxicity 
associated with a high influx of effector cells and interleukins (Okino et al. 2014). 
The full link between host-interaction and pathogenicity has yet to fully elucidated 
but these interactions, shown here, could explain the unique and complex 
relationship between host immune system and IBV. 
 
The IFN response is the primary battleground for the evolutionary arms race 
between virus and host (Randall et al. 2008). Coronaviruses have been shown to 
use a range of mechanisms to combat the IFN response with IBV being no 
exception (Fung et al. 2014). Here accessory protein 3a has been shown to have 
a dynamic relationship with two parts of the IFN cascade, MAVS and IRF7. While 
this has offered a glimpse into the relationship between IBV and host, much more 
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work is required to determine how IBV manipulates the IFN response and the 
impact this has on pathogenicity.  
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Figure 3.15 Proposed model for the mechanism of action of IBV 3a on IFNβ 
expression.  
During infection, IBV produces dsRNA which is detected by MDA-5 which initiates the IFN 
signalling cascade. IBV 3a modulates the IFN cascade by two proposed mechanism, (A) 
IBV 3a interacts with and inhibits RNF5 degradation of MAVS, leading to increased RLR 
signalling and thus increased IFNβ expression. (B) IBV 3a interacts with and inhibits 
CAND1, increasing the recruitment of CUL1 to the E3 SCF-ligase complex. These 
complexes target IRF3/7 for degradation leading to a reduction in IFNβ expression.  
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4. The role of Accessory Protein 3b 
4.1. Introduction 
Accessory protein 3b is a 7.4 kDa protein encoded by the second ORF of sgRNA3, 
which is translated by leaky ribosomal scanning (Le et al. 1994). Protein 3b is 
highly conserved among strains of IBV and TCoV suggesting an important role 
for this protein (Cavanagh et al. 2002, Britton et al. 2006). Little is known about 
the function of 3b, although it is known that this protein does not play a role in in 
vitro replication as recombinant IBV lacking 3b expression grew to similar titres 
as wild-type IBV (Hodgson et al. 2006). Furthermore, recombinant viruses with a 
scrambled 3b start codon expressed higher levels of IFNβ at 24 h.p.i suggesting 
3b can inhibit the IFN cascade in some, as yet unknown, manner (Kint et al. 2015). 
Protein 3b displays different localisation in mammalian and avian cells, with a 
nuclear localisation in Vero cells and a diffuse cytoplasmic pattern in DF-1 cells 
(Pendleton et al. 2006). A truncated variant of 3b has been detected in a serially 
passaged strain of Beau-R, resulting in higher viral titres in vitro suggesting an 
advantageous mutation (Shen et al. 2003). This truncation resulted in a different 
cellular localisation in mammalian COS-7 cells, from the nucleus to the cytoplasm, 
suggesting that the cytoplasmic localisation is important for the function of 3b. 
Protein 3b is degraded quickly by the proteasome in mammalian cells and is 
degraded independently of the proteasome in avian cells. This leads to a short 
half-life for 3b making it difficult to detect during transient expression and infection 
(Pendleton et al. 2006). In this chapter, interacting partners for 3b were identified 
which play a role in regulating IFN expression and apoptosis. Furthermore, a 
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recombinant virus lacking 3b expression was shown to induce less caspase-
dependent apoptosis during infection, suggesting 3b has a role in inducing 
apoptosis. 
 
Results 
4.2. Bioinformatic analysis of 3b 
IBV 3b is a highly conserved accessory protein present in IBV and TCoV strains 
with a sequence identity of 60.4% - 100% (Britton et al. 2006). To investigate the 
role of 3b, four isoforms of 3b were aligned, and a eukaryotic linear motif (ELM) 
search was performed to identify motifs which may suggest a function. Protein 3b 
is dispensable for in vitro replication and therefore has been suggested that 3b is 
a pathogenicity factor (Hodgson et al. 2006). For this reason, 3b from Beau-R 
(3bB), M41-CK (3bM), Qx (3bQ) and from a serially passaged strain of Beau-R 
which expresses a truncated form of 3b (3bT) were investigated. Beau-R and 
M41-CK are lab strains, which are apathogenic and pathogenic, respectively, 
while Qx is a highly pathogenic field strain. Protein 3bT is expressed from a 
serially passaged strain of Beau-R and has a C-terminal truncation resulting in a 
34 amino acid long protein (Shen et al. 2003). This truncated variant localises to 
the cytoplasm in COS-7 cells as opposed 3bB which localises to the nucleus. 
Peptide sequences of 3bM, 3bQ, and 3bT were aligned against 3bB and 
sequence identity determined (Figure 4.1). Sequence alignment of 3bB and 3bM 
showed that 3b is highly conserved between these two strains, with a sequence 
identity of 98.43% and only one amino acid difference (V > A). Interestingly the 
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high pathogenic strain, Qx, was more diverse with a sequence identity of 67.2% 
compared to 3bB. The truncated variant 3bT had a lower sequence identity of 
52.94%, although the N-terminus of 3bT was highly conserved with the N-
terminus of 3bB.  
 
The Eukaryotic Linear Motif (ELM) tool was used to identify any motifs that may 
help to determine function. This tool aims to identify motifs which have previously 
been shown to mediate protein-protein interactions. Due to the high incidence of 
false positives when using this tool, little can be inferred from these results alone. 
ELM analysis of 3bB and 3bM identified 11 motifs with LIG_DCNL_PONY_1 and 
DOC_AGCK_PIF_2 being the most significant and are described in Table 4.1. 
Interestingly the ELM search for 3bQ did not identify these two motifs. The third 
most significant interaction, AP2alpha_2, which did appear in Qx, is a motif which 
mediates binding to AP2, an adaptor protein of clathrin-coated vesicles (Edeling 
64 
63 
64 
64 
IBV3bB  1 MLNLEVIIETGEQVIQKISFNLQHISSVLNTEVFDPFDYCYYRGGNFWEIESAEDCSGDDEFIE 64 
IBV3bT  1 MLNLEVIIETGEQVIQKNQFQFTAYFKCIKHRSI 34 
    ******************  * 
Figure 4.1 Sequence alignment and sequence identity of 3b isoforms. 
Peptide sequences of 3b from M41-CK (red), Qx (green) and a truncated isoform 
identified in a serially passaged strain of Beau-R were aligned to 3b from Beau-R (yellow). 
The asterisk marks conserved amino acids.  
52.94% 
67.2% 
98.43%
Sequence Identity 
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et al. 2006). The 3bT variant, when expressed in mammalian cells, shows a 
diffuse cytoplasmic distribution compared to 3bB which localises to the nucleus. 
The ELM search only identified one nuclear retention domain, RVxF, which 
appears in 3bB/3bM but does not appear in 3bT (Lesage et al. 2004). Only one 
motif identified, DEG_Nend_Nbox_1, was conserved between all isoforms of 3b. 
This motif is a destabilising motif that is recognised by N-recognins and may in 
part be responsible for the short half-life of this protein (Varshavsky 2011). 
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Table 4.1 Eukaryotic linear motifs (ELM) identified in the 3b peptide sequence. 
ELM ID 
Matched 
Sequence 
in 3aB 
Pattern Position Elm Description Cell Compartment Probability 3b
B 
3b
M
 
3b
Q
 
3b
T 
LIG_DCNL
_PONY_1 MLNL ^M[MIL].[MIL] 1-4 
DCNL PONY domain binding motif variant based 
on the UBE2M and UBE2F interactions. 
ubiquitin ligase 
complex, nucleus 4.87E-07 X X  X 
DOC_AGC
K_PIF_2 FDPFDY 
F..[FWY][DE][
FY] 34-39  
In the DOC_AGCK_PIF_2 motif the 
phosphorylatable serine/threonine residue is 
replaced by an acidic aspartate or glutamate 
residue. 
cytosol, internal 
side of plasma 
membrane 
3.27E-06 X X   
LIG_AP2alp
ha_2 DPF DP[FW] 35-37  
DPF/W motif binds alpha and beta subunits of 
AP2 adaptor complex. 
clathrin-coated 
endocytic vesicle, 
cytosol 
0.00012 X X X  
DEG_Nend
_Nbox_1 MLN 
^M{0,1}[FYLI
W][^P] 1-3 
N-terminal motif that initiates protein degradation 
by binding to N-recognins.  cytosol 0.00023 X X X X 
LIG_Pex14
_2 FTAYF F...[WF] 22-26 
Fxxx[WF] motifs are present in Pex19 and S. 
cerevisiae Pex5 cytosolic receptors that bind to 
peroxisomal membrane docking member, Pex14 
cytosol, 
peroxisome, 
glycosome 
0.00046    X 
DOC_PP1_
RVXF_1 IQKISFN 
..[RK].{0,1}[VI
L][^P][FW]. 15-21  
Protein phosphatase 1 catalytic subunit (PP1c) 
interacting motif binds targeting proteins that 
dock to the substrate for dephosphorylation. 
nucleus, protein 
phosphatase type 
1 complex, 
cytosol 
0.00083 X X   
DOC_PP2A
_B56_1 LEAIIE 
([LMFYWIC]..
I.E)|(L..[IVLW
C].E). 
4-9 Docking site required for the regulatory subunit B56 of PP2A for protein dephosphorylation. 
nucleus, 
kinetochore, 
chromosome, 
centromeric 
region, cytosol 
0.00146 X X  X 
LIG_TRAF6 FDPFECCYY 
..P.E..[FYWH
DE] 34-42 
TRAF6 binding site. Members of the tumor 
necrosis factor receptor (TNFR) superfamily 
initiate intracellular signaling by recruiting the C-
domain of the TNFR-associated factors (TRAFs) 
through their cytoplasmatic tails. 
cytosol 0.001715    X 
LIG_SH2_S
TAT5 YCYY (Y)[VLTFIC].. 
25-28 
STAT5 Src Homology 2 (SH2) domain binding 
motif. cytosol 0.00330 
   X 
39-42 X X   
3bB – 3b Beau-R, 3bM – 3b M41-CK, 3bQ – 3b Qx, 3bT – 3b truncated (Beau-R). Results are ordered by p, the probability of the sequence occurring 
randomly
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4.3. Generation of 3b-GFP expression vectors 
To investigate the role of accessory protein 3b, vectors were generated for 
expression of 3b from Beau-R (3bB) and M41 (3bM) fused with a GFP tag at 
either the N- or C- terminus. These expression vectors were used for mass 
spectrometry protein purification. Previous work has shown that 3b fused with a 
FLAG tag was not detectable during transient expression, possibly due to the 
short half-life of this protein (Davies 2009). A GFP-tag was used to increase the 
stability of 3b during transient expression, due to its large size and biological 
stability (Chalfie 2001). For the generation of the 3bB and 3bM expression vectors, 
M41 and Beau-R viral RNA was isolated and reverse transcribed into cDNA using 
random primers. ORF3b was amplified by PCR using complementary primers 
with flanking restriction sites. The PCR product was purified and digested with the 
relevant restriction enzymes. Plasmids pEGFPC2 (Clontech) and pEGFPN1 
(Clontech) were also digested with the same restriction enzymes. Digested 
plasmids and PCR products were ligated and transformed. Vectors were 
sequenced by Sanger sequencing. The vectors generated were pEGFPC2-3bB, 
pEGFPN1-3bB, pEGFPC2-3bM and pEGFPN1-3bM (Figure 4.2A,B,C,D). To 
confirm expression of GFP-tagged 3b from these vectors, DF-1 cells were 
transfected with GFP-3bB, GFP-3bM, 3bB-GFP, 3bM-GFP vectors. After 16 hours, 
cells were lysed, proteins separated by SDS-PAGE, transferred to a membrane 
and labelled with anti-GFP. Bands with the predicted molecular weight of GFP-
tagged 3bB and 3bM were identified as expected, confirming the successful 
generation of these vectors (Figure 4.2E).  
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Figure 4.2 Expression maps and confirmation of expression of GFP-tagged 3b 
vectors. 
(A) pEGFPC2-3bB (B) pEGFPN1-3bB (C) pEGFPC2-3bM (D) pEGFPN1-3bM. (E) DF-
1 cells were transfected with pEGFPC2, pEGFPC2-3bB/3bM, pEGFPN1-3bB/3bM 
expression vectors. After 16 hours, cells were lysed, proteins separated by SDS-PAGE 
and transferred to a membrane. Membranes were labelled with anti-GFP. 
E 
A B 
C D 
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4.4. Mass spectrometry analysis of 3b-GFP pull-downs 
Mass spectrometry was utilised to identify any cellular interacting partners for 
GFP-3bM and 3bM-GFP that may allude to function. As 3bB and 3bM have a high 
sequence identity of 98.43% and are unlikely to function differently when 
expressed alone, the decision was made to save time and cost by investigating 
3bM only. HEK-293T cells were transfected with pEGFPC2-3bM or pEGFPN1-
3bM expression vectors or with a GFP control plasmid. After 16 hours, cells were 
lysed and GFP-3bM, 3bM-GFP or GFP immunoprecipitated using GFP ‘capture’ 
beads (Chromotek). Three biological replicates were performed for each plasmid. 
Before samples were processed, input and eluate samples were separated by 
SDS-PAGE and blots labelled with anti-GFP to confirm successful transfection 
and immunoprecipitation (Figure 4.3). GFP immunoprecipitation could be 
confirmed by directly visualising the GFP fluorescence when attached to the GFP 
capture beads. After confirmation, eluate samples were analysed by LC-MS/MS 
by Stuart Armstrong to identify cellular proteins in the eluates. 
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In total 69 and 54 cellular proteins were detected in higher amounts in the GFP-
3bM and 3bM-GFP eluates, respectively, compared to the GFP control. Of these, 
47 appeared in both samples, with 22 unique to GFP-3bM and 7 for 3bM-GFP 
(Appendix Table 7.3, 7.4). Proteins were identified by comparing unique peptides 
to a database of human proteins. Proteins, where only a single unique peptide 
was identified, were removed to reduce the chance of identifying the wrong 
protein. Cellular proteins deemed significant interactions have a p-value (-Log10) 
Figure 4.3 Western blot analysis of 3bM-GFP, GFP-3bM expression and 
immunoprecipitation.  
HEK-293T cells were transfected with (A) pEGFPC2-3bM and (B) pEGFPN1-3bM 
expression vectors. After 16 hours, cells were lysed and GFP immunoprecipitated using 
GFP ‘capture’ beads (Chromotek). Samples were eluted in the elution buffer. Input and 
eluate samples were separated by SDS-PAGE, transferred to a membrane and labelled with 
anti-GFP.  
A B 
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above one and a fold-change (Log2) above two. The p-value was determined by 
two-tailed unpaired ANOVA on the three replicates. The fold-change is the change 
in average relative protein abundance of each protein between GFP-tagged 3bM 
and the GFP control. For each identified protein, the confidence score (Log2) was 
calculated as the cumulative score of p, the chance of the unique peptide 
sequence occurring randomly. The higher the score, the higher the confidence in 
the correct protein identification. Of the 76 proteins identified, six were considered 
significant for GFP-3bM (Figure 4.4, Table 4.2). None of the proteins for 3bM-
GFP were considered significant, although the proteins that appeared significantly 
in GFP-3bM also appeared in the 3bM-GFP data, as labelled on the scatter plot 
(Figure 4.5). 
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Protein 
ID Protein 
Unique 
peptides 
Confidence 
Score 
Relative Protein Abundance 
P-value 
(-log10) 
Fold Change 
GFP-3bM/GFP 
(Log2) 
pEGFPC2-3bM pEGFPC2 
1 2 3 1 2 3 
BAG6* Large proline-rich protein BAG6 7 43.529 16470945.06 28858040.37 24418986.71 9586813.925 6962480.736 3957176.544 2.906321357 2.487846495 
VDAC2* 
Voltage-
dependent anion-
selective channel 
protein 2 
3 20.668 25898945.09 14765020.26 15152998.83 7499120.63 17683984.02 17660954.73 2.576106121 2.131061799 
COX5B* 
Cytochrome c 
oxidase subunit 
5B, mitochondrial 
4 23.644 30800063.72 19350935.8 16642052.05 29899955.47 5815533.034 17579004.05 2.136701975 2.009682233 
HSPB1* Heat shock protein beta-1 2 14.253 10848031.97 39054893.75 27991976.06 3245524.014 6800974.256 4806149.184 1.786641052 3.158306491 
CLTB* Clathrin light chain B 5 34.721 82785226.63 18960977.42 18320048.67 31371039.53 12264031.74 3230799.969 1.726453339 3.287103251 
RPS24* 40S ribosomal protein S24 3 22.269 30267999.7 24865980.78 17672955.62 28521964.15 29375905.76 4223711.897 1.327963149 2.103594221 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-3bM. Protein identifier (ID), protein name and number of 
unique peptides used to identify proteins are indicated. Relative abundance score for each protein is indicated. Confidence score (-Log2) is the score of the probability of the 
unique peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in protein identification. 
The p-value (-Log10) is a comparison of the cellular protein abundance between 3bM and GFP. The higher the p-value, the higher the probability the protein interacts with 
3b. The fold-change is the change in the abundance of the cellular protein between GFP-3bM and GFP. Cellular proteins which appear in both GFP-3bM and 3bM-GFP data 
are labelled with an asterisk (*).  
Table 4.2 Cellular proteins that significantly interact with GFP-3bM 
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Figure 4.4 Scatter plot representing results from the GFP-3bM co-IP.  
Proteins were identified in the GFP-3bM eluate by LC-MS/MS. Proteins are plotted by 
fold-change in relative abundance compared to the GFP control and p-value (Log10) of 
the t-test. Proteins with a p-value (-Log10) above 1 and a fold change above 2 have the 
highest chance of interacting with 3bM and are considered significant (blue). Results are 
from three biological replicates. 
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Figure 4.5 Scatter plot representing results from the 3bM-GFP co-IP.  
Proteins identified in the 3bM-GFP eluate by LC-MS/MS. Proteins are plotted by fold-
change in abundance over the GFP alone and p-value (-log10) of the t-test. Proteins with 
a p-value (-log10) above 1 and a fold change above 2 have the highest chance of 
interacting with 3bM and are considered significant (blue). Results are from three 
biological replicates. Proteins labelled were identified as significant interactions for GFP-
3bM. 
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LC-MS/MS identified six proteins that are significant interacting partners for 3bM 
(Table 4.3). Gene ontology (GO) analysis of the proteins failed to group the 
proteins based on function or location (data not shown). Nonetheless, three 
proteins were identified that play a role in regulating apoptosis. Voltage-
dependent anion channel 2 (VDAC2) inhibits apoptosis by interacting with and 
inhibiting the pro-apoptotic Bcl-2 homologous antagonist killer (BAK) protein 
(Cheng et al. 2003). BCL2 associated athanogene 6 (BAG6) is a multi-functional 
protein that has been shown to stabilise Apoptosis-inducing factor (AIF), a pro-
apoptotic protein as well as conferring resistance to ER-stress related apoptosis 
(Desmots et al. 2008). Cytochrome c oxidase subunit 5B (COX5B) is a protein 
mainly involved in the electron transport chain, but also interacts with and 
negatively regulates MAVS aggregation by repressing reactive oxygen species 
(ROS) production. COX5B is also a negative regulator of apoptosis as over-
expression of MAVS, or ROS can lead to intrinsic apoptosis (Zhao et al. 2012). 
Furthermore, mass spectrometry data also identified a ribosomal protein, 
ribosomal small protein 24 (RPS24), clathrin light chain B (CTLB) and heat shock 
protein B1. RPS24 is part of the 40S ribosomal complex, while HSPB1 is a 
molecular chaperone that is multi-functional (Bryantsev et al. 2007, Choesmel et 
al. 2008). It has also been reported that HSPB1 inhibits apoptosis by binding to 
both cytochrome C and the pro-apoptotic Bcl-2-associated X protein (BAX) 
protein as well as inhibiting activation of both procaspase-3 and 9 (Bruey et al. 
2000, Concannon et al. 2001, Havasi et al. 2008). CLTB is a structural protein 
that coats the cytoplasmic face of vesicles (Saffarian et al. 2009). Ribosomal 
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proteins and heat-shock proteins are common in mass spectrometry data and 
may represent ‘sticky’ proteins (Mellacheruvu et al. 2013). 
 
Table 4.3 Function and localisation of proteins classified as significant interacting 
partners for GFP-3bM 
Protein ID Protein Function Go Cellular Component 
BAG6* BCL2 Associated Athanogene 6 
Multi-functional protein, 
regulates AIF expression 
preventing ER-stress related 
apoptosis 
Cytoplasm/ 
Nucleus 
VDAC2* Voltage-Dependent Anion Channel 2 
Membrane channel, involved 
in intrinsic apoptosis 
Mitochondrial outer 
membrane 
COX5* 
Cytochrome C 
Oxidase Subunit 
5B 
Role in electron transport and 
negative MAVS regulatory 
protein 
Mitochondrial inner 
membrane 
HSPB1* Heat Shock Protein B-1 
Molecular chaperon, multi-
functional protein 
Nucleus/ 
Cytoplasm/ 
Cytoskeleton 
CLTB* Clathrin Light Chain B 
Clathrin regulatory protein 
essential for endocytosis 
Plasma membrane/ 
Cytoplasm 
RPS24* Ribosomal Protein S24 Small ribosomal protein 
Cytoplasm/ 
Nucleus 
An asterisk (*) indicates proteins that also appeared in the 3bM-GFP eluate but were not statistically 
significant. 
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4.5. Effect of protein 3b on apoptosis 
4.5.1. IBV induces apoptosis 
Mass spectrometry data for GFP-3bM identified three proteins involved in 
apoptosis, VDAC2, BAG6 and COX5B (Cheng et al. 2004, Desmots et al. 2008, 
Zhao et al. 2012). Previous studies have shown that IBV infection can induce 
caspase-dependent apoptosis in Vero cells (Liu et al. 2001, Li et al. 2007). To 
determine if IBV can also induce apoptosis in DF-1 cells a fluorescence-activated 
cell sorting (FACS) assay was used to measure levels of phosphatidylserine (PS) 
expression on the cell surface. In viable cells, PS is expressed on the interior of 
the plasma membrane, while during apoptosis PS is expressed on the exterior of 
the plasma membrane. Annexin V is used to label apoptotic cells due to its ability 
to bind to PS. As it cannot transverse the cellular membrane, it can only label 
externally expressed PS. DF-1 cells were mock infected, infected with Beau-R or 
BeauR-Sc3bAUG at an MOI of 4. After 24 hours, cells were gently trypsinised and 
labelled with Annexin V to detect apoptotic cells. Dead apoptotic cells were 
labelled with propidium iodide (PI). PI is a chromatin stain that cannot pass 
through the membrane of viable cells and so can only label dead cells which have 
a permeabilised membrane (Steinkamp et al. 1999). Cells were treated with the 
caspase-dependent apoptosis inducer staurosporine for 6 hours at a 
concentration of 1 µM as a positive control (Belmokhtar et al. 2001). Cells were 
sorted, and fluorescence measured using the MACSQuant FACS machine and 
software (Miltenyibiotec). Cells were first sorted by the side scatter area (SSC-A) 
and the forward scatter area (FSC-A) to sort cells by their cellular granularity and 
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size, respectively. DF-1 cells were then selected for and gated (Appendix 7.1). 
Gated DF-1 cells were sorted by forward scatter height (FSC-H) and FSC-A, to 
select for single cell populations. FCS-H and FCS-A have the same value when 
a single cell is detected. Cells were then plotted by Annexin V (FITC) fluorescence 
and PI fluorescence and represented as a density plot. Cells were separated into 
three gates, representing cells that are viable (dark green), viable cells 
undergoing apoptosis (light green) and cells which are dead from apoptosis (red) 
(Figure 4.6). The percentage of viable cells, viable cells undergoing apoptosis, 
and dead cells were calculated for mock, Beau-R and BeauR-Sc3bAUG infected 
cells. The percentage of mock infected cells that were viable was 82.60%, with 
26.80% of those cells undergoing apoptosis (Figure 4.6A). The remaining cells, 
17.57%, were dead as they stained for propidium iodide as well as annexin. Beau-
R infected cells saw 52.68% of cells viable, with 21.00% of those cells undergoing 
apoptosis. The remaining cells, 47.28%, were dead (Figure 4.6B). BeauR-
Sc3bAUG infected cells had 79.09% viability with 16.56% of those cells 
undergoing apoptosis. The remaining, 30.53%, were dead (Figure 4.6C). The 
staurosporine positive control actively induced apoptosis with 47.77% of cells 
viable, of which 20.52% were undergoing apoptosis, the remaining cells, 52.39%, 
were dead (Figure 4.6D). Compared to mock infected cells, Beau-R infected cells 
saw higher levels of dead cells but saw lower levels of actively apoptotic cells. 
This result suggests that at 24 h.p.i Beau-R causes a ~30% increase in apoptotic 
cell death compared to mock. This confirms that IBV infection induces apoptosis 
in DF-1 cells as seen previously for Vero cells (Liu et al. 2001). A similar pattern 
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was observed for BeauR-Sc3bAUG with saw an increase of 13% in apoptotic cells 
compared to the mock. This increase was smaller compared to Beau-R infected 
cells and suggests that 3b expression causes an increase in the rate of apoptosis. 
Scrambling of the 3b AUG codon does not abrogate apoptosis completely and 
suggests 3b is not solely responsible for IBV-induced apoptosis.  
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Figure 4.6 IBV 3b induces apoptosis. 
DF-1 cells were (A) mock infected or infected with (B) Beau-R or (C) BeauR-Sc3bAUG at 
an MOI of 4 for 24 hours. As a positive control, cells were treated with (D) staurosporine 
for 6 hours. Cells were harvested, washed with PBS and labelled with anti-PS and 
propidium iodide. Cells were sorted by forward scatter area (FSC-A), and side scatter area 
(SSC-A) to gate DF-1 cells. DF-1 cells were then sorted by forward scatter area (FSC-A) 
and forward scatter height (FSC-H) to gate single cell populations. Single DF-1 cells were 
then sorted by annexin V (FITC) and propidium iodide (PI) fluorescence and shown as a 
density plot. Cells were separated into three gates, representing cells that are viable (dark 
green), viable cells undergoing apoptosis (light green) and cells which are dead from 
apoptosis (red). 
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4.5.2. IBV 3b induces caspase-dependent apoptosis 
To further confirm that 3b can induce apoptosis during infection, a caspase assay 
was used. This assay also helped to determine whether 3b induces caspase-
dependent or caspase-independent apoptosis. To measure caspase activity, a 
caspase-Glo 3/7 kit (Promega) was used. Caspase 3/7 are the primary cysteine 
proteases which initiate the apoptotic signalling cascade leading to irreversible 
apoptosis (Taylor et al. 2008). DF-1 cells were either mock infected or infected 
with Beau-R or BeauR-Sc3bAUG at an MOI of 4. Cells were harvested at 12, 24 
and 36 h.p.i. Firefly luciferase activity was measured as a proxy for caspase 3/7 
enzymatic activity using the Caspase-Glo 3/7 assay (Promega). Results are 
shown as fold-change compared to the mock control and are from three biological 
replicates. At 12 h.p.i there was no significant difference between mock and IBV. 
At 24 h.p.i and 36 h.p.i, there was significantly more Firefly luciferase activity from 
cells infected with Beau-R compared to mock infected cells. BeauR-Sc3bAUG 
also showed significantly more Firefly luciferase activity compared to the mock 
control, although this was significantly less than Beau-R at 24 h.p.i. This result 
correlates with the FACS data and suggests that IBV does induce apoptosis 
during infection in DF-1 cells as in Vero cells, and that protein 3b is responsible, 
in part, for IBV-induced apoptosis.  
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Figure 4.7 Protein 3b induces caspase-dependent apoptosis.  
DF-1 cells were either mock infected or infected with Beau-R or BeauR-Sc3b at 
an MOI of 4. After 12, 24 or 36 hours, cells were lysed and caspase 3/7 activity 
measured. ** significance p < 0.01, *** significance p < 0.001 
*** 
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4.6. Discussion 
IBV accessory protein 3b is a small accessory protein at 7.4 kDa, expressed from 
sgRNA3 along with 3a and E (Le et al. 1994). Protein 3b is highly conserved 
between Beau-R and M41-CK but is less conserved with the highly pathogenic 
Qx strain with a 67.2% sequence identity (Figure 4.1). Furthermore, a truncated 
variant of Beau-R 3b, 3bT, which shows different localisation patterns in Vero cells 
compared to 3bB, only has a sequence identity of 52.49%, although the N-
terminal end was highly conserved. An ELM search only identified one motif 
(DEG_Nend_Nbox_1), a destabilising motif, that is conserved between all four 
isoforms of 3b (Table 4.1). IBV 3bT localises to the cytoplasm in COS-7 cells 
during transient expression while 3bB and 3bM both localise to the nucleus, this 
suggests that a nuclear localisation signal is present in the C-terminus of 3b (Shen 
et al. 2003). Only one nuclear retention motif was identified, RVxF, that is present 
in 3bB/3bM and not present in 3bT. This motif allows interaction with the catalytic 
domain of PP1c and is present and functionally important in IBV accessory protein 
4b (Chapter 5) and TGEV accessory protein 7 (Cruz et al. 2011). PP1 is a 
phosphatase protein which plays a role in a range of cellular pathways (Szyszka 
et al. 1989, Hartshorne et al. 2004). This motif was not present in the Qx isoform 
of 3b. Knockout of RVxF may help to determine the role of this motif in 3B/3bM 
nuclear localisation in mammalian cells, although why this motif would act 
differently in avian cells is not known (Lesage et al. 2004). None of these motifs 
are obviously important for the interacting partners identified by LC-MS/MS for 
3bM (Appendix 7.3, 7.4), which could suggest none of these motifs are important.  
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Mass spectrometry analysis of 3b identified six significant interacting partners for 
GFP-3bM and failed to identify any significant proteins for 3bM-GFP (Table 4.2). 
Compared to 3a and 4b, the number of interacting partners was lower for 3b. IBV 
3b has a very short half-life of 7.5 minutes in Vero cells (Pendleton et al. 2006) 
and could explain the low expression levels of GFP-tagged 3bM in the eluate 
samples and thus the low number of cellular interacting partners identified (Figure 
4.3). HEK-293T cells were used for the co-IP due to the high transfection rates 
and the ability to characterise mammalian proteins by mass spectrometry. 
Nonetheless, there are differences in 3b cellular localisation between mammalian 
and avian cells which could skew the accuracy of the mass spectrometry data. 
The M41 isoform of 3b was used for the co-IP; future work would be encouraged 
to repeat this assay with both 3bQ and 3bT to detect different interacting partners 
that could suggest reasons for the highly pathogenic nature of Qx or the different 
cellular compartmentalisation of 3bT.  
 
Three proteins that have a role in regulating apoptosis were identified by mass 
spectrometry. The first was BAG6 a molecular chaperone which interacts with and 
stabilises the pro-apoptotic protein AIF (Desmots et al. 2008). The second, 
VDAC2, is a pore-forming protein that localises to the outer membrane of the 
mitochondria where it is involved in the mitochondrial apoptotic pathway (Cheng 
et al. 2003). The third protein identified, COX5b, also localises to the mitochondria 
where it plays a role in ATP production (Galati et al. 2009) and has been shown 
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to inhibit ROS levels and thus has a role in regulating intrinsic apoptosis (Zhao et 
al. 2012). Viruses have been shown to express proteins that both inhibit and 
induce apoptosis (Koyama et al. 1998). Accessory proteins PB1-F2 from IAV and 
VP5 from IBDV have been shown to induce apoptosis through the interaction with 
VDAC1 and VDAC2, respectively (Zamarin et al. 2005, Li et al. 2012), while HIV-
1 Tat accessory protein has been shown to interact with COX5b to induce 
mitochondrial membrane permeabilisation, leading to apoptosis (Lecoeur et al. 
2012). Cellular apoptosis is a common feature of coronavirus infection, with 
alpha- beta- and gammacoronaviruses all able to induce apoptosis in some 
manner (Fung et al. 2014). No anti-apoptotic proteins have been identified for 
coronaviruses with viral proteins primarily inducing apoptosis (Liu et al. 2014). For 
example, SARS-CoV accessory proteins 3a and 3b have been shown to induce 
caspase-dependent apoptosis when overexpressed in Vero cells (Law et al. 2005, 
Khan et al. 2006) (Tan et al. 2004), while SARS-CoV 7a has also been shown to 
induce apoptosis by interacting with the pro-survival protein, Bcl-XL (Tan et al. 
2007). Previous work has shown that caspase-dependent apoptosis is actively 
induced during IBV infection (Li et al. 2007, Liao et al. 2013). Furthermore, IBV-
induced apoptosis has been shown to involve the Blc-2 family of proteins including 
Bak, a VDAC2 interacting protein (Zhong et al. 2012). The pro-apoptotic PERK 
and eIF2α pathways are also active during IBV infection, although it is not known 
if this is directed by the virus or is activated as a host response to infection (Liao 
et al. 2013). Inhibiting apoptosis during IBV infection does not affect viral titres, 
suggesting apoptosis is not required for IBV replication (Liu et al. 2001). Here, 
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IBV-induced apoptosis has been further confirmed in an avian cell line using 
FACS (Figure 4.6B) and has been shown to be caspase-dependent (Figure 4.7).  
Although BeauR-Sc3bAUG did also induce apoptosis and cell death in higher 
amounts compared to the mock control (Figure 4.6C), levels were significantly 
lower compared to wild-type Beau-R. The same effect was seen for the caspase 
3/7 assay which showed higher caspase activity when cells were infected with 
Beau-R compared to BeauR-Sc3bAUG (Figure 4.7). This result suggests that 3b 
expression, during Beau-R infection, increases cellular apoptosis. Scrambling of 
3b did not completely abrogate apoptosis as seen by FACS and caspase activity, 
suggesting that IBV either expresses additional pro-apoptotic protein/s or 
apoptosis is a cellular response to viral replication. Levels of caspase 3/7 at 36 
h.p.i were not significantly different between wild-type and BeauR-Sc3bAUG, 
most likely representing host-induced apoptosis, as the cell responds to depleted 
resources after peak replication. Both the FACS and caspase assay should be 
repeated measuring apoptosis during transient expression of 3b. These assays 
could also be used to measure and compare the apoptotic activity of 3bB, 3bM, 
3bQ, and 3bT and further include the use of Vero and DF-1 cells to determine the 
functionality of 3bB against 3bT in different cell lines. 
 
The apoptotic and innate immune signalling pathways are linked, with many 
coronavirus accessory proteins including SARS 3a and 7 shown to modulate both 
pathways (Alcami et al. 2000, Liu et al. 2014). Indeed, previous work has shown 
that recombinant IBV that lacks 3b expresses more IFNβ, suggesting 3b inhibits 
Chapter 4: The role of accessory protein 3b  The role of IBV accessory proteins 3a, 3b and 4b 
198 
 
IFNβ expression in some unknown manner (Kint et al. 2015). A potential 
mechanism, as alluded to in the mass spectrometry data, could be an interaction 
between 3b and COX5b, a protein that negatively regulates IFN expression by 
controlling MAVS aggregation at the mitochondria (Zhao et al. 2012). Future work 
should aim to confirm this interaction and determine if 3b can inhibit IFNβ 
expression using the chIFNβ luciferase assay. This assay will help to determine 
whether the effect of 3b on IFNβ expression occurs at the point of MAVS signalling 
as seen for accessory protein 3a.  
 
More work is required to determine the function of 3b during infection and has 
been hampered by the difficulties in transiently expressing 3b and detecting 3b 
during infection. Due to time constraints and a lack of an anti-3b antibody, none 
of the interacting partners for 3bM were confirmed by immunofluorescence or IP. 
Any future work should first focus on confirming these interactions during infection, 
either by raising an antibody against 3b or using the reverse genetic system to 
introduce an epitope tag onto 3b. Future work should also focus on comparing 
3bB/3bM with 3bT and 3bQ to determine any functional changes in apoptosis 
using the assays established here, and interferon signalling, using the chIFNβ 
assay previously used for 3a. Accessory protein 3b is non-essential for in vitro 
replication and thus could play a role as a pathogenicity factor. Determining 
differences between the function of 3b between low and highly pathogenic strains 
may help to establish the importance of this small accessory protein. 
Chapter 7: Appendix   The role of IBV accessory proteins 3a, 3b and 4b 
199 
5. The role of Accessory Protein 4b 
5.1. Introduction 
IBV expresses four known accessory proteins during infection, 3a and 3b from 
gene 3, and 5a and 5b from gene 5 (Casais et al. 2005, Britton et al. 2006, 
Hodgson et al. 2006). They were shown to be accessory proteins, as scrambling 
of the AUG start codon (ATG>ACC) had no effect on viral replication in vitro. 
Nonetheless, these proteins are highly conserved, and it is assumed they play a 
role in pathogenicity and/or viral-host interaction. IBV and the closely related 
TCoV contain an ORF known as ORF4b within the intergenic region (IR), a region 
in-between gene M and gene 5 (Bentley et al. 2013). This ORF from M41-CK has 
the potential to encode a 94 amino acid protein with a molecular weight of around 
11 kDa, while Beau-R ORF4b is smaller and could encode a protein with a 
molecular weight of 6 kDa. Due to a lack of a canonical TRS (CUUAACAA) it was 
assumed that there was no corresponding mRNA for expression of ORF4b 
(Bentley et al. 2013). For this reason, ORF4b was, until recently, believed to be a 
pseudogene. Bentley et al (2013) showed that IBV expressed a sgRNA that is 
regulated by a non-canonical TRS (CAA) (Bentley et al. 2013). This non-canonical 
TRS regulates the transcription of sgRNA 4b at lower levels than is expected for 
its genome location. Previous work has shown that deleting the intergenic region 
containing ORF4b from Beau-R has no effect on viral replication and if expressed 
is most likely an accessory protein (Bentley et al. 2013). Northern blot analysis 
has shown that sgRNA 4b is expressed by IBV strains M41-CK and Beau-R, and 
some strains of TCoV. It is not known whether this sgRNA is translated into a 
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protein. In this chapter, expression of 4b during M41-CK infection has been 
confirmed. Furthermore, the role of 4b is investigated and has been shown to play 
a role in regulating cellular translation and stress granule formation. 
 
Results 
5.2. Bioinformatic analysis of IBV and TCoV 4b 
Previous work has shown that M41-CK and Beau-R encode an ORF in the 
intergenic region known as ORF4b (Bentley et al. 2013). Beau-R ORF4b is 
predicted to encode a 50 amino acid protein while M41-CK is predicted to encode 
a 94 amino acid isoform. TCoV strains also contain an ORF in the intergenic 
region (Bentley et al. 2013). Frequency and sequence similarity of 3a, 3b, 5a, and 
5b has previously been determined by analysing and comparing the ORFs 
encoded by different strains of IBV (Britton 2007). The full-genome sequences of 
IBV and TCoV strains were downloaded from the viper database (viprdb.org) to 
determine the frequency and sequence similarity of ORF4b. In all, 178 sequences 
(Jan 2017) were downloaded and contained a mix of lab, vaccine, and field strains. 
ORF4b and the non-canonical TRS were identified in each strain using the 
unsorted six-frame translation tool in BioEdit. In the 178 strains studied, 78% of 
strains had both ORF4b and the non-canonical TRS (Table 5.1). ORF4b varied 
in size between the strains, the smallest length was 40 amino acids and the 
largest was 100 amino acids. The most common form of ORF4b was 94 amino 
acids with 69% of strains encoding this length. Due to the frequency of this length, 
this was considered the full-length version of ORF4b. The other IBV accessory 
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proteins have a high level of percentage similarity (Britton et al. 2006). To 
determine sequence similarity/identity of 4b, the sequence alignment for 4b was 
entered into the sequence identity and similarity (SIAS) tool (imed.med.ucm.es). 
Each sequence was aligned to each other sequence, and percentage similarity 
or identity was calculated. The average percentage similarity or identity was then 
calculated. Sequence identity for 4b was 86% while similarity was 81%.  
 
The M41-CK 4b peptide sequence was further characterised to determine any 
domains, motifs, or conserved regions. The Eukaryotic Linear Motif (ELM) tool 
was used to identify any motifs that may help to determine function. This tool aims 
to identify motifs which have previously been shown to mediate protein-protein 
interactions. In total 21 motifs were identified, ranked by the probability of the motif 
occurring randomly in a 94 amino acid protein (Table 5.2). Due to the high 
incidence of false positives when using this tool, little can be inferred from these 
results alone. Nonetheless, two motifs were of interest from the search, 
Phosphoprotein 1c (PP1c) SILK (.[GS]IL[KR][^DE]) and RVxF 
(..[RK].{0,1}[VIL][^P][FW].) Individually these motifs have a low probability of 
occurring randomly in a 94 amino acid protein. Furthermore, their presence 
together in the same peptide sequence is even more unlikely. Both motifs are 
involved in PP1c binding and cooperate to increase PP1c affinity. For this to occur 
these motifs should be near as they are in 4b (Hendrickx et al. 2009). PP1c_RVxF 
is at position 7-13 while PP1c_SILK is at position 15-20. PP1c is a multi-functional 
protein involved in the dephosphorylation of phosphorylated proteins (Szyszka et 
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al. 1989, Mochida et al. 2012). Due to the promiscuous nature of this protein, the 
exact cellular pathway being controlled cannot be determined. Sequence 
alignment of 4b isoforms showed that the N-terminal end of 4b is more conserved 
than the C-terminal end, due in part to the presence of C-terminal truncations in 
many 4b isoforms. RVxF and SILK motifs, as identified by the EML search, are 
present in 93.75% and 93% of 4b sequences, respectively (Figure 5.1).  
 
Table 5.1 Bioinformatic analysis of the ORF4b predicted peptide sequence in 
IBV/TCoV strains 
IBV/TCoV 
Strains 
Strains 
with 4b + 
TRS 
4b Isoforms Count IBV Strain 
Sequence 
Similarity 
Sequence 
Identity 
183 144 (78%) 
Elongated 3 (2%)  
81% 86% 
Full-length94 100 (69%) M41, QX 
Truncated92 1 (0.7%)  
Truncated80 31 (21.5%) 
 
Truncated50 7 (4.8%) Beau-R 
Truncated40 2 (1.4%)  
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ELM ID Matched sequence Pattern Position Description 
Cell 
Compartment Probability 
DEG_Nend_UBRb
ox_4 MCV ^M{0,1}(C). 1-3  
N-terminal motif that initiates protein degradation by 
binding to the UBR-box of N-recognins. This N-degron 
variant comprises N-terminal Cys as destabilizing residue. 
cytosol 1.77E-05 
DOC_PP1_SILK_1 ASILRA .[GS]IL[KR][^DE] 15-20 
Protein phosphatase 1 catalytic subunit (PP1c) interacting 
motif that often cooperates with and is located N-terminal 
to the RVXF motif to dock proteins to PP1c. 
cytosol, 
nucleus, 
protein 
phosphatase 
type 1 complex 
3.78E-05 
DOC_PP1_RVXF_
1 YLKLFFN 
..[RK].{0,1}[V
IL][^P][FW]. 7-13 
Protein phosphatase 1 catalytic subunit (PP1c) interacting 
motif binds targeting proteins that dock to the substrate for 
dephosphorylation.  
nucleus, 
protein 
phosphatase 
type 1 complex, 
cytosol 
8.30E-04 
DOC_MAPK_NFA
T4_5 
REYLKLFF
N 
[RK][^P][^P][
LIM].L.[LIVM
F]. 
5-13 An extended D site specifically recognized by the JNK kinases 
cytosol, neuron 
projection 
nucleus, protein 
complex, 
1.64E-04 
LIG_Pex14_2 
FILSF 
F...[WF] 
36-40 Fxxx[WF] motifs are present in Pex19 and S. cerevisiae 
Pex5 cytosolic receptors that bind to peroxisomal 
membrane docking member, Pex14 
cytosol, 
peroxisome, 
glycosome 
4.63E-04 FKKQF 45-49 
FFHSF 49-53 
LIG_SH3_4 KPIFQKGC KP..[QK]... 77-84 This is the motif recognized by those SH3 domains with a non-canonical class II recognition specificity 
focal adhesion, 
cytosol 6.78E-04 
LIG_BRCT_BRCA
1_1 NSIIF .(S)..F 22-26 
Phosphopeptide motif which directly interacts with the 
BRCT (carboxy-terminal) domain of the Breast Cancer 
Gene BRCA1 with low affinity 
nucleus, 
BRCA1-BARD1 
complex 
1.91E-03 
DOC_MAPK_MEF
2A_6 REYLKLFF 
[RK].{2,4}[LI
VMP].[LIV].[L
IVMF] 
5-12 A kinase docking motif that mediates interaction towards the ERK1/2 and p38 subfamilies of MAP kinases. 
cytosol, 
Transcription 
factor complex, 
nucleus 
2.58E-03 
TRG_ENDOCYTIC
_2 YLKL Y..[LMVIF] 7-10 
Tyrosine-based sorting signal responsible for the 
interaction with mu subunit of AP (Adaptor Protein) 
complex 
plasma 
membrane, 
clathrin-coated 
endocytic 
vesicle, cytosol 
2.59E-03 
Table 5.2 Eukaryotic linear motifs identified in 4b (M41) peptide sequence.  
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LIG_SH2_STAT5 YLKL (Y)[VLTFIC].. 7-10 STAT5 Src Homology 2 (SH2) domain binding motif. cytosol 3.30E-03 
LIG_TRAF2_1 SFQE [PSAT].[QE]E 39-42 
Major TRAF2-binding consensus motif. Members of the 
tumour necrosis factor receptor (TNFR) superfamily initiate 
intracellular signalling by recruiting the C-domain of the 
TNFR-associated factors (TRAFs) through their 
cytoplasmic tails. 
cytosol 4.30E-03 
LIG_14-3-
3_CanoR_1 RLWLSYK 
R[^DE]{0,2}[^
DEPG]([ST])(
([FWYLMV].)
|([^PRIKGN]
P)|([^PRIKG
N].{2,4}[VILM
FWYP])) 
86-92  Canonical Arg-containing phospho-motif mediating a strong interaction with 14-3-3 proteins. 
cytosol, 
internal side of 
plasma 
membrane, 
nucleus 
4.48E-03 
Results are ordered by the probability of the sequence occurring randomly (p). 
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Figure 5.1 Peptide sequence alignment of 4b.  
ORF4b was identified in IBV strains (viperdb.com) and aligned and translated using Clustalw. Amino acids with a (*) are conserved 
throughout, (:) indicates amino acids that are conserved within similar property groups. RVxF (red) and SILK (black) motifs identified by the 
ELM tool are labelled. 
Sequence Conservation 
0 
100 
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5.3. Generation of GFP-tagged 4b expression vectors 
Vectors for expression of GFP-tagged 4b from M41-CK (4bM) were generated for 
mass spectrometry protein purification and for protein visualisation by 
immunofluorescence. GFP was fused to the N- or C- terminus of 4bM and both 
constructs were used in conjunction to reduce the effect of the GFP tag on co-IPs. 
The 4b from Beau-R (4bB) was tagged at the N-terminus and was used for 
comparison to GFP-4bM in in vitro assays. For the construction of the 4bM 
expression vectors, M41 viral RNA was isolated and reverse transcribed into 
cDNA. The 4b ORF was amplified from the cDNA using complementary primers 
with flanking restriction sites by PCR. The resulting PCR product was purified and; 
along with the pEGFPC2 (Clontech) and pEGFPN1 (Clontech) plasmids, were 
digested with the relevant restriction enzymes. Digested vectors were purified by 
gel extraction. Digested vectors and PCR products were then ligated together. 
Vector sequences were confirmed by Sanger sequencing. The 4bB cDNA was 
ordered as a genestring from Invitrogen and contained flanking restriction sites. 
The GeneArt String (ThermoFisher) was digested with relevant restriction 
enzymes and ligated into a digested pEGFPC2 vector. The final vectors 
generated were pEGFPC2-4bM, pEGFPN1-4bM and pEGFPC2-4bB (Figure 
5.2A,B,C,). To confirm expression of GFP-tagged 4b from these vectors, DF-1 
cells were transfected with GFP-4bM, 4bM-GFP, GFP-4bB, or GFP vectors. After 
24 hours, cells were lysed, proteins separated by SDS-PAGE, transferred to a 
membrane and labelled with anti-GFP. Bands with the molecular weight of GFP-
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4bM, 4bM-GFP and GFP-4bB were identified as expected (Figure 5.2D,E,F), 
confirming expression from these vectors was successful. 
 
  
Figure 5.2 Plasmid map and confirmation of expression of the GFP-tagged 4b 
expression vector.  
(A) pEGFPC2-4bB, (B) pEGFPN1-4bM, (C) pEGFPC2-4bM.  DF-1 cells were transfected 
with GFP-4bM (D), 4bM-GFP (E) GFP-4bM (F) GFP-4bB and a GFP control. After 16 hours, 
cells were lysed, separated by SDS-PAGE, transferred to a membrane, and labelled with 
anti-GFP or anti-actin.  
A B 
C 
GFP-4bM
GFP
37
20
D 
E F 
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5.4. Detection of 4b during infection 
5.4.1. Validation of anti-4b 
Polyclonal anti-4b was raised against the DNGKVYYEGKSI peptide sequence 
present in the C-terminus of 4bM. Previous work with this antibody failed to detect 
4b during M41-CK infection (Bentley et al. 2013). To confirm whether anti-4b can 
indeed detect 4b, the antibody was first used to detect expression of GFP-tagged 
4b. DF-1 cells were transfected with GFP-4bM, 4bM-GFP or GFP expression 
vectors. After 16 hours, DF-1 cells were fixed, permeabilised and labelled with 
anti-4b at a concentration of 1:50 and visualised by confocal microscopy. GFP-4b 
signal colocalised with the anti-4b signal, while GFP signal did not (Figure 5.3). 
This result indicates that anti-4b specifically binds to the 4b peptide. In 
untransfected cells, a weak signal was detected predominantly in the nucleus, 
possibly suggesting anti-4b may also bind to a cellular nuclear protein. 
 
To further confirm that anti-4b can label 4b, the antibody was used to detect GFP-
4bM overexpression by western blot. DF-1 cells were transfected with the GFP-
4bM expression vector at varying doses, and after 16 hours cells were lysed. 
Samples were separated by SDS-PAGE, transferred to a membrane and labelled 
with anti-4b at a range of concentrations. The antibody failed to detect 4b 
expression when transfected with 250 ng and 500 ng of pEGFPC2-4bM but was 
able to detect GFP-4bM when transfected with a higher dose at 1000 ng (Figure 
5.4). The size of the band was around 35 kDa, the expected size of GFP-4bM. 
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This result demonstrates that anti-4b can detect GFP-tagged 4b by western blot 
and possibly by immunofluorescence.  
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Figure 5.3 Anti-4b can detect the presence of GFP-tagged 4bM.  
DF-1 cells were transfected with plasmids encoding N- and C-terminally GFP-tagged 
4b protein. After 24 hours, cells were fixed and stained with anti-4b and DAPI. 
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5.4.2. Detection of 4b during M41 infection 
After validating that anti-4b specifically binds to 4bM, the antibody was used to 
determine whether 4b is expressed during M41 infection. The antibody was raised 
against a C-terminal peptide sequence not present in ORF4b from Beau-R. 
Therefore, anti-4b can only be used to label the M41 4b isoform. The antibody 
was initially used to label 4b by western blot analysis. CK cells were mock infected 
or infected with M41 at an MOI above 4 and lysed 24 hours later. The samples 
were separated by SDS-PAGE and transferred to a nitrocellulose membrane. 
Membranes were labelled with anti-4b at a concentration of 1:50 and anti-actin 
Figure 5.4 Anti-4b can label GFP-4bM.  
DF-1 cells were transfected with the GFP-4bM 
expression vector. After 16 hours, cells were lysed 
and separated by SDS-PAGE. Blots were incubated 
with anti-4b. 
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for 16 hours. An actin band was detected at 40 kDa in both the mock and infected 
lanes; a band was also detected in the M41-CK lane at approximately 10 kDa 
(Figure 5.5A). This result provided preliminary evidence that 4b was expressed 
during M41 replication.  
 
To further confirm expression of 4b, a range of recombinant viruses were used as 
controls. These viruses, M41K-del4b and BeauR-IR(M41) were previously 
generated by Sarah Keep and Kirsten Bentley, respectively. M41K-del4b has a 
deletion of ORF4b in the M41-K backbone. BeauR-IR(M41) contains the 
intergenic region; the region between M and ORF5ab, from M41, inserted into 
Beau-R and therefore contains ORF4bM. Anti-4b was also tested against Beau-
R. As the antibody was raised against a peptide sequence at the C-terminus of 
4b, not present in Beau-R ORF4b, the antibody should be able to label Beau-R 
4b. Furthermore, anti-4b should also fail to label M41K-del4b due to deletion of 
ORF4b. Conversely, anti-4b should be able to label BeauR-IR(M41) as this 
recombinant IBV will express the full-length 4b. CK cells were infected with M41K-
del4b, BeauR-IR(M41), Beau-R and M41-CK for 24 hours. Cells were then lysed, 
proteins separated by SDS-PAGE, transferred to a membrane and labelled with 
anti-actin and anti-4b. Actin was present in all samples. Anti-4b was unable to 
detect a protein band in the M41K-del4b or Beau-R lane but did detect a protein 
band in the M41-CK and the BeauR-IR(M41) lane (Figure 5.5A, B). This confirms 
the 10 kDa band is indeed the predicted 4b protein.  
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After confirming 4b is expressed, IBV 4b levels were characterised during 
infection. CK cells were infected with M41-CK at an MOI of 4 or mock infected. 
Cells were harvested at 4, 8, 12, 16, 24 and 48 h.p.i. The samples were separated 
by SDS-PAGE, transferred to a membrane and labelled with anti-actin and anti-
4b. Western blot analysis showed that anti-4b could detect 4b expression from 16 
h.p.i and that peak 4b expression occurred at 24 hours (Figure 5.5C).  
 
IBV 4b was further characterised by immunofluorescence to study cellular 
localisation of 4b. CK cells were infected with M41-CK, and after 24 hours, cells 
were fixed, permeabilised and labelled with anti-4b. As a control for infection, cells 
were labelled with anti-dsRNA. The anti-4b signal appeared stronger in cells 
positive for dsRNA (Figure 5.6A). The anti-4b signal is predominantly cytoplasmic 
with a granular-like pattern and appeared to aggregate in large structures during 
infection. However, there was a high level of the anti-4b signal in non-infected 
cells. Furthermore, labelling of 4b did not occur in all infected cells. To confirm 
that the use of a primary CK cell line, which can have a high proportion of cell 
debris and stressed cells was not responsible for this observation, the experiment 
was repeated in DF-1 cells. M41 cannot infect DF-1 cells; therefore, a 
recombinant M41 virus with the spike protein from Beau-R (M41R-BeauR(S)) was 
used. The Beaudette spike permits M41-K entry into DF-1 cells. DF-1 cells were 
infected with M41R-BeauR(S) for 24 hours, then fixed, permeabilised and labelled 
with anti-4b and anti-dsRNA. The background 4b signal was lower in DF-1 cells 
but, as seen previously, not all infected cells contained 4b signal (Figure 5.6B). 
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Altogether, the western blot and immunofluorescence data confirms that the M41-
CK 4b transcript, previously identified by Bentley et al, is translated during 
infection and confirms 4b as the fifth IBV accessory protein. 
 
Figure 5.5 M41-K expresses an 11 kDa protein known as 4b during infection. 
CK cells were (A) Mock infected or infected with M41-K, (B) infected with Beau-R, 
M41-CK, BeauR-M41R(IR) or M41K-del4b at an MOI of 4. At 24 h.p.i cells were lysed, 
proteins separated by SDS-PAGE and transferred to a membrane and labelled with 
anti-4b and anti-actin. (C) CK cells were mock infected or infected with M41 at an MOI 
of 4. Cells were lysed at indicated time-points, proteins separated by SDS-PAGE, 
transferred to a membrane and labelled with anti-actin and anti-4b.   
A B 
C 
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A 
B 
Figure 5.6 Anti-4b can detect 4b during infection. 
CK cells were infected with either (A) M41-CK or (B) M41R-BeauR(S) at a MOI above 4. 
After 24 hours, cells were fixed and labelled with anti-dsRNA and anti-4b. The nuclei were 
stained with DAPI.  
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5.5. Effect of 4b on viral replication 
It is assumed that 4b is an accessory protein as 22% of IBV/TCoV strains lack 
ORF4b (Table 5.1). To confirm this, recombinant IBVs were generated with 
ORF4b deletions. Two viral isolates, M41K-del4b-2 and 16 were designed and 
generated using the M41-K reverse genetics system (Keep et al. unpublished). 
The generation of these IBVs and subsequent growth curves were completed by 
Sarah Keep, as part of another project. CK cells were infected with M41-CK, M41-
K, and M41K-del4b-2/16 at an MOI of 0.01. Two recombinant clones (clone 2 and 
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Figure 5.7 Protein 4b is not required for in vitro viral replication. 
CK cells were infected with M41-CK, M41-K, or M41-K-del-4b at an MOI of 0.01. 
The supernatant was harvested at the indicated time-point and titration calculated 
using the CK plaque assay. Data was from three experimental repeats. Growth 
curve completed by Sarah Keep. Results are from three biological replicates. 
Unpaired t-test *significant at p < 0.05. Error bars represent one standard 
derivation from the mean.   
* 
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clone 16) were generated to take into account IBV genome mutations that can 
arise during the reverse genetics system. The supernatant was removed at 0, 24, 
48, 72 and 96 h.p.i and virus titre determined by CK cell plaque assay. Results 
are from three biological repeats. The full-length molecular clone, M41-K, grew to 
similar titres as M41K-del4b, with both peaking at 48 h.p.i at 2-5x105 pfu/ml 
(Figure 5.7). M41-CK grew to higher titres at hour 48 compared to the molecular 
clone, M41-K, while the reason for this discrepancy is unknown, it is possibly due 
to the mixed population of viruses within the M41-CK inoculum. Despite this 
discrepancy, this result indicates that 4b has no effect on viral in vitro replication 
and is therefore an accessory protein. 
 
5.6. Mass spectrometry analysis of GFP-tagged 4b Co-IPs 
To determine the role of accessory protein 4b, mass spectrometry was utilised to 
identify proteins that interact with GFP-4bM or 4bM-GFP. HEK-293T cells were 
transfected with the pEGFPC2-4bM or pEGFPN1-4bM expression vectors or a 
GFP control plasmid. After 16 hours, cells were lysed and GFP-4bM/4bM-
GFP/GFP immunoprecipitated using GFP ‘capture’ beads (Chromotek). Three 
biological replicates were completed for each plasmid. Input and eluate GFP-4bM 
and 4bM-GFP samples were analysed by western blot to confirm successful 
transfection and immunoprecipitation (Figure 5.8). Samples were analysed by 
LC-MS/MS by Stuart Armstrong. 
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In total 87 and 137 cellular proteins were detected in higher amounts in the GFP-
4bM or 4bM-GFP samples, respectively, compared to the GFP control, of which 
24 appeared in both (Appendix Table 7.4, 7.5). Due to an unknown reason, 
replicate three did not align with the previous two replicates for either plasmid and 
was removed from the analysis (Appendix Table 7.4, 7.5). Proteins where 
identified by comparing unique peptides to a database of human proteins. 
Proteins where only a single unique peptide was identified, were removed to 
reduce the chance of identifying the wrong protein. The significance (p-value) of 
the mass spectrometry data was determined by two-tailed unpaired ANOVA on 
two biological replicates, as well as the fold-change in relative protein abundance 
Figure 5.8 Confirmation of GFP-4bM/4bM-GFP transfection and IP. 
HEK-293T cells were transfected with (A) GFP-4bM or 4bM-GFP expression vectors. 
After 16 hours, cells were lysed, and GFP-tagged 4bM immunoprecipitated using GFP 
‘capture’ beads (Chromotek). Input and eluate samples were separated by SDS-PAGE, 
transferred to a membrane and labelled with anti-GFP. 
A B 
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over the GFP control. Interacting proteins were then ranked by significance (p-
value). Proteins that had a p-value (-Log10) above one and a fold-change (Log2) 
above two were considered significant (Figure 5.9, Figure 5.10). For each protein, 
the confidence score was calculated, which is the cumulative value of p; the 
probability of the identified peptide sequence occurring randomly, for each unique 
peptide identified. The higher the confidence score, the higher the confidence in 
protein identification. Mass spectrometry data identified 15 cellular proteins for 
GFP-4bM that were significant, and 17 proteins for 4bM-GFP, eight proteins 
appeared in both datasets (Table 5.5).  
 
A panther over-representation test (pantherdb.org) was performed to categorise 
the cellular localisation of the significant proteins identified in the GFP-tagged 
4bM eluate. This test grouped cellular proteins by their Gene Ontology (GO) 
cellular compartment annotation and helped to determine if these cellular 
compartments are over-represented in the dataset. The test compared expected 
number of proteins to actual number of proteins. Cellular compartments with a p-
value below 0.05 were considered significant. The number of proteins that localise 
to these significant GO cellular components were represented as a Venn diagram. 
Of the 21 unique proteins identified, 13 proteins localise to the ribosomal 
translational machinery, while three proteins localise to and regulate stress 
granule or p-body assembly (Figure 5.11).
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Table 5.3 Cellular proteins identified by LC-MS/MS that significantly interact with GFP-4bM.  
Protein ID Protein Unique peptides Confidence 
Relative Protein Abundance 
p Value 
(-Log10) 
Fold Change 
GFP-4bM/GFP 
(Log2) 
pEGFPC2-4bM pEGFPN1 
1 2 1 2 
RRBP1* Ribosome-binding protein 1  4 255.74 1889.294019 3590.533721 100.8331958 80.90184734 1.99823936 4.914222002 
EF1D Elongation factor 1-delta  4 391.08 15495.05071 13726.6983 239.4231988 504.5743565 1.997433404 5.29560084 
RT18A* 28S ribosomal protein S18a, mitochondrial  2 140.61 745.3216979 6387.487721 0 0 1.795023111 10 
RL40* Ubiquitin-60S ribosomal protein L40  4 1272.81 192391.0279 309618.5155 36265.8443 28315.76306 1.769525206 2.958519537 
POP7* Ribonuclease P protein subunit p20  2 134.3 2829.72501 359.3812335 0 0 1.747300551 10 
RRS1* Ribosome biogenesis regulatory protein homolog  2 77.67 1556.740123 20216.67469 0 0 1.735695533 10 
RL14 60S ribosomal protein L14  8 582.74 41072.21332 106616.499 4213.913143 5345.27756 1.480392825 3.949527274 
CHCH1 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 1  
3 189.97 399.1320538 32.41494431 0 0 1.304962603 10 
PRDX2* Peroxiredoxin-2  3 263.01 5215.96236 16505.10114 1287.62327 855.4837881 1.152184348 3.341318915 
LS14A* Protein LSM14 homolog A  3 206.55 69195.71256 265077.3598 10689.58084 15915.39419 1.101850069 3.651259188 
RM43* 39S ribosomal protein L43, mitochondrial  3 236.52 13414.7761 10110.47499 987.1212169 3179.171192 1.052064956 2.497374119 
ATX2L* Ataxin-2-like protein  6 366.47 56290.80765 23285.8282 10275.79864 5527.036502 0.997400796 2.332161498 
LAP2B* Lamina-associated polypeptide 2, isoforms beta/gamma  3 367.06 136685.3054 216452.7164 80902.72867 92397.04123 0.98850445 1.026962423 
CHTOP* Chromatin target of PRMT1 protein  11 1048.35 203225.8432 356271.6694 128674.1111 105193.5423 0.972053732 1.258439383 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-4bM. Protein identifier (ID), protein name and number 
of unique peptides used to identify proteins are indicated. Relative abundance score for each protein is indicated. Confidence score (-Log2) is the score of the probability 
of the unique peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in protein 
identification. The p-value (-Log10) is a comparison of the cellular protein abundance between 4b and GFP. The higher the p-value, the higher the probability the 
protein interacts with 4b. The fold-change (Log2) is the change in the relative abundance of the cellular protein between GFP-4bM and GFP. Cellular proteins which 
appear in both GFP-4bM and 4bM-GFP data are labelled with an asterisk (*). Proteins which appeared in the third replicate are labelled with (*). 
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Table 5.4 Cellular proteins detected by LC-MS/MS that significantly interact with 4bM-GFP. 
Protein ID Protein Unique peptides Confidence 
Relative Protein Abundance 
p Value 
(-Log2) 
Fold Change 
(Log10) 
4bM-
GFP/GFP 
pEGFPN1-4bM pEGFPN1 
1 2 1 2 
POP7* Ribonuclease P protein subunit p20  2 134.3 911.8707526 1588.670511 0 0 2.896713159 10 
UBC1* NEDD8-conjugating enzyme Ubc12  2 44.93 1367.008451 2926.933855 0 0 2.67783124 10 
LAP2B* 
Lamina-associated polypeptide 2, isoforms 
beta/gamma  
3 367.06 308301.4581 308630.484 80902.72867 92397.04123 2.566031474 1.831841606 
EF1D Elongation factor 1-delta  4 391.08 22074.23517 26765.49226 239.4231988 504.5743565 2.09068515 6.036613458 
CHCH1* 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 1  
3 189.97 127168.0035 7353.350223 0 0 1.787452827 10 
CALM Calmodulin  7 841 159297.0479 235917.7982 36906.94512 42441.29678 1.775356602 2.316366979 
SRP14 Signal recognition particle 14 kDa protein  11 1902.3 470648.7836 588968.9287 205603.9915 238126.7524 1.636728076 1.255787446 
PDIP3 Polymerase delta-interacting protein 3  18 1732.04 111313.3434 167835.0644 46234.96748 37622.19365 1.450047289 1.735026432 
PABP4* Polyadenylate-binding protein 4  9 2074.35 51414.76432 57641.95842 16367.35231 9263.514578 1.442636493 2.089124527 
RPS25* 40S ribosomal protein S25  8 820.46 737016.6507 450290.2693 96942.49295 143057.6572 1.43241781 2.306585708 
ASHWN Ashwin  6 690.7 93116.90466 51436.06016 9247.174195 14188.57335 1.409175412 2.62481548 
RS3A 40S ribosomal protein S3a  14 1663.2 541864.1072 766618.8533 284098.6775 228316.5036 1.342278931 1.352510014 
HTRA2 Serine protease HTRA2, mitochondrial  3 391.28 3378.013648 6081.843557 1168.164744 746.6740556 1.295892979 2.304595462 
RRBP1* Serine protease HTRA2, mitochondrial  4 255.74 13264.28431 1920.542701 100.8331958 80.90184734 1.269542034 6.384650028 
RS30* 40S ribosomal protein S30  5 469.49 1550201.705 792446.3427 258417.5316 307780.9791 1.23218978 2.048760365 
NUP50* Nuclear pore complex protein Nup50  2 130.82 3210.501069 5226.965795 836.9350926 311.755658 1.198085759 2.876819482 
ATX2L* Ataxin-2-like protein  6 366.47 41675.76547 23737.19591 10275.79864 5527.036502 1.117991455 2.049393118 
IF2G* Eukaryotic translation initiation factor 2 subunit 3  10 1075.97 139134.0286 140818.5171 28920.04337 59192.69474 1.115893157 1.667759795 
TCPH* T-complex protein 1 subunit eta  2 214.33 3341.124075 8993.922182 921.0552625 1101.108238 1.107961795 2.60879157 
RUSD3* 
RNA pseudouridylate synthase domain-containing 
protein 3  
3 326.92 4693.749633 18760.2069 812.4205472 1109.279448 1.075139497 3.609376283 
KNOP1* Lysine-rich nucleolar protein 1  3 344.24 7699.489829 10379.41236 1375.459289 3321.386324 1.038569946 1.944542998 
TAF9B Transcription initiation factor TFIID subunit 9B  3 208.71 21205.1945 22073.88677 1634.801506 5817.237841 1.036993965 2.537962677 
IF2B1 Insulin-like growth factor 2 mRNA-binding protein 1  13 1681.43 240192.9464 148950.8683 86125.40777 94522.56675 1.030356349 1.107122347 
RL26L* 60S ribosomal protein L26-like 1  2 1535.13 7910.635426 5054.666181 0 52.82109283 1.029975496 7.939325902 
NHRF2* Na(+)/H(+) exchange regulatory cofactor NHE-RF2  6 658.58 123937.8009 87441.99072 42755.90333 19697.35678 1.021638929 1.758988669 
ATPO* ATP synthase subunit O, mitochondrial  4 454.17 47430.7275 98114.17914 23943.06679 14640.81302 1.006701625 1.915394227 
CHTOP Chromatin target of PRMT1 protein  11 1048.35 494204.2965 229409.3663 128674.1111 105193.5423 0.93673901 1.629527314 
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Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with 4bM-GFP. Protein identifier (ID), protein name and number 
of unique peptides used to identify proteins are indicated. Relative abundance score for each protein is indicated.  Confidence score (-Log2) is the score of the probability 
of the unique peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in protein 
identification. The p-value (-Log10) is a comparison of the cellular protein abundance between 4b and GFP. The higher the p-value, the higher the probability the protein 
interacts with 4b. The fold-change (Log2) is the change in the relative abundance of the cellular protein between GFP-4bM and GFP. Cellular proteins which appear in 
both GFP-4bM and 4bM-GFP data are labelled with an asterisk (*). Proteins which appeared in the third replicate are labelled with (*). 
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Figure 5.9 Scatter plot representing results from the GFP-4bM co-IP. 
Proteins were identified in the GFP-4bM IP eluate by LC-MS/MS. Proteins are plotted by 
fold-change in abundance (Log2) compared to GFP alone and p-value (-Log10) of the t-
test. Proteins with a p-value (-Log10) > 1 and a fold change (Log2) > 2 have the highest 
chance of interacting with 4b and are considered significant and are labelled (yellow). 
Results are representative of two biological replicates. 
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Figure 5.10 Scatter plot representing results from the 4bM-GFP co-IP. 
Proteins were identified in the 4bM-GFP IP eluate by LC-MS/MS. Proteins are plotted by 
fold-change in abundance (Log10) compared to GFP alone and p-value (-Log10) of the t-
test. Proteins with a p-value (-Log10) > 1 and a fold change (Log2) > 2 have the highest 
chance of interacting with 4b and are considered significant and are labelled (yellow). 
Results are representative of two biological replicates. 
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Table 5.5 Function and localisation of proteins classified as significant that interact 
with GFP-4bM and/or 4bM-GFP. 
Protein ID Protein GFP-4bM 4bM-GFP Function Location 
RRBP1* Ribosome-binding protein 1 X X 
Protein processing in 
endoplasmic reticulum 
Ribosome, 
Nucleus, Cytosol 
EF1D* Elongation factor 1-delta X X 
Responsible for the 
enzymatic delivery of 
aminoacyl tRNAs to the 
ribosome, interacts with 
HIV Tat 
Ribosome, 
Nucleus, Cytosol 
RT18A 28S ribosomal protein S18a X  
Part of the 40S 
ribosome 
Ribosome, 
Cytosol, Nucleus 
RL40 
Ubiquitin-60S 
ribosomal protein 
L40 
X  Part of the 60S ribosome 
Ribosome, 
Cytosol, Nucleus 
POP7* Ribonuclease P protein subunit p20 X X 
Component of 
ribonuclease P, 
component of RNase 
MRP complex 
Ribosome, 
Nucleus 
RRS1 
Ribosome 
biogenesis 
regulatory protein 
X  Ribosome regulatory protein 
Ribosome, 
Cytosol, Nucleus 
RL14 60S ribosomal protein L14 X  
Part of the 60S 
ribosome 
Ribosome, 
Cytosol, Nucleus 
RPS25 40S ribosomal protein S25  X 
Structural constituent of 
40S ribosome Nucleus, Cytosol 
CHCH1* 
Coiled-coil-helix-
coiled-coil-helix 
domain-containing 
protein 
X X Mitochondrial translation 
Mitochondria, 
cytoplasm 
RS30 40S ribosomal protein S30 X X 
Structural part of the 
60S ribosome 
Ribosome, 
Cytosol, Nucleus 
RL26L 60S ribosomal protein L26-like 1  X 
Component of the 60S 
ribosome 
Ribosome, 
Cytosol, Nucleus 
RM43 39S ribosomal protein L43 X  
Part of the 40S 
ribosome 
Ribosome, 
Cytosol, Nucleus 
ATX2L* Ataxin-2-like protein X X 
Involved in the 
regulation of stress 
granule and P-body 
formation 
Nucleus, Cytosol 
LS14A Protein LSM14 X  Stress granule and P-Body regulation Cytosol, Nucleus 
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The function and localisation of significant proteins (FC Log2 > 2, p-value Log10 > 1) that interact with GFP-
4bM and/or 4bM-GFP.  
 
PABP4 Polyadenylate-binding protein 4  X 
Binds the poly(A) tail of 
mRNA. Involved in 
stress granule 
regulation and mRNA 
processing 
Ribosome, 
Nucleus, Cytosol 
CALM Calmodulin  X 
Mediates the control of 
a large number of 
enzymes, ion channels, 
aquapobrins and other 
proteins by Ca(2+) 
Plasma 
membrane, 
Cytoskeleton, 
Nucleus, Cytosol 
UBC12 NEDD8-conjugating enzyme Ubc1  X 
Accepts the ubiquitin-
like protein NEDD8 
from the UBA3-NAE1 
E1 complex 
Cytosol 
ASHWN Ashwin  X tRNA processing and Gene Expression Nucleus, Cytosol 
HTRA2 Serine protease HTRA2  X 
Promotes or induces 
cell death 
Mitochondria, 
Nucleus, 
Cytosol, ER 
TCPH T-complex protein 1 subunit eta X X 
Molecular chaperone; 
assists the folding of 
proteins upon ATP 
hydrolysis 
Cytosol. 
Cytoskeleton 
RUSD3 
RNA 
pseudouridylate 
synthase domain-
containing protein 3 
 X 
poly(A) RNA binding 
and pseudouridine 
synthase activity 
Nucleus 
TAF9B 
Transcription 
initiation factor 
TFIID subunit 9B 
 X 
Involved in 
transcriptional 
activation 
Nucleus 
NUP50 
Nuclear pore 
complex protein 
Nup50 
X X 
Component of the 
nuclear pore complex 
that has a direct role in 
nuclear protein import 
Nucleus, 
Nuclear 
Envelope 
PRDX2 Peroxiredoxin-2 X  Involved in redox regulation of the cell Cytosol 
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Figure 5.11 IBV 4b interacts with a higher proportion of ribonucleoproteins. 
Significant interacting partners identified for GFP-tagged 4bM by LC-MS/MS 
were analysed by a panther over-representation test (pantherdb.org). Proteins 
which localise to cellular components that are over-represented in the data set 
(p < 0.05) were collated and shown as a Venn diagram. 
RPS25
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5.7. IBV 4b interaction with RPS25 and LAP2 
Localisation of 4b and cellular proteins were visualised to validate the 4b mass 
spectrometry data. RPS25 was a significant interaction for 4bM-GFP and was 
chosen as the candidate ribosomal protein as it is highly conserved, increasing 
the chance of labelling RPS25 in avian cells. Lamina polypeptide 2 (LAP2) is a 
nuclear envelope protein and was chosen as the candidate nuclear protein from 
the mass spectrometry data. DF-1 cells were first transfected with 4bM-GFP and 
GFP expression vectors, and after 24 hours, cells were fixed, permeabilised and 
labelled with anti-RPS25 and anti-LAP2. Both LAP2 and RPS25 were shown to 
partially colocalise with 4bM-GFP (Figure 5.12, Figure 5.13). Colocalisation 
studies allude to an interaction between 4b and RPS25 and LAP2, to further 
validate this observation a co-IP was performed. CK cells were infected with M41-
CK at an MOI above 4 or mock infected. After 24 hours cells were lysed. Cell 
lysates were incubated with anti-4b overnight and then incubated with magnetic 
protein G beads for 4 hours. Beads were separated and washed three times with 
co-IP wash buffer, and protein-antibody complexes eluted from the beads using 
acidic glycine.  A mock antibody sample was used to confirm specific pull-down 
of 4b. The input and eluate samples were separated by SDS-PAGE, transferred 
to a membrane and labelled with anti-RPS25 and anti-4b. The analysis confirmed 
successful immunoprecipitation of 4b from M41-CK infected cells (Figure 5.14A). 
Furthermore, RPS25 was also detectable in the 4b eluate but not detectable in 
the mock infected cells (Figure 5.14B). This result confirms that 4b could  interact 
with the small ribosomal protein S25 during M41 infection.   
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Figure 5.12 RPS25 partially colocalises with GFP-tagged 4b. 
DF-1 cells were transfected with GFP-tagged 4b expression vectors for 16 hours. Cells were fixed, 
permeabilised and labelled with anti-RPS25. Yellow boxes indicate enlarged areas. Cells were 
visualised by confocal microscopy. 
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A 
B 
Figure 5.13 LAP2 partially colocalises with GFP-tagged 4b. 
DF-1 cells were transfected with GFP-tagged 4b expression vectors for 16 hours. Cells were 
fixed, permeabilised, and labelled with anti-LAP2. Yellow boxes indicate enlarged areas. Cells 
were visualised by confocal microscopy. 
 
LAP2 
Chapter 7: Appendix   The role of IBV accessory proteins 3a, 3b and 4b 
235 
Figure 5.14 RPS25 interacts with 4b during M41-CK infection. 
CK cells were (A) infected with M41-CK or (B) mock infected. After 24 hours, cells 
were lysed and incubated with anti-4b or mock incubated as indicated. Samples 
were then incubated with antibody capture beads. Beads were removed, washed 
and protein-antibody complexes eluted. Input and eluate samples were analysed 
by western blot and labelled with anti-4b or anti-RPS25.  
A 
B 
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5.8. Effect of 4b on stress granule assembly 
Mass spectrometry data identified that GFP-tagged 4bM interacts with a high 
proportion of ribosomal and stress granule/p-body proteins (Figure 5.11). IBV has 
previously been shown to induce stress granule formation in a proportion of 
infected cells (Kint 2015). To confirm this, Vero cells were infected with Beau-R, 
M41K-BeauR(S) or mock infected. After 24 hours, cells were fixed, permeabilised 
and labelled with anti-G3BP1 and anti-dsRNA. Cells were labelled with anti-
G3BP1, a stress granule regulatory protein that localises to stress granules during 
stress (Matsuki et al. 2013). Mock infected cells were not positive for stress 
granules as opposed to dsRNA positive cells, which contained noticeable more 
G3BP1 puncta (Figure 5.15). This result confirms that Beau-R induces stress 
granule assembly during infection and that M41-K in Vero cells can also induce 
stress granule assembly.  
 
To determine if 4b can alone induce stress granule formation, Vero cells were 
transfected with either GFP-4bM or GFP expression vectors, and after 16 hours 
were fixed, permeabilised and labelled with anti-G3BP1. Sodium arsenite 
treatment induce oxidative stress and stress granule formation and was used as 
a positive control for induction and labelling stress granules. For each sample, 20 
GFP positive cells were randomly selected and the number of stress granule 
positive cells counted. The results are representative of three biological repeats. 
Significantly more GFP-4bM expressing cells contained stress granules 
compared to GFP expressing cells (Figure 5.16B,D). This result suggests 4b 
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expression alone induces stress granule formation. Furthermore, GFP-4bM signal 
colocalised with G3BP1 signal (Figure 5.16A,C), suggesting 4b is targeted to 
these stress granules.  
 
Beau-R 4b is truncated and lacks the C-terminal end present in 4bM. To determine 
if 4b from Beau-R can also induce stress granule formation, Vero cells were 
transfected with either GFP-4bB or GFP expression vectors for 16 hours. Cells 
were then fixed, permeabilised and labelled with anti-G3BP1. For each sample, 
20 GFP positive cells were randomly selected and the number of stress granule 
positive cells counted. The results are representative of three biological replicates. 
Significantly more GFP-4bB expressing cells contained stress granules compared 
to GFP expressing cells (Figure 5.16A,C), indicating that both M41-CK and Beau-
R 4b induce stress granule assembly.  
 
Previous work has shown that IBV can inhibit sodium arsenite-induced stress 
granule assembly (Kint 2015). To determine if 4b is responsible for this effect, 
Vero cells were transfected with GFP-4bM or GFP expression vector, for 18 hours. 
Cells were treated with sodium arsenite for one hour before fixing. Cells were 
fixed, permeabilised and labelled with anti-G3BP1. Expression of GFP-4bM failed 
to inhibit sodium arsenite-induced stress granule assembly, indicating 4bM is not 
responsible for this previously observed effect (Figure 5.17). Interestingly, GFP-
4bM did not localise with sodium arsenite-induced stress granules, as seen with 
GFP-4bM-induced stress granules. Collectively, these results demonstrate that 
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4b expression alone can induce and colocalise with stress granule but cannot 
inhibit or colocalise with sodium arsenite-induced stress granules. 
 
 
Figure 5.15 IBV induces stress granule assembly. 
Vero cells were infected with Beau-R, M41K-BeauR(S) or mock infected. After 24 hours, 
cells were fixed, permeabilised and labelled with anti-dsRNA, anti-G3BP1. The nucleus 
was stained with DAPI. 
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 A 
C 
Figure 5.16 IBV 4b induces and colocalises with stress granules.  
Vero cells were transfected with GFP-4bM (A), GFP-4bB (C) or GFP expression vectors. 
After 24 hours, cells were fixed, permeabilised and labelled with anti-G3BP1. For each 
transfection, 20 GFP-4bM (B), GFP-4bB (D) or GFP expressing cells were counted for the 
presence of stress granules as labelled with anti-G3BP1. The results are representative of 
three biological replicates. White arrows indicate stress granules that colocalise with GFP-
tagged 4b expression. ** significant p < 0.01. 
B 
D 
** 
** 
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Figure 5.17 GFP-4bM does not colocalise or inhibit sodium arsenite-induced stress 
granules. 
Vero cells were transfected with pEGFPC2-4b or pEGFPC2. Vero cells were treated with sodium 
arsenite for 1 hour before fixing. After 18 hours, cells were fixed and labelled with anti-G3BP1. The 
nucleus was stained with DAPI.  
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5.9. Effect of 4b on cellular translation 
IBV 4b induces stress granule formation when overexpressed in Vero cells. Stress 
granules are formed by aggregation of stalled translation initiation complexes 
(Beckham et al. 2008). For this reason, the effect of GFP-4bM/GFP-4bB 
expression on cellular translation was measured. DF-1 cells were transfected with 
increasing levels of GFP-4bM or GFP-4bB expression vector, made up to 2 μg 
with pEGFPC2, along with a Renilla luciferase expression vector. A plasmid 
expressing NS1 (IAV-PR8) was transfected as a positive control, NS1 has been 
shown to enhance cellular translation, through eIF2a phosphorylation (Lu et al. 
1995, Salvatore et al. 2002). After 16 hours, cells were lysed, and Renilla 
luciferase activity measured as a proxy for the cellular translational rate. 
Expression of GFP-4bM or GFP-4bB had a dose-dependent effect on Renilla 
luciferase expression with increasing levels of 4b resulting in higher levels of 
Renilla luciferase expression. This result suggests that 4b expression increased 
cellular translation (Figure 5.18).    
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5.10. Role of RVxF and SILK on 4b function 
Bioinformatic analysis of the 4b peptide sequence identified two domains; RVxF 
and SILK, in the highly conserved N-terminal end (Table 5.2). Individually these 
domains mediate PP1c binding but together provide higher affinity binding to 
PP1c (Hendrickx et al. 2009). PP1c is a multi-functional protein involved in 
dephosphorylation of a range of signalling proteins including the translational 
** **** 
Figure 5.18 IBV 4b increases cellular translation. 
DF-1 cells were transfected with increasing levels of GFP-4bM expression, made up with 
the GFP-4bB expression vector to 2 µg. Cells were also transfected with a Renilla luciferase 
expression vector. After 16 hours cells were lysed and Renilla luciferase activity measured. 
Results are shown as fold-change compared to the GFP control. ** significant p < 0.01, **** 
significant p < 0.0005. 
A B 
4bM-GFP 4bB-GFP 
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regulatory protein, eIF2α and PKR (Garcia-Bonilla et al. 2007). The cell can 
respond to infection by phosphorylating eIF2α and PKR, to limit cellular translation 
and thus inhibit viral replication (Dauber et al. 2009). To determine the significance 
of these motifs on the function of 4bB, the RVxF and SILK motifs were deleted 
both individually and together in the 4b expression vectors by site-directed 
mutagenesis. Mutagenesis only succeeded for the 4bB vector and due to time 
constraints was not repeated with the 4bM vector. Vero cells were transfected with 
either GFP, 4bB-GFP, 4bBGFP-delSILK, 4bBGFP-delRVxF or 4bBGFP-
delSILK/RVxF expression vectors along with a Renilla luciferase expression 
vector. After 16 hours, cells were lysed, Renilla luciferase expression measured 
and plotted as fold-change compared to the GFP control (Figure 5.19A). 
Expression levels of each protein were quantified by western blot to ensure 
consistent levels of expression. Lysed cells were separated by SDS-PAGE, 
transferred to a membrane and labelled with anti-GFP (Figure 5.19B). Deletion 
of SILK, RVxF or both abrogated the effect of 4bB on increased Renilla luciferase 
expression. This preliminary result suggests that these motifs, are in part, 
responsible for the effect of 4bB on increased rates of cellular translation.  
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Figure 5.19 Protein 4b effect on cellular translation is dependent on SILK and/or 
RVxF. 
(A) Vero cells were transfected with GFP-4bB, GFP4bB-delRVxF, GFP4bB-delSILK, 
GFP4bB-delRVxF/SILK or GFP expression vectors. After 16 hours, cells were lysed, 
and Renilla luciferase activity measured. (B) Lysed cells were separated by SDS-
PAGE, transferred to a membrane and labelled with anti-GFP. *significance p < 0.05. 
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5.11. Discussion 
Bioinformatic analysis of the IBV and TCoV strain database showed that 78% of 
strains contain ORF4b as well as the upstream non-canonical TRS (Table 5.1). 
Sequence conservation is lower compared to the other accessory proteins 
(Britton 2007). However, the strains with ORF4b have a sequence similarity of 
81%, which is as high as the most conserved accessory protein, 3a (Britton et al. 
2006, Britton 2007). RNA viruses tend not to express unessential sgRNA/ proteins, 
so although not all strains have ORF4b and because it is highly conserved when 
present, this suggests an essential role for this protein. The TRS for ORF4b (CAA) 
is also highly conserved, possibly suggesting an important role for the non-
canonical TRS and the low expression levels of 4b. Sequence alignment identified 
a range of 4b isoforms, with truncations at the C-terminal end (Figure 5.1). The 
most common 4b isoform was 94 amino acids long, with 69% of IBV/TCoV strains 
encoding this length, including M41-CK and QX. The apathogenic lab strain, 
Beau-R, encodes a truncated form of 4b which is only 50 amino acids. Beau-R 
was the only strain with the truncated50 4b isoform, although two field strains 
encode a smaller 4b isoform at 40 amino acids.  
 
ORF4b was previously thought to be a pseudogene. Bentley et al. (2013) showed; 
through northern blotting, that ORF4b is transcribed during infection and further 
concluded that the non-canonical TRS upstream of ORF4b is responsible for 
regulating transcription (Bentley et al. 2013). Furthermore, they showed that 
insertion of a GFP gene in place of ORF4b resulted in transcription and translation 
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of GFP (Bentley et al. 2013), suggesting the sgRNA produced by IBV can lead to 
the expression of a protein. Nonetheless, it was not known if transcript 4b was 
translated during infection. Utilising an antibody raised against the predicted 4b 
peptide sequence, 4b transcript translation has been confirmed and 4b protein is 
detectable during infection (Figure 5.5). Anti-4b can only be used to detect 4b 
during M41-CK infection, as the antibody was raised against a C-terminal epitope 
not present in Beau-R 4b. Therefore, it has not been possible to verify that Beau-
R 4b is also translated. Although truncated, Beau-R 4b is only 50 amino acids, 
IBV accessory protein 3a, which is similar in size is translated, suggesting Beau-
R could express the smaller isoform of 4b too (Britton et al. 2006). Nonetheless, 
confirmation of Beau-R 4b expression is still required to say that Beau-R also 
expresses 4b definitively. It has been confirmed with viral growth curves 
comparing M41-CK, M41-K, and two rIBV-M41-K lacking ORF4b that 4b is an 
accessory protein (Figure 5.7). M41-K and both M41K-del4b viral isolates grew 
to similar titres suggesting this protein is dispensable for in vitro replication and is 
thus the fifth accessory protein to be identified for IBV. 
 
Mass spectrometry was utilised to identify any cellular proteins that may interact 
with 4b. For this assay, HEK-293T cells were transfected with GFP-4bM or 4b-
GFPM expression vectors along with a GFP control. LC-MS/MS was used to 
identify cellular proteins that were co-immunoprecipitated in the GFP and 4b-
GFP/GFP-4b eluate. Due to the incomplete characterisation of the chicken 
genome, this assay was performed in HEK-293T cells; a human cell line as 
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opposed to a more relevant chicken cell line. Performing the assay in a human 
cell line increased the chance of characterising the cellular proteins by mass 
spectrometry but due to the differences in chicken and human cell biology may 
affect the interacting partners identified for 4b. Furthermore, these IPs were 
performed using transfected cells overexpressing 4b as opposed to M41-CK 
infected cells, further impacting interpretation of these results. To minimise the 
effect of the GFP-tag on 4b cellular interactions, 4b was tagged at either the N- 
or C- terminus, this increased the likelihood of detecting cellular proteins that 
interact with the C- or N- terminus of 4b, respectively. Furthermore, a GFP control 
was used to remove proteins that interact with the GFP-tag rather than 4b from 
the mass spectrometry data.  M41-CK 4b was used for the GFP co-IPs, as M41-
CK is a pathogenic strain and contains the full-length 4b sequence, as opposed 
to Beau-R. In the future, it would be interesting to perform GFP-tagged 4bB co-
IPs to determine if Beau-R 4b interacts with similar cellular proteins. Furthermore, 
it may also be used to identify cellular proteins that specifically interact with the 
C- terminus of 4bM. As Beau-R is apathogenic and M41-CK is pathogenic, this 
could have implications for the role of the full-length 4b in pathogenicity.  
 
In total 154 unique proteins were identified in higher amounts in GFP-tagged 4b 
IPs compared to the GFP control, with 72 appearing in both GFP-4bM and 4bM-
GFP eluates (Appendix Table 7.4, 7.5). In total 23 proteins were identified as 
significant for either GFP-4b and/or 4b-GFP, with eight of these detected in both 
GFP-4b and 4b-GFP eluates (Table 5.5). The IP was repeated three times to 
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determine the significance of the data. For an unknown reason, the third replicate 
failed to align with the first and second replicate (Appendix Table 7.4, 7.5), with 
a higher proportion of cellular proteins detected, 197 for GFP-4bM and 180 for 
4bM-GFP, with only 65 and 73 of these proteins appearing in the first two 
replicates, respectively. A higher yield of proteins could have occurred due to a 
more efficient transfection rate or a less stringent wash step during the co-IP, 
although there was no discernible difference in 4b volume in the third eluate 
compared to the first two (Figure 5.8). Nonetheless, 90% and 82% of proteins 
identified in the first two GFP-4bM and 4bM-GFP replicates did appear in the third, 
suggesting the data is reliable if not comparable. While repeats are an essential 
tool to determine the significance of the mass spectrometry data, the decision was 
made to validate the data from replicate one and two by co-IP and 
immunofluorescence to save time and cost. A high proportion of proteins identified 
were ribosomal and are involved in both translation and stress granule assembly 
(Table 5.5). Cellular translation machinery is highly conserved among eukaryotes 
(Sonenberg et al. 2009), reducing the risk that proteins identified as interacting 
partners are artefacts for 4bM. Ribosomal proteins regularly appear in mass 
spectrometry data and can be considered a background contaminant, therefore 
to validate 4b interacts with the ribosome, RPS25 was studied first (Mellacheruvu 
et al. 2013). RPS25 was a highly significant protein in the mass spectrometry data 
and has a high sequence similarity between the chicken and human isoforms. 
RPS25 is a ribosomal protein which has been shown to mediate cellular IRES 
expression and has previously been shown to play a role in viral translation during 
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Hepatitis C virus, poliovirus and adenovirus replication (Hertz et al. 2013). 
Furthermore, knockout of this protein had minimal effect on global cellular 
translation during homeostasis leading to the suggestion that RPS25 plays a role 
in viral translation (Landry et al. 2009).  Immunofluorescence confirmed that GFP-
4bM colocalises with RPS25 in DF-1 cells (Figure 5.12). Furthermore, co-IP of 
4b from M41-CK infected CK cells also confirms that 4bM interacts with RPS25 
during infection (Figure 5.14). Detection of RPS25 in the 4b co-IP further 
validates the mass spectrometry data and suggests a role for 4b in translation. 
RPS25 is a ribosomal protein but can also be present in stress granules as part 
of the stalled 40S ribosome complex (Kedersha et al. 2016). Three stress granule 
regulatory proteins were also identified by mass spectrometry including, LS14A, 
ATXL2, and PABP4. LS14A is present in p-bodies and stress granules and may 
have a role in shuttling mRNAs between the two structures (Yang et al. 2006). 
ATXL2 is a regulator of both p-bodies and stress granules while PABP4 relocates 
from the cytoplasm to stress granules during cellular stress (Kaehler et al. 2012) 
(Burgess et al. 2011). Expression of GFP-4bM alone induced stress granules in 
Vero cells; this was not seen with GFP expression (Figure 5.16A,C). Furthermore, 
GFP-4bM colocalised with these stress granules. The same effect was seen with 
GFP-4bB (Figure 5.16B,D). Stress granules are present during Beau-R and M41-
K infection (Figure 5.15), and it has been previously shown that IBV also 
expresses a protein that can inhibit sodium arsenite-induced stress granule 
formation (Kint 2015). Overexpression of 4b failed to inhibit sodium arsenite-
induced stress granules, suggesting 4b is not responsible for this previously 
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observed phenotype (Figure 5.17). As 4b can induce stress granules, it was 
assumed that 4b would also inhibit cellular translation, as stress granules are 
translationally silent (Buchan et al. 2009). Renilla luciferase expression, a proxy 
for gene expression and cellular translation, was measured in the presence of 
GFP-4bM or GFP-4bB. Interestingly, IBV 4b increased Renilla luciferase 
expression in a dose-dependent manner, suggesting 4b increased gene 
expression (Figure 5.18). This result implies that 4b-induced stress granules may 
not be canonical and may not have a role in arresting cellular translation. 
Alternatively, these stress granules may be a cellular response as the cell aims to 
curtail increased translation to preserve resources and energy (Kedersha et al. 
2005). This theory is further supported by the fact that not all GFP-4b expressing 
cells were positive for stress granules, suggesting a possible dose-dependent 
effect on stress granule assembly (Figure 5.16). Stress granules are separated 
into sub-families representing their structural and functional diversity. While stress 
granules play a role in the silencing and storing of mRNAs, they are not required 
by themselves for global translational repression (Mokas et al. 2009). Thus, the 
role of stress granules cannot be simplistically categorised. Indeed, stress 
granules can represent focal points for a range of signalling pathways, including 
interferon and apoptosis signalling (Kedersha et al. 2013). While many viruses 
encode proteins to inhibit stress granule assembly, other viruses have been 
shown to modulate stress granules for their benefit. Indeed, stress granules are 
present throughout the life-cycle of respiratory syncytial virus (RSV) infection and 
appear beneficial for the virus, with knockdown of G3BP1 and stress granule 
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assembly causing a reduction in RSV translation (Lindquist et al. 2010). Vaccinia 
virus has been shown to co-opt canonical stress granule assembly into novel 
aggregates that lack silenced cellular mRNAs (Simpson-Holley et al. 2011). 
Furthermore, HCV recruits stress granule proteins such as G3BP1 and ataxin-2 
to replication factories, which resemble stress granules but are indeed replication 
sites (Ariumi et al. 2011). Thus, the assembly of stress granules during infection 
cannot be suggested as solely negative for the virus. Future work should aim to 
categorise stress granule composition during IBV infection, and to determine if 
they have a beneficial or detrimental effect on viral replication.  
 
The observation that both 4b from M41-CK and Beau-R can induce and colocalise 
with stress granules and can increase cellular translation suggests that the 
domains required for this effect are in the N-terminal end of 4b (Figure 5.16B, D). 
Beau-R and M41-CK are lab strains which have been passaged extensively and 
are thus highly cell culture adapted viruses. Beau-CK was first isolated in 1937 
and has been passaged considerably more compared to M41-CK (Beaudette 
1937, Cunningham et al. 1947). A high passage number could explain the 
acquisition of a C-terminal truncation in Beau-R 4b. This observation has been 
suggested before as the reason why lab strains of HCoV-229E have a truncated 
isoform of protein 4, while clinical strains do not, and could suggest that the C-
terminal end of IBV 4b is not required for in vitro function (Farsani et al. 2012). 
This is further supported by the sequence identity of 89% between the 
truncated50 and FL 4b isoforms. Indeed, sequence similarity is much higher at 
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the N-terminal end and more divergent at the C-terminal end between the 4b 
isoforms suggesting the N-terminal end performs an important function (Figure 
5.1). This result could be further validated by deleting the C-terminal end of M41 
4b, to determine if function remains. Further functional analysis could look at the 
truncated40 4b identified in 2 field strains or even delete C-terminal or N-terminal 
amino acids until a stress granule phenotype is no longer detectable.  
 
Bioinformatic analysis of 4b failed to identify any transmembrane domains or 
signal peptides (data not shown). Although an ELM search of 4bM did identify two 
motifs in the highly-conserved N-terminus, which potentially relates to cellular 
translation and stress granule assembly, PP1c_RVxK and PP1c_SILK (Table 5.2). 
PP1c is the catalytic subunit of PP1, a ubiquitous protein that has a role in many 
cellular pathways including glycogen metabolism, cell cycle and cellular 
translation (Hartshorne et al. 2004, Mochida et al. 2012, Walsh et al. 2013). PP1 
regulates these pathways by dephosphorylating cellular proteins and can 
reinitiate cellular translation by dephosphorylating eIF2α (Garcia-Bonilla et al. 
2007). RVxF and SILK motif are regularly found together in cellular proteins, and 
while individually they can mediate binding to phosphatase protein 1c (PP1c), 
their presence together is thought to enhance this interaction (Hendrickx et al. 
2009). They have no role in stimulation or inhibition of PP1c activity, and are 
thought to bind to PP1 to promote interaction with a secondary site (Wakula et al. 
2003). The SILK motif (SILR) appears in 93% of 4b sequences, while RVxF 
appears in 93.7% of 4b appearing as either KLxF or RLxF. Nonetheless, PP1c 
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was not identified in any of the mass spectrometry data. This fact alone does not 
confirm that 4b cannot interact with PP1c as the interaction may be weak and/or 
transient. Furthermore, the 4b/PP1c interaction may be dependent on a cellular 
antiviral state. As the co-IP was performed with cells overexpressing GFP-tagged 
4b, the PKR/eIF2α pathway would not be activated, and subsequent PP1 activity 
would be lower. If the mass spectrometry co-IP was repeated cells could be 
treated with the dsRNA analogue, poly(I:C), to induce an antiviral state and 
activate the PKR pathway. Alternatively, as anti-4b can immunoprecipitate 4b 
during infection (Figure 5.14A), infected cells could be used instead, although 
low levels of 4b may make this technically difficult. Interestingly, two PP1c 
interacting proteins were detected, eIF2α and PKR, although not significantly 
(Appendix Table 7.5, 7.6) (Szyszka et al. 1989, Garcia-Bonilla et al. 2007). 
During IBV infection, eIF2a phosphorylation is suppressed, which has been linked 
with increased GADD34 expression, a protein that interacts with PP1, through an 
RVxF domain, to dephosphorylate eIF2a (Wang et al. 2009). Furthermore, auto-
phosphorylation of PKR is also suppressed during IBV infection; this has been 
linked, in part, with the activity of IBV nsp2 (Wang et al. 2009). The RVxF motif 
has been identified and is functionally important in accessory protein 7 of TGEV, 
which has been shown to mediate dephosphorylation of eIF2a (Cruz et al. 2011). 
Although PP1c was not identified in the 4b mass spectrometry data, the presence 
of these two motifs along with the incidence of RVxF in another coronavirus 
accessory protein means these motifs warrants further investigation. To 
determine the importance of RVxF and SILK on 4b function, these motifs were 
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deleted individually and collectively from 4bB. Deletion of these motifs together 
and individually abrogated the effect of 4bB on cellular translation (Figure 5.19). 
Interestingly, deletion of a single motif had a similar effect as deletion together. 
This result could suggest that 4b function is dependent on the presence of both 
motifs, although these motifs have been shown to function independently of each 
other, especially RVxF which is shown to mediate strong PP1c binding alone 
(Wakula et al. 2003, Hendrickx et al. 2009). Deletion of these motifs, especially in 
a relatively small protein, may have had a deleterious effect on 4b structure or 
effect neighbouring motifs that could affect the 4b function independent of 
SILK/RVxF presence. Future work should aim to mutate these motifs instead of 
deleting them (SILK > SAAA, RVxF > RKAGA) to abrogate PP1c protein 
interaction while aiming to maintain 4b structure (Hendrickx et al. 2009). 
 
The non-canonical TRS is highly conserved for ORF4b (Table 5.1). The M41-K 
vaccinia reverse genetic system was used to mutate the ORF4b non-canonical 
TRS to a canonical TRS (canTRS4b-M41K) to investigate the importance of it. 
Due to time constraints, the rIBV was not generated. Nonetheless, the mutation 
has been successfully inserted into the M41-K genome within the vaccinia virus 
backbone (data not shown). Future work will aim to express M41K-canTRS4b 
from within the vaccinia virus backbone to generate this recombinant IBV. M41K-
canTRS4b is expected to express 4b at a higher level compared to the wild-type 
virus (Bentley et al. 2013). Comparing viral growth levels between M41K-
canTRS4b and wild-type M41-K will help to determine the effect of higher 4b 
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levels on viral replication. Deletion of 4b from M41-K did not affect viral replication 
(Figure 5.7), possibly suggesting that higher levels of 4b may not affect replication 
either. Nonetheless, the non-canonical TRS is highly conserved, possibly 
suggesting a requirement for lower levels of 4b expression (Table 5.1). TGEV 
accessory protein 7b, which also increases cellular translation during infection, 
has a deleterious effect on TGEV pathogenicity, possibly suggesting 4b may act 
similarly (Cruz et al. 2011). Therefore, there may be a requirement for lower levels 
of 4b, as higher levels may impact pathogenicity and negatively affect in vivo 
replication and/or transmission. 
 
Protein 4b is the fifth accessory protein to be identified for IBV. Mass spectrometry 
data suggests 4b can interact with multiple parts of the cellular translational 
machinery, including but not limited to, ribosomes, PKR, stress granule and p-
body regulatory proteins. The exact mechanism of how 4b increases cellular 
translation or induces stress granule assembly is not known but two motifs, which 
are highly conserved, SILK and RVxF, suggests this protein can interact with 
PP1c, a protein known to dephosphorylate PKR and eIF2α (Szyszka et al. 1989, 
Garcia-Bonilla et al. 2007). Future work should aim to confirm the effect of 4b on 
translation during infection and determine the exact mechanism of 4b interaction 
with stress granules, p-bodies, and translation.  
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6. Discussion 
The first aim of this project was to identify host-cell interaction partners for IBV 
accessory proteins 3a and 3b that may allude to function. The second aim was to 
determine if sgRNA 4b is translated and detectable during infection, and if so, 
determine the role of this protein. 
  
6.1. Accessory protein 3a 
The cellular antiviral response offers a considerable barrier for viral replication. 
The continuing evolutionary arms race between coronavirus and host has 
generated a set of accessory proteins which play an increasingly multi-functional 
role in controlling and modulating cell signalling pathways. These host-cell 
interactions often have significant impacts on disease progression and outcome 
(Knodler et al. 2001). The role of coronavirus accessory proteins is diverse and 
complex, with almost constant research finding new avenues for how these 
proteins function. This is best represented by the most researched area of virus 
host-cell interaction, the IFN signalling pathway. The type I IFN response is crucial 
for the control of coronaviruses and offers a significant challenge to infection 
(Ireland et al. 2008, Li et al. 2010). Previous work has shown that IBV accessory 
proteins 3a, 3b, and 5b all play a role in modulating the IFN response (Kint et al. 
2015, Kint et al. 2016). Here, using mass spectrometry and in vitro IFNβ assays, 
a mechanism of action for 3a is proposed, by which 3a modulates the levels of 
IFN signalling proteins, MAVS and IRF7, through interaction with the IFN 
regulatory proteins, RNF5 and CAND1. These interactions can, in part, explain 
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the dual effect of 3a on IFNβ signalling. Low levels of 3a has an agnostic effect 
on IFNβ expression while higher levels have an overall inhibitory effect. This is an 
interesting observation, and while cellular proteins such as LGP2 have been 
shown to have opposite effects on IFN expression depending on dose, this is the 
first instance of this phenotype in a viral protein (Rodriguez et al. 2014). This 
allows 3a to have a more dynamic relationship with IFNβ expression, wherein 3a 
can inhibit IFNβ expression during peak viral replication but can also stimulate 
IFNβ expression later in infection, possibly to prevent excessive host damage. It 
has been shown that the decrease in 3a levels 36 h.p.i coincides with increased 
IFNβ expression and that 3a is responsible for this. More work is still required to 
determine if this is due to the role of 3a in increasing levels of MAVS during 
infection. A proposed mechanism of action is that 3a can affect IFN signalling by 
interacting with the cellular proteins, RNF5 and CAND1. More work is required to 
link these interactions with increased or decreased IFN expression both in vitro 
and in vivo. Work here mainly focused on the IFN pathway, but 3a most likely has 
additional roles during infection, highlighted by the range of interacting partners 
identified in the mass spectrometry data. Future work would be encouraged to 
look at the other highly significant proteins identified, including FNDC3a, SUCGL2, 
and DAAF5, all which appear to play a role in pathways other than IFN expression. 
Alternatively, anti-3a; which can immunoprecipitate 3a from infected CK cells 
(data not shown), could be used to gather more relevant mass spectrometry data 
from virus infected cells. This would help to reduce false positives that may occur 
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in the current dataset. Future work should also focus on the effect of 3a in 
combination with 3b, which may also interact with a MAVS regulatory protein.   
 
6.2. Accessory protein 3b 
The role of IBV accessory protein 3b was a difficult protein to investigate. IBV 3b 
is quickly turned over in cells and can localise to two cellular compartments based 
on whether it is expressed in avian or mammalian cells (Pendleton et al. 2006). 
Mass spectrometry data suggested that 3b interacts with proteins that regulate 
mitochondrial membrane permeabilisation and thus may have a role in apoptosis. 
HEK-293T cells were used for the GFP co-IP to characterise and identify 
interacting partners for IBV accessory proteins. This cell line has limitations, as 
mammalian cell biology can differ from avian cells, potentially affecting the 
function of 3b. This limitation is most apparent for 3b, which when overexpressed 
in mammalian and chicken cells colocalises differently. Due to time constraints 
and the lack of a 3b antibody, these interactions were not confirmed by IP or 
immunofluorescence. Nonetheless, recombinant IBV that lack 3b induced less 
caspase-dependent apoptosis, suggesting 3b is involved in apoptosis in some 
manner, whether this response is a cellular or viral response is unknown. The 
apoptotic pathway is closely linked to the IFN pathway, with both cascades 
proceeding through the mitochondria (Barber 2001). Protein 3b has already been 
shown to antagonise IFN expression, which could lead to increased pro-apoptotic 
signalling (Kint et al. 2015) (Randall et al. 2008). Whether apoptosis is a 
consequence of inhibiting IFN expression or is actively induced by 3b is unknown 
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and warrants further investigation. The apoptosis assays established here should 
be used to qualify transient 3b apoptotic activity, this should include looking at 3b 
from different strains of IBV including a truncated form of 3b from a Beau-R strain. 
Future work should also investigate how 3b inhibits IFN expression and should 
utilise the chIFNβ-luciferase assay used for 3a to determine at which point 3b can 
affect the IFN cascade. 
 
6.3. Accessory protein 4b 
Sub-genomic RNA 4b was first identified by Bentley et al. and work completed 
here confirms that this sgRNA is translated into a detectable protein during 
infection and is referred to as 4b. Protein 4b is an 11 kDa protein and is the fifth 
accessory protein to be identified for IBV along with 3a, 3b, 5a, and 5b. Protein 
4b interacts with cellular proteins which are involved in translation, as well as 
stress granule (SG) and p-body assembly. Previous work has shown that IBV can 
both induce SG assembly and inhibit sodium arsenite-induced SG assembly (Kint 
2015). Whether these SGs inhibit viral replication and are indeed a cellular 
response to infection is unknown. IBV induced SGs do not disassemble when 
treated with cycloheximide, supporting the idea that these SGs are non-canonical 
(Kint 2015). Here we show that 4b can induce SG assembly when expressed 
alone, while simultaneously increasing rates of cellular translation. This result 
supports the idea that these SGs are non-canonical and may not be coupled with 
cellular translational arrest. Future work needs to determine the structural 
composition of these SGs and determine if they are indeed translationally silent. 
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Neither antibody targeting G3BP1 nor TIA-1 worked in avian cells, so future work 
should look at different SG antibodies for use in avian cells or focus on Beau-R 
which can replicate in Vero cells. Interestingly, the two viral proteins that have 
been shown to play a role in regulating cellular translation, 5b and 4b, were unable 
to inhibit sodium arsenite-induced SG formation, even though IBV can (Kint 2015). 
This suggests that another IBV viral protein may be responsible for inhibiting 
these canonical SGs during infection. To confirm this is the case for 4b, cells 
should be infected with M41K-del4b or BeauR-delIR and then treated with sodium 
arsenite to determine if IBV can still inhibit SG assembly as seen with 5b (Kint 
2015). While IBV 5b has been shown to regulate cellular translation, there is no 
proposed mechanism of action. Furthermore, the interplay between how 4b and 
5b function together is unknown, especially considering they appear to have 
opposite roles in regulating cellular translation (Kint 2015, Kint et al. 2016). Future 
work should also investigate the role of 4b in the assembly of p-bodies, as proteins 
that play a role in SG assembly, LS14A and ATXL2, also regulate p-body 
assembly (Yang et al. 2006, Kaehler et al. 2012). Previous work has shown that 
p-body assembly is modulated during IBV infection and may be responsible for 
decreased cellular mRNA decay seen during infection (Kint 2015). 
 
Sub-genomic RNA 4b is expressed under the control of a non-canonical TRS 
(Bentley et al. 2013). This is the first sgRNA identified; which is regulated by a 
non-canonical TRS, that is translated into a detectable protein. This non-
canonical TRS results in lower levels of sgRNA 4b than is expected for its genome 
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location and raises questions as to the role of this non-canonical TRS (van der 
Most et al. 1995). As this non-canonical TRS is highly conserved, it suggests there 
is a reason why 4b is expressed at lower levels, and that higher levels may not 
be beneficial for the virus. Work here has started to examine these questions by 
synthesising a recombinant M41-K virus containing a canonical TRS upstream of 
ORF4b (data not shown). Work should continue to generate this rIBV and 
examine the effect of increased 4b expression levels on replication and 
pathogenicity. The effect of this non-canonical TRS should be investigated in IBV 
and highlights the range of mechanisms coronaviruses could employ to regulate 
levels of sgRNA and protein during infection. 
 
6.4. IBV accessory proteins 
Current knowledge as to the role of coronavirus accessory proteins varies 
between genera, with SARS-CoV and MHV accessory proteins amongst the best 
characterised, and IBV amongst the least (Liu et al. 2014). Regardless, more 
functional and structural work is required across the board to determine the 
pathogenic significance of these small proteins. While the function of some 
coronavirus accessory proteins has been determined, this most likely represents 
just the tip of the iceberg. While small, these proteins are usually multi-functional. 
The best example of this is SARS 7a which so far has been shown to inhibit 
cellular translation, activate the MAPK signalling pathway, suppress cell cycle 
progression and induce apoptosis (Liu et al. 2014). The function of this accessory 
protein is still only partially understood and continues to be investigated. This 
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feature is common for coronavirus accessory proteins and implies that IBV 
accessory proteins 3a, 3b, and 4b most likely play multiple roles during infection 
too. Future work should look at the other interacting partners identified by mass 
spectrometry. Due to time constraints, these interacting partners were not 
investigated, but they could be used to identify additional functions for these 
accessory proteins. The mechanism of action for 5a or 5b has yet to be 
determined; future work would be encouraged to use mass spectrometry to 
investigate these accessory proteins further. 
 
Results shown here have predominantly relied on using 3a, 3b, and 4b expression 
vectors. These vectors have helped to determine interacting partners for these 
proteins and potential mechanism of actions. Nonetheless, these observed 
results need to be validated in the context of viral infection to determine their 
clinical significance. This can be difficult as the roles of accessory proteins can 
often overlap. For example, 3a, 3b, and 5b all play a role in inhibiting IFN 
expression, with 3a also able to stimulate IFN expression (Kint et al. 2015, Kint et 
al. 2016), while 4b and 5b appear to have opposite effects on cellular translation. 
The function of these proteins needs to be compared in the context of other 
accessory proteins to gain a complete picture of the complex relationship between 
IBV and host. Deletion of TGEV, SARS-CoV, and MHV accessory proteins leads 
to attenuation of the virus in the host (Paul et al. 1997, de Haan et al. 2002, Zhao 
et al. 2009, Liu et al. 2014). Recombinant M41 viruses lacking 3a, 3b, or 4b should 
be used for in vivo experiments to determine their role in pathogenicity. This 
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experiment should be complemented with recombinant viruses lacking accessory 
proteins in different combinations and include 5a and 5b. Discerning the role of 
these accessory proteins during infection is further complicated by the fact that 
IBV potentially expresses more, as yet unidentified, accessory proteins. ORF4b 
was first identified in 1980, and it was not confirmed as a sgRNA until recently 
(Stern et al. 1980, Bentley et al. 2013). Here we have shown that 4b is translated 
and detectable during IBV infection. This ORF was believed not to encode a 
sgRNA as it lacked a canonical TRS, highlighting the potential for IBV to express 
additional sgRNA under the control of a non-canonical TRS or indeed alternative 
expression systems. Considering coronaviruses have the largest positive-sense 
RNA genome, the potential to encode additional accessory proteins is highly 
probable if not certain (Hussain et al. 2005, Han Di et al. 2017). Indeed, an 
additional sgRNA has recently been detected during Beau-R infection expressed 
from the 3′-end of the genome and referred to as sgRNA 7 (Keep et al, 
Unpublished). Whether this sgRNA is translated into a protein during infection is 
unknown as is the function of this putative protein. The full repertoire of IBV 
accessory proteins needs to be identified, and their function determined to gain a 
better understanding of how IBV causes infectious bronchitis in domestic fowl. 
While northern blotting has helped to identify both sgRNA 4b and 7 (Keep et al. 
Unpublished) (Bentley et al. 2013), future work should use the development of 
next-generation sequencing and RNA-seq to identify the full range of novel 
sgRNAs (Bentley et al. 2013) (Han Di et al. 2017).  
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While 3a, 3b, and 4b are highly conserved between M41-CK and Beau-R strains, 
there is the potential for them; in the context of infection, to function differently. 
Functional differences between accessory proteins may explain the differences 
seen in pathogenicity between Beau-R and M41-CK. Furthermore, while M41-CK 
is a pathogenic strain of IBV, it is still a lab-adapted strain and therefore is not a 
reliable reflection of a field strain of IBV. Although accessory proteins 3a and 3b 
are highly conserved between Beau-R and M41-CK, they are less conserved with 
the clinically important field strain, Qx. Qx and Qx-like IBV strains are highly 
pathogenic and were first isolated in 1998 in China (ShuShuang 1998). These 
strains cause severe nephrotoxicity and are the biggest risk to the poultry industry 
(Beato et al. 2005, Valastro et al. 2010). It is not known why Qx is highly 
pathogenic but could be due to the differences in accessory protein peptide 
sequences, which are lower at 80.9% and 61.9% for 3a and 3b, respectively. 
Another field strain, recently identified in Australia, contained a single unrelated 
X1 gene in place of 3a and 3b, and deletion of 5a altogether, the significance of 
these deletions is not known but does show the potential for IBV to mutate these 
accessory proteins in the field (Mardani et al. 2008). Future work should aim to 
repeat assays, established here, with a panel of accessory proteins from a range 
of IBV strains to determine the significance of these proteins in disease outcome. 
Alternatively, determining the functional conservation of these accessory proteins 
between IBV strains could make them more attractive as cross-protective targets 
for vaccines and/or therapies. 
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6.5. Implications for vaccine design and novel therapies 
Currently, domestic fowl are vaccinated against IBV using inactivated and live 
attenuated viruses (Box et al. 1980). For the generation of attenuated vaccines, 
clinical field strains of IBV are isolated and attenuated by serially passaging them 
in embryonated eggs. This process aims to create a vaccine that strikes a balance 
between attenuation and immunogenicity. This requires a process of trial and 
error and therefore can be labour intensive, costly and will not necessarily confer 
protection against different IBV serotypes (Davelaar et al. 1984, Jordan 2017). 
Furthermore, there is a danger that these vaccines can revert to virulence when 
used in vivo, either through mutations or recombination with field strains (Hopkins 
et al. 1986). There is thus a growing need for vaccines which are rationally 
designed that are attenuated but maintain immunogenicity. This would require a 
better understanding of how to introduce attenuating mutations. This could 
include mutating or indeed deleting accessory protein ORFs, as has been 
adapted for the generation of feline infectious peritonitis virus (FIPV) attenuated 
vaccines (Haijema et al. 2004). Deletion of accessory proteins, compared to 
deletion of nsps or structural proteins, is better tolerated by coronaviruses as they 
are non-essential for replication and assembly (Cavanagh et al. 2007). 
Furthermore, these deletions are less likely to revert to a virulent state compared 
to mutations and are therefore considered a safer way to prevent viral reversions. 
Determining which accessory proteins or combination of accessory proteins could 
be targeted for vaccine design will require a better understanding of the role of 
these proteins and determine how essential they are in vivo. These deletions 
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could lead to the creation of safer, more stable vaccines that can be generated 
quickly in response to a range of current and emerging IBV strains. 
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7. Appendix 
 
Table 7.1 Cellular proteins identified my LC-MS/MS that significantly interact with GFP-3aM. 
Protein 
ID 
Unique 
peptides Confidence 
Relative Protein Abundance 
p Value 
(-Log10) 
Fold Change 
(Log2) 
GFP-3aM/GFP 
pEGFPC2-3aM pEGFPC2 
1 2 3 1 2 3 
SUCB2 2 51.8 34391.31213 56821.77764 41196.20091 0 0 0 15.42968233 6.777403376 
FND3A 2 34.79 74980.93704 24630.06568 33157.9421 0 0 0 15.43359571 5.344140575 
GCP2 2 197.65 235809.9946 105676.1593 110856.7974 0 345.0779654 89.30009403 10.02425004 1.897724605 
PLCD 2 67.93 84058.48747 29179.2505 55446.0788 337.888514 0 0 8.963558546 1.888070933 
RNF5 3 65.41 40010.10628 41698.36451 40304.88571 23.67064605 0.851848723 533.6542995 7.772101223 1.847905735 
SYIM 2 166.85 5264.343093 38673.28811 35924.49767 272.9815635 348.4995779 0 7.005657106 1.313803241 
DAAF5 6 260.95 185725.9629 107943.9298 164079.893 1605.611852 2255.546652 1306.758243 6.468832572 4.399280401 
CAND1 3 99.7 26745.14688 119865.8145 61450.09147 1327.312472 803.21403 283.1585313 6.429625692 2.681942232 
DRS7B 2 69.99 73008.75546 24830.37773 40296.64166 0 2227.736805 0 5.954364395 1.410611949 
ODR4 2 83.56 94227.5916 30091.39846 43740.62521 0 3355.46799 20.37944099 5.637579572 1.332618828 
SAAL1 2 59.11 224746.8404 137702.9975 147900.2826 3261.366937 7876.208585 2769.976351 5.197546941 3.298068207 
STX18 2 108.09 107680.8457 55375.96374 76556.75843 763.3016918 4024.461995 2021.70543 5.137023465 2.704016395 
NENF 2 40.87 32215.33579 110626.9175 56483.8135 2249.998017 0 3817.127125 5.037973511 0.943901617 
HEAT3 2 61.68 264681.0087 126284.1501 164801.5922 0 9178.051879 7830.600162 5.030138812 0.900741473 
REEP5 5 390.12 749915.828 305879.2859 410196.8144 18877.25139 19977.9151 8195.371688 4.961522125 3.037728514 
NTF2 2 121.86 29436.05641 315620.5138 198763.9562 11592.76449 0 5969.017607 4.95261945 0.826531151 
AL9A1 2 67.04 4154.176253 40434.74772 21783.00598 708.3351856 1021.334608 754.4832324 4.739747273 1.885859908 
F134C 4 272.76 1141784.237 364034.8883 527764.8573 11166.44445 44095.2193 28322.67335 4.604648142 2.442071003 
CLCC1 5 219 168918.3877 94932.29125 125618.1712 4675.755832 7539.017183 4068.684829 4.580028948 3.658382062 
WLS 3 121.35 299226.2514 122157.0627 191376.7091 3018.354566 14975.83988 9071.20919 4.500800369 2.417495595 
TRABD 3 258.46 356891.6626 151716.4333 245364.0152 13656.55863 13034.83679 9349.082979 4.386821094 3.395254749 
MA1A2 2 66.59 215645.5795 96319.35766 62781.13751 1646.540633 14837.10708 1696.101165 4.36550919 1.879797504 
COQ9 2 60.35 110354.4636 76056.90201 122233.2208 7079.981262 2429.067748 5573.197655 4.355023232 3.020661266 
ERGI1 3 88.57 184876.8847 77101.71274 100338.6505 8938.181852 4635.605864 4641.070818 4.314065791 3.029781331 
IPO8 2 119.01 127020.6783 69452.4371 88508.53162 3149.79612 8148.584352 3345.938955 4.282455959 2.995663854 
CHCH9 2 160.86 67572.62096 360826.731 302878.3555 15159.59511 20122.69634 5962.35567 4.148140585 1.893115032 
ABHGA 4 127.54 189095.1787 78592.56183 128659.5804 9674.639923 9766.763034 4021.874744 4.078288755 2.729636927 
PM34 2 87.79 57197.3547 34254.4407 10667.73784 0 5332.612201 983.0557967 4.015179705 0.850035226 
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UCHL1 3 186.42 25494.22872 252579.1275 157222.2642 884.5261098 27887.49564 0 3.919257 0.855370301 
ALG1 4 151.32 170129.9637 82346.94547 107946.4187 8060.06312 15773.06095 58.78622242 3.915098275 1.07826702 
EMD 6 265.85 354469.7995 237282.4663 259536.9101 42448.24268 5526.157523 9727.697304 3.882953619 2.103879379 
PSMD9 2 85.09 97466.21523 109471.8329 93926.33154 8888.832258 4863.059305 6760.611141 3.874537882 3.944032605 
TOIP2 3 84.63 77623.31948 39297.2789 53983.44755 4152.550815 3693.52834 3819.042182 3.872913332 3.727616163 
NU205 3 209.73 165607.2579 73567.56396 88393.00183 12717.15794 3246.093207 7151.734314 3.824893291 2.375776447 
UBQL2 2 205.45 156916.6578 90090.28071 134626.7302 2436.664802 12446.06126 12506.86639 3.800488751 2.122942277 
HSBP1 3 258.09 1069888.163 432952.447 680367.7133 55457.68021 64433.27794 39498.43168 3.775822299 2.999605956 
GPAT4 3 108.01 96599.88757 37275.85499 79000.39059 1881.336243 14054.51056 0 3.739666621 0.829059527 
ETFB 4 185.54 41798.71172 207835.8111 108182.2776 7522.672393 17400.36104 2073.603152 3.728369544 1.607173674 
COG6 2 71.11 180632.3455 78810.92161 115020.1304 16867.94446 9927.445399 2235.819871 3.689148112 1.89616613 
RAB18 2 117.45 243256.9894 169447.9014 189251.4121 21479.72484 6982.005359 18221.40531 3.688685394 2.713937351 
ADCK4 2 85.8 94351.38794 124276.4933 169895.0733 9743.372986 5945.63161 14697.11473 3.676515496 2.93702803 
NU188 2 84.14 95331.89597 53360.69943 64829.48226 13794.7404 3787.279944 72.7493266 3.596255344 1.123306796 
ERGI3 2 53.68 219301.3449 102332.5309 127577.4655 6756.005925 21309.44446 9099.654538 3.595373766 2.468726847 
BAG6 15 916.5 1063956.239 530962.658 711738.9269 42002.06133 91895.37871 63409.09066 3.547293393 2.908753429 
TMX3 3 184.24 177673.0447 90569.12216 113261.9522 17618.31514 12170.97451 3153.771662 3.533652102 2.034140564 
UB2V1 2 100.47 27592.55046 130924.2247 72665.3887 12104.53234 6519.486272 1478.853929 3.523556524 1.538065097 
MPU1 2 108.56 206718.9505 115636.736 154836.9192 11968.55877 16688.87392 13403.17914 3.504029947 3.617445411 
UCHL5 2 38.07 92429.56 63525.80973 72599.37128 7537.009138 7284.613162 5715.556648 3.476229818 4.170116506 
TNPO3 2 71.37 144621.9199 89592.6772 120392.315 338.2526679 21920.99861 10189.34018 3.449992898 1.206894959 
HSDL1 3 128.07 238412.8931 138049.5039 165886.3749 9517.300629 9194.526284 34139.25141 3.359216101 2.255200215 
DHC24 7 401.81 1051291.496 339981.1588 610383.6646 68147.61699 62371.05979 66381.60123 3.345657234 2.60705999 
ASNS 4 218.18 27236.7698 171430.9769 107043.9983 14413.26977 13620.8357 3076.178357 3.296708518 1.39532784 
CY1 2 175.68 390624.129 223018.99 286975.9681 28300.7047 61543.82476 3119.625862 3.276170592 1.4398207 
SODM 3 202.75 16683.22434 386429.2848 167136.3902 1116.735273 3051.20702 55062.56807 3.267179335 0.897462498 
FACD2 10 514.36 595535.0484 319918.416 363208.044 28414.5887 51827.93688 54517.52588 3.24616961 2.873840686 
NUP93 7 300.43 423476.3608 274439.1391 353048.6688 0 41416.03572 69362.66653 3.245961035 0.671846092 
MSH2 3 173.35 111077.8734 99696.44018 134385.7525 0 31144.80963 6206.07863 3.208051101 0.734164784 
OLA1 3 84.02 6739.60173 96279.51464 45580.26839 1905.775694 11890.49948 2289.52478 3.207568554 1.010022552 
AFG32 2 87.66 266218.8291 69763.81298 129982.134 29522.17136 10236.30475 12436.5197 3.1582375 1.884998623 
NCLN 3 110.84 151810.5306 118798.335 51161.51211 4026.983579 5593.222541 27600.09858 3.111869746 1.635810305 
TM109 3 193.95 2128557.196 741617.905 1571766.115 116270.3236 309108.138 91861.27652 3.102285278 1.979519337 
VATA 2 129.7 167583.1096 159772.5775 145135.6368 82.06007278 27494.21844 27481.07532 3.10128066 0.884954229 
ABCE1 2 100.28 180280.4528 228714.1151 176016.8733 5853.351265 15469.80009 47476.7658 3.087986108 1.812994348 
APT 2 69.2 81678.52251 294963.2647 132224.1422 10003.55635 31941.67625 18455.73939 3.074641929 1.85368189 
TMX2 2 106.81 371290.2604 164004.6936 155805.9568 30719.98496 41544.65033 9831.420076 3.073511572 1.87689274 
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PIGS 2 107.23 138516.2391 42629.73737 87801.7788 4391.904365 26815.13072 1538.305236 3.037964418 1.372564613 
OPA1 4 134.56 130650.4255 74911.63272 80284.10455 3403.949867 28348.88231 3080.573341 3.036695492 1.614628993 
VAPB 4 268.94 416506.9089 248489.2161 232945.3183 7744.79615 68440.53099 34218.44871 3.023831853 1.637538183 
RN126 3 251.08 525994.1889 280502.4686 334225.2035 67045.77592 49805.14736 23678.40168 3.021003945 2.392041083 
RAC2 2 102.54 80460.41231 167604.9329 103378.7411 12685.50953 15828.63451 14877.31877 3.017812051 3.091374769 
THEM6 3 179.98 302460.6286 180902.6637 221584.6424 21322.33488 46595.37978 20573.93694 2.993903447 2.650100687 
DCAKD 3 114 153464.2264 83490.88646 117275.0733 15636.9141 17987.39211 11058.22892 2.986904211 3.081243797 
SRPRB 13 1168.22 2356606.499 1252445.881 1772697.713 158027.6169 300604.9945 235622.8531 2.954536867 2.842057521 
MPRD 2 63.4 403758.5618 189455.7616 276185.7067 69385.26371 22423.46862 22296.68755 2.929652826 2.094753638 
VDAC2 2 165.53 185298.4981 63587.4718 71200.78036 12150.61983 26309.77203 3554.436452 2.929492465 1.509309944 
XPOT 5 315.05 192152.0222 87834.0223 111134.1342 18165.44461 22238.0125 11344.55236 2.918036695 2.552757573 
CB047 2 115.34 284719.5493 130033.8812 190940.3121 8955.553702 55631.74442 15759.10915 2.914283087 1.746291063 
LAT1 3 283.6 534554.2065 250774.0012 333575.6027 27904.31074 80223.30157 42965.13305 2.88857972 2.250548912 
EI24 3 79.84 198309.5484 94782.3236 94516.17662 7846.197007 26812.32063 19324.82657 2.84401227 1.992223219 
UCK2 4 351.21 631346.4811 332289.1155 395077.2849 65389.18535 73917.666 50587.2553 2.838973586 3.02699373 
VATH 2 90.98 456719.8086 188749.7682 292946.563 46618.49369 49388.45914 38127.75768 2.80654521 2.675757196 
AAAS 5 212.77 362041.0814 157400.2565 256438.8803 25003.63463 43440.29387 42638.97024 2.804197213 2.502024053 
FUND2 3 170.07 155872.4144 66284.67575 81778.76974 789.0479602 2925.884841 40106.34656 2.794063392 1.207379135 
SC61B 3 258.61 869805.8076 438596.665 524439.0833 17462.80943 148948.4918 98268.19402 2.791763736 1.495266895 
PSD13 5 257.79 277050.6305 256645.2022 295326.395 32953.82472 64093.08353 22728.28042 2.791081698 2.569841114 
RDH11 7 463.66 850810.1228 437694.0325 614862.5361 85815.05262 120185.5841 69154.65644 2.790235542 2.811724745 
PSD11 5 162 444330.9905 280377.2573 290097.3742 31561.4464 94631.09858 21669.9923 2.778874937 1.972596832 
AMFR 7 463.85 533332.3635 261206.8513 292356.2496 23102.56658 85447.40766 50282.16974 2.774638376 1.985911313 
DDRGK 3 267.52 191321.119 126482.1814 121025.2369 24844.11805 34792.27865 5121.311773 2.760533508 1.626837608 
NTPCR 4 209.44 224270.7179 168624.377 238995.4131 14326.87493 46072.97841 33918.06515 2.74407081 2.264501734 
DJB12 2 137.64 357081.3372 141342.3714 266288.1612 77299.67567 20968.1364 18545.99923 2.710705409 1.726837144 
CERS2 4 176.44 588705.7071 301052.9363 440293.7639 51635.83294 96843.20871 54830.06952 2.709736317 2.600350873 
HM13 2 130.39 383225.6361 102529.1486 156671.5571 23272.99079 59221.12809 19069.04482 2.661153809 1.59629211 
SAE1 2 72.69 3890.241389 36693.09155 21523.55023 2610.669668 4297.940906 3084.428027 2.635757835 1.013332855 
CND1 6 200.77 257381.7777 128069.9417 154547.4966 20634.99669 47027.58195 19621.23527 2.629171265 2.214347347 
PTN1 4 183.41 264518.1559 108556.2263 131336.4813 11256.64812 52480.40639 18327.22862 2.619772988 1.677121747 
PLCA 2 193.64 441886.5586 180590.0349 272120.6475 54541.70239 41216.35918 50904.62574 2.60873643 2.521353275 
DHRS7 4 237.89 401883.9402 226211.3298 335157.6891 49773.69627 69167.30762 39677.61297 2.602352605 2.815173693 
AT2B4 3 154.72 257229.1241 140766.591 216913.1939 27902.04311 46870.77667 26887.84526 2.596611135 2.683630362 
DPM3 2 151.82 578373.8828 313474.5882 356597.4686 35643.24243 63884.25145 107629.4208 2.591337469 2.133913771 
FANCI 7 434.1 395294.5467 231748.3048 266809.9435 23677.31952 100412.6155 24300.87146 2.590635546 1.794114836 
RTN4 6 613.34 2121249.96 1560747.279 2014244.737 159811.5296 493862.9157 303631.4221 2.572958576 2.277626803 
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RBM4B 2 98.18 61416.63114 33119.93986 38152.43033 4916.94302 8950.836281 8663.772401 2.558030212 2.556655045 
PSMD3 2 245.18 114804.9216 146011.2766 98208.84142 10785.86589 37228.27732 13231.40081 2.551407678 2.055153907 
PEX19 3 111.31 256611.5387 124402.0876 204015.0439 36221.04114 34849.66186 29990.88899 2.533272516 2.826869318 
PIGT 2 48.14 39631.64016 16687.27352 21902.80234 3557.777583 6985.109388 2970.958715 2.5331309 2.071575356 
MTX1 2 107.82 199779.0345 56382.52488 205912.0841 29400.98041 29975.51966 21267.56121 2.5184826 1.658718923 
ARF4 2 414.66 83496.06429 106467.4647 86529.65113 5987.003745 24529.6364 17948.45289 2.51222597 1.917368162 
ETFD 2 146.39 254740.0909 81643.01257 124750.6509 20051.33662 39664.18429 22563.43741 2.486589839 1.869501809 
STX12 4 147.51 307407.5334 145356.9347 210470.3903 61214.81117 28791.95736 31703.75157 2.446065961 2.223126199 
RAB21 4 383.93 430263.783 217757.6447 316930.8193 83941.37533 71040.20029 23516.33662 2.434550349 1.795960819 
6PGD 2 202.65 10499.64748 181438.9582 125112.9789 656.0449376 46718.1316 11398.14584 2.431508775 0.636587868 
STX7 3 183.19 149866.5358 72172.90691 81657.27117 11483.51137 31535.27042 13658.48211 2.421789279 1.961911663 
LCLT1 3 168.03 200207.5912 111411.7384 119419.2734 5447.028811 55163.06776 21584.71025 2.39069793 1.34525365 
UBAC2 5 251.41 668492.4328 174492.2968 234308.6343 93470.15552 68910.54127 44404.09217 2.381209202 1.521798462 
ECI1 2 152.4 44721.30075 325787.7461 203058.5391 91157.88129 15060.8219 4655.904244 2.371034499 0.907516206 
PCH2 7 370.58 274138.1814 148990.0612 178754.7844 87842.22272 8037.414571 27574.76832 2.285504812 1.297333141 
MPRI 2 67.67 61257.91371 35037.66052 57683.06477 5967.373519 0 25714.99018 2.280978345 0.630583361 
SURF4 3 450.51 2326733.372 836510.7474 1029086.667 144164.5799 454369.4798 265216.8944 2.279065249 1.593777903 
COPB 4 332.27 296998.3826 236737.9807 266841.8865 35332.90626 98141.41381 31800.93454 2.276171684 2.02700218 
FACR1 9 593.27 1131804.623 441702.1667 696066.4254 213096.4901 103756.5821 154503.4005 2.267530585 1.966736971 
STX5 2 93.65 326547.1604 161188.8443 221641.6748 44161.93164 35794.55173 67578.96681 2.265492286 2.316270349 
RAB14 3 338.45 524554.0248 288185.7662 361188.4104 50150.38516 130743.0036 65390.84296 2.252948007 2.071224371 
MET7A 2 139.31 229386.7968 112371.5828 151099.6361 13528.88939 27408.65651 62597.17065 2.251057486 1.601637099 
PA1B2 2 71.19 19435.50139 226748.5071 113624.075 32622.97839 30395.61155 14075.2522 2.222540064 0.697874191 
SMN 4 207.52 262084.9768 233184.8888 193074.1244 48302.97518 76662.02219 24690.24407 2.201486903 2.048564816 
RFT1 2 140.05 324282.9051 121907.1591 149878.7574 45844.43004 46461.21891 37649.44843 2.197465689 2.029915184 
CHIP 2 65.87 28242.34548 61483.79093 58918.28396 6133.876898 12710.07019 13884.49323 2.183248553 1.860971788 
F10A1 10 779.1 3605670.176 2452277.739 3487307.46 679652.1486 888615.1282 546578.9523 2.174231028 2.896366525 
ABCD3 2 88.1 222127.9399 164279.1518 123607.2643 5461.72324 48391.36376 59235.48518 2.173084707 1.135779148 
RDH10 3 163.73 658740.3396 289840.3984 429233.7152 90977.6557 181422.7298 33755.62092 2.170042724 1.426778706 
DIC 3 191.4 355047.2263 153114.2225 218580.3995 62962.51284 45317.41289 55214.31943 2.152203129 2.274592668 
PO210 7 264.46 224424.012 183069.182 169095.6943 34828.00755 54028.21941 44162.32255 2.11591559 3.19640142 
P5CR2 2 362.2 165490.5299 197684.6675 178764.2287 25452.9813 54442.29878 46460.18873 2.1006435 2.497937846 
PRRC1 2 121.83 191405.489 114688.5823 129522.4701 15714.16825 35294.36761 51502.05182 2.087285813 1.794921878 
S23IP 4 265.91 333884.4498 232062.4698 223640.2458 29033.73614 102326.7892 54677.72385 2.085499271 1.806077084 
T161A 2 63.17 108825.4657 61651.22554 68263.3478 15846.4006 18637.01003 22077.70179 2.077558141 2.683946144 
TMED9 5 363.38 1253653.149 578157.0519 672913.3144 183378.6419 264903.5635 149474.1244 2.067021953 2.074456562 
AR6P1 3 131.23 489285.9693 288949.3972 338721.8629 92220.09666 40426.1019 138925.167 2.040170668 1.726018494 
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RAB5B 2 287.25 209507.8602 128353.7983 178747.3835 41129.10539 41887.6554 43006.70038 2.035380556 3.181315249 
ATD3A 6 832.07 2174020.325 732954.0369 1057578.753 370243.8775 219969.4182 378111.5939 2.033595172 1.663259947 
SUCB1 2 224.49 125568.8631 179226.2471 151200.0127 25714.07654 69586.44793 16196.27991 2.032016032 1.639898078 
TMM33 7 354.95 1913965.496 630100.331 842094.0235 229505.3295 316503.1442 283805.0703 2.02879097 1.702447933 
RCN1 4 328.55 114844.7278 393001.1036 246926.7618 47442.28536 74828.6619 63206.94519 2.024794799 1.565444115 
MARE1 3 164.79 14586.43427 194809.063 93146.59853 0 45259.61522 29212.05129 2.022372346 0.491568553 
MPCP 11 551.93 1519012.27 599678.7053 776219.856 211155.7967 436821.1525 65996.64336 2.019576291 1.208816589 
SCO1 3 135.25 267182.7672 158740.3064 192179.9676 39971.35238 73570.49852 38950.57203 2.019109804 2.279390498 
HAT1 2 70.98 176300.8231 231910.0048 138430.4227 15584.79959 56372.4518 63386.10531 2.013970258 1.504908034 
Mar-01 3 233.52 285533.5531 147277.7749 223659.877 82800.02608 21974.86641 58031.0013 2.011578803 1.561397873 
SRP68 3 193.7 247354.2736 223401.8082 249725.8688 58556.49659 51674.64419 69666.83771 2.001783313 3.925192934 
C1TM 6 282.73 76445.7557 135918.569 77561.71409 7132.805171 51015.37847 14870.90373 1.989339368 1.293398868 
QSOX2 3 87.06 181515.4228 80955.29865 85893.66218 35056.65314 19863.34026 33935.7694 1.97105988 1.850552396 
CLIC1 3 147.11 159679.7802 313173.0779 171506.3469 48473.37817 85632.60667 31100.87375 1.963591577 1.739869388 
K1C16 6 896.75 634148.1226 13902.34101 24385.96719 111394.6317 47460.89166 14533.60633 1.955384434 0.091986338 
GLOD4 2 47.07 39042.4188 65764.11851 34278.01425 5813.640626 19941.26068 10213.71309 1.951151696 1.611385842 
MDHC 3 188.47 44062.47206 316729.3776 198180.2147 40452.67279 61326.46933 42895.40497 1.949965056 0.82642353 
S27A4 2 159.47 686536.1367 313250.2675 284714.1313 32305.10326 155840.4444 152453.3628 1.915061766 1.16176331 
TX264 4 283.77 353600.9702 188089.7761 286604.1717 71557.47008 69826.86624 79845.60829 1.904597862 2.607115396 
HACD3 5 192.05 2044158.665 889978.6587 1527204.912 345115.9435 453076.6049 397519.4028 1.89960794 2.109669028 
LMAN1 5 278.39 532350.6678 289643.012 380234.2629 223574.4598 61841.85617 37485.39674 1.896543459 1.317443261 
DOPD 2 43.58 78154.66967 346456.4452 193534.5437 66388.66515 90274.04708 11232.00161 1.880390024 0.864746575 
TADBP 7 362.24 677673.5068 438401.1665 484921.5147 55745.611 235724.2106 143394.4233 1.880332874 1.509162043 
TOIP1 5 362.25 724970.0886 346455.229 428759.7917 127589.2426 211457.7701 68716.24068 1.879336853 1.585176227 
PGRC1 8 544.74 7190611.276 2337724.334 4210640.402 964713.607 1820666.496 952562.9378 1.877957992 1.487841993 
CLPX 5 256.97 372370.7867 253158.8082 271319.9362 183007.2748 31220.11911 32347.98074 1.862837232 1.293285518 
CLP1L 6 462.89 1099057.754 496726.4984 854324.3089 188434.0715 292772.8666 192777.0209 1.862059514 1.99511794 
1433E 8 755.39 485224.7279 2058266.75 1723499.87 241864.9486 564152.1879 371147.5666 1.857902996 1.069537988 
MCM7 5 233.53 54755.89475 299819.6128 144540.0737 0 60105.84541 79376.93784 1.839286885 0.506607224 
ATLA3 4 177.86 607014.2984 208716.3727 461729.2732 81660.84858 135913.3665 143169.649 1.824231294 1.514220802 
NB5R3 11 1068.11 2942457.748 1437941.474 2413545.359 538991.948 891941.9006 498781.2555 1.815861581 1.950931001 
AL3A2 10 467.97 954358.9097 385144.8805 610034.3343 344528.1103 140600.6936 74382.36965 1.80089352 1.25249498 
LYRIC 3 186.64 204017.8462 144055.0502 165197.6785 45816.76736 54301.91846 49752.51657 1.775996358 3.391480078 
AIMP2 2 157.35 434221.3218 370577.2195 338611.3064 0 249441.5843 93244.44265 1.738383349 0.535017138 
AAAT 5 291.91 1035868.958 555266.2629 570492.1298 138892.6747 358594.5269 152214.7086 1.734267982 1.583465991 
COA3 3 90.72 152857.2877 79127.61545 81604.82339 14629.23177 41341.30971 38984.80021 1.72355723 1.447967598 
RABL3 2 62.67 362113.092 115814.1364 176064.3707 92861.54616 44960.15419 60477.42249 1.721593808 1.336400677 
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MLEC 2 69.02 473668.1593 191265.2603 198548.7865 33126.35612 172313.686 58781.39574 1.708418923 1.10090919 
MOT1 3 146.7 262953.6356 163721.5827 159043.8462 27194.3385 117157.2269 35338.33316 1.704699545 1.33936514 
TM9S3 3 99.86 338322.1774 177693.1647 189739.7425 67423.70282 94448.82684 55605.75846 1.698296241 1.969450349 
CISD2 3 225.16 891771.3081 370908.0438 536969.8582 179108.8401 263083.3578 116092.319 1.688643271 1.54087933 
BZW1 15 742.34 2082286.572 982767.3991 1540951.792 287899.0364 562926.9626 582413.5114 1.684236496 1.679138974 
PSB2 2 62.44 162932.3471 150762.5455 205339.2152 25772.3858 68556.80197 67306.81466 1.68308077 1.687266397 
NU155 3 89.74 153929.5525 105056.7851 84231.93582 6827.48093 88566.4508 12346.79293 1.671562692 1.025695612 
ABCB7 3 91.37 154525.1627 40750.40382 66118.21038 58378.47615 3143.301558 20851.2607 1.665980685 0.765280749 
COX41 5 230.12 876093.7553 465518.8491 528809.5859 211474.0377 243425.3455 136143.3299 1.662029652 1.92641881 
SYG 4 210.8 21967.63963 179390.3839 94800.49705 22808.47813 42736.53556 28556.81676 1.654074902 0.597483651 
ARL8B 4 134.79 440315.1427 229372.949 370445.8304 34708.77127 187437.9255 113579.0373 1.631414262 1.146229705 
RB11B 8 323.76 1530218.068 878446.6758 1058369.56 379861.7182 451136.2005 292623.2257 1.625546432 2.248657426 
VINC 2 84.65 3345.126868 212383.3075 114565.2532 69962.0515 33709.62884 3811.269505 1.619641576 0.178833765 
GBF1 5 121.6 185959.1285 82336.92752 118426.2366 78409.7636 35977.26594 11866.82963 1.614970444 1.048263066 
GNAI3 5 266.06 239421.2769 186974.3089 205171.6687 70119.78593 85618.8583 52542.95687 1.60040097 2.674630023 
U520 3 164.77 90113.60304 101838.5995 113086.1379 29203.21014 46442.22281 25084.23022 1.598501992 2.356230587 
DHE3 12 673.63 687612.2038 872286.9386 917710.729 133782.9743 246992.5144 457464.9272 1.563513048 1.513627344 
CLPB 6 314.67 210800.2161 131792.8405 151873.5535 96298.76651 45419.83482 25905.36126 1.5606447 1.388848329 
NDUF3 4 357.93 243018.7106 142320.9362 245046.3478 80827.66237 62144.55298 72883.65345 1.546167164 2.233636649 
GSTK1 2 55.05 16186.65559 49072.87397 35273.9776 20390.09965 9507.719796 4542.317582 1.545513634 0.994113742 
PNPH 3 138.47 9702.505813 145714.8472 97089.07334 38225.82388 25422.83534 23286.39825 1.538310124 0.282328629 
HYEP 12 547.03 1372311.943 901331.626 1305449.206 223539.6003 527736.482 481596.2703 1.537570505 1.674760666 
PSMD8 3 116.53 306319.4431 189560.0919 235292.1162 20733.99124 199433.1 32111.78966 1.535190697 1.02569642 
LETM1 13 911.56 1606282.621 886615.3141 1131003.296 399721.7827 543982.8929 310013.3385 1.531330742 1.953405366 
NDUS8 2 193.31 321679.1571 157515.6666 173571.1649 57596.6143 107197.6796 61069.88053 1.531110434 1.609709118 
SRP54 8 247.58 528591.6526 293390.7552 412996.565 123348.4084 167904.587 136242.0212 1.530506971 2.239598887 
ILVBL 8 656.25 1472221.812 720810.5337 1089549.18 368946.029 406868.9636 367779.1521 1.521255704 2.074617222 
NDUF4 3 119.91 124740.3488 78569.69299 93558.83118 12492.34591 46493.73947 44563.05895 1.519510201 1.236263746 
GCN1L 121 10375.8 5895202.577 2226907.642 3263971.792 1562425.343 1005354.823 1407304.586 1.518213871 1.465515292 
SYAC 2 173.36 34320.99991 366576.268 119129.6625 7341.458533 19895.2853 156422.2191 1.501557033 0.545026245 
CD2A1 3 286.37 87745.79875 246640.0294 177071.5025 20587.49041 95310.6342 65464.0572 1.495740233 0.958786916 
AT2A2 24 1467.59 1778927.097 859507.2756 1068048.307 468296.9351 472341.9496 377840.7699 1.491175461 1.916192624 
IPO7 12 965.9 1116931.437 521663.0254 1047887.537 302960.0548 465510.9681 187392.2424 1.490842009 1.363860225 
PSD10 4 180.62 79991.54839 93818.79211 83696.04723 20685.85927 38271.69437 32902.75394 1.487094701 2.288148413 
GDIR1 2 105.79 3170.350911 124517.907 83407.79658 30546.4226 15669.44096 29094.65572 1.486976316 0.086066969 
BAP31 10 577.54 2291410.52 1429632.517 1512410.174 596362.0988 653427.3093 619999.4871 1.484887805 2.579340767 
AL1B1 5 317.51 411460.3247 332036.5343 329549.836 133641.2194 154431.3339 96625.96352 1.479912686 2.572432775 
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EAA1 2 187.43 430500.2778 226703.2967 274984.9166 32915.84049 60470.77371 240986.4838 1.479162921 1.01742804 
FKBP8 4 232.19 590142.5363 275906.1035 368821.632 207003.9766 182722.709 54920.41138 1.473626817 1.104271982 
TM9S4 2 162.23 284882.0947 139804.7569 154051.7407 87930.54206 59928.40971 61043.46346 1.470082679 1.736446809 
TFR1 19 1190.91 2168178.845 1274930.322 1645592.346 774360.8119 683518.0254 403658.9368 1.450802679 1.810301541 
PSME3 4 235.53 521798.3829 367699.7702 342213.2525 122035.9927 217235.0521 114435.0454 1.440834336 1.876338062 
IDH3A 2 75.12 155516.7764 533529.2882 402876.1937 136485.4715 110449.1696 158821.62 1.428184882 1.065520622 
EFTU 24 2192.81 3905735.67 3965093.829 4506906.656 1147125.977 2124340.895 1338229.307 1.425003902 2.232183863 
SNAA 2 162.58 181120.8422 209308.6055 191973.7508 44424.16917 125066.045 49239.17666 1.412871189 1.521955328 
AT1B3 7 643.05 3139642.155 1242591.416 2138248.773 1252242.664 800640.4564 413953.8404 1.402316322 1.12233299 
GEMI4 4 294.07 274903.3574 130324.3349 184886.9627 99941.27524 47457.62964 76206.78278 1.400038401 1.468076706 
TBB6 4 1150.6 598193.7179 390685.6512 565640.8254 132904.5126 194456.1174 262699.4631 1.397535564 1.847623874 
MDHM 18 1482.55 910235.0751 7358641.984 6736036.133 1320686.564 2527258.562 1852802.016 1.396212056 0.395540615 
SPTC1 11 767.37 1421792.087 723673.5128 1322641.441 394584.7973 502548.9611 421266.5573 1.395359934 1.834235761 
AATM 14 970.45 200015.2001 952970.3618 635898.7173 185427.6634 211800.2424 284138.329 1.392557703 0.754192474 
RAB2A 4 881.65 1205941.943 651203.375 795920.1916 333761.2038 417720.6856 259842.0618 1.391415098 1.85439654 
TMED7 4 244.45 408779.0298 183217.7753 192591.0853 75490.9057 145432.819 79686.30824 1.384041908 1.310237668 
VAPA 6 250.1 1125602.634 554339.9794 757009.0141 410010.4702 310155.6507 215013.3216 1.381762493 1.57378653 
TBCA 4 220.12 19178.59606 370565.4222 197778.8563 66035.78554 77584.17745 83322.29339 1.37231976 0.165651983 
IF4G1 2 129.65 5677.800046 72204.19231 13643.12553 35290.74368 0 71.59678173 1.371953964 0.701952557 
KBL 3 120.93 193259.8619 126266.6932 148053.4603 36138.45205 59940.63531 84741.12397 1.370657325 1.638008385 
PFD3 2 47.14 45845.52154 120793.7861 82397.23112 30861.14486 14130.45438 51472.66174 1.368290988 1.00271753 
ACTN4 3 412.41 124455.7895 345418.42 186536.1784 29110.64029 170284.1771 55414.92167 1.36517765 0.879748629 
ASNA 7 439.65 439297.6567 299152.9703 357424.1467 156833.078 179470.0913 89566.05185 1.363600579 1.814683643 
PLAP 7 269.72 386204.0236 229618.6268 244659.0182 151708.0158 79882.3715 103523.2044 1.360494257 1.730256655 
ADCK3 10 707.53 608309.0884 342008.0546 404590.1944 212906.8425 169263.4487 146143.0012 1.358728575 1.982367263 
PDS5A 3 279.77 211896.9084 122719.6186 142935.8149 79206.78187 76878.55821 30723.28423 1.354097807 1.329087926 
CNBP 4 328.11 60248.64378 199398.3688 109177.2924 35269.88575 69965.31422 39385.09469 1.35066371 1.003518584 
HCDH 5 222.14 93217.39025 862927.2814 540448.2836 117342.1566 202441.3493 267722.3432 1.349006769 0.373186466 
PPIF 4 393.48 32946.19881 588177.2244 283495.5339 97298.85428 33885.87558 224461.3715 1.346867881 0.260041582 
CTR1 3 188.63 369793.9078 177136.6536 264975.6049 90610.02876 66829.98003 165065.8094 1.331987814 1.309561085 
S61A1 6 637.7 1677526.015 651454.3851 1495493.004 496845.6598 659248.7179 364916.649 1.330230503 1.193156719 
SRPR 6 475.78 600685.112 364426.8105 464079.7002 104557.5548 210653.875 255256.0686 1.324982764 1.457925283 
TELO2 9 677.19 416870.4428 224747.2763 361160.2477 82217.51598 159866.9753 158875.5917 1.322471679 1.487936823 
SFXN1 7 571 1193346.878 487650.6005 594971.9734 169943.8703 442910.0073 297234.8664 1.322402058 1.105747226 
PGRC2 2 224.32 1088122.379 443144.4146 583886.0527 220557.0256 352907.1811 274925.9823 1.317962077 1.346205823 
SYMC 13 896.62 896067.5845 683683.1103 800239.6508 231911.2753 432630.1125 291929.2315 1.315163163 2.043403994 
DHB12 17 1526.96 5888141.653 3277256.845 5619004.362 2064644.99 2098850.702 1790411.911 1.312167236 1.971053456 
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COMT 9 1240.17 2079569.651 1360594.402 2338929.715 759047.0294 958490.3313 614635.2221 1.309168725 1.899638107 
TBA1C 2 3750.23 15873295.3 9735732.725 12331964.27 4526137.186 6522285.72 4374908.495 1.298642994 2.034912601 
ATX10 4 309.47 305451.3559 180250.1068 268872.7557 122938.6814 83042.30817 101175.8589 1.296687258 1.981736603 
QCR2 8 586.67 631909.0204 440327.5588 522236.9523 314113.0692 171748.396 164241.3618 1.294340316 1.78885544 
ZW10 4 174.41 526511.8836 219559.8645 293437.3906 165493.3701 136582.542 127807.3155 1.273885713 1.422623542 
TXD17 3 223.52 77980.95667 237897.4885 169102.1787 56889.45266 105275.5897 39666.62939 1.264774527 0.921735123 
XPO7 6 349.47 368682.4445 192788.4607 238310.0207 194675.1855 73638.32886 67214.51703 1.253171574 1.151763913 
AT5F1 8 592.7 550607.7617 209850.3752 260201.7685 184077.6707 147662.8301 97323.64003 1.250236988 1.097885086 
PTH2 3 214.75 488315.3521 303695.2336 395715.167 135385.6454 283261.3479 82102.34076 1.246041252 1.190431754 
ACOD 5 379.7 1120723.771 450404.5745 680353.101 256986.3232 494685.9463 206854.0846 1.231984586 1.083395995 
DYLT1 2 103.27 321685.4535 163855.4819 178872.8872 74625.82382 120412.9159 89755.39212 1.222162668 1.496544208 
RS21 3 200.84 142635.8547 367550.1747 289800.5127 65903.07973 245484.4864 33324.02357 1.214585925 0.788550507 
UN45A 6 328.98 431416.4797 322853.6093 439257.5935 144138.2411 221955.307 153560.8365 1.199607699 2.130974659 
TMM43 5 458.38 759311.711 300612.1309 371029.3274 336798.3542 197340.6922 91071.28675 1.19456293 0.866878146 
TBA1B 2 4168.03 51143902.05 30010676.04 38189816.15 16270883.92 21366087.04 14553404.46 1.193275118 1.883943209 
CND2 4 215.78 174262.3347 95068.63389 128773.5422 27755.41836 96282.99122 50375.62827 1.190631057 1.083785898 
F213A 2 51.16 734908.1847 310550.6617 504888.5382 382450.5351 115614.4672 183237.9476 1.186223156 0.967488504 
SGMR1 2 244.26 1136693.475 239539.1218 1671511.053 61342.10757 907700.56 372922.3507 1.183394496 0.44677714 
NCDN 2 172.08 311948.9831 139614.3877 166608.7221 87686.50449 148167.0145 37535.10257 1.177055326 0.895713877 
MTDC 4 174.31 316615.889 500154.487 618222.5092 133262.4804 290656.2731 210730.4863 1.177012221 1.2926771 
DHB4 11 940.57 423752.8909 867612.4217 754285.9516 191437.1813 359746.913 355106.3457 1.174514849 1.256543478 
LPPRC 51 3205.68 2475215.978 1928022.939 2337486.028 953677.5506 1200347.849 842341.4045 1.169689513 2.503576655 
4F2 13 1114.62 2435845.108 1435589.575 1842864.303 578517.3379 1473616.897 500016.1943 1.162863157 1.146171888 
MOGS 8 448.54 468532.9264 290970.0936 381442.6553 116628.0577 222035.8677 171277.196 1.161827515 1.615985596 
UBL4A 9 402.5 630074.1917 308538.4966 477521.6944 175424.9339 385013.4299 82133.79237 1.140027802 0.889597858 
UBQL1 3 403.15 726627.1763 437932.0304 558872.3245 325991.4622 268941.3402 187273.8139 1.13966234 1.655668334 
COPA 8 331.5 446233.2552 362885.3051 354885.0857 133405.7633 218566.9576 176543.694 1.139075392 2.129037044 
DJB11 2 207.7 352007.8113 269196.5148 302200.0621 101231.9964 140626.2628 177721.3957 1.138017864 1.957124446 
RPN1 22 2078.12 4503030.428 1890188.829 3814516.142 1543207.726 2336413.762 764092.1443 1.136311926 0.911953879 
RENR 2 82.93 225864.8593 92722.14731 63745.20206 95613.79645 68226.02186 10850.76181 1.130024926 0.561931937 
RCN2 4 304.03 724176.9814 584155.2591 472636.9754 345129.7583 244036.2786 226114.3355 1.127294391 1.923360102 
FAM3C 4 213.32 202597.4044 86685.37756 118472.125 40297.59484 93243.33005 53421.12134 1.12495681 1.047547175 
PDIA3 23 1803.71 440808.0713 1931468.654 2248285.7 432829.4145 883580.6169 804387.2385 1.123461752 0.465846338 
BAG2 4 277.87 270105.668 84814.98164 337061.4924 86516.58315 187420.3529 44460.55165 1.119905854 0.592120142 
ETFA 8 426.2 649445.0457 619035.64 663214.0686 250379.8764 392632.1983 247856.0925 1.116583279 2.189343165 
UCRIL 2 113 216874.2228 107670.6205 163200.9986 120703.7548 37577.63311 68205.30124 1.106703309 0.997724783 
SC22B 6 909.07 913494.0006 396451.1644 566084.6783 291931.517 316460.1257 266635.3806 1.100283301 1.338573236 
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LMAN2 5 369.86 1565619.565 611088.4881 1250799.023 441646.7675 778882.7436 380758.8348 1.097926525 0.965185292 
PPT1 7 647.21 904416.326 627832.2952 960099.8642 234437.2806 444817.1925 486006.2537 1.096853009 1.392083565 
PREB 2 205.87 431340.9647 252090.6128 315427.04 184606.3898 121262.3915 164876.799 1.085332938 1.686573967 
GRPE1 4 147.53 145660.5861 329383.8949 360388.7218 122338.2641 194830.7625 77252.12258 1.08278757 0.885419493 
K2C6A 2 985.81 608473.8189 394028.1239 144317.0086 184679.6456 149182.1043 210770.1443 1.074284275 0.609456191 
KAD2 13 1026.54 407025.9826 1598078.699 1527803.65 402176.3687 690704.3235 586474.7896 1.072948668 0.56162922 
STML2 10 885.96 1797565.531 1036292.854 1362745.351 619718.5724 826773.0221 553369.4586 1.069322476 1.671064393 
TIM8B 2 97.62 95010.8299 172077.0448 158448.8148 65239.57565 82260.57253 55313.51051 1.06912871 1.525626449 
TIM50 8 616.52 1557407.42 608050.0514 979278.34 637061.9893 486899.524 384332.4861 1.060021153 1.041945307 
RIR1 2 93.72 23414.55646 94828.03362 65098.87237 45295.00333 22511.09439 20571.67618 1.052777589 0.590587142 
APMAP 15 1045.31 2663882.832 1631034.368 2323781.454 729200.1271 1413408.357 1061254.34 1.046735208 1.430037949 
RAB1A 4 966.58 2048671.831 1085437.392 1625079.977 622046.8375 1020849.914 667969.9537 1.042281764 1.379733089 
ATP5L 4 331.73 902899.9839 409387.5845 430215.6655 364007.0254 315908.3374 166951.7829 1.040953767 0.940241788 
TMED2 5 385.44 751831.2913 301720.019 752857.691 250055.6273 363646.9478 266041.2931 1.037969122 0.934673829 
ADT3 5 929.59 2075770.092 988898.2336 1396818.772 802549.9606 778297.2517 596089.7574 1.035225031 1.358218843 
PRS6A 11 676.03 1063031.4 625901.5297 996878.1399 337575.5328 575041.8302 405179.2891 1.027230057 1.444606987 
MBB1A 5 160.72 69671.89106 60143.14046 65892.52985 14638.63957 67257.27865 14710.03086 1.018515558 0.899961723 
RAB1B 4 1094.16 4765184.488 2552392.601 3700725.227 1382974.4 2060475.519 2008167.978 1.0151456 1.437282409 
TRAP1 19 1871.94 919438.2359 1027955.136 979284.9527 410036.2323 412575.3711 626546.484 1.0140492 2.130724274 
CH60 58 7652.33 86186971.87 35453853.17 75345308.91 33228319.12 28515924.18 35919788.95 1.012194832 1.051912965 
SCPDL 2 105.04 413639.6579 249191.7228 418034.4101 8233.232308 117318.2096 411872.7864 1.008054129 0.599524027 
SSRA 4 304.72 1231518.759 549688.0062 748274.9035 381673.201 537663.6516 338485.5245 1.007913577 1.141512342 
AN32A 2 189.77 25542.71163 312839.4815 137349.9582 81572.97965 102151.0951 53378.72572 1.004636827 0.147078067 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-3aM. Protein identifier (ID) and number of unique 
peptides used to identify proteins are indicated. Relative abundance score for each protein are shown.  Confidence score (-Log2) is the score of the probability of 
the peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in protein identification. 
The p value (-Log10) is a comparison of the cellular protein abundance between GFP-3aM and GFP. The higher the p value, the higher the probability the protein 
interacts with 3aM. The fold-change (Log2) is the change in the relative abundance of the cellular protein detected between GFP-3aM and GFP 
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Table 7.2 Panther GO Cellular component of GFP-3aM interacting partner 
GO cellular component complete Expected Actual Fold Enrichment p value 
proteasome regulatory particle 0.14 4 27.67 2.07E-02 
cytoplasm 74.29 122 1.64 3.44E-15 
endoplasmic reticulum 11.68 53 4.54 7.13E-19 
nuclear pore 0.49 6 12.18 1.59E-02 
nuclear envelope 2.88 16 5.55 5.31E-05 
membrane 62.63 104 1.66 1.01E-09 
nuclear membrane 1.99 10 5.02 4.81E-02 
endoplasmic reticulum membrane 6.68 43 6.44 4.10E-20 
endoplasmic reticulum-Golgi intermediate compartment 0.76 7 9.18 1.80E-02 
mitochondrial membrane 4.63 17 3.68 5.71E-03 
mitochondrion 11.33 27 2.38 2.67E-02 
Golgi membrane 4.63 17 3.67 5.82E-03 
Golgi apparatus 9.79 26 2.66 5.88E-03 
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Table 7.3 Cellular proteins that have a higher chance of interacting with GFP-3bM 
Name Unique Peptides 
Confidence 
Score 
Relative Protein Abundance 
p Value 
(-Log10) 
Fold Change 
(Log2) 
GFP-3bM/GFP 
pEGFPC2-3bM pEGFPC2 
1 2 3 1 2 3 
BAG6 7 43.529 16470945.06 28858040.37 24418986.71 4865916.052 3169799.154 4398407.984 2.906321357 2.487846495 
VDAC2 3 20.668 25898945.09 14765020.26 15152998.83 3653834.859 3770985.049 5317622.748 2.576106121 2.131061799 
COX5B 4 23.644 30800063.72 19350935.8 16642052.05 7956320.71 4038701.248 4591550.556 2.136701975 2.009682233 
HSPB1 2 14.253 10848031.97 39054893.75 27991976.06 1997591.283 1360843.752 5366537.023 1.786641052 3.158306491 
CLTB 5 34.721 82785226.63 18960977.42 18320048.67 5815815.212 2910206.307 3573954.904 1.726453339 3.287103251 
RPS24 3 22.269 30267999.7 24865980.78 17672955.62 13033037.28 2198868.656 1708655.359 1.327963149 2.103594221 
RPL11 5 36.951 40493864.61 52234874.32 39416053.52 32932986.23 3020215.369 5380914.677 1.090897383 1.676714625 
ENO1 8 55.729 40518853.02 40645998.68 24602984.52 26007961.69 1135321.92 2932785.241 1.02136672 1.81421306 
ALDOA 9 76.912 35958013.86 21848032.05 31849116.13 26253928.86 4178778.909 2107629.723 0.951639751 1.462157437 
GAPDH 9 83.934 171130302.1 111709760.2 243190225 120099924.2 63961923.98 105049932.9 0.922894036 0.863518469 
PCBP1 5 44.212 37269961.68 57406071.72 42436137.1 24614071.79 3328406.014 25599991.58 0.851018945 1.356601052 
UBL4A 8 58.202 125140193.6 9007716.553 10411971.99 2914526.321 3665986.392 10919246.74 0.745663027 3.046260239 
RPL22 5 57.219 148430260.1 44116041.23 25634972.25 64839067.2 2492980.211 4298971.156 0.740122908 1.606870919 
GNB2L1 4 24.287 7630678.961 14685000.71 28960034.79 13102420.32 4413831.119 4327792.804 0.7371529 1.231035705 
HSPE1 6 46.846 75512911.11 14169052.98 6707482.71 6977796.051 6770307.827 4959385.7 0.720658975 2.36525923 
HSP90AA1 7 47.26 31104931.64 42325976 33364024.8 19387050.55 3033748.375 28180033.68 0.718304409 1.077610162 
PCBP2 4 32.484 50025141.25 61691996.49 58589954.75 80057875.75 2657816.369 7516918.858 0.713260623 0.91641768 
RPLP2 6 89.327 856572428.9 47936126.49 54482138.63 69639861.6 2412604.496 25154967.68 0.69553017 3.302378265 
HSPA8 29 323.31 2720604315 974468290.8 716921541 1732994584 43409877.03 160749610.4 0.663120241 1.187492174 
CCT3 15 144.17 259350875.7 15856049.11 64914165.49 64944769.35 3368278.502 6371051.196 0.656284213 2.18717545 
RPL24 5 33.803 34827896.37 21167976.07 33097983.79 45133020.58 2783599.07 4470795.11 0.64945998 0.76610568 
C1QBP 7 82.756 315369959 77766743.98 99174783.01 135999867 2543458.281 40128113.55 0.617040337 1.462262365 
SLC25A5 7 48.22 130199620.3 51523954.87 208150242.7 154280448.1 12145007.12 23440987.31 0.59610664 1.038022331 
TCP1 15 100.96 65977921.79 49299852.69 83975200.54 97941027.79 6493163.02 17490036.93 0.590161309 0.708616431 
HSP90AB1 17 198.43 288360836.8 152319984.9 424020860 290979041.1 66742852 121930178 0.588899506 0.850214209 
RPL7 8 99.725 53487928.66 35588061.13 32100000.86 81394050.01 2662167.655 5493522.175 0.552533088 0.436342731 
ATP5A1 18 323.31 693139262.2 71439071.8 445549351.3 286849746.1 2954515.22 95303112.76 0.533759295 1.651826627 
RPS2 7 44.332 33112899.3 32597093.56 50521004.9 43501143.82 3518770.521 23261003.48 0.519218588 0.725789937 
RPL37A 3 22.295 36240009.56 20856012.26 17812047.15 33788992.55 5132534.538 9967152.697 0.50528658 0.615620685 
RPS3 20 164.96 284450031.5 46227884.27 140190174.7 173550466.2 682509.6884 38619067.68 0.503678416 1.145472017 
CCT7 13 84.011 128840417.5 4089463.056 16403950.96 16184954.79 3191669.862 3780197.027 0.488085111 2.689031885 
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RAB10 3 24.12 17148986.73 3197560 7812917.773 6456585.584 2101925.347 4701892.095 0.466134277 1.086495275 
LDHA 4 24.612 25278017.77 18828960.26 152299926 13528044.74 2944456.644 61489212.74 0.443430598 1.333007928 
SLC25A6 7 138.16 512028899.9 36062098.11 211230072.1 342590522.5 2486887.819 30642910.57 0.441749443 1.015050895 
ATP5B 14 121.09 217340229.5 34229099.44 40732019.24 60009184.98 7295725.405 45613893.98 0.438886149 1.372170725 
DCD 4 40.945 210040166 422029907.7 720248744.7 178949838.4 327441059.7 338420096 0.399830386 0.678734802 
HSPA1B 21 323.31 4728088847 731209716.2 773888242.3 3594390480 94285984.75 269969278.1 0.380221451 0.654962983 
RPL28 9 63.733 107079717.7 12259017.3 30229001.71 59295118.36 1475773.618 15536950.15 0.377905449 0.97089577 
RPS4X 10 84.556 61880005.96 21130008.33 17233949.19 38562894.3 2434256.899 20082979.68 0.375717945 0.714740304 
EEF1D 7 52.266 54011002.85 17853950.56 10885014.55 27112973.36 2331844.25 15586028.24 0.375388394 0.877845176 
CCT4 17 122.27 285129090.9 10445006.11 15065967.64 94276835.63 1356568.06 4416003.852 0.37226896 1.634531289 
RPL7A 9 57.804 208160342.5 15482015.9 31323020.42 79352921.32 2270816.974 19874014.68 0.358651391 1.328853572 
HNRNPC 4 28.411 15176965.19 23045951.54 17630010.52 11213007.91 2217972.427 36528014.46 0.31845376 0.160888445 
ATP1A1 18 151.71 227709619.8 4445394.426 28149969.04 64693166.79 1751828.361 7058694.734 0.314572863 1.824314351 
RPS27 3 66.714 75105748.59 14693044.22 26253928.86 56846965.34 6235353.836 12682976.26 0.314427662 0.615171284 
RPS11 13 90.247 197819581.5 22030974.87 36710005.63 103519692.8 1659066.173 37976931.34 0.308383886 0.841714402 
LDHB 4 34.963 26433974.08 30655019.79 160180135 13110051.34 25753050.56 73397113.94 0.292202513 0.952636463 
PHB2 9 76.913 99024350.65 8556918.98 24550005.3 38402050.21 1210935.003 33513058 0.257541681 0.853514781 
RPL34 3 17.891 25620050.79 2019210.658 19790983.88 14628008.15 1270046.598 6872768.813 0.254392527 1.05862086 
RPL12 5 47.468 69413839.72 27741068.09 20321027.28 36089854.72 2951342.658 55366116.66 0.254088651 0.315394712 
RPS3A 12 79.644 167730522 19298026.73 33039991.96 100059991.9 2748017.955 37325027.82 0.246384444 0.651155799 
TUFM 9 84.826 74189927.77 4556738.028 34198032.74 74931032.75 1624517.664 7340871.919 0.242185378 0.428935359 
RPL26 6 39.845 56135885.92 4402556.231 13354012.87 29710921.17 3067389.623 6169875.725 0.232220766 0.923870906 
RPS16 6 38.53 168720495.9 5775041.967 67640781.85 88210679.81 1980522.966 31428933.91 0.211873354 0.99343738 
RPL4 6 47 13958978.16 3769338.685 26386926.82 30469025.02 2390780.085 3930196.46 0.211039364 0.261963516 
SLC25A3 9 65.634 113820091.2 3865195.617 22063066.71 47687902.73 5203424.58 5376366.286 0.209870788 1.262063175 
MIF 2 46.843 265320332.9 4183693452 56046851.72 274859670.8 2444004846 2544939.625 0.192490377 0.727192487 
KHSRP 11 88.777 118049770.8 5152210.118 15253954.86 73652951.3 4842162.28 4710895.83 0.165857618 0.734667272 
YBX1 6 77.296 114010384.8 6191896.819 42681868.53 65750111.26 3111567.257 31068085.38 0.154573755 0.704859875 
PARK7 9 77.879 234009198.5 16129965.31 6881205.985 72174206.23 24767072.25 4559012.708 0.104450203 1.340398837 
CCT5 7 54.548 10863984.57 9423816.391 12799019.88 16536951.84 7242016.334 8969710.551 0.089702967 0.014819975 
DSP 13 80.915 39931114.41 131689949.2 162899846.1 19591981.76 171760136.3 141300369.8 0.084795112 0.008080568 
PCNA 6 42.685 47957063.94 5940405.566 41911999.09 42224880.37 4393349.979 32751099.39 0.080844818 0.271586618 
DSG1 4 27.711 7532983.82 51825184.08 27228987.47 13790008.4 17466049.52 29728019.14 0.075830193 0.505720422 
PHGDH 10 63.859 62223232.11 1654128.634 81199077.43 46335994.48 892331.3494 76330166.37 0.059627628 0.23161906 
PHB 6 39.758 27628999.8 2891807.323 18688014.98 8769906.313 4528368.711 25139977.1 0.053963238 0.356374248 
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HSPD1 19 164.46 201929997 44284853.18 110039786.1 208719478 33247902.66 111249992.7 0.0394662 0.012352485 
TUBB 5 105.4 584359114.3 65052898.35 684459529.5 900380767.7 92133980 227720668.6 0.035846679 0.128460226 
RPS18 11 109.93 315179836.3 5330058.734 49098989.6 128080002.5 20083954.14 45776061.33 0.030857672 0.930388914 
RPL13 8 75.412 140759787.5 2346078.734 37921954.84 126529627.7 2236978.562 29139039.76 0.027698281 0.197148676 
 
 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-3bM. Protein identifier (ID), protein name and 
number of unique peptides used to identify proteins are indicated. Relative abundance score for each protein is indicated. Confidence score (-Log2) is the score of 
the probability of the unique peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the 
confidence in protein identification. The p value (-Log10) is a comparison of the cellular protein abundance between GFP-3bM and GFP. The higher the p value, the 
higher the probability the protein interacts with 3b. The fold-change is the change in the abundance of the cellular protein between GFP-3bM and GFP. Cellular 
proteins which appear in both GFP-3bM and 3bM-GFP data are labelled with an asterisk (*).  
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Table 7.4 Cellular proteins that have a higher chance of interacting with 3bM-GFP 
Name Unique Peptides 
Confidence 
Score 
Relative Protein Abundance 
p Value 
(-Log10) 
Fold Change 
(Log2) 
3bM-GFP/GFP 
pEGFPN1-3bM pEGFPC2 
1 2 3 1 2 3 
VDAC2 3 20.668 7499120.63 17683984.02 17660954.73 3653834.859 3770985.049 5317622.748 1.690929301 1.749453318 
GNB2L1 4 24.287 13319993.11 28875047.82 16578038.7 13102420.32 4413831.119 4327792.804 1.173502982 1.427915511 
RAB10 3 24.12 7248896.703 7734089.345 10889995.33 6456585.584 2101925.347 4701892.095 0.988435436 0.964321683 
RPL34 3 17.891 33095001.49 21090939.12 19311006.17 14628008.15 1270046.598 6872768.813 0.981830341 1.690497848 
ENO1 8 55.729 43553037.39 23601905.43 30798996.29 26007961.69 1135321.92 2932785.241 0.976636643 1.703487501 
UBL4A 8 58.202 11586969.89 13873707.14 9620563.714 2914526.321 3665986.392 10919246.74 0.958133267 1.003364682 
RPL4 6 47 22745061.5 54760033.75 31838962.73 30469025.02 2390780.085 3930196.46 0.937528239 1.57148918 
COX5B 4 23.644 29899955.47 5815533.034 17579004.05 7956320.71 4038701.248 4591550.556 0.897123299 1.683970657 
CCT7 13 84.011 12852983.96 18792973.26 16677041.01 16184954.79 3191669.862 3780197.027 0.891818962 1.061272716 
PCBP1 5 44.212 39500018.69 62620860.61 40698999.68 24614071.79 3328406.014 25599991.58 0.870506088 1.415441218 
TXN 8 74.762 65599887.28 71818889.02 73566213.45 68024919.1 35628045.36 16483965.35 0.810331678 0.812460664 
RPL11 5 36.951 35840067.03 29110978.55 22231932.14 32932986.23 3020215.369 5380914.677 0.791499813 1.076713437 
RPS24 3 22.269 28521964.15 29375905.76 4223711.897 13033037.28 2198868.656 1708655.359 0.720477986 1.874612889 
BAG6 7 43.529 9586813.925 6962480.736 3957176.544 4865916.052 3169799.154 4398407.984 0.716080118 0.721774474 
RPS16 6 38.53 121419929.5 126850151.4 72148196.7 88210679.81 1980522.966 31428933.91 0.703601776 1.39757433 
HSP90AA1 7 47.26 18661996.48 54775977.91 46738885.59 19387050.55 3033748.375 28180033.68 0.662310619 1.247926103 
CLTB 5 34.721 31371039.53 12264031.74 3230799.969 5815815.212 2910206.307 3573954.904 0.660787232 1.929882152 
HSPB1 2 14.253 3245524.014 6800974.256 4806149.184 1997591.283 1360843.752 5366537.023 0.64804722 0.767497695 
RPL22 5 57.219 82947203.1 39254099.67 20849941.5 64839067.2 2492980.211 4298971.156 0.635298036 0.997875685 
RPS2 7 44.332 35329010.33 75877036.64 35783967.07 43501143.82 3518770.521 23261003.48 0.619112475 1.06451321 
RPL28 9 63.733 63371902.86 61155122.01 23688934.93 59295118.36 1475773.618 15536950.15 0.551876405 0.957797569 
RPL7A 9 57.804 101970033.4 53656886.23 34927983.06 79352921.32 2270816.974 19874014.68 0.542206142 0.908758939 
RPL26 6 39.845 43033892.35 13976017.65 13896998.65 29710921.17 3067389.623 6169875.725 0.512512157 0.864370044 
RPS3 20 164.96 210330087.5 146929617.8 45108000.46 173550466.2 682509.6884 38619067.68 0.482430135 0.918663577 
RPL37A 3 22.295 52213154.97 18019054.8 16098020.93 33788992.55 5132534.538 9967152.697 0.469591309 0.820365397 
DCD 4 40.945 315479276.9 289109344.7 547308871.1 178949838.4 327441059.7 338420096 0.462019381 0.447311822 
LDHA 4 24.612 12178980.21 78696710.67 73145207.21 13528044.74 2944456.644 61489212.74 0.45041621 1.073041926 
PHB 6 39.758 10957991.09 19369051.89 27157926.53 8769906.313 4528368.711 25139977.1 0.444406619 0.580642051 
RPS4X 10 84.556 35733898.95 62386044.31 14313964.79 38562894.3 2434256.899 20082979.68 0.430064416 0.880302133 
HSPE1 6 46.846 126960106.3 5443639.13 6455287.859 6977796.051 6770307.827 4959385.7 0.404933041 2.891933156 
PHB2 9 76.913 42219027.17 29566087.35 30126923.09 38402050.21 1210935.003 33513058 0.394505515 0.478867263 
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KHSRP 11 88.777 171449683.5 20313985.77 13315008.37 73652951.3 4842162.28 4710895.83 0.385739356 1.301417867 
ATP5A1 18 323.31 145590401.1 130969896.1 167809598.8 286849746.1 2954515.22 95303112.76 0.3720535 0.206500336 
PHGDH 10 63.859 29555022.85 65835847.18 70886128.38 46335994.48 892331.3494 76330166.37 0.366807771 0.428394439 
ATP1A1 18 151.71 30875945.92 13915987.96 30131935.28 64693166.79 1751828.361 7058694.734 0.35678092 0.027608729 
RPS11 13 90.247 168190385.9 57429155.06 18702010.05 103519692.8 1659066.173 37976931.34 0.325650392 0.771196109 
RPL13 8 75.412 252260660.9 33398963.61 25278017.77 126529627.7 2236978.562 29139039.76 0.321100985 0.977562524 
LDHB 4 34.963 16333039.97 110460092.5 83594228.29 13110051.34 25753050.56 73397113.94 0.316356266 0.906201298 
RPS18 11 109.93 299070423.2 72505143.13 36085102.08 128080002.5 20083954.14 45776061.33 0.314351283 1.071758248 
ALDOA 9 76.912 36116881.67 2661927.78 31965891.63 26253928.86 4178778.909 2107629.723 0.309970216 1.120392877 
EEF2 16 104.18 19693961.4 241520431.7 44248033.39 101549648.1 18015058.49 12268963.18 0.30937431 1.212276056 
TCP1 15 100.96 27152091.58 58804776.14 45061125.1 97941027.79 6493163.02 17490036.93 0.30767216 0.103780117 
HSP90AB1 17 198.43 85717711.65 290720990.7 366409076.3 290979041.1 66742852 121930178 0.293327236 0.631078323 
EEF1A1P5 17 173.88 762731477.9 540698832.4 87211194.7 1126000249 27094937.81 79071803.79 0.279504582 0.174552762 
RPL24 5 33.803 24584062.43 28537982.28 5507896.427 45133020.58 2783599.07 4470795.11 0.253060155 0.16241734 
YBX1 6 77.296 183950199.5 18471017.43 14940033.01 65750111.26 3111567.257 31068085.38 0.221402004 1.121108416 
RPL7 8 99.725 42467916.64 64667163.73 3869726.033 81394050.01 2662167.655 5493522.175 0.207443344 0.309860999 
HSPD1 19 164.46 103660426.9 141919737 123030434.2 208719478 33247902.66 111249992.7 0.200133559 0.061541246 
RPS3A 12 79.644 95219914.65 52581064 6527096.779 100059991.9 2748017.955 37325027.82 0.103238136 0.139203417 
PCBP2 4 32.484 45361971.26 61706964.88 1571052.542 80057875.75 2657816.369 7516918.858 0.076608235 0.267834397 
CCT8 9 75.209 19055973.81 37274095.28 26072037.56 45174021 17755959.66 18759005.37 0.067203462 0.012539646 
PKM 6 48.927 34480085.12 169249930.4 4917214.979 35247070.02 13881979.81 32662004.56 0.063649946 1.351050804 
PARK7 9 77.879 76991188.2 19776036.84 8359411.79 72174206.23 24767072.25 4559012.708 0.049432133 0.050644397 
DSG1 4 27.711 22170070.16 4975085.883 56796945.15 13790008.4 17466049.52 29728019.14 0.019923738 0.460961972 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with 3bM-GFP. Protein identifier (ID), protein name and number 
of unique peptides used to identify proteins are indicated. Relative abundance score for each protein is indicated. Confidence score (-Log2) is the score of the probability 
of the unique peptide sequence occurring randomly, added together for each unique peptide. The higher the confidence score, the higher the confidence in protein 
identification. The p value (-Log10) is a comparison of the cellular protein abundance between 3bM-GFP and GFP. The higher the p value, the higher the probability 
the protein interacts with 3b. The fold-change is the change in the abundance of the cellular protein between GFP-3bM and GFP. Cellular proteins which appear in both 
GFP-3bM and 3bM-GFP data are labelled with an asterisk (*).  
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Figure 7.1 IBV 3b induces apoptosis. 
DF-1 cells were mock infected or infected with Beau-R or BeauR-Sc3bAUG at an MOI of 4 for 24 hours. As a positive control, 
cells were treated with (D) staurosporine for 6 hours. Cells were harvested, washed with PBS and labelled with anti-PS and 
propidium iodide. (A) Cells were sorted by forward scatter area (FSC-A), and side scatter area (SSC-A) to gate DF-1 cells. 
(B) DF-1 cells were then sorted by forward scatter area (FSC-A) and forward scatter height (FSC-H) to gate single cell 
populations. (C) Single DF-1 cells were then sorted by annexin V (FITC) and propidium iodide (PI) fluorescence and shown 
as a density plot. Cells were separated into three gates, representing cells that are viable (dark green), viable cells 
undergoing apoptosis (light green) and cells which are dead from apoptosis (red). 
 
A 
B 
C 
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Table 7.5 Cellular proteins identified by LC-MS/MS that interact with 4bM-GFP 
Name Unique Peptide 
Confidence 
Score 
Relative Protein Abundance 
p Value 
(-Log2) 
Fold Change 
(Log10) 
4bM-GFP/GFP 
pEGFPN1-4bM pEGFPN1 
1 2 3 1 2 3 
LAP2B 3 367.06 308301.4581 308630.484 721836.6619 80902.72867 92397.04123 24409.89257 1.748856032 2.759451338 
RL34 3 189.71 528427.6891 282680.832 1578712.974 164306.7962 75411.48874 42751.15199 1.480517467 3.08073618 
TCPH 2 214.33 3341.124075 8993.922182 41135.24955 921.0552625 1101.108238 2917.09935 1.163171647 3.436370007 
DESP 10 621.61 585581.0348 113195.1917 1417524.335 37282.9971 122572.7351 8009.798482 1.136799303 3.656166612 
DSG1 4 380.4 255888.2483 128315.5368 739277.6606 78286.60921 117522.5949 51076.30009 1.097646584 2.186062262 
PRDX6 2 389.29 3837.703586 12580.77905 59278.77169 2581.596323 1076.176879 3524.981782 1.023050489 3.397631763 
RS2 6 290.56 56730.16038 179024.2354 150958.2496 60416.24602 58061.0729 16145.7868 0.91312853 1.522335896 
POP7 2 134.3 911.8707526 1588.670511 647618.2754 0 0 3480.976415 0.892347224 7.545067562 
LRC59 3 385.18 5635.367448 926780.8934 180529.2952 2806.613199 3906.844135 12404.58578 0.873895322 5.86330435 
RL11 2 168.39 1168.419944 0 148438.3374 0 0 0 0.859694832 10 
K1C17 3 513.47 316032.344 16713.1404 284010.8027 19824.06716 34851.66881 4060.045856 0.83919468 3.392388951 
CASK_BOVIN 2 162.13 124675.5449 12799.90292 7020.604791 8038.580892 3360.13759 172.4779952 0.826040607 3.642420127 
TIM14 3 302.16 4537.983877 32298.5626 782860.5011 1437.734931 1329.487708 15095.84856 0.746353508 5.520038752 
RM43 3 236.52 47539.26502 2638.642934 149635.5899 987.1212169 3179.171192 10525.4074 0.697187968 3.765580815 
PRDX2 3 263.01 2194.851774 75765.74001 1463.378974 1287.62327 855.4837881 0 0.694090889 5.211798663 
HDGF 2 178.65 44.57430193 0 379734.0245 0 0 0 0.686747809 10 
NHRF2 6 658.58 123937.8009 87441.99072 780723.0634 42755.90333 19697.35678 165598.1996 0.674666623 2.121130294 
EIF2A 4 360.96 26191.1189 43491.86927 1841034.114 91.64032414 34015.52374 25612.43638 0.653694747 4.999765867 
RS28 12 1010.4 9335907.542 1561375.14 348358602.1 1327670.645 2829222.062 1312178.327 0.648898822 6.037572178 
K1C10;1::sp 31 5728.78 189782196.9 23099693.88 258417835 33932067.03 40516832.58 31209457.17 0.646420393 2.157237964 
HDGR3 2 164.41 1445.063931 10798.94118 820505.6078 3324.502837 2512.857452 310.4074153 0.634102218 7.081676315 
NDUS3 2 412.34 20629.71799 1999.259114 50514.42269 1347.559789 33.79957874 11929.76846 0.630852132 2.458094874 
K1C14;1::sp 6 1961.58 4821928.186 952135.7381 5343121.205 1102543.308 2382982.831 250710.1779 0.627316243 1.573133931 
ANXA2 3 192.23 2800.499492 2048.317129 510901.443 6.097818185 403.7181974 11178.20336 0.61532189 5.475966735 
UBL4A 2 109.74 4.670518648 0 11585.8507 0 0 0 0.602751727 10 
K2C1;1::sp 32 4927.35 340676833.2 30965711.8 340741933.4 49839413.71 95306169.77 16717900.51 0.600757635 2.137878529 
CKAP2 2 60.97 10499.23545 0 265646.9065 248.7785753 0 0 0.559263271 10.11635401 
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RS15A 2 128.47 20261.0697 2371.321675 1547851.233 291.7003083 6161.207923 10836.00181 0.549973469 6.50521817 
PSIP1 9 699.4 297264.6488 187054.7042 4652998.681 152311.7922 153462.2957 250435.4747 0.549866111 3.207314935 
LBR 3 264.33 60858.39061 50330.00959 276069.6311 33390.01468 85903.10905 26381.32755 0.549275387 1.410547283 
CRIPT 2 112.35 3088.452999 3208.453899 708960.0249 0 957.8799199 20052.40092 0.548269363 5.089294223 
K2C5 14 2081.41 13074916.38 726923.1183 12272841 1414399.585 2952717.418 496617.2506 0.548066484 2.422513265 
PLAK 3 327.34 4818.853753 8284.501143 1048185.416 1074.73093 3788.566625 11982.52712 0.537782351 5.977282393 
F207A 3 125.74 2665.674085 24716.52682 436914.6617 1544.690352 1371.284639 24661.12907 0.52864817 4.073504663 
K1C16 9 1889.28 9008377.583 741193.6442 4929766.083 1359080.113 2244486.942 443015.7484 0.524458609 1.859010818 
RRBP1 4 255.74 13264.28431 1920.542701 394072.296 100.8331958 80.90184734 74288.45556 0.522041875 2.458272572 
K22E 24 4408.38 48444035.36 5049567.12 69356896.11 10055459.69 13549305.94 5999830.284 0.519990389 2.053010646 
RT18C 2 58.65 2883.006852 555.2213157 77469.25066 127.0382721 0 15768.68076 0.515541976 2.34763479 
KNOP1 3 344.24 7699.489829 10379.41236 243852.3416 1375.459289 3321.386324 29970.67561 0.503323516 2.917531568 
ALBU 3 1068.08 125050.4352 16386.09102 241384.1391 75783.41164 32564.13499 477.5206335 0.498310502 1.814657799 
FETUA 2 117.82 901.5507811 0 209905.5078 272.9358479 0 0 0.475440062 9.593145566 
RS18 7 637.21 872335.419 95302.95698 4363039.16 58917.7636 444318.8968 254097.6107 0.455576846 2.815316792 
ECHB 3 237.82 5651.63785 1349.749736 103377.5059 0 4140.803886 9516.751654 0.446184338 3.014693133 
COA3 3 155.7 182997.7145 3890.780845 45583.77057 7180.032985 337.0304998 46960.17009 0.44311373 2.093333264 
DCD 4 554.6 7741768.006 915169.5098 7449578.338 2143771.519 2293672.703 1233108.336 0.419749597 1.506083217 
LS14A 3 206.55 11842.01799 177278.6436 323990.9499 10689.58084 15915.39419 112936.5305 0.402397647 1.87857837 
FRG1;1::sp 3 402.12 7309.775246 14467.08766 925237.035 6127.762579 15927.57922 13340.0076 0.3947007 4.741753876 
RS5 5 711.7 20612.23866 120821.6199 7483139.053 92099.47641 63118.72208 20555.59642 0.394149962 5.438864619 
TCPZ 2 179.73 1199.589166 1297.870216 201008.7171 29.93943986 1038.618996 12706.84516 0.383667311 3.884906088 
NOL7 2 63.6 98.80464168 35238.41465 85286.30717 0 7009.940392 3269.580222 0.382212751 3.552666427 
CYTA 2 72.13 35086.67208 13102.29212 633011.4202 43598.46219 29109.56956 6829.090441 0.380777752 3.098378981 
PTBP1;1::sp 17 2384.54 1359942.816 669208.1566 7918979.31 316431.2917 593615.2138 2734783.841 0.379470209 1.448573738 
ILF3 6 362.57 19295.6386 747.6190726 683302.3509 1383.82142 1.110636144 148921.5051 0.375319674 2.226326975 
SMD3 8 1276.85 3983972.397 823151.9969 19107583.45 672201.0136 356235.5355 7850347.088 0.374320526 1.429464215 
RM11 9 867.54 326613.254 207668.7433 3917107.051 90138.53586 182371.7422 813028.4955 0.372844298 2.035844339 
MZT2B;1::sp 2 174.18 120976.7424 2216.960967 128355.4955 1795.271526 6879.219477 38154.61604 0.372612496 2.425363161 
RT18A 2 140.61 0.708102515 1513.809318 191815.2413 0 0 4575.837512 0.370734063 5.400884091 
DNJC9 2 205.6 5799.140826 3132.524111 542057.7279 92003.45981 76080.78194 104154.1123 0.368786989 1.017154211 
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CH059 2 80.34 14425.65752 439.037194 507501.4148 0 20303.50923 8805.629401 0.368527127 4.165517245 
K1C9 35 4527.82 202871229 23664448.74 177687456.6 34449667.34 119938769.7 21831498.89 0.362688523 1.197774745 
MO4L2 5 426.83 178194.1 81147.25623 2345399.322 45786.37813 112930.1598 327320.9936 0.357437546 2.422000121 
RS3 11 665.84 1042603.38 397058.0176 9900319.723 103965.8704 1582205.053 973210.7352 0.354198918 2.092255494 
RLA0L 3 321.82 14062.81281 101583.8782 924632.1616 26880.82039 27883.76908 72081.77094 0.354120705 3.035816273 
RS25 8 820.46 737016.6507 450290.2693 114415617 96942.49295 143057.6572 9122771.33 0.343777923 3.626098432 
CALM 7 841 159297.0479 235917.7982 7479835.884 36906.94512 42441.29678 2164486.043 0.335778308 1.811323085 
RL40;1::sp 4 1272.81 55522.90208 273535.8095 1239132.52 36265.8443 28315.76306 676364.1166 0.334203973 1.081661728 
ATX2L 6 366.47 41675.76547 23737.19591 995318.3981 10275.79864 5527.036502 301483.3553 0.326191135 1.74120269 
RPAB4 2 53.62 5902.929403 11104.92896 1849652.16 0 43353.01395 156093.6491 0.325461146 3.226384297 
RM33 4 577.42 37947.07336 204204.1302 2648419.034 2369.810485 39473.18832 1278996.567 0.319695314 1.129898886 
CLCB 5 237 1421826.711 95529.78205 1743416.526 66432.62061 876560.7064 275393.0336 0.305347598 1.420242323 
HNRPU 2 354.96 1883.362992 4543.78438 294555.4664 2367.458807 6860.563168 4501.213468 0.302043876 4.45435696 
ETFB 6 621.65 537566.5881 39224.24334 84346.52153 36946.0763 13725.35752 276247.706 0.291320832 1.016016183 
YMEL1 2 243.81 0 4327.831587 227468.7478 7605.080226 5223.752685 55348.95324 0.288371908 1.765485618 
FA32A 3 147.74 32040.06876 5639.276833 2171594.494 191390.6031 36055.59699 164.0759761 0.283824066 3.278934654 
RT23 5 384.75 77119.10118 43852.63677 1400043.349 74024.30344 12153.41793 273335.9389 0.28342201 2.080915969 
RS11 20 1847.17 2266909.351 423529.4725 31007174.35 453840.1356 463438.894 6099591.553 0.277446056 2.263746749 
RS30 5 469.49 1550201.705 792446.3427 152466671.4 258417.5316 307780.9791 23915915.66 0.276968678 2.66069227 
RRS1 2 77.67 1500.306172 0 9446.452205 0 0 4917.172274 0.268245905 1.154602907 
CCD86 6 497.8 114831.6293 1812.880952 1430282.907 1216.727289 11919.17867 175319.1642 0.261830714 3.037112992 
FUS 14 1831.48 3685606.117 1901792.793 84521950.29 1774477.653 2654482.073 10201056.15 0.25969758 2.622745465 
HORN 7 600.98 451844.8349 16814.55612 753363.6645 120053.8168 154355.9794 22895.11619 0.258969095 2.039256298 
CHTOP 11 1048.35 494204.2965 229409.3663 52691335.7 128674.1111 105193.5423 7056342.969 0.250384887 2.873211168 
FBRL 9 591.73 149097.126 33877.92389 1191823.115 39266.9082 144545.3401 129949.4515 0.248774545 2.131478669 
MTDC 6 539.87 267619.8633 23832.71905 216758.5335 117326.4233 24942.54693 85693.52994 0.248578431 1.15663141 
RS16 7 465.83 90375.31989 155875.0319 7133250.092 186493.7407 112231.4964 343970.578 0.246060433 3.521315173 
RL24 11 735.49 186124.5488 1364066.5 3426832.923 339789.1816 411618.8524 1093529.538 0.245603837 1.431711336 
HMGB3 3 116.21 15275.19571 0 100871.2016 22324.78987 6399.830654 6646.368224 0.245597984 1.715305951 
MRP 2 234.67 539268.976 57135.97328 728363.9282 81540.9579 265998.1235 203925.6753 0.243048783 1.264400092 
BCL7C 2 133.69 2843.926801 13014.84444 448795.5628 27292.18599 6785.680799 4781.96392 0.242390916 3.579806344 
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MAZ 9 523.58 301425.3047 37373.40311 929345.6964 25748.2669 82879.28831 485751.5684 0.238895259 1.093263685 
PDIP3 18 1732.04 111313.3434 167835.0644 16015118.17 46234.96748 37622.19365 3447699.524 0.236334138 2.205988258 
RL37A 3 286.14 18872.78109 28081.80356 3542375.425 13141.21064 21390.57544 226225.8851 0.233428072 3.782932972 
RM53 7 576.9 215644.0538 70550.38238 9864277.45 40524.17816 70774.87065 1764249.682 0.233165503 2.436162146 
ERH 4 533.05 19087.59523 25014.06553 2091441.896 146133.4181 291599.2943 348179.9428 0.227869972 1.442162436 
RL23 8 549.21 416720.2986 267180.3389 13197825.93 148440.2075 358869.2129 2200608.289 0.22465744 2.357931214 
IF2B1 13 1681.43 240192.9464 148950.8683 11976948.72 86125.40777 94522.56675 2482918.57 0.223943585 2.214958477 
PABP2 3 335.01 490984.8964 113121.8831 3894622.923 127658.3143 529656.8577 471806.2036 0.221545811 1.99431711 
MAP4 13 1275.28 141843.7498 112704.6698 3787402.89 114820.4676 83991.45317 696461.5392 0.217255543 2.174651619 
RL12 11 1709.04 5890951.431 2630862.224 627869609.2 3988049.059 4123285.319 27927923 0.217132568 4.142273203 
RRP12 2 62.27 0 27.67559495 65632.78339 2531.035433 0 0 0.209627149 4.697225225 
RL7A 15 1180.14 230822.9384 144452.4731 34160736.52 69729.70612 170777.4276 3382447.501 0.204221562 3.25286285 
E5D0B6_9GAMC 3 117.1 130.2404694 11466.89289 146326.7442 39765.17175 14715.27896 10325.91359 0.204185828 1.285021914 
L10K 5 221.39 5819.620125 12646.90678 839885.9265 4182.273806 2801.669346 207490.8138 0.2011596 2.000762307 
1433Z 2 308.14 146755.8069 14913.4842 665318.761 30435.37785 171632.8661 40993.69135 0.200767745 1.766542508 
RL30 12 1719.29 7585014.161 5873825.376 989329524.8 2701626.283 4122333.545 149841185.3 0.200288293 2.678261011 
RL26 4 1766.26 62263.57059 177318.1504 7865708.783 31796.40626 70558.9224 1943503.322 0.198191512 1.986157423 
CWC15 7 434.62 7093.990711 100114.652 1299288.702 10788.52486 9493.688533 436629.6537 0.198110699 1.62211901 
RS21 5 485.38 269379.2183 191815.7883 13047394.55 451410.6962 404269.1472 468423.1361 0.195186247 3.350789815 
HNRDL 4 368.42 332247.258 150297.052 1911459.774 388242.0993 310276.938 250778.5932 0.193061221 1.334493226 
NUSAP 5 334.48 17574.56615 52926.25375 769067.4886 10487.81278 55465.93703 158336.4305 0.190649329 1.904281251 
CC124 16 1589.84 2302422.256 830571.7663 30171142.28 712281.6558 1188905.201 9389635.706 0.190440768 1.560550774 
RL37 4 142.19 125528.0227 7785.044418 1347916.311 6422.829873 48712.27439 272993.5739 0.189442607 2.174461474 
RL28 4 235.96 354718.8173 17717.60424 445788.0212 75476.4273 143707.9318 52440.66559 0.188121122 1.590880235 
RS24 2 151.09 0 1716.515544 1183436.443 2029.27008 942.1790308 527665.9861 0.187420484 1.159274905 
RL13 17 1569.04 991969.6281 380053.7402 34942005.32 729911.902 334565.6869 5157816.964 0.187083862 2.545008396 
SZRD1 3 175.07 211339.5013 0 168579.6382 6074.83052 9951.534515 167850.4229 0.183004466 1.046953024 
RT26 2 38.15 101.6085717 0 22612.51317 0 0 9691.778787 0.172034071 1.228756142 
RL35A 9 587.59 892990.314 154422.7912 4991964.88 1280536.245 618383.6547 180886.2548 0.171414474 1.537950899 
RL38 5 531.73 191737.0547 6346.397575 841612.6169 26002.27603 19062.068 223392.2068 0.170835678 1.953401337 
HMGN1 3 301.28 119367.8722 88466.94361 5043852.448 173670.2558 112414.645 480691.5641 0.158355656 2.775903045 
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CETN2 3 279.76 2596.234633 5508.59917 2694501.9 15542.4189 68017.29577 803870.9601 0.155355146 1.606645268 
SRP14 11 1902.3 470648.7836 588968.9287 120041637.9 205603.9915 238126.7524 32758311.32 0.153466867 1.866869943 
RS20 6 646.42 48568.27576 66534.66659 32962481.28 33027.11146 56765.547 2557110.729 0.152844397 3.643476431 
RPA34 6 937.12 65034.92821 9500.081215 2265385.055 95456.03659 25346.56721 76091.10377 0.152574401 3.570970335 
RS19 16 2106.63 6072377.988 1436218.848 124408594.8 2328065.063 1635694.791 39755743.05 0.147339645 1.593283689 
NOP2 2 121.91 715.5481332 1102.455414 193045.1975 17744.20132 23400.36736 3475.464117 0.147227409 2.126698192 
RM48 3 222.52 8647.711693 0 655025.9875 22513.51431 628.6164117 35253.1409 0.147205338 3.506550642 
PKRI1 2 223.75 0 0 223775.1307 687.1336117 0 0 0.144319273 8.34724334 
RM46 2 276.75 0 1419.281255 215864.1344 676.3158918 1491.544303 13891.12799 0.143825305 3.758125161 
RSMN 8 525.57 152110.2384 6862.185751 5264192.57 14275.12229 12569.84025 1746605.611 0.140607577 1.612575941 
RL31 18 1625.83 3475783.08 1423298.398 127244635.8 865097.856 1901116.778 47510818.7 0.139829391 1.394136405 
MK 3 268.4 1669.769088 451.0793763 1100645.657 22071.67427 8086.723512 78100.71386 0.139232058 3.348566994 
PAIRB 24 2871.75 7108699.273 1867869.803 101775713.7 2494203.573 3702862.006 30336214.87 0.137642792 1.600053226 
TIM8A 3 301.21 100457.1189 5091.888431 3566709.941 340422.874 102067.1445 458823.6708 0.136913153 2.026566586 
ZN593 3 330.28 22916.63454 143922.7836 2534149.793 77958.43994 58463.07347 368618.5152 0.132669822 2.419018234 
HNRPK 4 339.4 13995.07057 54228.85377 1007292.794 84895.48846 225235.1203 159391.5682 0.131007942 1.195764744 
NEP1 4 478.6 9534.470493 26897.47359 602157.3189 121230.6922 57320.30354 82806.68287 0.127151183 1.28886275 
RT11 5 484.85 16122.88633 13072.18186 6884427.525 9643.404158 9827.465578 1092768.889 0.12438029 2.635974036 
RPC4 4 104.04 29340.11681 1261.029451 195719.8984 48379.81885 16775.21623 38193.96134 0.117108167 1.130846362 
EIF3H 2 226.03 160210.0843 0 722802.4756 7819.19591 43733.59049 8868.019343 0.104902888 3.86931663 
HAP28 8 824.87 48086.67152 108091.3055 6431567.793 716774.141 587601.6983 288821.1269 0.10036107 2.047860243 
WIBG 13 1490.01 854812.0337 362479.1405 27446536.58 2741224.612 1434374.308 6889740.55 0.098992933 1.373183568 
RT28 10 960.77 572563.4129 341231.3667 51783055.87 357757.7044 437990.456 12646131.1 0.098921718 1.970981893 
YBOX3 12 2360.52 1308101.733 286131.5555 30274649.44 267691.4365 696462.0599 14016588.76 0.096220899 1.089039334 
RLA2 9 1508.17 719002.5153 142946.6191 34053119.28 343859.3744 366183.183 6278885.994 0.093935785 2.320706596 
EAF6 2 402.41 0 2193.109264 302222.4249 49.0997585 1772.162761 130588.2683 0.093347265 1.201035009 
NDUV2 4 169.89 5554.830323 0 357544.2354 285.4170822 1061.773122 82364.44795 0.08805109 2.116863103 
H3C 2 90.68 19007.83797 1999.537284 175388.5561 19841.47068 15686.18473 8083.351098 0.08743598 2.17100085 
RL29 11 1005.06 8280277.127 618713.1613 89179397.32 1663107.619 3195759.42 27629947.79 0.080055565 1.593992145 
HMGB1 4 285.97 62070.03667 606.4103879 980015.9015 170790.8233 21926.71075 42904.18307 0.077129849 2.145769123 
TCPQ 8 664.98 20087.20782 46872.97716 1022357.655 9917.601685 152123.0448 234553.0973 0.075588752 1.457691138 
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RL23A 17 1998.62 2046355.297 1578772.213 140167606.5 1486114.806 1741380.808 56082298.4 0.070780949 1.27764851 
CA131 4 362.08 459731.4611 15051.1954 16756665.08 99766.45913 892420.6533 384973.2718 0.066713788 3.645275427 
NUCL 52 6666.07 20655585 3969742.9 304259397.9 20190215.49 25811243.31 104216125.2 0.066270243 1.130528307 
DECR 4 267.39 3493.079249 2515.371366 861658.316 25400.05935 11591.77791 9504.368047 0.059985099 4.221956189 
ROA0 6 567.61 5310.197463 8049.069985 2775666.031 6305.350453 21785.60862 270761.9985 0.058067968 3.222253295 
HNRPD 12 1555.33 2288197.773 1117668.4 42471276.81 2053883.709 2351566.019 12031312.97 0.057727515 1.480849369 
THOC4 18 2330.74 3857522.939 3678987.063 285424879.5 4165126.592 3140828.475 125899034.7 0.055429719 1.137062413 
EWS 7 1114.34 1655726.492 189900.5331 18806231.84 493942.7959 991388.4464 5850920.347 0.054890393 1.493156623 
G3BP1 7 594.99 325165.4507 45272.80342 2414039.973 50080.29734 419927.0561 856727.9917 0.054597056 1.069526399 
RS14 11 1595.96 1586713.923 148163.0609 25844232.71 429167.9847 643343.6462 9801358.507 0.051916487 1.342710381 
RS12 6 452.39 234743.6266 89243.02432 5399182.6 245987.1872 600323.9956 450951.943 0.047788919 2.141343139 
CIRBP 7 1010.7 301462.8121 191576.3568 33565447.84 168205.6521 346443.8233 14018436.6 0.045904084 1.228673258 
CASB_BOVIN 2 179.48 1461.097548 0 0 182.9677614 0.936170805 0 0.04364592 2.990028268 
PRKRA 5 236.56 43453.73027 128.3210948 1293701.806 22012.38653 56772.79106 16137.75078 0.042986775 3.816405312 
NDUS6 5 651.41 32760.80297 74364.94617 4499347.454 125019.4178 175997.0266 912573.3627 0.041860702 1.924381747 
NONO 16 1722.95 317896.4586 279029.2546 15338559.43 1641369.257 816026.2927 1623510.44 0.03980941 1.96528156 
MIC19 7 558.58 3203945.583 598900.4602 56267.82814 263868.8608 1082840.91 579598.4311 0.039006405 1.002431067 
SNRPA 6 804.38 126445.7763 34111.81477 4360441.333 75577.47981 93475.17815 1466573.78 0.038896311 1.466798287 
RL9 7 795.67 189311.452 35896.22632 14064785.9 302323.3695 206117.4148 2805090.428 0.034783903 2.108563854 
NOP14 2 36.91 0 91.44264821 171179.8779 861.6157942 0 4371.227858 0.034637051 5.032544627 
RL8 10 1196.15 244364.6875 17929.41347 10229554.57 78889.61242 68729.43924 4627639.92 0.028220677 1.135618024 
NHP2 2 177.1 4794.475394 1888.813934 907653.4755 1001.516656 10545.74179 423773.2698 0.026058204 1.070647577 
RBMS1 3 108.49 33276.06663 271.1406131 1081505.053 7771.861959 6960.848232 104765.05 0.02363382 3.222055845 
NPM 21 2584.33 2138165.19 425655.7154 82239342.26 2301441.784 3118133.218 14234363.52 0.020867636 2.10929963 
CNBP 5 426.62 0 99701.70041 3436597.754 6406.292553 1599.38971 6987.023579 0.020216508 7.881835857 
RM49 2 346.44 10442.8254 4826.936918 615923.529 18549.26459 7197.301219 173381.0573 0.018324597 1.664388505 
RS10 19 1734.35 2316955.501 682417.5391 91912186.2 4433699.334 3217941.789 12732761.27 0.016115574 2.219118141 
HMGN2 4 665.01 113578.5992 73192.77361 4412319.132 287263.9221 290059.0693 515910.0116 0.01331153 2.07274767 
NDUA2 3 385.82 160660.238 31527.50832 5156504.787 52944.47059 174939.1792 2332862.53 0.011132515 1.062622013 
H1X 15 2059.49 203904.6256 320615.4861 34081282.06 411600.2731 625863.7488 10120116.11 0.008972496 1.63298978 
RM18 2 99.17 368498.06 209.0801653 50987.72505 9315.364779 4369.201246 105298.4192 0.003901826 1.818585533 
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CALL5 5 829.63 33304.24203 28017.56083 5130793.884 88099.63343 39461.05163 1282412.538 0.003872097 1.880654765 
SRP09 9 871.03 428266.3847 196934.1396 82898179.62 751013.074 1077451.01 8220552.917 0.002660748 3.055125715 
HNRPR 2 425.57 2568.370477 24264.21788 584576.6189 23793.93311 17731.20257 88379.63916 0.001531502 2.234683818 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with 4bM-GFP. Protein identifier (ID), protein name and number 
of unique peptides used to identify proteins are indicated. Confidence score is the score of the probability of the unique peptide sequence occurring randomly, added 
together for each unique peptide. The higher the confidence score, the higher the confidence in protein identification. The -Log2 p value is a comparison of the cellular 
protein abundance between 4bM-GFP and GFP. The higher the p value, the higher the probability the protein interacts with 4bM. The fold-change is the change in 
the abundance of the cellular protein between GFP-4bM and GFP. Cellular proteins which appear in both GFP-4bM and 4bM-GFP data are labelled with an asterisk 
(*). Proteins which appear in the third replicate are labelled (*). 
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Table 7.6 Cellular proteins identified by LC-MS/MS that interact with GFP-4bM. 
Name Unique Peptide 
Confidence 
Score 
Relative Protein Abundance 
p Value 
(-Log10) 
Fold Change 
(Log2) 
GFP-4bM/GFP 
pEGFPC2-4bM pEGFPN1 
1 2 3 1 2 3 
LAP2B 3 367.06 136685.3054 216452.7164 392330.6564 80902.72867 92397.04123 24409.89257 1.245425587 1.914764357 
RRS1 2 77.67 1556.740123 20216.67469 30394.43262 0 0 4917.172274 0.999504058 3.407260099 
PRDX2 3 263.01 5215.96236 16505.10114 227062.8667 1287.62327 855.4837881 0 0.974611688 6.859045568 
LS14A 3 206.55 69195.71256 265077.3598 172551.0425 10689.58084 15915.39419 112936.5305 0.960634287 1.860790867 
RLA0L 3 321.82 90613.70622 120295.2302 1395195.765 26880.82039 27883.76908 72081.77094 0.949946223 3.662411915 
RRP12 2 62.27 790.2868236 1826.565518 73865.67688 2531.035433 0 0 0.932141673 4.917330623 
RT18A 2 140.61 745.3216979 6387.487721 249956.4255 0 0 4575.837512 0.928848462 5.812089569 
HDGR3 2 164.41 3768.138364 14764.81383 6398.227269 3324.502837 2512.857452 310.4074153 0.903562663 2.019816578 
POP7 2 134.3 2829.72501 359.3812335 82829.75435 0 0 3480.976415 0.850293596 4.627089077 
PSIP1 9 699.4 228268.3059 315697.4688 1063818.038 152311.7922 153462.2957 250435.4747 0.797961412 1.531372977 
UBL4A 2 109.74 0 219.5166039 125234.708 0 0 0 0.79426677 12 
RM43 3 236.52 13414.7761 10110.47499 952572.9486 987.1212169 3179.171192 10525.4074 0.78451836 6.053953068 
RS2 6 290.56 79362.52455 81137.98086 1036934.237 60416.24602 58061.0729 16145.7868 0.764722498 3.152949084 
IF2B2 2 497.86 0 127.7464791 172821.5504 0 0 0 0.759702539 12 
PHB2 8 713.88 99289.62987 116778.3876 3589120.913 73490.16727 28103.76015 53308.46372 0.75561545 4.618536767 
TIM14 3 302.16 4293.606251 25456.40159 993963.807 1437.734931 1329.487708 15095.84856 0.698949446 5.840688503 
NHRF2 6 658.58 117581.3879 96626.84277 801436.7071 42755.90333 19697.35678 165598.1996 0.690956883 2.154964825 
ALBU 3 1068.08 140779.9275 48159.22437 149265.0735 75783.41164 32564.13499 477.5206335 0.629963575 1.635883773 
RT18C 2 58.65 7589.78398 874.8109784 163755.5698 127.0382721 0 15768.68076 0.620578817 3.437543891 
RL14 8 582.74 41072.21332 106616.499 2877863.98 4213.913143 5345.27756 278459.7082 0.607136322 3.392963325 
YMEL1 2 243.81 10916.3814 101042.6663 213454.43 7605.080226 5223.752685 55348.95324 0.604443908 2.254900346 
CL065 2 118.03 0 0 468076.6922 13299.32869 64294.07444 11433.41851 0.588077695 2.394432972 
CRIPT 2 112.35 7897.1543 3704.151862 190778.6196 0 957.8799199 20052.40092 0.584978943 3.267898843 
RL40 4 1272.81 192391.0279 309618.5155 980663.2205 36265.8443 28315.76306 676364.1166 0.584319447 1.000760449 
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RM39 5 426.25 41849.98436 51265.52214 1333620.066 20181.15531 14832.39725 78911.87357 0.577354535 3.646556302 
G3P 5 316.53 48448.80105 25205.89476 872362.8818 40284.75983 20077.36409 21757.11279 0.544102432 3.526074867 
P5CR2 2 150.76 14844.08324 5525.250762 225259.0594 3799.352065 11599.55541 6430.221355 0.53129773 3.492150878 
COA3 3 155.7 354180.8467 2338.813523 351670.5033 7180.032985 337.0304998 46960.17009 0.521099172 3.700411457 
HSPB1 2 186.59 70909.68319 117303.671 172438.5174 0 19071.62716 150223.0021 0.516249351 1.091070705 
CASB_BOVIN 2 179.48 0 2311.715856 108136.046 182.9677614 0.936170805 0 0.500474228 9.230196141 
RS15A 2 128.47 4213.299073 6073.555598 714339.7386 291.7003083 6161.207923 10836.00181 0.498461298 5.389318928 
ETFB 6 621.65 101866.9631 79344.66573 1105203.696 36946.0763 13725.35752 276247.706 0.496031274 1.97635075 
H4 3 190.69 2359.894419 67538.96573 174918.591 0 3631.896338 50381.02264 0.4930372 2.180329979 
RL38 5 531.73 263926.3563 26451.87981 1959954.348 26002.27603 19062.068 223392.2068 0.475453235 3.067377723 
RS15 4 605.86 28492.70436 40025.40123 702125.6639 5617.555967 12556.24725 126239.8159 0.470972528 2.415857324 
FRG1 3 402.12 3985.391534 142906.1815 103972.7796 6127.762579 15927.57922 13340.0076 0.46611044 2.825275759 
ILF3 6 362.57 16120.7154 3600.479751 687434.6158 1383.82142 1.110636144 148921.5051 0.459895443 2.234121329 
CKAP2 2 60.97 6911.654187 0 1803.961137 248.7785753 0 0 0.456293235 5.130668371 
FETUA 2 117.82 2208.743297 3476.771502 0 272.9358479 0 0 0.439040652 4.380657186 
F207A 3 125.74 1680.31623 23144.90107 330384.9932 1544.690352 1371.284639 24661.12907 0.438921911 3.687130183 
ANXA2 3 192.23 375.7952171 1829.758816 464823.7678 6.097818185 403.7181974 11178.20336 0.436321194 5.332807223 
RL11 2 168.39 0 0 84580.01029 0 0 0 0.427243412 12 
ECHB 3 237.82 1314.561067 3076.313885 170197.1485 0 4140.803886 9516.751654 0.426338798 3.6761834 
EIF2A 4 360.96 36264.45686 10181.8508 93962.19191 91.64032414 34015.52374 25612.43638 0.425624087 1.233353853 
CG050 10 711.38 794322.3343 372768.1185 11004238.87 209786.5088 188270.1 1863209.117 0.42516845 2.428284303 
SF3B2 3 284.5 25368.78841 2277.64473 275343.0038 0 5449.38623 66843.73706 0.420083879 2.067337172 
SF3A2 5 496.49 177611.4362 11138.48437 849549.523 2967.731071 105296.2257 43477.51588 0.410907832 2.774535224 
RRBP1 4 255.74 1889.294019 3590.533721 191498.4704 100.8331958 80.90184734 74288.45556 0.407230414 1.403301736 
UBP2L 2 197.76 4101.430355 4264.351672 204759.573 2740.664026 6.342555383 52407.68854 0.394260448 1.95014663 
EF2 3 213.09 0 851.485626 129169.6 3854.229012 11827.57435 18527.84178 0.368150971 1.92627056 
MTDC 6 539.87 516719.0503 13645.57736 1727321.669 117326.4233 24942.54693 85693.52994 0.351522593 3.307976613 
RL32 3 182.78 7649.564981 442.9076681 1811133.166 64373.88596 233600.9704 212847.3643 0.349840182 1.832431303 
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IF2G 10 1075.97 61705.9887 241988.4221 4755076.513 28920.04337 59192.69474 718805.9276 0.348247374 2.648291743 
TCPE 4 479.39 7624.936222 11029.49369 462145.2232 7913.166364 5119.823646 27894.47236 0.347914411 3.554294732 
CHCH1 3 189.97 399.1320538 32.41494431 481406.1776 0 0 98705.09468 0.345033146 2.287350894 
TCPG 3 344.99 0 4237.347796 419807.7582 7373.887538 51589.47409 55827.39829 0.342445785 1.885211217 
GSCR2 4 165.26 4304.367806 1442.353144 134910.3399 2792.694824 21.04425417 28039.63671 0.340324426 2.188681722 
RL24 11 735.49 322207.7208 870325.5528 4100636.399 339789.1816 411618.8524 1093529.538 0.337055123 1.520559901 
ATX2L 6 366.47 56290.80765 23285.8282 621618.7474 10275.79864 5527.036502 301483.3553 0.335570862 1.144031766 
DLDH 2 130.21 38606.73861 17238.20966 575061.6371 7456.063811 15038.39415 143364.5582 0.311381842 1.92746897 
CWC15 7 434.62 24204.19489 67123.52447 1271211.916 10788.52486 9493.688533 436629.6537 0.300368039 1.57631038 
NOP16 3 386.64 19371.29931 22854.07835 965287.9179 12177.78038 20450.8859 78377.44787 0.300342876 3.182087831 
HNRPU 2 354.96 649.47959 0 97546.96571 2367.458807 6860.563168 4501.213468 0.294807484 2.838419514 
ECI2 3 469.71 194.1740958 860.2587756 258254.6821 3655.253638 0 7198.008297 0.288019994 4.578472306 
RL23 8 549.21 600629.2195 280155.1907 13566230.99 148440.2075 358869.2129 2200608.289 0.278729798 2.415515675 
CH059 2 80.34 336.4611986 2965.761671 330159.8157 0 20303.50923 8805.629401 0.277260919 3.51797848 
H3C 2 90.68 21267.88252 4789.607341 337836.6671 19841.47068 15686.18473 8083.351098 0.274274978 3.060754694 
TCEA1 2 251.28 1204.013257 6864.717137 225171.9324 98016.39855 9892.807824 0 0.272811081 1.112001373 
CN166 4 198.09 40351.51631 822.3364252 473604.4353 93.58354826 4509.741244 133500.1636 0.268408505 1.898201444 
RS16 7 465.83 166659.8425 134988.7258 2104096.111 186493.7407 112231.4964 343970.578 0.266968404 1.904275554 
LDHB 3 177.52 1434.260544 19903.32299 252108.0739 1765.863782 12880.13092 12466.00142 0.263880376 3.33425091 
RAE1L 8 533.54 30294.66842 47083.29105 1111146.725 51069.9901 26732.04131 107661.6265 0.262668387 2.679963447 
BAG2 2 171.7 15301.32256 12834.40149 327885.901 583.2792941 38700.06828 77082.89526 0.258447345 1.613292273 
NUSAP 5 334.48 28289.23015 57971.48438 585885.6145 10487.81278 55465.93703 158336.4305 0.257229082 1.583408889 
RT26 2 38.15 35.39387216 2.945639484 211523.3691 0 0 9691.778787 0.256805061 4.448173246 
RS29 2 245.64 19791.90463 306784.1052 2814437.076 47131.58672 19786.94775 618071.5964 0.253818138 2.197074846 
PLRG1 3 328.31 0 13962.73989 381210.9995 9227.299327 38475.67275 18611.04607 0.252269433 2.575101299 
RUSD3 3 326.92 794.8369688 3441.612958 441008.9106 812.4205472 1109.279448 21806.29013 0.249577409 4.229938771 
MAZ 9 523.58 253968.0702 37526.16321 1297036.04 25748.2669 82879.28831 485751.5684 0.24491254 1.418237234 
RS18 7 637.21 351602.7786 63098.84191 3319981.788 58917.7636 444318.8968 254097.6107 0.244333109 2.30198383 
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RM18 2 99.17 292707.9472 1560.239305 414562.4967 9315.364779 4369.201246 105298.4192 0.243890301 2.574685775 
TCPZ 2 179.73 785.6225366 504.4722431 78017.5312 29.93943986 1038.618996 12706.84516 0.240406334 2.52536501 
TCPD 10 2004.09 73509.01231 121405.2856 7121766.719 26200.93356 207936.7472 534836.9716 0.237912575 3.250181415 
ILF2 7 1103.26 135824.0916 23319.32383 4189817.889 34286.65927 18589.86583 700783.9112 0.234754336 2.528684307 
PABP4 9 2074.35 24056.19916 75291.47456 1655879.319 16367.35231 9263.514578 733881.2503 0.230750875 1.208512731 
UBC12 2 44.93 0 832.2905385 146969.4232 0 0 27653.27328 0.230224934 2.418140832 
RM11 9 867.54 151125.3728 209190.2615 3127413.518 90138.53586 182371.7422 813028.4955 0.224984376 1.683876751 
H13 5 1500.85 29034.78708 47858.47094 996634.6588 12962.57495 15205.84947 476442.9093 0.216204222 1.089115193 
LRC59 3 385.18 2308.410025 1436.621264 2248647.759 2806.613199 3906.844135 12404.58578 0.214311399 6.880379768 
ANXA5 4 524.61 9319.635153 4423.553482 756678.2026 4425.706093 2934.680728 102253.474 0.208025046 2.81321752 
RL39 4 156.19 1182920.235 29542.99612 5443035.607 539746.1887 21356.66003 747627.7105 0.207916684 2.346378695 
TCPB 6 1005.82 6187.943111 123018.3045 1018627.197 3151.074685 171763.2511 69939.57323 0.203037301 2.228920242 
RS5 5 711.7 43686.74395 18559.91698 1241139.393 92099.47641 63118.72208 20555.59642 0.201451414 2.890472554 
NUP50 2 130.82 0 290.045336 125613.1616 836.9350926 311.755658 27784.65194 0.200177589 2.121510117 
PUR6 3 414.37 0 1379.463089 363458.0133 3917.621284 773.9031583 48035.2728 0.199423584 2.79064566 
RM16 2 130.3 1258.118524 0 385862.7039 20158.34559 524.1948198 11621.5325 0.194813116 3.582995932 
RT17 5 514.22 31384.02708 31368.68112 5675358.482 115014.6319 559427.7922 1438319.943 0.190255218 1.441445415 
FBRL 9 591.73 56038.10845 44233.65465 2114030.434 39266.9082 144545.3401 129949.4515 0.189567846 2.819110966 
WBP11 3 128.54 190.4402564 39436.97706 212852.958 27180.56644 21265.07384 66364.76136 0.189037215 1.136917901 
RL36 5 324.02 16893.69453 21957.30289 2159382.515 20107.06041 4595.047123 416151.9453 0.187903782 2.31797162 
RL6 12 1215.91 89194.67067 130598.4888 6744180.292 26359.6608 61646.17888 2701052.268 0.184910139 1.320132711 
RS6 5 577.24 21935.78239 19563.13094 1098232.569 2039.149188 65734.97938 225429.7413 0.18016579 1.958717919 
NDUS3 2 412.34 82.00785534 1308.376665 336075.4959 1347.559789 33.79957874 11929.76846 0.177919829 4.664036927 
PRC2A 8 601.51 54077.99927 49269.27377 2182502.024 43741.65679 29699.57999 532443.6898 0.174453324 1.915614573 
PRDX6 2 389.29 5824.340736 111.3381708 414853.7558 2581.596323 1076.176879 3524.981782 0.174310921 5.872417368 
RS25 8 820.46 288740.1475 318635.3012 19656627.9 96942.49295 143057.6572 9122771.33 0.166049349 1.113911669 
CCD86 6 497.8 82941.98936 813.8838954 907277.9591 1216.727289 11919.17867 175319.1642 0.158360819 2.3947137 
SLIRP 5 668.2 310784.3238 479724.4919 5915759.285 272630.6668 469694.333 1770659.321 0.158128141 1.41610849 
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RPC4 4 104.04 11139.45825 858.1228715 348395.3874 48379.81885 16775.21623 38193.96134 0.157458402 1.802046484 
RS27 3 274.5 991.927907 13671.51179 2260848.945 15463.82479 75866.09265 605444.2587 0.156517214 1.707428378 
RL19 4 433.41 62435.78477 45337.5899 807403.8942 13225.46156 102706.4427 334549.4187 0.153334319 1.022583926 
RS11 20 1847.17 1041608.405 287012.4994 32962019.51 453840.1356 463438.894 6099591.553 0.153094092 2.288915189 
HNRPR 2 425.57 15066.98252 27719.90786 328680.6884 23793.93311 17731.20257 88379.63916 0.152454428 1.51578184 
PPIB 6 454.8 2537.129537 1021660.158 1691987.663 239815.8839 458290.2208 521903.225 0.152171828 1.154689538 
NDUV2 4 169.89 1047.149669 0 299957.7591 285.4170822 1061.773122 82364.44795 0.149214841 1.846286899 
TPP1 2 250.38 251.9888728 12388.1215 665143.3869 36496.12138 7205.344898 143031.2791 0.147697288 1.85984957 
CNBP 5 426.62 0 78869.13605 20485.00854 6406.292553 1599.38971 6987.023579 0.145592045 2.728319371 
RL34 3 189.71 20753.54309 399229.7033 199775.3846 164306.7962 75411.48874 42751.15199 0.144733685 1.133611681 
TCPH 2 214.33 54.15194008 5736.654566 142023.8674 921.0552625 1101.108238 2917.09935 0.144590569 4.903349941 
DHB4 3 330.81 4432.67773 1416.267286 584326.227 21480.8691 17822.31852 85931.85094 0.141677606 2.23650497 
RM33 4 577.42 6716.397905 97896.38463 3042663.647 2369.810485 39473.18832 1278996.567 0.136544646 1.252648656 
ATPO 4 454.17 55259.28899 24711.84198 9426964.058 23943.06679 14640.81302 2377041.832 0.136457386 1.976583391 
TCPQ 8 664.98 14219.49543 85381.03168 1975596.814 9917.601685 152123.0448 234553.0973 0.13441194 2.387514712 
MZT2B 2 174.18 63937.87193 261.8027504 365858.108 1795.271526 6879.219477 38154.61604 0.133750456 3.19905308 
HSP7C 14 2842.54 2231284.922 1898931.789 36935884.08 1382029.798 2623007.2 12907186.78 0.125958971 1.279881599 
ODP2 8 954.55 21889.34142 42846.02153 4381255.937 9885.771108 136902.8334 389142.9612 0.125900378 3.052384429 
NOL7 2 63.6 0 15320.24048 252236.2454 0 7009.940392 3269.580222 0.124224849 4.701998611 
NEP1 4 478.6 6757.192113 38007.10654 591549.5441 121230.6922 57320.30354 82806.68287 0.122895923 1.283712961 
RT22 4 259.98 19373.56347 8107.176561 345618.2378 10297.82793 14053.97568 99163.7614 0.121008225 1.594865551 
TIM13 5 542.38 7314.087445 97593.34525 1583209.303 83956.37464 130971.5206 506560.136 0.117710769 1.226367305 
NOP2 2 121.91 645.1354719 4160.317795 113036.3068 17744.20132 23400.36736 3475.464117 0.116435222 1.401087404 
RM46 2 276.75 1542.36332 0 397124.6368 676.3158918 1491.544303 13891.12799 0.114346153 4.633731288 
RM12 5 506.56 21264.83129 99372.11731 27610590.42 4687.77731 176572.5054 4493041.101 0.112954707 2.568688808 
PRDX1 9 725.53 75631.01433 104877.3735 3393229.781 44546.75383 139521.1036 1041372.327 0.112843159 1.544133873 
RL26;1::sp 4 1766.26 65028.31624 63582.71303 6607550.977 31796.40626 70558.9224 1943503.322 0.11116462 1.719220364 
PSMD9 5 429.31 16907.85817 19955.68764 692347.5956 23889.02085 12581.65858 205283.1679 0.108646953 1.592797755 
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GAMC 3 117.1 49.74049152 6144.805299 1359371.841 39765.17175 14715.27896 10325.91359 0.108249959 4.397220143 
ATPA 5 585.69 22500.50375 85899.59422 1153686.376 36845.40491 150572.8055 132825.1752 0.107445195 1.978570084 
RS20 6 646.42 579.0077153 61612.4528 9176648.32 33027.11146 56765.547 2557110.729 0.103553661 1.803406151 
ALDOA_RABIT 8 942.64 79905.08116 234720.4892 3842447.884 613761.5173 464878.2043 612779.3888 0.090882038 1.297334056 
RRP1B 14 1122.6 84469.21361 45163.02797 6040654.025 24206.46652 69612.39399 2827096.248 0.088549589 1.078916995 
ODO2 2 222.64 255.2390504 5412.387 296529.0073 998.9872516 8353.036221 10118.87445 0.085880124 3.956096266 
RL29 11 1005.06 1678668.57 332188.2173 73744298.86 1663107.619 3195759.42 27629947.79 0.082831186 1.221400961 
L10K 5 221.39 619.5363638 29177.75714 754418.3965 4182.273806 2801.669346 207490.8138 0.082275413 1.87044265 
H2A1 3 263.47 61890.04989 183868.0189 7943892.775 120160.0035 91195.4997 2397912.99 0.080541121 1.650156541 
RM30 3 339.08 20136.18048 36137.62977 4936378.793 12693.45351 49342.48046 1260720.449 0.080497665 1.916259146 
RL10A 4 222.81 32340.1257 663.2119757 695842.5463 69347.15917 17371.20699 2766.563627 0.079456668 3.025897143 
RRP15 2 43.27 0 0 52726.49102 0 0 2270.837328 0.077392675 4.537231721 
RM53 7 576.9 48897.61312 68747.74905 5282086.136 40524.17816 70774.87065 1764249.682 0.07704076 1.525574923 
RM49 2 346.44 8400.430176 13178.89384 616933.3299 18549.26459 7197.301219 173381.0573 0.076539001 1.681021845 
K1M1_SHEEP 2 97.03 823322.0116 1884.450008 2466.076575 56985.25759 2087.991099 8080.454361 0.07330154 3.623521229 
RADI 3 292.8 1276.820321 2793.724434 344340.7173 11824.21741 3608.911776 9552.921937 0.072069053 3.801596442 
RL26L 2 1535.13 147.2170475 0 581751.2698 0 52.82109283 64025.16671 0.071104375 3.182866745 
CETN2 3 279.76 1488.701207 61705.01624 2249022 15542.4189 68017.29577 803870.9601 0.068420337 1.381569673 
CALL5 5 829.63 31663.57775 137455.319 2712466.561 88099.63343 39461.05163 1282412.538 0.067430128 1.031195042 
AIFM1 8 791.58 12785.04357 53534.93217 1619764.06 41086.60702 27209.24747 383046.1809 0.066844612 1.901383389 
RM50 4 308.15 22802.22121 9684.061411 2314162.59 106489.0868 32849.50774 53959.06661 0.066743098 3.601705903 
HSP71 13 4839.79 313937.9202 549129.7105 39993281.67 331431.4626 769334.5772 9476648.281 0.066488475 1.949573299 
RBM42 4 714.33 3431.925232 2611.17898 2383359.171 5091.92704 16166.33982 1135716.613 0.061696366 1.046292222 
SZRD1 3 175.07 46765.84424 1532.137108 357323.342 6074.83052 9951.534515 167850.4229 0.056155024 1.141394126 
NDUF3 2 168.47 3905.438277 2252.612087 232103.678 7094.32273 2380.497681 52372.59143 0.056003722 1.945762104 
PKRI1 2 223.75 4018.840649 0 0 687.1336117 0 0 0.052702406 2.548116814 
EAF6 2 402.41 0 6108.586332 463840.9979 49.0997585 1772.162761 130588.2683 0.051275839 1.827499023 
RUVB1 3 277.01 7454.966311 61580.10777 497283.4449 89259.21614 40186.13658 108876.1436 0.049103582 1.248704621 
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RSMN 8 525.57 52909.06267 4783.536683 3587504.42 14275.12229 12569.84025 1746605.611 0.048103374 1.03943767 
SMD2 9 815.58 161202.6051 423803.4386 13700545.07 184768.7434 404060.9541 6118897.468 0.04773414 1.090660781 
RT23 5 384.75 18086.71816 26934.47996 959249.5559 74024.30344 12153.41793 273335.9389 0.047215049 1.482029782 
RS4X 12 1341.34 266787.3504 703801.3498 10555095.59 1237808.613 861814.4661 2931704.002 0.044819997 1.195841521 
RM40 11 1137.06 59202.59249 74669.1711 30088552.55 204598.2707 154716.5644 10926309.05 0.044214512 1.421133218 
MO4L2 5 426.83 70121.64595 39704.88898 879517.1858 45786.37813 112930.1598 327320.9936 0.037661068 1.025404111 
MAP4 13 1275.28 31002.13332 155975.338 2199883.516 114820.4676 83991.45317 696461.5392 0.036938333 1.414714221 
MIC25 5 232.22 17325.64742 28300.04572 585606.8654 51499.58727 83650.97443 46465.28194 0.036516693 1.797281556 
CN142 2 377.38 574.8183629 1769.320016 767076.025 898.6720897 7774.952562 241464.5037 0.031330256 1.621046654 
RS30 5 469.49 196217.0826 317834.8634 54553256.91 258417.5316 307780.9791 23915915.66 0.027913362 1.169467957 
ATPB 8 1084.52 32882.6668 88180.54767 2741527.691 185303.1278 118448.3316 261451.0331 0.026790133 2.340481776 
RM48 3 222.52 1013.053001 1892.257122 448590.4172 22513.51431 628.6164117 35253.1409 0.026255291 2.950788874 
RT11 5 484.85 19862.43716 3045.230341 3134389.963 9643.404158 9827.465578 1092768.889 0.025965265 1.505222451 
RL8 10 1196.15 156599.4109 24340.62926 11167457.57 78889.61242 68729.43924 4627639.92 0.02589878 1.248837724 
DECR 4 267.39 1095.17304 711.6874345 1986432.575 25400.05935 11591.77791 9504.368047 0.025484544 5.418234717 
RL18A 5 284.29 9569.732586 0 601877.4624 113761.2116 173063.6648 0 0.023227164 1.092057757 
NDUS6 5 651.41 45356.58798 94302.96016 3628291.079 125019.4178 175997.0266 912573.3627 0.01920719 1.634499187 
HMGB3 3 116.21 2764.822217 630.1648205 391238.2569 22324.78987 6399.830654 6646.368224 0.018486765 3.479874041 
RM27 8 804.78 53202.57721 30865.51652 4353742.211 104427.6979 92983.44477 973617.1645 0.017748165 1.92207205 
TFAM 8 619.58 33084.36566 109513.1919 3542728.364 334309.849 37371.65836 1353183.432 0.017443821 1.095308813 
CH60 16 2119.53 50512.22841 177118.5022 5617752.563 152843.9592 313216.8359 1329032.963 0.016878314 1.70323843 
RL7A 15 1180.14 46470.00832 68067.1145 16977133.87 69729.70612 170777.4276 3382447.501 0.014170616 2.238054805 
NDUA7 4 489.3 6003.177168 7257.224809 1348364.958 16934.16481 18553.40545 238632.5962 0.013622064 2.312449439 
FUBP2 3 281.69 1646.485024 0 271445.8257 0 14524.55348 58941.32457 0.013460215 1.894242457 
KNOP1 3 344.24 99.55676848 9264.101378 192975.5358 1375.459289 3321.386324 29970.67561 0.012118014 2.545119212 
CDC5L 6 394.93 257127.5667 2033.469535 894909.265 140662.539 199278.5544 20700.49781 0.011926849 1.678093418 
RS27A 2 1136.52 55.97676721 6643.764464 2996064.962 3483.214521 717.7935609 666214.0282 0.011739125 2.163165018 
C1QBP 12 2532.82 4663150.473 5149154.641 301925543.4 4611073.482 10128748.46 130502771.6 0.011188956 1.101868728 
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LBR 3 264.33 2865.734436 31862.5971 720113.4792 33390.01468 85903.10905 26381.32755 0.009399217 2.37342646 
RL31 18 1625.83 990674.5097 563983.9765 165393276.8 865097.856 1901116.778 47510818.7 0.008421317 1.731426822 
RS13 7 342.94 165566.696 108891.8948 13040581.44 338274.9795 258954.6147 2980815.153 0.00669407 1.895813431 
RPA34 6 937.12 158510.8674 537.1006512 2492325.787 95456.03659 25346.56721 76091.10377 0.006162489 3.751251146 
GRPE1 5 398.86 18479.01281 184233.9991 2632336.844 375444.5525 45112.63794 563577.9351 0.004216963 1.526445784 
PRDX3 4 412.73 8725.855792 329610.5264 5731049.364 65251.36328 144651.8569 1764526.44 0.000529848 1.620114544 
Shown are cellular proteins identified by label-free mass spectrometry/mass spectrometry that interact with GFP-4bM. Protein identifier (ID), protein name and number 
of unique peptides used to identify proteins are indicated. Confidence score is the score of the probability of the unique peptide sequence occurring randomly, added 
together for each unique peptide. The higher the confidence score, the higher the confidence in protein identification. The -Log2 p value is a comparison of the cellular 
protein abundance between GFP-4bM and GFP. The higher the p value, the higher the probability the protein interacts with 4bM. The fold-change is the change in the 
abundance of the cellular protein between GFP-4bM and GFP. Cellular proteins which appear in both GFP-4bM and 4bM-GFP data are labelled with an asterisk (*). 
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